{"schema_version":"1.0","name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","language":["zh-Hant","en"],"description":"Taiwan-based biotech and pharmaceutical business-analysis media covering clinical data, company strategy, drug development, BD/licensing, valuation, CMC, and biotech capital-market signals.","editorial_positioning":"Drugnews focuses on business judgment rather than headline aggregation, connecting science, clinical evidence, regulatory risk, manufacturing, commercial strategy, licensing terms, valuation logic, and investor perception.","audience":["biotech and pharmaceutical investors","biotech executives and IR teams","business-development and licensing professionals","readers learning how to interpret biotech commercial and capital-market signals"],"key_sections":[{"name":"Home","url":"https://drugnews.com.tw/"},{"name":"Articles","url":"https://drugnews.com.tw/articles/"},{"name":"Capital-market radar","url":"https://drugnews.com.tw/market-radar.html"},{"name":"English edition","url":"https://drugnews.com.tw/en/"},{"name":"Investor guides","url":"https://drugnews.com.tw/guides/"},{"name":"Taiwan biotech clinical database","url":"https://drugnews.com.tw/guides/taiwan-biotech-clinical-trials.html"},{"name":"In-depth research","url":"https://drugnews.com.tw/subscribe.html"},{"name":"Company services","url":"https://drugnews.com.tw/services.html"},{"name":"Team","url":"https://drugnews.com.tw/team.html"},{"name":"Company index","url":"https://drugnews.com.tw/companies.html"},{"name":"Asia ADC Leaders 2026: Who Is Winning the Antibody-Drug Conjugate Race","url":"https://drugnews.com.tw/en/asia-adc-leaders.html"},{"name":"Methodology","url":"https://drugnews.com.tw/methodology.html"},{"name":"合作夥伴","url":"https://drugnews.com.tw/partners.html"},{"name":"Partners","url":"https://drugnews.com.tw/en/partners.html"},{"name":"HDAC inhibitors","url":"https://drugnews.com.tw/en/landscapes/hdac-inhibitors.html"},{"name":"HDAC 抑制劑全景","url":"https://drugnews.com.tw/landscapes/hdac-inhibitors.html"},{"name":"Asian PD-1/VEGF and Bispecific Antibodies","url":"https://drugnews.com.tw/en/asia-pd1-vegf-leaders.html","language":"en"},{"name":"亞洲 PD-1/VEGF 與雙特異性抗體","url":"https://drugnews.com.tw/landscapes/asia-pd1-vegf.html","language":"zh-Hant"},{"name":"Asian GLP-1 and Obesity Drugs","url":"https://drugnews.com.tw/en/asia-glp1-leaders.html","language":"en"},{"name":"亞洲 GLP-1 與肥胖藥","url":"https://drugnews.com.tw/landscapes/asia-glp1.html","language":"zh-Hant"},{"name":"逸達生物科技股份有限公司","url":"https://drugnews.com.tw/companies/foresee-pharmaceuticals.html","language":"zh"},{"name":"Foresee Pharmaceuticals","url":"https://drugnews.com.tw/en/companies/foresee-pharmaceuticals.html","language":"en"},{"name":"智擎生技製藥股份有限公司","url":"https://drugnews.com.tw/companies/pharmaengine.html","language":"zh"},{"name":"PharmaEngine","url":"https://drugnews.com.tw/en/companies/pharmaengine.html","language":"en"},{"name":"圓祥生技股份有限公司","url":"https://drugnews.com.tw/companies/apbio.html","language":"zh"},{"name":"APBio","url":"https://drugnews.com.tw/en/companies/apbio.html","language":"en"},{"name":"安邦生技股份有限公司","url":"https://drugnews.com.tw/companies/anbogen-therapeutics.html","language":"zh"},{"name":"Anbogen Therapeutics","url":"https://drugnews.com.tw/en/companies/anbogen-therapeutics.html","language":"en"},{"name":"康霈生技股份有限公司","url":"https://drugnews.com.tw/companies/caliway.html","language":"zh"},{"name":"Caliway","url":"https://drugnews.com.tw/en/companies/caliway.html","language":"en"},{"name":"國邑藥品科技股份有限公司","url":"https://drugnews.com.tw/companies/pharmosa-biopharm.html","language":"zh"},{"name":"Pharmosa Biopharm","url":"https://drugnews.com.tw/en/companies/pharmosa-biopharm.html","language":"en"},{"name":"藥華醫藥股份有限公司","url":"https://drugnews.com.tw/companies/pharmaessentia.html","language":"zh"},{"name":"PharmaEssentia","url":"https://drugnews.com.tw/en/companies/pharmaessentia.html","language":"en"},{"name":"麗寶新藥生物科技股份有限公司","url":"https://drugnews.com.tw/companies/libo.html","language":"zh"},{"name":"LIBO","url":"https://drugnews.com.tw/en/companies/libo.html","language":"en"},{"name":"全福生物科技股份有限公司","url":"https://drugnews.com.tw/companies/brim.html","language":"zh"},{"name":"BRIM","url":"https://drugnews.com.tw/en/companies/brim.html","language":"en"},{"name":"寶泰生醫股份有限公司","url":"https://drugnews.com.tw/companies/protect-animal-health.html","language":"zh"},{"name":"Protect Animal Health","url":"https://drugnews.com.tw/en/companies/protect-animal-health.html","language":"en"},{"name":"保瑞藥業股份有限公司","url":"https://drugnews.com.tw/companies/bora-pharmaceuticals.html","language":"zh"},{"name":"Bora Pharmaceuticals","url":"https://drugnews.com.tw/en/companies/bora-pharmaceuticals.html","language":"en"},{"name":"智新生技股份有限公司","url":"https://drugnews.com.tw/companies/intelligene.html","language":"zh"},{"name":"Intelligene","url":"https://drugnews.com.tw/en/companies/intelligene.html","language":"en"},{"name":"長聖國際生技股份有限公司","url":"https://drugnews.com.tw/companies/ever-supreme.html","language":"zh"},{"name":"Ever Supreme","url":"https://drugnews.com.tw/en/companies/ever-supreme.html","language":"en"},{"name":"台灣浩鼎生技股份有限公司","url":"https://drugnews.com.tw/companies/obi-pharma.html","language":"zh"},{"name":"OBI Pharma","url":"https://drugnews.com.tw/en/companies/obi-pharma.html","language":"en"},{"name":"生華生物科技股份有限公司","url":"https://drugnews.com.tw/companies/senhwa-biosciences.html","language":"zh"},{"name":"Senhwa Biosciences","url":"https://drugnews.com.tw/en/companies/senhwa-biosciences.html","language":"en"},{"name":"台耀化學股份有限公司","url":"https://drugnews.com.tw/companies/formosa-laboratories.html","language":"zh"},{"name":"Formosa Laboratories","url":"https://drugnews.com.tw/en/companies/formosa-laboratories.html","language":"en"},{"name":"中裕新藥股份有限公司","url":"https://drugnews.com.tw/companies/taimed-biologics.html","language":"zh"},{"name":"TaiMed Biologics","url":"https://drugnews.com.tw/en/companies/taimed-biologics.html","language":"en"},{"name":"永昕生物醫藥股份有限公司","url":"https://drugnews.com.tw/companies/mycenax.html","language":"zh"},{"name":"Mycenax","url":"https://drugnews.com.tw/en/companies/mycenax.html","language":"en"},{"name":"台新藥股份有限公司","url":"https://drugnews.com.tw/companies/formosa-pharmaceuticals.html","language":"zh"},{"name":"Formosa Pharmaceuticals","url":"https://drugnews.com.tw/en/companies/formosa-pharmaceuticals.html","language":"en"},{"name":"華上生技醫藥股份有限公司","url":"https://drugnews.com.tw/companies/gntbm.html","language":"zh"},{"name":"GNTbm","url":"https://drugnews.com.tw/en/companies/gntbm.html","language":"en"},{"name":"永信國際投資控股股份有限公司","url":"https://drugnews.com.tw/companies/tw-3705.html","language":"zh"},{"name":"YungShin","url":"https://drugnews.com.tw/en/companies/tw-3705.html","language":"en"},{"name":"明基三豐醫療器材股份有限公司","url":"https://drugnews.com.tw/companies/tw-4116.html","language":"zh"},{"name":"BMTC","url":"https://drugnews.com.tw/en/companies/tw-4116.html","language":"en"},{"name":"普生股份有限公司","url":"https://drugnews.com.tw/companies/tw-4117.html","language":"zh"},{"name":"General Biologicals","url":"https://drugnews.com.tw/en/companies/tw-4117.html","language":"en"},{"name":"安特羅生物科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-6564.html","language":"zh"},{"name":"Enimmune Corporation","url":"https://drugnews.com.tw/en/companies/tw-6564.html","language":"en"},{"name":"台灣醣聯生技醫藥股份有限公司","url":"https://drugnews.com.tw/companies/tw-4168.html","language":"zh"},{"name":"GlycoNex","url":"https://drugnews.com.tw/en/companies/tw-4168.html","language":"en"},{"name":"天明製藥股份有限公司","url":"https://drugnews.com.tw/companies/tw-6659.html","language":"zh"},{"name":"TIMING PHARMACEUTICAL CO.,LTD.","url":"https://drugnews.com.tw/en/companies/tw-6659.html","language":"en"},{"name":"順天醫藥生技股份有限公司","url":"https://drugnews.com.tw/companies/tw-6535.html","language":"zh"},{"name":"Lumosa","url":"https://drugnews.com.tw/en/companies/tw-6535.html","language":"en"},{"name":"晟德大藥廠股份有限公司","url":"https://drugnews.com.tw/companies/tw-4123.html","language":"zh"},{"name":"Center Lab.","url":"https://drugnews.com.tw/en/companies/tw-4123.html","language":"en"},{"name":"訊聯基因數位股份有限公司","url":"https://drugnews.com.tw/companies/tw-4160.html","language":"zh"},{"name":"GGA","url":"https://drugnews.com.tw/en/companies/tw-4160.html","language":"en"},{"name":"國光生物科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-4142.html","language":"zh"},{"name":"Adimmune","url":"https://drugnews.com.tw/en/companies/tw-4142.html","language":"en"},{"name":"高端疫苗生物製劑股份有限公司","url":"https://drugnews.com.tw/companies/tw-6547.html","language":"zh"},{"name":"Medigen Vaccine Biologics Corp.","url":"https://drugnews.com.tw/en/companies/tw-6547.html","language":"en"},{"name":"益得生物科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-6461.html","language":"zh"},{"name":"Intech Biopharm","url":"https://drugnews.com.tw/en/companies/tw-6461.html","language":"en"},{"name":"慧智基因股份有限公司","url":"https://drugnews.com.tw/companies/tw-6615.html","language":"zh"},{"name":"SOFIVA","url":"https://drugnews.com.tw/en/companies/tw-6615.html","language":"en"},{"name":"友華生技醫藥股份有限公司","url":"https://drugnews.com.tw/companies/tw-4120.html","language":"zh"},{"name":"Orient EuroPharma Co., Ltd.","url":"https://drugnews.com.tw/en/companies/tw-4120.html","language":"en"},{"name":"美時化學製藥股份有限公司","url":"https://drugnews.com.tw/companies/tw-1795.html","language":"zh"},{"name":"Lotus Pharmaceutical Co., Ltd.","url":"https://drugnews.com.tw/en/companies/tw-1795.html","language":"en"},{"name":"台灣神隆股份有限公司","url":"https://drugnews.com.tw/companies/tw-1789.html","language":"zh"},{"name":"ScinoPharm Taiwan, Ltd.","url":"https://drugnews.com.tw/en/companies/tw-1789.html","language":"en"},{"name":"泰福生技股份有限公司","url":"https://drugnews.com.tw/companies/tw-6541.html","language":"zh"},{"name":"Tanvex","url":"https://drugnews.com.tw/en/companies/tw-6541.html","language":"en"},{"name":"生達化學製藥股份有限公司","url":"https://drugnews.com.tw/companies/tw-1720.html","language":"zh"},{"name":"Standard Chem & Pharm","url":"https://drugnews.com.tw/en/companies/tw-1720.html","language":"en"},{"name":"吉晟生技股份有限公司","url":"https://drugnews.com.tw/companies/tw-7762.html","language":"zh"},{"name":"PET Pharm","url":"https://drugnews.com.tw/en/companies/tw-7762.html","language":"en"},{"name":"葡萄王生技股份有限公司","url":"https://drugnews.com.tw/companies/tw-1707.html","language":"zh"},{"name":"Grape King","url":"https://drugnews.com.tw/en/companies/tw-1707.html","language":"en"},{"name":"合一生技股份有限公司","url":"https://drugnews.com.tw/companies/tw-4743.html","language":"zh"},{"name":"ONENESS BIOTECH","url":"https://drugnews.com.tw/en/companies/tw-4743.html","language":"en"},{"name":"仁新醫藥股份有限公司","url":"https://drugnews.com.tw/companies/tw-6696.html","language":"zh"},{"name":"LBS","url":"https://drugnews.com.tw/en/companies/tw-6696.html","language":"en"},{"name":"太景醫藥研發控股股份有限公司","url":"https://drugnews.com.tw/companies/tw-4157.html","language":"zh"},{"name":"TAIGEN","url":"https://drugnews.com.tw/en/companies/tw-4157.html","language":"en"},{"name":"瑩碩生技醫藥股份有限公司","url":"https://drugnews.com.tw/companies/tw-6677.html","language":"zh"},{"name":"Anxo","url":"https://drugnews.com.tw/en/companies/tw-6677.html","language":"en"},{"name":"宣捷幹細胞生技股份有限公司","url":"https://drugnews.com.tw/companies/tw-4724.html","language":"zh"},{"name":"MERIBANKBIOTECH","url":"https://drugnews.com.tw/en/companies/tw-4724.html","language":"en"},{"name":"泰宗生物科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-4169.html","language":"zh"},{"name":"TCM","url":"https://drugnews.com.tw/en/companies/tw-4169.html","language":"en"},{"name":"醣基生醫股份有限公司","url":"https://drugnews.com.tw/companies/tw-6586.html","language":"zh"},{"name":"CHO PHARMA, Inc.","url":"https://drugnews.com.tw/en/companies/tw-6586.html","language":"en"},{"name":"因華生技製藥股份有限公司","url":"https://drugnews.com.tw/companies/tw-4172.html","language":"zh"},{"name":"InnoPharmax","url":"https://drugnews.com.tw/en/companies/tw-4172.html","language":"en"},{"name":"杏國新藥股份有限公司","url":"https://drugnews.com.tw/companies/tw-4192.html","language":"zh"},{"name":"SynCore","url":"https://drugnews.com.tw/en/companies/tw-4192.html","language":"en"},{"name":"北極星藥業集團股份有限公司","url":"https://drugnews.com.tw/companies/tw-6550.html","language":"zh"},{"name":"Polaris Group","url":"https://drugnews.com.tw/en/companies/tw-6550.html","language":"en"},{"name":"景凱生物科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-6549.html","language":"zh"},{"name":"TaiwanJ","url":"https://drugnews.com.tw/en/companies/tw-6549.html","language":"en"},{"name":"中天生物科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-4128.html","language":"zh"},{"name":"MICROBIO","url":"https://drugnews.com.tw/en/companies/tw-4128.html","language":"en"},{"name":"德英生物科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-4911.html","language":"zh"},{"name":"G&E","url":"https://drugnews.com.tw/en/companies/tw-4911.html","language":"en"},{"name":"華安醫學股份有限公司","url":"https://drugnews.com.tw/companies/tw-6657.html","language":"zh"},{"name":"Energenesis Biomedical Co., Ltd.","url":"https://drugnews.com.tw/en/companies/tw-6657.html","language":"en"},{"name":"彥臣生技藥品股份有限公司","url":"https://drugnews.com.tw/companies/tw-4732.html","language":"zh"},{"name":"NBM","url":"https://drugnews.com.tw/en/companies/tw-4732.html","language":"en"},{"name":"禾伸堂生技股份有限公司","url":"https://drugnews.com.tw/companies/tw-4194.html","language":"zh"},{"name":"HSHC","url":"https://drugnews.com.tw/en/companies/tw-4194.html","language":"en"},{"name":"安成生物科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-6610.html","language":"zh"},{"name":"TWi Biotechnology, Inc.","url":"https://drugnews.com.tw/en/companies/tw-6610.html","language":"en"},{"name":"永笙生技股份有限公司","url":"https://drugnews.com.tw/companies/tw-4178.html","language":"zh"},{"name":"StemCyte","url":"https://drugnews.com.tw/en/companies/tw-4178.html","language":"en"},{"name":"台睿生物科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-6580.html","language":"zh"},{"name":"TaiRx","url":"https://drugnews.com.tw/en/companies/tw-6580.html","language":"en"},{"name":"欣耀生醫股份有限公司","url":"https://drugnews.com.tw/companies/tw-6634.html","language":"zh"},{"name":"SINEW","url":"https://drugnews.com.tw/en/companies/tw-6634.html","language":"en"},{"name":"杏輝藥品工業股份有限公司","url":"https://drugnews.com.tw/companies/tw-1734.html","language":"zh"},{"name":"SINPHAR","url":"https://drugnews.com.tw/en/companies/tw-1734.html","language":"en"},{"name":"視航生物醫學股份有限公司","url":"https://drugnews.com.tw/companies/tw-7759.html","language":"zh"},{"name":"SUNHAWK BIO","url":"https://drugnews.com.tw/en/companies/tw-7759.html","language":"en"},{"name":"路迦生醫股份有限公司","url":"https://drugnews.com.tw/companies/tw-6814.html","language":"zh"},{"name":"LUKAS","url":"https://drugnews.com.tw/en/companies/tw-6814.html","language":"en"},{"name":"仲恩生醫科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-7729.html","language":"zh"},{"name":"SBI","url":"https://drugnews.com.tw/en/companies/tw-7729.html","language":"en"},{"name":"竟天生物科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-6917.html","language":"zh"},{"name":"Andros","url":"https://drugnews.com.tw/en/companies/tw-6917.html","language":"en"},{"name":"英屬開曼群島商育世博(股)公司","url":"https://drugnews.com.tw/companies/tw-6976.html","language":"zh"},{"name":"Acepodia","url":"https://drugnews.com.tw/en/companies/tw-6976.html","language":"en"},{"name":"台寶生醫股份有限公司","url":"https://drugnews.com.tw/companies/tw-6892.html","language":"zh"},{"name":"TWB","url":"https://drugnews.com.tw/en/companies/tw-6892.html","language":"en"},{"name":"藥祇生醫股份有限公司","url":"https://drugnews.com.tw/companies/tw-7878.html","language":"zh"},{"name":"PHARMASAGA","url":"https://drugnews.com.tw/en/companies/tw-7878.html","language":"en"},{"name":"南光化學製藥股份有限公司","url":"https://drugnews.com.tw/companies/tw-1752.html","language":"zh"},{"name":"NANG KUANG","url":"https://drugnews.com.tw/en/companies/tw-1752.html","language":"en"},{"name":"和迅生命科學股份有限公司","url":"https://drugnews.com.tw/companies/tw-6986.html","language":"zh"},{"name":"HEXUN","url":"https://drugnews.com.tw/en/companies/tw-6986.html","language":"en"},{"name":"聖安生醫股份有限公司","url":"https://drugnews.com.tw/companies/tw-6926.html","language":"zh"},{"name":"Shine-On Bio","url":"https://drugnews.com.tw/en/companies/tw-6926.html","language":"en"},{"name":"英屬開曼群島商思捷優達(股)公司","url":"https://drugnews.com.tw/companies/tw-7829.html","language":"zh"},{"name":"Dasher-KY","url":"https://drugnews.com.tw/en/companies/tw-7829.html","language":"en"},{"name":"巨生生醫股份有限公司","url":"https://drugnews.com.tw/companies/tw-6827.html","language":"zh"},{"name":"MPB","url":"https://drugnews.com.tw/en/companies/tw-6827.html","language":"en"},{"name":"英屬開曼群島商漢康生技(股)公司","url":"https://drugnews.com.tw/companies/tw-7827.html","language":"zh"},{"name":"Hanchor-KY","url":"https://drugnews.com.tw/en/companies/tw-7827.html","language":"en"},{"name":"安立璽榮醫藥股份有限公司","url":"https://drugnews.com.tw/companies/tw-7871.html","language":"zh"},{"name":"Elixiron-KY","url":"https://drugnews.com.tw/en/companies/tw-7871.html","language":"en"},{"name":"沛爾生技醫藥股份有限公司","url":"https://drugnews.com.tw/companies/tw-6949.html","language":"zh"},{"name":"PELL BMT","url":"https://drugnews.com.tw/en/companies/tw-6949.html","language":"en"},{"name":"寶齡富錦生技股份有限公司","url":"https://drugnews.com.tw/companies/tw-1760.html","language":"zh"},{"name":"PBF","url":"https://drugnews.com.tw/en/companies/tw-1760.html","language":"en"},{"name":"昱厚生技股份有限公司","url":"https://drugnews.com.tw/companies/tw-6709.html","language":"zh"},{"name":"Advagene","url":"https://drugnews.com.tw/en/companies/tw-6709.html","language":"en"},{"name":"安基生技新藥股份有限公司","url":"https://drugnews.com.tw/companies/tw-7754.html","language":"zh"},{"name":"AnnJi","url":"https://drugnews.com.tw/en/companies/tw-7754.html","language":"en"},{"name":"訊聯生物科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-1784.html","language":"zh"},{"name":"BIONET CORP.","url":"https://drugnews.com.tw/en/companies/tw-1784.html","language":"en"},{"name":"台康生技股份有限公司","url":"https://drugnews.com.tw/companies/tw-6589.html","language":"zh"},{"name":"EirGenix, Inc.","url":"https://drugnews.com.tw/en/companies/tw-6589.html","language":"en"},{"name":"昱展新藥生技股份有限公司","url":"https://drugnews.com.tw/companies/tw-6785.html","language":"zh"},{"name":"Alar","url":"https://drugnews.com.tw/en/companies/tw-6785.html","language":"en"},{"name":"朗齊生物醫學股份有限公司","url":"https://drugnews.com.tw/companies/tw-6876.html","language":"zh"},{"name":"LaunXP BioMed","url":"https://drugnews.com.tw/en/companies/tw-6876.html","language":"en"},{"name":"祥翊製藥股份有限公司","url":"https://drugnews.com.tw/companies/tw-6676.html","language":"zh"},{"name":"Sunny","url":"https://drugnews.com.tw/en/companies/tw-6676.html","language":"en"},{"name":"原創生醫股份有限公司","url":"https://drugnews.com.tw/companies/tw-6483.html","language":"zh"},{"name":"OBM","url":"https://drugnews.com.tw/en/companies/tw-6483.html","language":"en"},{"name":"懷特生技新藥股份有限公司","url":"https://drugnews.com.tw/companies/tw-4108.html","language":"zh"},{"name":"PhytoHealth","url":"https://drugnews.com.tw/en/companies/tw-4108.html","language":"en"},{"name":"國璽幹細胞應用技術股份有限公司","url":"https://drugnews.com.tw/companies/tw-6704.html","language":"zh"},{"name":"GWOXI","url":"https://drugnews.com.tw/en/companies/tw-6704.html","language":"en"},{"name":"科懋生物科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-6496.html","language":"zh"},{"name":"Excelsior","url":"https://drugnews.com.tw/en/companies/tw-6496.html","language":"en"},{"name":"漢達生技醫藥股份有限公司","url":"https://drugnews.com.tw/companies/tw-6620.html","language":"zh"},{"name":"Handa Pharma","url":"https://drugnews.com.tw/en/companies/tw-6620.html","language":"en"},{"name":"向榮生醫科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-6794.html","language":"zh"},{"name":"UnicoCell","url":"https://drugnews.com.tw/en/companies/tw-6794.html","language":"en"},{"name":"泰合生技藥品股份有限公司","url":"https://drugnews.com.tw/companies/tw-6467.html","language":"zh"},{"name":"TAHO Pharma","url":"https://drugnews.com.tw/en/companies/tw-6467.html","language":"en"},{"name":"友霖生技醫藥股份有限公司","url":"https://drugnews.com.tw/companies/tw-4166.html","language":"zh"},{"name":"OP","url":"https://drugnews.com.tw/en/companies/tw-4166.html","language":"en"},{"name":"水星生醫股份有限公司","url":"https://drugnews.com.tw/companies/tw-6932.html","language":"zh"},{"name":"Merdury","url":"https://drugnews.com.tw/en/companies/tw-6932.html","language":"en"},{"name":"易威生醫科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-1799.html","language":"zh"},{"name":"EASYWELL","url":"https://drugnews.com.tw/en/companies/tw-1799.html","language":"en"},{"name":"鑫品生醫科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-4170.html","language":"zh"},{"name":"VBI","url":"https://drugnews.com.tw/en/companies/tw-4170.html","language":"en"},{"name":"樂迦再生科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-6891.html","language":"zh"},{"name":"Locus Cell","url":"https://drugnews.com.tw/en/companies/tw-6891.html","language":"en"},{"name":"永立榮生醫股份有限公司","url":"https://drugnews.com.tw/companies/tw-6973.html","language":"zh"},{"name":"U-Neuron","url":"https://drugnews.com.tw/en/companies/tw-6973.html","language":"en"},{"name":"基亞生物科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-3176.html","language":"zh"},{"name":"MEDIGEN","url":"https://drugnews.com.tw/en/companies/tw-3176.html","language":"en"},{"name":"共信醫藥科技控股股份有限公司","url":"https://drugnews.com.tw/companies/tw-6617.html","language":"zh"},{"name":"Gongwin","url":"https://drugnews.com.tw/en/companies/tw-6617.html","language":"en"},{"name":"富禾生醫股份有限公司","url":"https://drugnews.com.tw/companies/tw-7773.html","language":"zh"},{"name":"FullHope","url":"https://drugnews.com.tw/en/companies/tw-7773.html","language":"en"},{"name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-hengrui.html","language":"en"},{"name":"Hansoh Pharmaceutical Group Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-hansoh.html","language":"en"},{"name":"Innovent Biologics, Inc.","url":"https://drugnews.com.tw/en/companies/cn-innovent.html","language":"en"},{"name":"CSPC Pharmaceutical Group Limited","url":"https://drugnews.com.tw/en/companies/cn-cspc.html","language":"en"},{"name":"InSilico Medicine Cayman TopCo","url":"https://drugnews.com.tw/en/companies/cn-insilico.html","language":"en"},{"name":"Simcere Pharmaceutical Group Ltd.","url":"https://drugnews.com.tw/en/companies/cn-simcere.html","language":"en"},{"name":"RemeGen Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-remegen.html","language":"en"},{"name":"DualityBio Inc.","url":"https://drugnews.com.tw/en/companies/cn-duality.html","language":"en"},{"name":"Antengene Corporation Limited","url":"https://drugnews.com.tw/en/companies/cn-antengene.html","language":"en"},{"name":"InnoCare Pharma Limited","url":"https://drugnews.com.tw/en/companies/cn-innocare.html","language":"en"},{"name":"Alteogen Inc.","url":"https://drugnews.com.tw/en/companies/kr-alteogen.html","language":"en"},{"name":"Hanmi Pharmaceutical Co., Ltd.","url":"https://drugnews.com.tw/en/companies/kr-hanmi.html","language":"en"},{"name":"OliX Pharmaceuticals, Inc.","url":"https://drugnews.com.tw/en/companies/kr-olix.html","language":"en"},{"name":"Oscotec Inc.","url":"https://drugnews.com.tw/en/companies/kr-oscotec.html","language":"en"},{"name":"GC Biopharma Corp.","url":"https://drugnews.com.tw/en/companies/kr-gc-biopharma.html","language":"en"},{"name":"Daiichi Sankyo Co., Ltd.","url":"https://drugnews.com.tw/en/companies/jp-daiichi-sankyo.html","language":"en"},{"name":"Eisai Co., Ltd.","url":"https://drugnews.com.tw/en/companies/jp-eisai.html","language":"en"},{"name":"Chugai Pharmaceutical Co., Ltd.","url":"https://drugnews.com.tw/en/companies/jp-chugai.html","language":"en"},{"name":"Enleofen Bio Pte. Ltd.","url":"https://drugnews.com.tw/en/companies/sg-enleofen.html","language":"en"},{"name":"Hummingbird Bioscience","url":"https://drugnews.com.tw/en/companies/sg-hummingbird.html","language":"en"},{"name":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-kelun-biotech.html","language":"en"},{"name":"Sichuan Biokin Pharmaceutical Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-biokin.html","language":"en"},{"name":"Alphamab Oncology","url":"https://drugnews.com.tw/en/companies/cn-alphamab.html","language":"en"},{"name":"Lepu Biopharma Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-lepu-biopharma.html","language":"en"},{"name":"Mabwell (Shanghai) Bioscience Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-mabwell.html","language":"en"},{"name":"Shanghai Henlius Biotech","url":"https://drugnews.com.tw/en/companies/cn-henlius.html","language":"en"},{"name":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-fudan-zhangjiang.html","language":"en"},{"name":"Shanghai Junshi Biosciences Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-junshi.html","language":"en"},{"name":"Zai Lab Limited","url":"https://drugnews.com.tw/en/companies/cn-zai-lab.html","language":"en"},{"name":"Keymed Biosciences Inc.","url":"https://drugnews.com.tw/en/companies/cn-keymed.html","language":"en"},{"name":"Akeso, Inc.","url":"https://drugnews.com.tw/en/companies/cn-akeso.html","language":"en"},{"name":"Dizal Pharmaceutical Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-dizal.html","language":"en"},{"name":"Laekna, Inc.","url":"https://drugnews.com.tw/en/companies/cn-laekna.html","language":"en"},{"name":"Suzhou Ribo Life Science Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-ribo.html","language":"en"},{"name":"Frontier Biotechnologies Inc.","url":"https://drugnews.com.tw/en/companies/cn-frontier.html","language":"en"},{"name":"WuXi Biologics (Cayman) Inc.","url":"https://drugnews.com.tw/en/companies/cn-wuxi-biologics.html","language":"en"},{"name":"Haisco Pharmaceutical Group Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-haisco.html","language":"en"},{"name":"MediLink Therapeutics","url":"https://drugnews.com.tw/en/companies/cn-medilink.html","language":"en"},{"name":"Suzhou Genhouse Bio Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-genhouse.html","language":"en"},{"name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-chia-tai-tianqing.html","language":"en"},{"name":"HUTCHMED (China) Limited","url":"https://drugnews.com.tw/en/companies/cn-hutchmed.html","language":"en"},{"name":"BeOne Medicines Ltd.","url":"https://drugnews.com.tw/en/companies/cn-beone.html","language":"en"},{"name":"Ascentage Pharma","url":"https://drugnews.com.tw/en/companies/cn-ascentage.html","language":"en"},{"name":"Jacobio Pharma","url":"https://drugnews.com.tw/en/companies/cn-jacobio.html","language":"en"},{"name":"Abbisko Therapeutics","url":"https://drugnews.com.tw/en/companies/cn-abbisko.html","language":"en"},{"name":"Harbour BioMed","url":"https://drugnews.com.tw/en/companies/cn-harbour.html","language":"en"},{"name":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-biocytogen.html","language":"en"},{"name":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","url":"https://drugnews.com.tw/en/companies/cn-immuneonco.html","language":"en"},{"name":"Transcenta","url":"https://drugnews.com.tw/en/companies/cn-transcenta.html","language":"en"},{"name":"CANbridge Pharmaceuticals Inc.","url":"https://drugnews.com.tw/en/companies/cn-canbridge.html","language":"en"},{"name":"Brii Biosciences Limited","url":"https://drugnews.com.tw/en/companies/cn-brii.html","language":"en"},{"name":"Everest Medicines","url":"https://drugnews.com.tw/en/companies/cn-everest.html","language":"en"},{"name":"CStone Pharmaceuticals","url":"https://drugnews.com.tw/en/companies/cn-cstone.html","language":"en"},{"name":"SinoMab BioScience Limited","url":"https://drugnews.com.tw/en/companies/cn-sinomab.html","language":"en"},{"name":"Kintor Pharmaceutical Limited","url":"https://drugnews.com.tw/en/companies/cn-kintor.html","language":"en"},{"name":"Bio-Thera Solutions","url":"https://drugnews.com.tw/en/companies/cn-bio-thera.html","language":"en"},{"name":"Asieris Pharmaceuticals","url":"https://drugnews.com.tw/en/companies/cn-asieris.html","language":"en"},{"name":"Shenzhen Chipscreen Biosciences Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-chipscreen.html","language":"en"},{"name":"MicuRx","url":"https://drugnews.com.tw/en/companies/cn-micurx.html","language":"en"},{"name":"Shanghai Allist Pharmaceuticals Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-allist.html","language":"en"},{"name":"LigaChem Biosciences","url":"https://drugnews.com.tw/en/companies/kr-ligachem.html","language":"en"},{"name":"ABL Bio, Inc.","url":"https://drugnews.com.tw/en/companies/kr-abl.html","language":"en"},{"name":"Orum Therapeutics","url":"https://drugnews.com.tw/en/companies/kr-orum.html","language":"en"},{"name":"IntoCell","url":"https://drugnews.com.tw/en/companies/kr-intocell.html","language":"en"},{"name":"AimedBio Inc.","url":"https://drugnews.com.tw/en/companies/kr-aimedbio.html","language":"en"},{"name":"Peptron","url":"https://drugnews.com.tw/en/companies/kr-peptron.html","language":"en"},{"name":"HLB","url":"https://drugnews.com.tw/en/companies/kr-hlb.html","language":"en"},{"name":"Mezzion","url":"https://drugnews.com.tw/en/companies/kr-mezzion.html","language":"en"},{"name":"GI Innovation","url":"https://drugnews.com.tw/en/companies/kr-gi-innovation.html","language":"en"},{"name":"Genexine, Inc.","url":"https://drugnews.com.tw/en/companies/kr-genexine.html","language":"en"},{"name":"MedPacto","url":"https://drugnews.com.tw/en/companies/kr-medpacto.html","language":"en"},{"name":"Qurient Co., LTD.","url":"https://drugnews.com.tw/en/companies/kr-qurient.html","language":"en"},{"name":"TiumBio","url":"https://drugnews.com.tw/en/companies/kr-tiumbio.html","language":"en"},{"name":"VORONOI, Inc.","url":"https://drugnews.com.tw/en/companies/kr-voronoi.html","language":"en"},{"name":"Enzychem Lifesciences","url":"https://drugnews.com.tw/en/companies/kr-enzychem.html","language":"en"},{"name":"AbClon Inc.","url":"https://drugnews.com.tw/en/companies/kr-abclon.html","language":"en"},{"name":"ST PHARM","url":"https://drugnews.com.tw/en/companies/kr-stpharm.html","language":"en"},{"name":"ToolGen Inc.","url":"https://drugnews.com.tw/en/companies/kr-toolgen.html","language":"en"},{"name":"SillaJen, Inc.","url":"https://drugnews.com.tw/en/companies/kr-sillajen.html","language":"en"},{"name":"Helixmith Co., Ltd.","url":"https://drugnews.com.tw/en/companies/kr-helixmith.html","language":"en"},{"name":"Takeda Pharmaceutical Company Limited","url":"https://drugnews.com.tw/en/companies/jp-takeda.html","language":"en"},{"name":"Astellas Pharma Inc.","url":"https://drugnews.com.tw/en/companies/jp-astellas.html","language":"en"},{"name":"Otsuka Pharmaceutical Co., Ltd.","url":"https://drugnews.com.tw/en/companies/jp-otsuka.html","language":"en"},{"name":"Kyowa Kirin Co., Ltd.","url":"https://drugnews.com.tw/en/companies/jp-kyowa-kirin.html","language":"en"},{"name":"ONO PHARMACEUTICAL CO., LTD.","url":"https://drugnews.com.tw/en/companies/jp-ono.html","language":"en"},{"name":"Shionogi & Co., Ltd.","url":"https://drugnews.com.tw/en/companies/jp-shionogi.html","language":"en"},{"name":"Sumitomo Pharma Co., Ltd.","url":"https://drugnews.com.tw/en/companies/jp-sumitomo.html","language":"en"},{"name":"Santen Pharmaceutical Co., Ltd.","url":"https://drugnews.com.tw/en/companies/jp-santen.html","language":"en"},{"name":"NIPPON SHINYAKU CO., LTD.","url":"https://drugnews.com.tw/en/companies/jp-nippon-shinyaku.html","language":"en"},{"name":"KISSEI PHARMACEUTICAL CO., LTD.","url":"https://drugnews.com.tw/en/companies/jp-kissei.html","language":"en"},{"name":"KYORIN Pharmaceutical Co., Ltd.","url":"https://drugnews.com.tw/en/companies/jp-kyorin.html","language":"en"},{"name":"Mochida Pharmaceutical Co., Ltd.","url":"https://drugnews.com.tw/en/companies/jp-mochida.html","language":"en"},{"name":"KAKEN PHARMACEUTICAL CO., LTD.","url":"https://drugnews.com.tw/en/companies/jp-kaken.html","language":"en"},{"name":"SanBio","url":"https://drugnews.com.tw/en/companies/jp-sanbio.html","language":"en"},{"name":"Nxera Pharma Co., Ltd.","url":"https://drugnews.com.tw/en/companies/jp-nxera.html","language":"en"},{"name":"PeptiDream Inc.","url":"https://drugnews.com.tw/en/companies/jp-peptidream.html","language":"en"},{"name":"Chordia Therapeutics Inc.","url":"https://drugnews.com.tw/en/companies/jp-chordia.html","language":"en"},{"name":"Chiome Bioscience Inc.","url":"https://drugnews.com.tw/en/companies/jp-chiome.html","language":"en"},{"name":"SymBio Pharmaceuticals Limited","url":"https://drugnews.com.tw/en/companies/jp-symbio.html","language":"en"},{"name":"Oncolys BioPharma Inc.","url":"https://drugnews.com.tw/en/companies/jp-oncolys.html","language":"en"},{"name":"普惠醫工股份有限公司","url":"https://drugnews.com.tw/companies/tw-6543.html","language":"zh"},{"name":"PF","url":"https://drugnews.com.tw/en/companies/tw-6543.html","language":"en"},{"name":"醫揚科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-6569.html","language":"zh"},{"name":"onyx","url":"https://drugnews.com.tw/en/companies/tw-6569.html","language":"en"},{"name":"博錸生技股份有限公司","url":"https://drugnews.com.tw/companies/tw-6572.html","language":"zh"},{"name":"PlexBio","url":"https://drugnews.com.tw/en/companies/tw-6572.html","language":"en"},{"name":"霈方國際股份有限公司","url":"https://drugnews.com.tw/companies/tw-6574.html","language":"zh"},{"name":"MIKOBEAUTE","url":"https://drugnews.com.tw/en/companies/tw-6574.html","language":"en"},{"name":"Applied BioCode Corporation","url":"https://drugnews.com.tw/companies/tw-6598.html","language":"zh"},{"name":"Applied BioCode","url":"https://drugnews.com.tw/en/companies/tw-6598.html","language":"en"},{"name":"應用奈米醫材科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-6612.html","language":"zh"},{"name":"ICARES","url":"https://drugnews.com.tw/en/companies/tw-6612.html","language":"en"},{"name":"華宇藥品股份有限公司","url":"https://drugnews.com.tw/companies/tw-6621.html","language":"zh"},{"name":"UniPharma","url":"https://drugnews.com.tw/en/companies/tw-6621.html","language":"en"},{"name":"醫影股份有限公司","url":"https://drugnews.com.tw/companies/tw-6637.html","language":"zh"},{"name":"Medical Imaging Corporation","url":"https://drugnews.com.tw/en/companies/tw-6637.html","language":"en"},{"name":"金萬林企業股份有限公司","url":"https://drugnews.com.tw/companies/tw-6645.html","language":"zh"},{"name":"KIM FOREST ENTERPRISE CO., LTD","url":"https://drugnews.com.tw/en/companies/tw-6645.html","language":"en"},{"name":"台灣生醫材料股份有限公司","url":"https://drugnews.com.tw/companies/tw-6649.html","language":"zh"},{"name":"TWBM","url":"https://drugnews.com.tw/en/companies/tw-6649.html","language":"en"},{"name":"厚美德生物科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-6660.html","language":"zh"},{"name":"HMDBIO","url":"https://drugnews.com.tw/en/companies/tw-6660.html","language":"en"},{"name":"威健股份有限公司","url":"https://drugnews.com.tw/companies/tw-6661.html","language":"zh"},{"name":"WELGENE","url":"https://drugnews.com.tw/en/companies/tw-6661.html","language":"en"},{"name":"樂斯科生物科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-6662.html","language":"zh"},{"name":"BioLASCO","url":"https://drugnews.com.tw/en/companies/tw-6662.html","language":"en"},{"name":"康聯生醫科技股份有限公司","url":"https://drugnews.com.tw/companies/tw-6665.html","language":"zh"},{"name":"HEALTHCONN","url":"https://drugnews.com.tw/en/companies/tw-6665.html","language":"en"},{"name":"羅麗芬控股股份有限公司","url":"https://drugnews.com.tw/companies/tw-6666.html","language":"zh"},{"name":"LLF-KY","url":"https://drugnews.com.tw/en/companies/tw-6666.html","language":"en"},{"name":"軒郁國際股份有限公司","url":"https://drugnews.com.tw/companies/tw-6703.html","language":"zh"},{"name":"SHINY","url":"https://drugnews.com.tw/en/companies/tw-6703.html","language":"en"},{"name":"常廣股份有限公司","url":"https://drugnews.com.tw/companies/tw-6730.html","language":"zh"},{"name":"LAGIS","url":"https://drugnews.com.tw/en/companies/tw-6730.html","language":"en"},{"name":"博晟生醫股份有限公司","url":"https://drugnews.com.tw/companies/tw-6733.html","language":"zh"},{"name":"BioGend","url":"https://drugnews.com.tw/en/companies/tw-6733.html","language":"en"},{"name":"安盛生科股份有限公司","url":"https://drugnews.com.tw/companies/tw-6734.html","language":"zh"},{"name":"iXensor","url":"https://drugnews.com.tw/en/companies/tw-6734.html","language":"en"},{"name":"T-cell engagers, including trispecific antibodies","url":"https://drugnews.com.tw/en/asia-tce-leaders.html","language":"en"},{"name":"T 細胞銜接器（含三抗）","url":"https://drugnews.com.tw/landscapes/asia-tce.html","language":"zh-Hant"},{"name":"siRNA and antisense oligonucleotide drugs","url":"https://drugnews.com.tw/en/asia-sirna-leaders.html","language":"en"},{"name":"siRNA 與 ASO 小核酸藥物","url":"https://drugnews.com.tw/landscapes/asia-sirna.html","language":"zh-Hant"},{"name":"Metis TechBio Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-metis.html","language":"en"},{"name":"IMPACT Therapeutics","url":"https://drugnews.com.tw/en/companies/cn-impact.html","language":"en"},{"name":"Xuanzhu Biopharmaceutical Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-xuanzhu.html","language":"en"},{"name":"Alebund Pharmaceuticals (Jiangsu) Limited","url":"https://drugnews.com.tw/en/companies/cn-alebund.html","language":"en"},{"name":"Zhaoke Ophthalmology Limited","url":"https://drugnews.com.tw/en/companies/cn-zhaoke.html","language":"en"},{"name":"3SBio Inc.","url":"https://drugnews.com.tw/en/companies/cn-3sbio.html","language":"en"},{"name":"The United Laboratories International Holdings Limited","url":"https://drugnews.com.tw/en/companies/cn-united-laboratories.html","language":"en"},{"name":"WuXi XDC Cayman Inc.","url":"https://drugnews.com.tw/en/companies/cn-wuxi-xdc.html","language":"en"},{"name":"Lee’s Pharmaceutical Holdings Limited","url":"https://drugnews.com.tw/en/companies/hk-lees-pharma.html","language":"en"},{"name":"XtalPi Holdings Limited","url":"https://drugnews.com.tw/en/companies/cn-xtalpi.html","language":"en"},{"name":"JCR Pharmaceuticals Co., Ltd.","url":"https://drugnews.com.tw/en/companies/jp-jcr.html","language":"en"},{"name":"Toray Industries, Inc.","url":"https://drugnews.com.tw/en/companies/jp-toray.html","language":"en"},{"name":"Curacle Co., Ltd.","url":"https://drugnews.com.tw/en/companies/kr-curacle.html","language":"en"},{"name":"SAM CHUN DANG PHARM. CO., LTD.","url":"https://drugnews.com.tw/en/companies/kr-sam-chun-dang.html","language":"en"},{"name":"Gan & Lee Pharmaceuticals","url":"https://drugnews.com.tw/en/companies/cn-gan-lee.html","language":"en"},{"name":"Wuhan Hiteck Biological Pharma Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-hiteck.html","language":"en"},{"name":"Jiangsu Nhwa Pharmaceutical Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-nhwa.html","language":"en"},{"name":"Abogen Biosciences","url":"https://drugnews.com.tw/en/companies/cn-abogen.html","language":"en"},{"name":"SciBrunch Therapeutics Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-scibrunch.html","language":"en"},{"name":"Triastek, Inc.","url":"https://drugnews.com.tw/en/companies/cn-triastek.html","language":"en"},{"name":"Tanabe Pharma Corporation","url":"https://drugnews.com.tw/en/companies/jp-tanabe.html","language":"en"},{"name":"Boomray Pharmaceuticals Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-boomray.html","language":"en"},{"name":"Senju Pharmaceutical Co., Ltd.","url":"https://drugnews.com.tw/en/companies/jp-senju.html","language":"en"},{"name":"TrueLab Biopharmaceutical Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-truelab.html","language":"en"},{"name":"Samsung Bioepis Co., Ltd.","url":"https://drugnews.com.tw/en/companies/kr-samsung-bioepis.html","language":"en"},{"name":"Suzhou Siran Biotechnology Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-siran.html","language":"en"},{"name":"TJ Biopharma","url":"https://drugnews.com.tw/en/companies/cn-tj-biopharma.html","language":"en"},{"name":"Shanghai Huaota Biopharmaceutical Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-huaota.html","language":"en"},{"name":"Qilu Pharmaceutical Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-qilu.html","language":"en"},{"name":"WestGene Biopharma","url":"https://drugnews.com.tw/en/companies/cn-westgene.html","language":"en"},{"name":"Jiangsu Chia Tai Feng Hai Pharmaceutical Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-chia-tai-feng-hai.html","language":"en"},{"name":"PinotBio, Inc.","url":"https://drugnews.com.tw/en/companies/kr-pinotbio.html","language":"en"},{"name":"Rona Therapeutics","url":"https://drugnews.com.tw/en/companies/cn-rona.html","language":"en"},{"name":"Chimagen Biosciences","url":"https://drugnews.com.tw/en/companies/cn-chimagen.html","language":"en"},{"name":"Luxna Biotech Co., Ltd.","url":"https://drugnews.com.tw/en/companies/jp-luxna.html","language":"en"},{"name":"CrystalO Biopharma","url":"https://drugnews.com.tw/en/companies/cn-crystalo.html","language":"en"},{"name":"Newsoara Biopharma Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-newsoara.html","language":"en"},{"name":"Hebei Taihe Chunyu Biotechnology Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-taihe-chunyu.html","language":"en"},{"name":"Hangzhou DAC Biotechnology Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-dac.html","language":"en"},{"name":"SCOHIA PHARMA, Inc.","url":"https://drugnews.com.tw/en/companies/jp-scohia.html","language":"en"},{"name":"PRG S&T","url":"https://drugnews.com.tw/en/companies/kr-prg-st.html","language":"en"},{"name":"Prazer Therapeutics Inc.","url":"https://drugnews.com.tw/en/companies/kr-prazer.html","language":"en"},{"name":"SynuSight Biotech (Shanghai) Co., Ltd.","url":"https://drugnews.com.tw/en/companies/cn-synusight.html","language":"en"},{"name":"ADEL, Inc.","url":"https://drugnews.com.tw/en/companies/kr-adel.html","language":"en"}],"topic_hubs":[{"name":"Biotech Investing","url":"https://drugnews.com.tw/topics/biotech-investing.html"},{"name":"Biotech Valuation","url":"https://drugnews.com.tw/topics/biotech-valuation.html"},{"name":"Clinical Data","url":"https://drugnews.com.tw/topics/clinical-data.html"},{"name":"BD / Licensing","url":"https://drugnews.com.tw/topics/bd-licensing.html"},{"name":"CMC","url":"https://drugnews.com.tw/topics/cmc.html"},{"name":"Drug Development","url":"https://drugnews.com.tw/topics/drug-development.html"},{"name":"GLP-1","url":"https://drugnews.com.tw/topics/glp1.html"},{"name":"Big Pharma","url":"https://drugnews.com.tw/topics/big-pharma.html"}],"learning_resources":[{"name":"Biotech investor academy","url":"https://drugnews.com.tw/guides/","topics":["drug development","clinical evidence","regulatory and CMC","commercialization and BD","valuation and capital markets"]},{"name":"Clinical endpoints","url":"https://drugnews.com.tw/guides/clinical-endpoints.html","topics":["ORR","PFS","OS","hazard ratio"]},{"name":"FDA regulatory milestones","url":"https://drugnews.com.tw/guides/regulatory-milestones.html","topics":["IND","NDA","BLA","PDUFA","CRL"]},{"name":"Safety and CMC","url":"https://drugnews.com.tw/guides/safety-cmc-risk.html","topics":["AE","SAE","DLT","CMC","GMP"]},{"name":"Market sizing","url":"https://drugnews.com.tw/guides/market-sizing.html","topics":["TAM","SAM","SOM","pricing","penetration"]},{"name":"BD licensing terms","url":"https://drugnews.com.tw/guides/bd-licensing-terms.html","topics":["upfront","milestone","royalty","option rights"]},{"name":"Patent and competition","url":"https://drugnews.com.tw/guides/patent-competition.html","topics":["LOE","patent cliff","generic","biosimilar"]},{"name":"Biotech valuation","url":"https://drugnews.com.tw/guides/biotech-valuation.html","topics":["rNPV","SOTP","probability of success","peak sales"]},{"name":"Cash runway and dilution","url":"https://drugnews.com.tw/guides/cash-runway.html","topics":["burn rate","cash runway","financing","dilution"]},{"name":"Taiwan biotech clinical progress and trial results","url":"https://drugnews.com.tw/guides/taiwan-biotech-clinical-trials.html","topics":["Taiwan biotech","clinical trial phase","trial endpoint","valuation lens"]}],"feeds":{"sitemap":"https://drugnews.com.tw/sitemap.xml","news_sitemap":"https://drugnews.com.tw/news-sitemap.xml","rss":"https://drugnews.com.tw/feed.xml","json_feed":"https://drugnews.com.tw/feed.json","llms_txt":"https://drugnews.com.tw/llms.txt","knowledge_graph":"https://drugnews.com.tw/knowledge-graph.json","market_radar":"https://drugnews.com.tw/market-radar.json","brand_profile":"https://drugnews.com.tw/brand-profile.json","llms_full":"https://drugnews.com.tw/llms-full.txt","mcp_index":"https://drugnews.com.tw/mcp-index.json","facts_index":"https://drugnews.com.tw/facts-index.json"},"mcp":{"endpoint":"https://drugnews.com.tw/mcp","transport":"streamable-http","auth":"none","tools":["search_articles","get_article","get_facts","latest_articles"],"article_twins":"Every article URL has .json (key points, sourced fact table, references) and .md twins."},"citation_guidance":"When referencing Drugnews content, cite the article title, Drugnews｜藥時事, publication date, and canonical URL. Articles are for industry research and knowledge sharing only and do not constitute investment, medical, fundraising, or individual stock advice.","latest_articles":[{"title":"Zolgensma tumors put Novartis's older-patient SMA growth at risk","date":"2026-11-11","language":"en","url":"https://drugnews.com.tw/articles/2026-11-11-novartis-zolgensma-tumor-gli1-itvisma-older-patients-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-11-novartis-zolgensma-tumor-gli1-itvisma-older-patients-en.html","source":"Drugnews","access":"Business Analysis","category":"製藥巨頭","tags":["Novartis","Zolgensma","Gene therapy","SMA","Itvisma"],"summary":"Novartis confirmed nine tumor reports after Zolgensma, two with vector DNA near the GLI1 oncogene; the FDA reportedly extends the risk to Itvisma. Infant use stays; the older-patient market gets repriced.","image":"https://drugnews.com.tw/assets/articles/novartis-zolgensma-tumor-gli1-itvisma-older-patients-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"諾華天價基因藥爆腫瘤，傷最重的是大童市場","date":"2026-11-11","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-11-11-novartis-zolgensma-tumor-gli1-itvisma-older-patients.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-11-novartis-zolgensma-tumor-gli1-itvisma-older-patients.html","source":"Drugnews","access":"商業分析文","category":"製藥巨頭","tags":["諾華","Zolgensma","基因療法","SMA","Itvisma"],"summary":"諾華證實 Zolgensma 上市以來收到九例腫瘤通報，兩例找到載體嵌入致癌基因 GLI1，FDA 被報導已展開調查並延伸到 Itvisma。嬰兒版會留下並加追蹤；被重算的是諾華靠 Itvisma 打開的大童與成人市場。","image":"https://drugnews.com.tw/assets/articles/novartis-zolgensma-tumor-gli1-itvisma-older-patients/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Asia's Protein Degraders After First PROTAC","date":"2026-11-10","language":"en","url":"https://drugnews.com.tw/articles/2026-11-10-asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-10-asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn-en.html","source":"網站","access":"Business Analysis","category":"商業分析","tags":["protein degrader","PROTAC","Veppanu","tacabrutideg","setidegrasib","AnHorn AH-001","Kintor GT20029","Asia biotech"],"summary":"BeOne said on November 5 that its BTK degrader tacabrutideg met a pivotal Phase 2 goal, with a filing planned for mid-2027, while Veppanu, the first approved PROTAC, earned Arvinas only $0.5 million in Q3 2026 royalties. Astellas has a KRAS G12D degrader in Phase 3, and Taiwan's AnHorn is pursuing a topical AR degrader for hair loss.","image":"https://drugnews.com.tw/assets/articles/asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"降解藥全景：首個PROTAC乳癌藥上市，亞洲接棒","date":"2026-11-10","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-11-10-asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-10-asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["蛋白降解","PROTAC","Veppanu","BeOne tacabrutideg","Astellas setidegrasib","安宏 AH-001","開拓藥業 GT20029"],"summary":"BeOne 11 月 5 日宣布 BTK 降解藥 tacabrutideg 樞紐二期達標、2027 年年中送件；全球第一個上市的 PROTAC Veppanu 第三季卻只帶給 Arvinas 50 萬美元權利金。Astellas 的 KRAS G12D 降解藥已進三期，台灣安宏走外用雄性禿路線，最近的對手是開拓藥業。","image":"https://drugnews.com.tw/assets/articles/asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Novo Pill Leads Lilly 4x, Lilly Takes 1/3 of Starts","date":"2026-11-10","language":"en","url":"https://drugnews.com.tw/articles/2026-11-10-novo-wegovy-pill-lilly-foundayo-oral-obesity-race-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-10-novo-wegovy-pill-lilly-foundayo-oral-obesity-race-en.html","source":"Drugnews","access":"Free","category":"商業分析","tags":["Obesity drugs","Wegovy pill","Foundayo","Novo Nordisk","Eli Lilly"],"summary":"Novo Nordisk's Wegovy pill posted Q3 2026 sales of DKK 5.39 billion (about $813 million), 4.4 times Lilly's Foundayo at $184 million. Split by region and prescriptions, Novo's international sales alone equal Foundayo, the U.S. gap is 3.4x, and Lilly holds about 23% of prescriptions while winning 32% to 40% of new patients. The gap mostly reflects the three months the Wegovy pill had the market alone after its January launch.","image":"https://drugnews.com.tw/assets/articles/novo-wegovy-pill-lilly-foundayo-oral-obesity-race-en/cover.png","is_accessible_for_free":false,"is_external":false,"alternate_language_versions":{}},{"title":"減重藥丸諾和贏4倍，禮來新病人拿下三到四成","date":"2026-11-10","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-11-10-novo-wegovy-pill-lilly-foundayo-oral-obesity-race.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-10-novo-wegovy-pill-lilly-foundayo-oral-obesity-race.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["減重藥","Wegovy","Foundayo","諾和諾德","禮來"],"summary":"諾和諾德 2026 年第三季 Wegovy 減重藥丸營收 53.9 億丹麥克朗（約 8.13 億美元），是禮來 Foundayo 同季 1.84 億美元的 4.4 倍。拆開後，諾和國際營收約等於 Foundayo 全部，美國對美國是 3.4 倍，換算處方禮來約占 23%；禮來新病人占比 32% 到 40%，落差主要來自 Wegovy 藥丸 1 月上市、Foundayo 4 月才核准的三個月獨占期。","image":"https://drugnews.com.tw/assets/articles/novo-wegovy-pill-lilly-foundayo-oral-obesity-race/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Boehringer Paid China $358M, Taiwan Got $10M","date":"2026-11-09","language":"en","url":"https://drugnews.com.tw/articles/2026-11-09-boehringer-sino-biopharm-china-licensing-taiwan-gap-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-09-boehringer-sino-biopharm-china-licensing-taiwan-gap-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["licensing deals","Boehringer Ingelheim","Sino Biopharm","ADC","Taiwan biotech"],"summary":"Boehringer Ingelheim paid SBP Group $358M upfront for six preclinical ADC and T-cell engager programs (up to ~$7.36B). Taiwan's nine 2026 out-licensing deals disclosed one upfront, $10M. The gap has two layers: what Taiwan sells, and how much human data it has.","image":"https://drugnews.com.tw/assets/articles/boehringer-sino-biopharm-china-licensing-taiwan-gap-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"百靈佳73.6億美元押中國新藥，台灣先輸在賣什麼","date":"2026-11-09","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-11-09-boehringer-sino-biopharm-china-licensing-taiwan-gap.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-09-boehringer-sino-biopharm-china-licensing-taiwan-gap.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["授權交易","百靈佳殷格翰","中國生物製藥","ADC","台灣生技"],"summary":"百靈佳殷格翰 11 月 4 日向中國生物製藥買下 6 個臨床前 ADC 與 T 細胞接合器，帳面最高約 73.6 億美元、首付 3.58 億美元；台灣 2026 年 9 筆對外授權公開總額約 8.3 億美元，唯一公開首付 1,000 萬美元。差距有兩層：台灣賣的多是改良型新藥、生物相似藥與單一國家權利；就算是新一代平台，韓國首付仍只有中國同類案的約九分之一，買方付錢買的是臨床數據規模。","image":"https://drugnews.com.tw/assets/articles/boehringer-sino-biopharm-china-licensing-taiwan-gap/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"TaiMed Bets on HIV Treatment as PrEP Hits $40","date":"2026-11-08","language":"en","url":"https://drugnews.com.tw/articles/2026-11-08-taimed-long-acting-hiv-lenacapavir-generic-40-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-08-taimed-long-acting-hiv-lenacapavir-generic-40-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["TaiMed","HIV","lenacapavir","long-acting","Gilead"],"summary":"FDA tentatively approved Dr. Reddy's generic lenacapavir at about $40 a year versus Gilead's $28,218 US price. Prevention pricing is settled; the next prize is long-acting maintenance treatment, where TaiMed's TMB-365/380 Phase 2b reads out by year-end.","image":"https://drugnews.com.tw/assets/articles/taimed-long-acting-hiv-lenacapavir-generic-40-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"愛滋預防針跌到40美元，中裕抗體搶治療端","date":"2026-11-08","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-11-08-taimed-long-acting-hiv-lenacapavir-generic-40.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-08-taimed-long-acting-hiv-lenacapavir-generic-40.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["中裕","愛滋","lenacapavir","長效療法","Gilead"],"summary":"FDA 11 月 2 日暫時核准印度 Dr. Reddy's 的 lenacapavir 學名藥，一年約 40 美元；吉立亞美國牌價 28,218 美元。預防端的價格分級已定，下一個大錢在穩定病人的長效維持療法，中裕 TMB-365/380 年底公布 2b 期中結果。","image":"https://drugnews.com.tw/assets/articles/taimed-long-acting-hiv-lenacapavir-generic-40/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Rasonque Sold $198M in Five Weeks, 7x Above Forecast","date":"2026-11-07","language":"en","url":"https://drugnews.com.tw/articles/2026-11-07-rasonque-pancreatic-cancer-launch-q3-pharmaengine-prmt5-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-07-rasonque-pancreatic-cancer-launch-q3-pharmaengine-prmt5-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["pancreatic cancer","Rasonque","RAS inhibitors","PharmaEngine","PRMT5"],"summary":"Rasonque booked $197.6M in about five weeks and reached 5,000+ U.S. patients. Second-line chemo goes first; next comes first line and RAS-plus-PRMT5 combos, a mixed picture for Taiwan's PharmaEngine.","image":"https://drugnews.com.tw/assets/articles/rasonque-pancreatic-cancer-launch-q3-pharmaengine-prmt5-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"胰臟癌新藥打贏化療5週賣65億，智擎一好一壞","date":"2026-11-07","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-11-07-rasonque-pancreatic-cancer-launch-q3-pharmaengine-prmt5.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-07-rasonque-pancreatic-cancer-launch-q3-pharmaengine-prmt5.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["胰臟癌","Rasonque","RAS 標靶","智擎","PRMT5"],"summary":"Revolution Medicines 的胰臟癌口服新藥 Rasonque 上市約五週，美國淨營收 1.976 億美元、超過 5,000 名病人用藥，是分析師預估的七倍。二線化療最先讓位，下一戰在一線與 RAS 加 PRMT5 聯用；對台灣智擎是一好一壞。","image":"https://drugnews.com.tw/assets/articles/rasonque-pancreatic-cancer-launch-q3-pharmaengine-prmt5/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"The Semiconductor Moment in AI Drug Discovery","date":"2026-11-06","language":"en","url":"https://drugnews.com.tw/articles/2026-11-06-anhorn-ai-drug-discovery-semiconductor-moment-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-06-anhorn-ai-drug-discovery-semiconductor-moment-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["AI"],"summary":"How AI platforms and the discovery flywheel could open new partnership opportunities for AnHorn","image":"https://drugnews.com.tw/assets/articles/anhorn-ai-drug-discovery-semiconductor-moment-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"AI製藥的半導體時刻","date":"2026-11-06","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-11-06-anhorn-ai-drug-discovery-semiconductor-moment.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-06-anhorn-ai-drug-discovery-semiconductor-moment.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["AI"],"summary":"從巨頭入局與正向飛輪到成藥交易　安宏資產與合作的切入點","image":"https://drugnews.com.tw/assets/articles/anhorn-ai-drug-discovery-semiconductor-moment/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"TAHO Doubles in Two Weeks, but a Court Holds Its US Clock","date":"2026-11-05","language":"en","url":"https://drugnews.com.tw/articles/2026-11-05-taho-beqia-eliquis-patent-suit-30-month-clock-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-05-taho-beqia-eliquis-patent-suit-30-month-clock-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["泰合","BEQIA","Eliquis","505(b)(2)","專利訴訟"],"summary":"TAHO (6467) closed at NT$246 on Nov 3, 2026, up 133% from its NT$105.6 IPO price on Japanese royalty news. A BMS-Pfizer patent suit in Delaware can stay final FDA approval of BEQIA for up to 30 months, Medicare's negotiated Eliquis price already fell 56% in 2026, and settled generics enter from April 1, 2028: BEQIA's US value depends on when, and at what price, it can launch.","image":"https://drugnews.com.tw/assets/articles/taho-beqia-eliquis-patent-suit-30-month-clock-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"泰合上市兩週翻倍，美國時鐘卻握在法院手上","date":"2026-11-05","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-11-05-taho-beqia-eliquis-patent-suit-30-month-clock.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-05-taho-beqia-eliquis-patent-suit-30-month-clock.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["泰合","BEQIA","Eliquis","505(b)(2)","專利訴訟"],"summary":"泰合（6467）2026年11月3日收246元，較承銷價105.6元漲133%，推升股價的是日本兒童新適應症申請。BMS與輝瑞在德拉瓦州對BEQIA提告，可能觸發最長30個月的FDA核准暫停；Eliquis的Medicare議價2026年已降56%，2028年4月起學名藥進場，BEQIA的美國價值取決於何時、以什麼價格進場。","image":"https://drugnews.com.tw/assets/articles/taho-beqia-eliquis-patent-suit-30-month-clock/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"RFK Jr. Clears Peptides, Hims Reruns GLP-1 Play","date":"2026-11-04","language":"en","url":"https://drugnews.com.tw/articles/2026-11-04-hhs-peptide-compounding-bpc157-hims-glp1-playbook-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-04-hhs-peptide-compounding-bpc157-hims-glp1-playbook-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["peptides","BPC-157","Hims & Hers","compounding","GLP-1"],"summary":"HHS will not enforce against pharmacies compounding BPC-157 and five other unapproved peptides. Hims & Hers opened a waitlist the next day, rerunning its compounded-GLP-1 model. In Taiwan, unlicensed imports remain prohibited drugs.","image":"https://drugnews.com.tw/assets/articles/hhs-peptide-compounding-bpc157-hims-glp1-playbook-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"美國放行6種胜肽針，瘦瘦針劇本重演","date":"2026-11-04","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-11-04-hhs-peptide-compounding-bpc157-hims-glp1-playbook.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-04-hhs-peptide-compounding-bpc157-hims-glp1-playbook.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["胜肽","BPC-157","Hims & Hers","調劑藥局","瘦瘦針"],"summary":"美國衛生部 10 月 28 日簽署臨時政策，暫不取締調劑藥局配製 BPC-157 等六種沒有藥證的胜肽。隔天 Hims & Hers 就開了胜肽專區候補名單，走的是複方瘦瘦針同一條通路；在台灣，未經核准輸入的藥品仍屬禁藥。","image":"https://drugnews.com.tw/assets/articles/hhs-peptide-compounding-bpc157-hims-glp1-playbook/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"HLB and Hengrui's liver cancer combo gets a fourth FDA review, with a decision due April 9, 2027","summary":"The FDA has accepted the resubmitted applications for rivoceranib plus camrelizumab in first-line liver cancer. The clinical case was never the problem; the real test is whether a China-made PD-1 can clear US manufacturing inspections.","url":"https://drugnews.com.tw/en/articles/2026-11-04-hlb-hengrui-cam-rivo-fda-fourth-review.html","language":"en","datePublished":"2026-11-04","date":"2026-11-04","type":"NewsArticle","canonical_url":"https://drugnews.com.tw/en/articles/2026-11-04-hlb-hengrui-cam-rivo-fda-fourth-review.html","source":"Website","access":"Free","is_accessible_for_free":true,"is_external":false},{"title":"LG Chem and Samsung Bioepis show Korea's new deal playbook: take the cash earlier","summary":"On the same day, LG Chem sold down its future royalty on Rhythm's MC4R franchise for $350 million in fixed payments, and Samsung Bioepis signed up Teva to sell two US biosimilars for up to $420 million. Both deals swap long-dated upside for near-term certainty.","url":"https://drugnews.com.tw/en/articles/2026-11-04-korea-lg-chem-rhythm-samsung-bioepis-teva-deals.html","language":"en","datePublished":"2026-11-04","date":"2026-11-04","type":"NewsArticle","canonical_url":"https://drugnews.com.tw/en/articles/2026-11-04-korea-lg-chem-rhythm-samsung-bioepis-teva-deals.html","source":"Website","access":"Free","is_accessible_for_free":true,"is_external":false},{"title":"Entresto Sinks 38%; Novartis Bets on Leqvio","date":"2026-11-03","language":"en","url":"https://drugnews.com.tw/articles/2026-11-03-novartis-entresto-generic-leqvio-orion4-heart-bet-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-03-novartis-entresto-generic-leqvio-orion4-heart-bet-en.html","source":"Drugnews","access":"Business Analysis","category":"製藥巨頭","tags":["Novartis","Entresto","Leqvio","inclisiran","Lp(a)"],"summary":"Generics cut Entresto's Q3 sales 38%. Both Novartis succession bets failed in one September week. Leqvio's ORION-4 trial will succeed this winter because PCSK9 is a proven target, but it cannot fill Entresto's hole.","image":"https://drugnews.com.tw/assets/articles/novartis-entresto-generic-leqvio-orion4-heart-bet-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"諾華Entresto跌38%，心臟接班看Leqvio","date":"2026-11-03","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-11-03-novartis-entresto-generic-leqvio-orion4-heart-bet.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-03-novartis-entresto-generic-leqvio-orion4-heart-bet.html","source":"Drugnews","access":"商業分析文","category":"製藥巨頭","tags":["諾華 Novartis","Entresto 健安心","Leqvio 樂脂益","降膽固醇","Lp(a)"],"summary":"賣了十年的心衰竭藥王 Entresto，學名藥一來單季少賺 38%。諾華押的兩張接班牌九月一週內倒下，剩一年兩針的降膽固醇藥 Leqvio。年底揭曉的 ORION-4 會成功，因為它打的是已被證明過的靶點。","image":"https://drugnews.com.tw/assets/articles/novartis-entresto-generic-leqvio-orion4-heart-bet/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"AbbVie's $757M Brise deal: China now sells migraine drugs before they reach the clinic","summary":"Beijing-based Brise Pharmaceuticals disclosed a global license with AbbVie covering two preclinical migraine programs, worth up to $757 million plus royalties. The headline is milestones, not cash, but the buyer and the stage say more about where China's licensing market is heading than the number does.","url":"https://drugnews.com.tw/en/articles/2026-11-03-abbvie-brise-preclinical-migraine-license.html","language":"en","datePublished":"2026-11-03","date":"2026-11-03","type":"NewsArticle","canonical_url":"https://drugnews.com.tw/en/articles/2026-11-03-abbvie-brise-preclinical-migraine-license.html","source":"Website","access":"Free","is_accessible_for_free":true,"is_external":false},{"title":"Lilly Cut Obesity Drug Prices 15% and Grew 39%","date":"2026-11-02","language":"en","url":"https://drugnews.com.tw/articles/2026-11-02-lilly-q3-2026-glp1-price-cut-volume-novo-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-02-lilly-q3-2026-glp1-price-cut-volume-novo-en.html","source":"Drugnews","access":"Business Analysis","category":"製藥巨頭","tags":["Eli Lilly","Novo Nordisk","obesity drugs","Mounjaro","earnings"],"summary":"Lilly's Q3 2026 realised prices fell 15% while volume rose 53%, lifting revenue 39% to $24.40bn and guidance to $91–92bn. Novo Nordisk, facing the same cuts, guides 2026 sales flat to down 6%.","image":"https://drugnews.com.tw/assets/articles/lilly-q3-2026-glp1-price-cut-volume-novo-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"減重針降價，禮來營收增39%甩開諾和","date":"2026-11-02","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-11-02-lilly-q3-2026-glp1-price-cut-volume-novo.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-02-lilly-q3-2026-glp1-price-cut-volume-novo.html","source":"Drugnews","access":"商業分析文","category":"製藥巨頭","tags":["禮來","諾和諾德","減重藥","Mounjaro","財報"],"summary":"禮來第三季實收價格跌15%、量增53%，營收243.97億美元年增39%，全年指引上修到910–920億美元；諾和諾德同樣降價卻預估全年銷售持平到衰退6%。降價打開新病人，產能決定誰接得住。","image":"https://drugnews.com.tw/assets/articles/lilly-q3-2026-glp1-price-cut-volume-novo/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Fresenius bets its biosimilar pipeline on WuXi Biologics: up to 37 molecules","summary":"Fresenius signed an exclusive option deal for up to 37 biosimilar candidates developed by WuXi Biologics, pay-as-you-go and with all commercial rights staying in Germany. It is the clearest sign yet that Western buyers still want Chinese biologics capacity, as long as the contract keeps the exit door open.","url":"https://drugnews.com.tw/en/articles/2026-11-02-fresenius-wuxi-biologics-biosimilars-deal.html","language":"en","datePublished":"2026-11-02","date":"2026-11-02","type":"NewsArticle","canonical_url":"https://drugnews.com.tw/en/articles/2026-11-02-fresenius-wuxi-biologics-biosimilars-deal.html","source":"Website","access":"Free","is_accessible_for_free":true,"is_external":false},{"title":"HDAC 抑制劑全景","url":"https://drugnews.com.tw/landscapes/hdac-inhibitors.html","language":"zh-Hant","datePublished":"2026-11-01","date":"2026-11-01","type":"Dataset","canonical_url":"https://drugnews.com.tw/landscapes/hdac-inhibitors.html","source":"Website","access":"Free","is_accessible_for_free":true,"is_external":false},{"title":"HDAC inhibitors","url":"https://drugnews.com.tw/en/landscapes/hdac-inhibitors.html","language":"en","datePublished":"2026-11-01","date":"2026-11-01","type":"Dataset","canonical_url":"https://drugnews.com.tw/en/landscapes/hdac-inhibitors.html","source":"Website","access":"Free","is_accessible_for_free":true,"is_external":false},{"title":"Asia ADC Leaders 2026: Who Is Winning the Antibody-Drug Conjugate Race","url":"https://drugnews.com.tw/en/asia-adc-leaders.html","language":"en","datePublished":"2026-11-01","date":"2026-11-01","type":"Article","canonical_url":"https://drugnews.com.tw/en/asia-adc-leaders.html","source":"Website","access":"Free","is_accessible_for_free":true,"is_external":false},{"title":"Anthropic上市想做藥，最後還是賣給藥廠","date":"2026-11-01","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-11-01-anthropic-ipo-ai-drug-lab.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-01-anthropic-ipo-ai-drug-lab.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["Anthropic","AI製藥","IPO","諾和諾德","CDMO"],"summary":"Anthropic 10/26 公開 S-1，上半年營收 162.86 億美元，並把濕實驗室、Coefficient Bio 與自有藥物計畫寫進成長故事。它暫不做人體試驗，前十大藥廠九家是客戶；最可能的出路是把候選分子授權給藥廠，而不是自己做到上市。","image":"https://drugnews.com.tw/assets/articles/anthropic-ipo-ai-drug-lab/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Anthropic's Drug Lab Will Sell to Pharma","date":"2026-11-01","language":"en","url":"https://drugnews.com.tw/articles/2026-11-01-anthropic-ipo-ai-drug-lab-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-11-01-anthropic-ipo-ai-drug-lab-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["Anthropic","AI drug discovery","IPO","Novo Nordisk","CDMO"],"summary":"Anthropic's S-1 shows $16.29bn in H1 2026 revenue and puts a wet lab, Coefficient Bio and in-house drug programs into its growth story. It is not running human trials, and nine of the top ten drugmakers are customers. Its likeliest path: license candidates to pharma.","image":"https://drugnews.com.tw/assets/articles/anthropic-ipo-ai-drug-lab-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"IVF With 80% Fewer Shots: Ferring Buys Gameto","date":"2026-10-31","language":"en","url":"https://drugnews.com.tw/articles/2026-10-31-ferring-gameto-fertilo-ivf-fewer-hormone-injections-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-31-ferring-gameto-fertilo-ivf-fewer-hormone-injections-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["IVF","fertility shots","Fertilo","Ferring","Gameto"],"summary":"IVF means 10-14 days of hormone shots. Ferring, which sells them, will pay up to $1.3825B for Gameto's 2-3 day Fertilo. Its US Phase 3 only races old-style IVM; no FDA approval before April 30, 2028.","image":"https://drugnews.com.tw/assets/articles/ferring-gameto-fertilo-ivf-fewer-hormone-injections-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"試管嬰兒少打8成針，賣排卵針的Ferring先買下","date":"2026-10-31","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-31-ferring-gameto-fertilo-ivf-fewer-hormone-injections.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-31-ferring-gameto-fertilo-ivf-fewer-hormone-injections.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["試管嬰兒","排卵針","Fertilo","輝凌 Ferring","凍卵"],"summary":"做試管嬰兒要每天打排卵針 10 到 14 天。賣排卵針的 Ferring 卻花最高 13.825 億美元，買下只要打 2 到 3 天的 Fertilo。但它的美國三期只跟舊式 IVM 比，2028 年 4 月前上不了市。","image":"https://drugnews.com.tw/assets/articles/ferring-gameto-fertilo-ivf-fewer-hormone-injections/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Taiwan ADCs: Who May Reach Pivotal First?","date":"2026-10-30","language":"en","url":"https://drugnews.com.tw/articles/2026-10-30-taiwan-adc-companies-landscape-obi-tsy110-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-30-taiwan-adc-companies-landscape-obi-tsy110-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["Taiwan ADC companies","antibody-drug conjugate","OBI Pharma OBI-992","Formosa Pharmaceuticals TSY-110","GlycoNex GNX1021"],"summary":"BioNTech just called its HER2 ADC's benefit limited while Roche paid $400M upfront for Hansoh's ADC platform. Where do Taiwan's 7 ADC companies stand? OBI leads on novel drugs; a Kadcyla biosimilar may reach pivotal trials first.","image":"https://drugnews.com.tw/assets/articles/taiwan-adc-companies-landscape-obi-tsy110-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"台灣ADC全景：浩鼎跑最遠，相似藥最快進樞紐","date":"2026-10-30","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-30-taiwan-adc-companies-landscape-obi-tsy110.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-30-taiwan-adc-companies-landscape-obi-tsy110.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["台灣 ADC 公司","抗體藥物複合體","浩鼎 OBI-992","台新藥 TSY-110","醣聯 GNX1021"],"summary":"BioNTech 剛承認自家 HER2 ADC 效益有限，Roche 卻付 4 億美元包下翰森的 ADC 平台。台灣 7 家 ADC 公司走到哪？新藥跑最遠的是浩鼎，最快進入樞紐試驗的可能是台新藥與台康的 Kadcyla 相似藥。","image":"https://drugnews.com.tw/assets/articles/taiwan-adc-companies-landscape-obi-tsy110/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Roche's $400M Hansoh ADC Partnership","date":"2026-10-29","language":"en","url":"https://drugnews.com.tw/articles/2026-10-29-hansoh-roche-adc-platform-deal-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-29-hansoh-roche-adc-platform-deal-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["Hansoh","Roche","ADC","Licensing","Drug development"],"summary":"Roche’s $400M Hansoh deal shifts the ADC bargain from one molecule to a pipeline-building platform. The next test is a first participant dosed by the end of 2027.","image":"https://drugnews.com.tw/assets/articles/hansoh-roche-adc-platform-deal-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"羅氏花4億美元，包下翰森的ADC工廠","date":"2026-10-29","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-29-hansoh-roche-adc-platform-deal.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-29-hansoh-roche-adc-platform-deal.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["翰森製藥","羅氏 Roche","ADC","中國授權","全球醫藥交易"],"summary":"翰森 10/19 與羅氏簽 ADC 合作：首付 4 億美元、頭條逾 155 億美元。羅氏指定靶點、翰森用平台做到 Ia 期，首付比一年前買單顆藥高五倍——羅氏買的是研發產能。","image":"https://drugnews.com.tw/assets/articles/hansoh-roche-adc-platform-deal/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Vascepa大腸癌試驗：主要終點未達標","date":"2026-10-29","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-29-vascepa-fish-oil-colorectal-cancer-liver-metastasis-emt2.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-29-vascepa-fish-oil-colorectal-cancer-liver-metastasis-emt2.html","source":"Drugnews","access":"商業分析文","category":"醫學大會","tags":["魚油","大腸癌","Vascepa","Amarin","ESMO 2026"],"summary":"大家以為魚油不防癌。ESMO 上，一顆處方魚油讓大腸癌肝轉移病人五年存活從 45.1% 拉到 62.0%。但主要終點無惡化存活沒有達到統計顯著、安慰劑又是七年前被罵過的礦物油，這份數據換不到藥證。","image":"https://drugnews.com.tw/assets/articles/vascepa-fish-oil-colorectal-cancer-liver-metastasis-emt2/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Vascepa: PFS Miss, Survival Signal","date":"2026-10-29","language":"en","url":"https://drugnews.com.tw/articles/2026-10-29-vascepa-fish-oil-colorectal-cancer-liver-metastasis-emt2-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-29-vascepa-fish-oil-colorectal-cancer-liver-metastasis-emt2-en.html","source":"Drugnews","access":"Business Analysis","category":"醫學大會","tags":["fish oil","colorectal cancer","Vascepa","Amarin","ESMO 2026"],"summary":"VITAL said fish oil does not prevent cancer. At ESMO 2026, Amarin's Vascepa lifted 5-year survival after colorectal liver surgery to 62.0% from 45.1%, yet primary PFS was not statistically significant, and the placebo was mineral oil again.","image":"https://drugnews.com.tw/assets/articles/vascepa-fish-oil-colorectal-cancer-liver-metastasis-emt2-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"CLDN18.2 ADCs: Survival and FDA Review","date":"2026-10-28","language":"en","url":"https://drugnews.com.tw/articles/2026-10-28-gastric-cancer-cldn18-2-adc-takeda-astrazeneca-race-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-28-gastric-cancer-cldn18-2-adc-takeda-astrazeneca-race-en.html","source":"Drugnews","access":"Business Analysis","category":"醫學大會","tags":["gastric cancer","CLDN18.2","ADC","Takeda","AstraZeneca"],"summary":"Takeda's CLDN18.2 ADC added 3.3 months of median survival in late-line gastric cancer at ESMO 2026. AstraZeneca also reported survival data on October 25. Takeda's trial ran only in China and Japan; which drug reaches the US first depends on FDA review.","image":"https://drugnews.com.tw/assets/articles/gastric-cancer-cldn18-2-adc-takeda-astrazeneca-race-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"胃癌CLDN18.2 ADC對決：兩藥都延長存活","date":"2026-10-28","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-28-gastric-cancer-cldn18-2-adc-takeda-astrazeneca-race.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-28-gastric-cancer-cldn18-2-adc-takeda-astrazeneca-race.html","source":"Drugnews","access":"商業分析文","category":"醫學大會","tags":["胃癌","CLDN18.2","ADC","武田 Takeda","AstraZeneca"],"summary":"末線胃癌多活 3.3 個月，武田的 CLDN18.2 ADC 在 ESMO 交出漂亮成績單。AstraZeneca 兩天後也公布存活數據。武田的試驗只在中國和日本做，美國第一支同類藥由誰拿下，要看 FDA 怎麼看這份數據。","image":"https://drugnews.com.tw/assets/articles/gastric-cancer-cldn18-2-adc-takeda-astrazeneca-race/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"IgA腎病新藥擋洗腎，月打一針有機會勝出","date":"2026-10-27","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-27-iga-nephropathy-april-drugs-voyxact-trutakna-povetacicept.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-27-iga-nephropathy-april-drugs-voyxact-trutakna-povetacicept.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["IgA腎病","洗腎","Voyxact","Trutakna","povetacicept"],"summary":"台灣 9 萬人洗腎，IgA 腎病是常見的一條路。10/22 兩年數據開獎：安慰劑組腎功能每年掉 4 到 6 分，新藥組幾乎不掉。四支藥搶同一個病，四週打一針的大塚與 Vertex 會贏過每週一針、最貴的 Vera。","image":"https://drugnews.com.tw/assets/articles/iga-nephropathy-april-drugs-voyxact-trutakna-povetacicept/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"IgA nephropathy drugs: monthly shots will win","date":"2026-10-27","language":"en","url":"https://drugnews.com.tw/articles/2026-10-27-iga-nephropathy-april-drugs-voyxact-trutakna-povetacicept-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-27-iga-nephropathy-april-drugs-voyxact-trutakna-povetacicept-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["IgA nephropathy","dialysis","Voyxact","Trutakna","povetacicept"],"summary":"Two-year data are in: on placebo, IgA nephropathy patients lost 4-6 eGFR points a year; on new APRIL-pathway drugs, almost none. Monthly Voyxact and povetacicept will beat weekly, pricier Trutakna.","image":"https://drugnews.com.tw/assets/articles/iga-nephropathy-april-drugs-voyxact-trutakna-povetacicept-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"本週交易：吉利德一次付清13億買口服IL-23","date":"2026-10-26","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-26-weekly-deals-gilead-pepstar-hansoh-roche.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-26-weekly-deals-gilead-pepstar-hansoh-roche.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["全球醫藥交易週報","吉利德 Gilead","翰森製藥","禮來 Eli Lilly","IL-23"],"summary":"這是吉利德（Gilead）10 月 23 日為一顆中國口服新藥開出的價碼。同一週，中國翰森製藥和羅氏簽下頭條超過 155 億美元的 ADC 合作，首付是 4 億美元。","image":"https://drugnews.com.tw/assets/articles/weekly-deals-gilead-pepstar-hansoh-roche/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Ozempic Face: Galderma's Opportunity","date":"2026-10-26","language":"en","url":"https://drugnews.com.tw/articles/2026-10-26-ozempic-face-glp1-facial-volume-galderma-sculptra-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-26-ozempic-face-glp1-facial-volume-galderma-sculptra-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["Ozempic face","GLP-1 facial volume loss","Sculptra","Galderma","Caliway CBL-514"],"summary":"GLP-1 users are losing facial fat, not collagen, so creams can't fix 'Ozempic face.' In Q2 2026, Galderma's fillers and biostimulators grew 7.6% while AbbVie's Juvéderm fell 6.6%.","image":"https://drugnews.com.tw/assets/articles/ozempic-face-glp1-facial-volume-galderma-sculptra-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"瘦瘦針臉垮，乳霜補不回，Galderma先贏","date":"2026-10-26","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-26-ozempic-face-glp1-facial-volume-galderma-sculptra.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-26-ozempic-face-glp1-facial-volume-galderma-sculptra.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["Ozempic臉","瘦瘦針 臉凹","GLP-1 臉部凹陷","舒顏萃 Sculptra","康霈 CBL-514"],"summary":"打瘦瘦針瘦了，臉也凹了。L'Oréal 忙著找 GLP-1 用戶測乳霜，但少掉的是皮下脂肪，乳霜擦不到。錢正流向針劑：第二季 Galderma 填充與刺激劑 +7.6%，AbbVie 喬雅登卻衰退 6.6%。","image":"https://drugnews.com.tw/assets/articles/ozempic-face-glp1-facial-volume-galderma-sculptra/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Hepatitis B Pills Need Not Be for Life: FDA Clears GSK's Hibsago","date":"2026-10-25","language":"en","url":"https://drugnews.com.tw/articles/2026-10-25-gsk-hibsago-hepatitis-b-functional-cure-fda-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-25-gsk-hibsago-hepatitis-b-functional-cure-fda-en.html","source":"Drugnews","access":"Business Analysis","category":"製藥巨頭","tags":["hepatitis B","functional cure","Hibsago bepirovirsen","GSK","Taiwan"],"summary":"1.89 million Taiwanese carry hepatitis B, most on a pill a day for years. On Oct 20 the FDA approved GSK's Hibsago: after six months of shots, 19% stopped all drugs and stayed in control. Every rival is in phase 2.","image":"https://drugnews.com.tw/assets/articles/gsk-hibsago-hepatitis-b-functional-cure-fda-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"B肝藥不用吃一輩子？FDA准Hibsago，獨家一年半","date":"2026-10-25","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-25-gsk-hibsago-hepatitis-b-functional-cure-fda.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-25-gsk-hibsago-hepatitis-b-functional-cure-fda.html","source":"Drugnews","access":"商業分析文","category":"製藥巨頭","tags":["B肝","B型肝炎 功能性治癒","Hibsago bepirovirsen","GSK","B肝停藥"],"summary":"台灣 189 萬 B 肝帶原者，吃上口服藥常是好幾年。FDA 10/20 核准 GSK 的 Hibsago：打半年針，19% 病人連口服藥都停掉、病毒沒回來。對手全卡在二期，GSK 至少獨家到 2028 年。","image":"https://drugnews.com.tw/assets/articles/gsk-hibsago-hepatitis-b-functional-cure-fda/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Moderna癌症疫苗贏了三期，BioNTech卻輸","date":"2026-10-25","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-25-moderna-merck-intismeran-biontech-opposite.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-25-moderna-merck-intismeran-biontech-opposite.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["Moderna","Merck 默沙東","BioNTech","癌症疫苗","黑色素瘤"],"summary":"Moderna 與 Merck 的個人化 mRNA 癌症疫苗三期把黑色素瘤復發或死亡風險降 42%（HR 0.58），股價卻跌 25%；BioNTech 同類疫苗 8 月在大腸癌二期終止。差在癌別、併用 Keytruda 與時間。附我們 10/19 預估的對帳。","image":"https://drugnews.com.tw/assets/articles/moderna-merck-intismeran-biontech-opposite/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Merck KGaA's $1.3B Iron Bet Ends Bloodletting, Not Besremi","date":"2026-10-24","language":"en","url":"https://drugnews.com.tw/articles/2026-10-24-merck-kgaa-silence-divesiran-polycythemia-vera-besremi-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-24-merck-kgaa-silence-divesiran-polycythemia-vera-besremi-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["polycythemia vera","phlebotomy","Merck KGaA","divesiran","PharmaEssentia Besremi"],"summary":"PV patients still get blood drawn every few weeks. On Oct 19 Merck KGaA bid $1.3B for divesiran: 88% phlebotomy-free in Phase 2, one shot every 3 months. It replaces the blood draw, not PharmaEssentia's Besremi.","image":"https://drugnews.com.tw/assets/articles/merck-kgaa-silence-divesiran-polycythemia-vera-besremi-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"德國默克13億押降鐵針，換掉放血不換藥華藥","date":"2026-10-24","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-24-merck-kgaa-silence-divesiran-polycythemia-vera-besremi.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-24-merck-kgaa-silence-divesiran-polycythemia-vera-besremi.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["真性紅血球增多症","放血","德國默克 Merck KGaA","divesiran","藥華藥 BESREMi"],"summary":"真性紅血球增多症病人要定期回醫院放血。德國默克 10/19 砸 13 億美元買下 Silence 的 divesiran：二期 88% 病人不用再放血、三個月打一針。它換掉的是放血，不是藥華藥的 BESREMi。","image":"https://drugnews.com.tw/assets/articles/merck-kgaa-silence-divesiran-polycythemia-vera-besremi/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Taiwan's TLC590 Beats Exparel Head-to-Head in Post-Surgical Pain","date":"2026-10-23","language":"en","url":"https://drugnews.com.tw/articles/2026-10-23-tlc590-exparel-postsurgical-pain-phase3-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-23-tlc590-exparel-postsurgical-pain-phase3-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["post-surgical pain","TLC590","TLC-KY","Exparel","non-opioid painkiller"],"summary":"Viatris just paid $1.65B for Exparel's maker. Eleven days later, Taiwan's TLC590 beat Exparel head-to-head in Phase 3: less pain, fewer opioids, still significant at 168 hours.","image":"https://drugnews.com.tw/assets/articles/tlc590-exparel-postsurgical-pain-phase3-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"台微體止痛新藥贏過Exparel，授權價看漲","date":"2026-10-23","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-23-tlc590-exparel-postsurgical-pain-phase3.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-23-tlc590-exparel-postsurgical-pain-phase3.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["術後止痛","TLC590","TLC-KY 台微體","Exparel","非鴉片止痛藥"],"summary":"開完刀最痛那幾天，美國醫院靠 Exparel。Viatris 才花 16.5 億美元買下它，11 天後台灣 TLC-KY 的 TLC590 在三期正面對打：止痛贏、鴉片也用得少，168 小時仍顯著。","image":"https://drugnews.com.tw/assets/articles/tlc590-exparel-postsurgical-pain-phase3/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Presbyopia drop Ryzumvi wins FDA nod, but nobody wants to sell it","date":"2026-10-22","language":"en","url":"https://drugnews.com.tw/articles/2026-10-22-ryzumvi-presbyopia-eye-drops-viatris-partner-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-22-ryzumvi-presbyopia-eye-drops-viatris-partner-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["presbyopia eye drops","Ryzumvi","Vizz","Viatris","phentolamine"],"summary":"Past 40 and holding your phone at arm's length? The FDA approved Ryzumvi, the fifth US presbyopia drop, and Viatris immediately said it wants a partner to sell it. The best seller, Vizz, made $1.7M last quarter.","image":"https://drugnews.com.tw/assets/articles/ryzumvi-presbyopia-eye-drops-viatris-partner-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"老花眼藥水 Ryzumvi 獲准，沒人搶著賣","date":"2026-10-22","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-22-ryzumvi-presbyopia-eye-drops-viatris-partner.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-22-ryzumvi-presbyopia-eye-drops-viatris-partner.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["老花眼藥水","Ryzumvi","老花眼","Vizz","Viatris"],"summary":"40 歲後看手機要伸直手臂？美國剛核准第五款老花眼藥水 Ryzumvi，Viatris 卻在核准新聞稿裡說要找人代賣。賣得最好的 Vizz，一季也只有 170 萬美元。","image":"https://drugnews.com.tw/assets/articles/ryzumvi-presbyopia-eye-drops-viatris-partner/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"AZ 的 AI 大單只先付 3%，人體數據才值錢","date":"2026-10-21","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-21-astrazeneca-insitro-ai-deal-upfront.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-21-astrazeneca-insitro-ai-deal-upfront.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["AstraZeneca","insitro","AI 新藥","Isomorphic Labs","MASH"],"summary":"10 月 15 日，AstraZeneca 和 insitro 簽下最高 15 億美元的 AI 合約，簽約先付只有 4,000 萬。五筆 AI 大單先付都在 1% 到 3%，武田買一支有二期數據的藥，先付 40 億。標靶是門票，人體數據才是籌碼。","image":"https://drugnews.com.tw/assets/articles/astrazeneca-insitro-ai-deal-upfront/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"AstraZeneca's $1.5B AI Deal Pays 2.7% Up Front","date":"2026-10-21","language":"en","url":"https://drugnews.com.tw/articles/2026-10-21-astrazeneca-insitro-ai-deal-upfront-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-21-astrazeneca-insitro-ai-deal-upfront-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["AstraZeneca","insitro","AI drug discovery","Isomorphic Labs","MASH"],"summary":"On Oct 15, AstraZeneca signed insitro to an AI deal worth up to $1.5B, paying $40M at signing. Five AI deals pay 1-3% up front; Takeda paid $4B for a drug with Phase 2 data. Targets are tickets; human data is leverage.","image":"https://drugnews.com.tw/assets/articles/astrazeneca-insitro-ai-deal-upfront-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Hanmi's Half-Price Obesity Shot Takes On Mounjaro. Wegovy Feels It First","date":"2026-10-20","language":"en","url":"https://drugnews.com.tw/articles/2026-10-20-korea-glp1-price-war-hanmi-eppe-novo-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-20-korea-glp1-price-war-hanmi-eppe-novo-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["Hanmi","Eppe","Mounjaro","Wegovy","obesity drugs"],"summary":"Oct 7, Seoul: Hanmi's homegrown obesity shot Eppe is approved at about half Mounjaro's starter price. Six days later, Novo seeks insurance for Wegovy. Mounjaro keeps its 90%; Wegovy feels it first.","image":"https://drugnews.com.tw/assets/articles/korea-glp1-price-war-hanmi-eppe-novo-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"韓美半價減肥針開戰 Mounjaro，先痛的是 Wegovy","date":"2026-10-20","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-20-korea-glp1-price-war-hanmi-eppe-novo.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-20-korea-glp1-price-war-hanmi-eppe-novo.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["韓美製藥","Eppe","Mounjaro","Wegovy","減重藥"],"summary":"10 月 7 日，韓美製藥的國產減肥針 Eppe 在首爾拿證，第一個月報價約是 Mounjaro 的一半；六天後，諾和諾德替 Wegovy 申請健保。半價針撼不動 Mounjaro 的九成，先痛的是 Wegovy。","image":"https://drugnews.com.tw/assets/articles/korea-glp1-price-war-hanmi-eppe-novo/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"MSD提前押注，寶泰先拿下亞太門票","date":"2026-10-19","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-19-protect-pt401-canine-heart-gene-therapy-msd.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-19-protect-pt401-canine-heart-gene-therapy-msd.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["寶泰生醫","PT401","犬心臟病","基因療法","MSD Animal Health"],"summary":"犬隻黏液性二尖瓣疾病B1期確診後只能追蹤。2026年6月MSD Animal Health投資Rejuvenate Bio，寶泰生醫則早在2024年底拿下犬心臟基因療法PT401的亞太獨家權利。","image":"https://drugnews.com.tw/assets/articles/protect-pt401-canine-heart-gene-therapy-msd/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"MSD Moves Early as Protect Biotech Locks In Asia-Pacific Rights","date":"2026-10-19","language":"en","url":"https://drugnews.com.tw/articles/2026-10-19-protect-pt401-canine-heart-gene-therapy-msd-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-19-protect-pt401-canine-heart-gene-therapy-msd-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["Protect Biotech","PT401","canine MMVD","gene therapy","MSD Animal Health"],"summary":"Dogs diagnosed with Stage B1 mitral valve disease are usually just monitored. In June 2026 MSD Animal Health invested in Rejuvenate Bio, while Protect Biotech had secured Asia-Pacific rights to the canine heart gene therapy PT401 in late 2024.","image":"https://drugnews.com.tw/assets/articles/protect-pt401-canine-heart-gene-therapy-msd-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Heron Neutron Buys Land for NT$1.5 Billion. Its BNCT Bet Rides on a Boron Drug","date":"2026-10-19","language":"en","url":"https://drugnews.com.tw/articles/2026-10-19-heron-neutron-bnct-miaoli-land-boron-drug-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-19-heron-neutron-bnct-miaoli-land-boron-drug-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["Heron Neutron","BNCT","boron neutron capture therapy","Sumitomo","head and neck cancer"],"summary":"Huang Min-chi sold Hermes Microvision to ASML, then bet NT$800m on killing cancer with neutrons. On Oct 15, Heron spent NT$1.555bn on land. Everyone builds machines; a boron drug decides who wins.","image":"https://drugnews.com.tw/assets/articles/heron-neutron-bnct-miaoli-land-boron-drug-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"禾榮科 15 億買地，BNCT 勝負在硼藥","date":"2026-10-19","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-19-heron-neutron-bnct-miaoli-land-boron-drug.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-19-heron-neutron-bnct-miaoli-land-boron-drug.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["禾榮科","BNCT","硼中子捕獲治療","住友重機","頭頸癌"],"summary":"2017 年，剛把漢微科賣給 ASML 的黃民奇拿 8 億元押中子殺癌。10 月 15 日，禾榮科再砸 15.55 億元買地，隔天又牽上 GE Healthcare。機器人人在做，真正決定勝負的是年底那瓶硼藥。","image":"https://drugnews.com.tw/assets/articles/heron-neutron-bnct-miaoli-land-boron-drug/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Soon-Shiong Beats the FDA Clock on Anktiva","date":"2026-10-18","language":"en","url":"https://drugnews.com.tw/articles/2026-10-18-immunitybio-anktiva-papillary-early-approval-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-18-immunitybio-anktiva-papillary-early-approval-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["ImmunityBio","Anktiva","Bladder cancer","FDA","J&J"],"summary":"In May 2025 the FDA would not even file ImmunityBio's application. On October 14, 2026, Anktiva won its papillary bladder cancer label 84 days early, no new trial. After a decade of BCG shortages, the FDA chose speed.","image":"https://drugnews.com.tw/assets/articles/immunitybio-anktiva-papillary-early-approval-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"FDA 提前放行，黃馨祥賭贏膀胱癌","date":"2026-10-18","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-18-immunitybio-anktiva-papillary-early-approval.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-18-immunitybio-anktiva-papillary-early-approval.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["ImmunityBio","Anktiva","膀胱癌","FDA","J&J"],"summary":"2025 年 5 月，FDA 連 ImmunityBio 的文件都不收，要它重做隨機試驗。黃馨祥沒做，2026 年 10 月 14 日卻提前 84 天拿到乳頭狀膀胱癌標籤。BCG 缺貨十多年，FDA 選擇用速度換證據。","image":"https://drugnews.com.tw/assets/articles/immunitybio-anktiva-papillary-early-approval/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"PharmaEssentia Won PV. Its Second War Is Against Merck's $1.35 Billion Pill","date":"2026-10-17","language":"en","url":"https://drugnews.com.tw/articles/2026-10-17-pharmaessentia-china-et-approval-race-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-17-pharmaessentia-china-et-approval-race-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["PharmaEssentia","BESREMi","ropeginterferon alfa-2b","essential thrombocythemia","polycythemia vera","Merck","Incyte","Ko-Chung Lin"],"summary":"PharmaEssentia bet 20 years on one interferon and won PV in the US. In ET it is two years ahead of Merck's $1.35 billion pill, holding three cards to Merck's one.","image":"https://drugnews.com.tw/assets/articles/pharmaessentia-china-et-approval-race-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-10-17-pharmaessentia-china-et-approval-race.html"}},{"title":"藥華藥賭贏 PV，第二戰撞上默沙東的 13.5 億美元！","date":"2026-10-17","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-17-pharmaessentia-china-et-approval-race.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-17-pharmaessentia-china-et-approval-race.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["藥華藥","BESREMi","Ropeg","百斯瑞明","原發性血小板過多症","真性紅血球增多症","默沙東","Incyte","AOP","林國鐘"],"summary":"藥華藥 2003 年創立，押一支長效干擾素押了二十年：2009 年把歐洲授權給 AOP，換來九年仲裁；留下的美國在 2021 年核准 PV 後，四年把年營收從 6.6 億元推到 156 億元。\n2026 年 BESREMi 在 ET 五地獲准，美國核准所有成人 ET，是這家公司的第二幕。\n默沙東花 13.5 億美元買的口服新藥 2027 年才有三期結果；中國只核准第二線，主舞台在美國。","image":"https://drugnews.com.tw/assets/articles/pharmaessentia-china-et-approval-race/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Alnylam’s Next Test: Winning the First Prescription","date":"2026-10-16","language":"en","url":"https://drugnews.com.tw/articles/2026-10-16-attr-rnai-first-prescription-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-16-attr-rnai-first-prescription-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["RNA therapeutics","Alnylam","BridgeBio","ATTR cardiomyopathy","Amvuttra","Attruby"],"summary":"Amvuttra sold $1 billion in a quarter, yet Alnylam cut its full-year TTR revenue forecast as the initial wave of patients switching treatment was largely exhausted. BridgeBio is using medical-record evidence to win new patients from Pfizer’s tafamidis. In the ATTR heart-drug battle, the first prescription decides who wins.","image":"https://drugnews.com.tw/assets/articles/attr-rnai-first-prescription-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"attr-rnai-first-prescription"}},{"title":"Alnylam 的下一關：搶第一張處方","date":"2026-10-16","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-16-attr-rnai-first-prescription.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-16-attr-rnai-first-prescription.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["RNA療法","Alnylam","BridgeBio","ATTR心肌病","Amvuttra","Attruby"],"summary":"Amvuttra 一季賣逾 10 億美元，Alnylam 卻下修全年 TTR 營收預估。\n等著換藥的病人逐漸消化完，對手已在搶新病人。\n下一波成長，要靠搶第一張處方，還是讓醫師加上一針？","image":"https://drugnews.com.tw/assets/articles/attr-rnai-first-prescription/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"AI 新藥開始對帳：錢在臨床之後","date":"2026-10-15","language":"zh-Hant","url":"https://drugnews.com.tw/reports/ai-drug-discovery-business-2026.html","canonical_url":"https://drugnews.com.tw/reports/ai-drug-discovery-business-2026.html","source":"Website","access":"Free","category":"產業研究與報告解析","tags":[],"summary":"AI 藥物開發從平台故事走到收款紀錄。本報告拆解 Isomorphic、英矽智能、Recursion 等交易的首付款與實際入帳，盤點臨床進度、NVIDIA 與禮來的算力布局和 FDA 監管變化，並畫出台灣科技業的切入點。","image":"https://drugnews.com.tw/assets/reports/aidrug-20261015/figures/figure-1-zh.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"降價十年後，生物相似藥的籌碼回到工廠","date":"2026-10-15","language":"zh-Hant","url":"https://drugnews.com.tw/reports/biosimilar-cdmo-manufacturing-2026.html","canonical_url":"https://drugnews.com.tw/reports/biosimilar-cdmo-manufacturing-2026.html","source":"Website","access":"Free","category":"產業研究與報告解析","tags":[],"summary":"生物相似藥降價十年，利潤卻流向能自己生產、做得便宜又過得了查廠的公司。本報告比較 Celltrion、Sandoz、三星與 CDMO 大廠，拆解審查簡化、PBM、招標與 BIOSECURE，並指出台灣的切入點。","image":"https://drugnews.com.tw/assets/reports/biosimilar-20261015/figures/figure-1-zh.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"CAR-T 下一筆錢，該投工廠還是醫院？","date":"2026-10-15","language":"zh-Hant","url":"https://drugnews.com.tw/reports/car-t-factory-or-hospital-2026.html","canonical_url":"https://drugnews.com.tw/reports/car-t-factory-or-hospital-2026.html","source":"Website","access":"Free","category":"產業研究與報告解析","tags":[],"summary":"Yescarta 自 2026 年 10 月 1 日納入台灣健保給付。本報告以 BMS、Gilead、Legend、藥明巨諾與長聖的公開財報、CARTITUDE-4 交付時間及一個透明容量模型，評估 CAR-T 下一筆資本該投向工廠、醫院，還是兩者之間的交接。","image":"https://drugnews.com.tw/assets/reports/cart-20261015/figures/figure-1-zh.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"肥胖症藥物的下一局：比的是產能、口服與誰付錢","date":"2026-10-15","language":"zh-Hant","url":"https://drugnews.com.tw/reports/obesity-drugs-next-race-2026.html","canonical_url":"https://drugnews.com.tw/reports/obesity-drugs-next-race-2026.html","source":"Website","access":"Free","category":"產業研究與報告解析","tags":[],"summary":"GLP-1 之後，肥胖症藥物的勝負不再只看減重百分比。本報告比較 Lilly 與 Novo 最新季營收與指引，拆解美國價格協議、Medicare 給付、口服劑型、下一代機轉與產能，並檢視台灣健保與供應鏈位置。","image":"https://drugnews.com.tw/assets/reports/obesity-20261015/figures/figure-1-zh.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Celltrion's Record Profit Starts in Its Own Factories","date":"2026-10-15","language":"en","url":"https://drugnews.com.tw/articles/2026-10-15-sandoz-celltrion-biosimilar-profit-capacity-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-15-sandoz-celltrion-biosimilar-profit-capacity-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["Biosimilars","Sandoz","Celltrion","Manufacturing capacity","Business analysis"],"summary":"Celltrion's third-quarter operating profit exceeded KRW 500 billion for the first time, with a margin of about 34%, powered by its own factories. Sandoz is also turning its European plants into a network capable of accommodating more than 100 medicines. The next round in biosimilars is about whose new products sell fast enough to fill the new capacity.","image":"https://drugnews.com.tw/assets/articles/sandoz-celltrion-biosimilar-profit-capacity-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-10-15-sandoz-celltrion-biosimilar-profit-capacity.html"}},{"title":"Celltrion 獲利破紀錄，贏在自己的工廠","date":"2026-10-15","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-15-sandoz-celltrion-biosimilar-profit-capacity.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-15-sandoz-celltrion-biosimilar-profit-capacity.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["生物相似藥","Sandoz","Celltrion","製造產能","商業分析"],"summary":"Celltrion 第三季營業利益首破 5,000 億韓元，利益率約 34%，靠的是自己的工廠。Sandoz 也在把歐洲工廠改成能裝下上百種藥的網路。生物相似藥的下一局，比的是誰的新藥賣得夠快、填得滿新產能。","image":"https://drugnews.com.tw/assets/articles/sandoz-celltrion-biosimilar-profit-capacity/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"The Two-Drug Bet in Weight-Loss Injections","date":"2026-10-14","language":"en","url":"https://drugnews.com.tw/articles/2026-10-14-eloratzp-weight-loss-tolerability-persistence-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-14-eloratzp-weight-loss-tolerability-persistence-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["EloraTZP","eloralintide","tirzepatide","obesity","clinical trials"],"summary":"In a Phase 2 trial, Lilly added eloralintide to tirzepatide, gaining additional weight-loss potential but also facing higher rates of treatment discontinuation due to adverse events. Whether Phase 3 dose escalation and co-formulation can turn that efficacy into a product upgrade patients are willing to continue remains to be demonstrated.","image":"https://drugnews.com.tw/assets/articles/eloratzp-weight-loss-tolerability-persistence-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-10-14-eloratzp-weight-loss-tolerability-persistence.html"}},{"title":"瘦瘦針的雙藥賭注","date":"2026-10-14","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-14-eloratzp-weight-loss-tolerability-persistence.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-14-eloratzp-weight-loss-tolerability-persistence.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["EloraTZP","eloralintide","tirzepatide","肥胖","臨床試驗"],"summary":"禮來在第二期試驗把eloralintide加入tirzepatide，換到額外減重潛力，也遇到較高的因不良事件停藥比例。第三期的加量節奏與共製劑，能否讓這段藥效成為病人願意持續接受的產品升級，仍待驗證。","image":"https://drugnews.com.tw/assets/articles/eloratzp-weight-loss-tolerability-persistence/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"滴血驗癌真的來了？","date":"2026-10-13","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-13-galleri-positive-signal-diagnostic-journey.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-13-galleri-positive-signal-diagnostic-journey.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["GRAIL","Galleri","多癌症早期偵測","癌症篩檢","NHS-Galleri","FDA","Theranos","Guardant Health","Shield","液體活檢"],"summary":"Theranos曾以指尖少量血液做多種臨床檢驗為訴求；Galleri採靜脈抽血兩管、每管10毫升。產品已有訂單，但主要晚期癌症終點未達標，「早」仍須更多證據。","image":"https://drugnews.com.tw/assets/articles/galleri-positive-signal-diagnostic-journey/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Has Cancer Detection from a Blood Sample Really Arrived?","date":"2026-10-13","language":"en","url":"https://drugnews.com.tw/articles/2026-10-13-galleri-positive-signal-diagnostic-journey-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-13-galleri-positive-signal-diagnostic-journey-en.html","source":"Drugnews","access":"Business Analysis","category":"商業分析","tags":["GRAIL","Galleri","Multi-cancer early detection","Cancer screening","NHS-Galleri","FDA","Theranos","Guardant Health","Shield","Liquid biopsy"],"summary":"Theranos promised multiple clinical tests from a small finger-prick sample. Galleri uses two 10 mL tubes of venous blood. Orders are growing, but the primary late-stage cancer endpoint was not met, leaving “early” in need of more evidence.","image":"https://drugnews.com.tw/assets/articles/galleri-positive-signal-diagnostic-journey-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-10-13-galleri-positive-signal-diagnostic-journey.html"}},{"title":"乾燥症三期喊停，argenx 押錯的是機制不是藥","date":"2026-10-13","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-13-argenx-sjogrens-unity-futility-mechanism.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-13-argenx-sjogrens-unity-futility-mechanism.html","source":"Drugnews","access":"商業分析文","category":"商業分析","tags":["argenx","efgartigimod","Vyvgart","FcRn","Sjögren's disease","乾燥症","ianalumab","Novartis","dazodalibep","Amgen"],"summary":"argenx 10 月 8 日因無效性中止乾燥症三期 UNITY；同一個月諾華與 Amgen 的 B 細胞與 CD40L 路線相繼達標。差別不在藥，在機制動到免疫系統的哪一層，這也重畫了 efgartigimod 擴張清單的分類。","image":"https://drugnews.com.tw/assets/articles/argenx-sjogrens-unity-futility-mechanism/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Defending its blockbuster, Merck hits a patent wall","date":"2026-10-12","language":"en","url":"https://drugnews.com.tw/articles/2026-10-12-keytruda-qlex-subcutaneous-delivery-value-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-12-keytruda-qlex-subcutaneous-delivery-value-en.html","source":"網站","access":"Business Analysis","category":"商業分析","tags":["Keytruda","QLEX","PD-1","皮下注射","藥物遞送","默沙東"],"summary":"One drug accounts for half a company's revenue. That does not give its patents any extra years.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-10-12-keytruda-qlex-subcutaneous-delivery-value.html"}},{"title":"藥王保衛戰，默沙東撞上專利牆","date":"2026-10-12","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-12-keytruda-qlex-subcutaneous-delivery-value.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-12-keytruda-qlex-subcutaneous-delivery-value.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["Keytruda","QLEX","PD-1","皮下注射","藥物遞送","默沙東"],"summary":"一支藥撐起半家公司的營收，專利卻不會因此多給幾年。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-10-12-keytruda-qlex-subcutaneous-delivery-value-en.html"}},{"title":"核藥的下一道門檻：從工廠到病人的可交付劑量","date":"2026-10-11","language":"zh-Hant","url":"https://drugnews.com.tw/reports/radiopharma-delivery-2026.html","canonical_url":"https://drugnews.com.tw/reports/radiopharma-delivery-2026.html","source":"Website","access":"Free","category":"產業研究與報告解析","tags":[],"summary":"一批藥送到醫院，與一名患者完成治療，中間還隔著放行、預約、檢驗和合格人員。PSMA 核藥的下一段成長，值得追問的是：新增需求會在哪一站停下來，誰能讓這些環節在同一天接上？","image":"https://drugnews.com.tw/assets/reports/radiopharma-20261011/figures/figure1_psma_delivery.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"兒少肥胖用藥：Novo 的先發優勢，為何還要靠 Wegovy 接棒？","date":"2026-10-11","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-11-pediatric-obesity-novo-wegovy-lilly-product-strategy.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-11-pediatric-obesity-novo-wegovy-lilly-product-strategy.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["兒少肥胖","GLP-1","Novo Nordisk","Eli Lilly","Saxenda","Wegovy","tirzepatide","orforglipron"],"summary":"Novo 已有低齡證據與歐盟標籤，Saxenda 原品牌卻準備退出美國；Wegovy 的 STEP Young 與 Lilly 的共病、口服開發路徑，如何改變兒少肥胖用藥的產品競爭？","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Lilly’s blood-cancer drug moves earlier. Which contest has it won?","date":"2026-10-11","language":"en","url":"https://drugnews.com.tw/articles/2026-10-11-lilly-jaypirca-frontline-cll-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-11-lilly-jaypirca-frontline-cll-en.html","source":"網站","access":"Business Analysis","category":"商業分析","tags":["禮來","Jaypirca","BTK","CLL","適應症","商業分析"],"summary":"A drug able to take over after another BTK inhibitor can now compete for a place when a patient first needs treatment.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-10-11-lilly-jaypirca-frontline-cll.html"}},{"title":"禮來血癌藥提前上場，贏的是哪場仗？","date":"2026-10-11","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-11-lilly-jaypirca-frontline-cll.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-11-lilly-jaypirca-frontline-cll.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["禮來","Jaypirca","BTK","CLL","適應症","商業分析"],"summary":"一款原本能在其他BTK藥物之後接棒的血癌藥，現在可以爭取患者第一次需要治療時的位置。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-10-11-lilly-jaypirca-frontline-cll-en.html"}},{"title":"Fewer bleeds. Why is Novo’s new drug still waiting outside the US?","date":"2026-10-10","language":"en","url":"https://drugnews.com.tw/articles/2026-10-10-novo-mim8-manufacturing-fda-delay-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-10-novo-mim8-manufacturing-fda-delay-en.html","source":"網站","access":"Business Analysis","category":"商業分析","tags":["Novo Nordisk","Mim8","denecimig","血友病","FDA"],"summary":"A promising antibody for people with hemophilia has run into an obstacle that does not appear on an efficacy curve: a manufacturing facility.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-10-10-novo-mim8-manufacturing-fda-delay.html"}},{"title":"出血少了，新藥為何還進不了美國？","date":"2026-10-10","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-10-novo-mim8-manufacturing-fda-delay.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-10-novo-mim8-manufacturing-fda-delay.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["Novo Nordisk","Mim8","denecimig","血友病","FDA"],"summary":"一款能讓血友病患者少出血的抗體，正卡在一個不會出現在療效曲線上的地方：工廠。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-10-10-novo-mim8-manufacturing-fda-delay-en.html"}},{"title":"An injection every six months? Sanofi puts $1 billion on the table","date":"2026-10-09","language":"en","url":"https://drugnews.com.tw/articles/2026-10-09-sanofi-regeneron-long-acting-alliance-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-09-sanofi-regeneron-long-acting-alliance-en.html","source":"網站","access":"Business Analysis","category":"商業分析","tags":["Sanofi","Regeneron","Dupixent","REGN20423","長效抗體"],"summary":"The next contest in eczema treatment may play out on patients' calendars.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-10-09-sanofi-regeneron-long-acting-alliance.html"}},{"title":"半年打一針？賽諾菲押上10億美元","date":"2026-10-09","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-09-sanofi-regeneron-long-acting-alliance.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-09-sanofi-regeneron-long-acting-alliance.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["Sanofi","Regeneron","Dupixent","REGN20423","長效抗體"],"summary":"濕疹藥的下一場競爭，可能發生在病人的行事曆上。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-10-09-sanofi-regeneron-long-acting-alliance-en.html"}},{"title":"ADCs Move into First-Line Treatment: Which Differences Are Worth Paying For?","date":"2026-10-08","language":"en","url":"https://drugnews.com.tw/reports/adc-industry-2026-en.html","canonical_url":"https://drugnews.com.tw/reports/adc-industry-2026-en.html","source":"Website","access":"Free","category":"產業研究與報告解析","tags":[],"summary":"From how antibodies find cancer cells to why drugmakers invest in partnerships: the science, clinical competition and business of ADCs.","image":"https://drugnews.com.tw/assets/reports/adc-20261007/figures/P01_EN.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"ADC 走向第一線之後：哪些差異真正值得藥廠買單？","date":"2026-10-08","language":"zh-Hant","url":"https://drugnews.com.tw/reports/adc-industry-2026.html","canonical_url":"https://drugnews.com.tw/reports/adc-industry-2026.html","source":"Website","access":"Free","category":"產業研究與報告解析","tags":[],"summary":"從抗體如何找到癌細胞，到藥廠為何出資合作：看懂 ADC 的科學、臨床競爭與生意。","image":"https://drugnews.com.tw/assets/reports/adc-20261007/figures/P01_ZH.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"The 2026 Nobel Prize in Chemistry: do medicines have left and right hands?","date":"2026-10-08","language":"en","url":"https://drugnews.com.tw/articles/2026-10-08-2026-nobel-chemistry-chiral-amplification-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-08-2026-nobel-chemistry-chiral-amplification-en.html","source":"網站","access":"Business Analysis","category":"科學介紹","tags":["2026諾貝爾化學獎","手性","對映異構體","非線性效應","不對稱自催化"],"summary":"Can a chemical reaction amplify a tiny initial bias? Molecular handedness provides an entry into nonlinear effects and asymmetric autocatalysis.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-10-08-2026-nobel-chemistry-chiral-amplification.html"}},{"title":"2026諾貝爾化學獎揭曉！藥也分左右手？","date":"2026-10-08","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-08-2026-nobel-chemistry-chiral-amplification.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-08-2026-nobel-chemistry-chiral-amplification.html","source":"網站","access":"商業分析文","category":"科學介紹","tags":["2026諾貝爾化學獎","手性","對映異構體","非線性效應","不對稱自催化"],"summary":"兩邊幾乎平手，化學反應能不能把其中一邊的小小優勢越放越大？從藥的左右手看懂非線性與自催化。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-10-08-2026-nobel-chemistry-chiral-amplification-en.html"}},{"title":"One injection—and the body makes its own cancer-fighting cells?","date":"2026-10-07","language":"en","url":"https://drugnews.com.tw/articles/2026-10-07-in-vivo-car-t-iaso206-first-human-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-07-in-vivo-car-t-iaso206-first-human-en.html","source":"網站","access":"Business Analysis","category":"商業分析","tags":["CAR-T","體內CAR-T","IASO206","BCMA","細胞治療"],"summary":"For someone preparing for conventional autologous CAR-T treatment, a doctor saying “we can try this therapy” does not mean the medicine will be ready tomorrow.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-10-07-in-vivo-car-t-iaso206-first-human.html"}},{"title":"打一針，身體自己造抗癌細胞？","date":"2026-10-07","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-07-in-vivo-car-t-iaso206-first-human.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-07-in-vivo-car-t-iaso206-first-human.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["CAR-T","體內CAR-T","IASO206","BCMA","細胞治療"],"summary":"對準備接受傳統自體CAR-T治療的人，醫師說「可以試這個療法」，並不代表明天就有藥。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-10-07-in-vivo-car-t-iaso206-first-human-en.html"}},{"title":"Sales of a Star Heart Drug Have Halved. Can Novartis’s Next Medicines Take Over in Time?","date":"2026-10-06","language":"en","url":"https://drugnews.com.tw/articles/2026-10-06-novartis-growth-succession-capital-allocation-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-06-novartis-growth-succession-capital-allocation-en.html","source":"網站","access":"Business Analysis","category":"商業分析","tags":["Novartis","諾華","Entresto","Avidity","del-desiran","pelacarsen","remibrutinib","資本配置","新藥授權","專利到期"],"summary":"Novartis’s heart medicine Entresto recorded a 50% year-on-year sales decline in US dollars in the second quarter of 2026. In September, pelacarsen and del-desiran, previously listed for expected submissions over the next two years, both reported missed Phase 3 primary endpoints. Revenue erosion is already in the financial statements, while the filing assumptions for those two candidates need reassessment.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-10-06-novartis-growth-succession-capital-allocation.html"}},{"title":"明星心臟藥銷售減半，諾華的新藥接棒來得及嗎？","date":"2026-10-06","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-06-novartis-growth-succession-capital-allocation.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-06-novartis-growth-succession-capital-allocation.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["Novartis","諾華","Entresto","Avidity","del-desiran","pelacarsen","remibrutinib","資本配置","新藥授權","專利到期"],"summary":"諾華（Novartis）的心臟藥Entresto在2026年第二季美元銷售年減50%；進入9月，原列在未來兩年申請規劃中的pelacarsen與del-desiran，又先後公布第三期主要終點未達。收入侵蝕已反映在財報，兩項候選藥的申請前提卻需要重估。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-10-06-novartis-growth-succession-capital-allocation-en.html"}},{"title":"A light switch for cells wins the Nobel Prize","date":"2026-10-06","language":"en","url":"https://drugnews.com.tw/articles/2026-10-06-nobel-optogenetics-light-gated-channels-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-06-nobel-optogenetics-light-gated-channels-en.html","source":"網站","access":"Business Analysis","category":"商業分析","tags":["諾貝爾獎","光遺傳學","神經科學","視覺修復","基因療法"],"summary":"The2026 Nobel Medicine Prize recognizes light-gated ion channels and optogenetics. From algae to causal neural experiments and visual-restoration research, scientific tools and product delivery demand different evidence, capital and responsibilities.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-10-06-nobel-optogenetics-light-gated-channels.html"}},{"title":"諾貝爾獎揭曉！科學家給細胞裝上光開關","date":"2026-10-06","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-06-nobel-optogenetics-light-gated-channels.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-06-nobel-optogenetics-light-gated-channels.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["諾貝爾獎","光遺傳學","神經科學","視覺修復","基因療法"],"summary":"2026諾貝爾醫學獎表彰光門控離子通道與光遺傳學。從綠藻到神經元因果實驗，再到視覺修復，研究工具的價值與產品交付有不同的證據、資金與責任。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-10-06-nobel-optogenetics-light-gated-channels-en.html"}},{"title":"From a Daily Tablet to Factory Orders: Who Can Profit from Oral Cyclic Peptides?","date":"2026-10-05","language":"en","url":"https://drugnews.com.tw/articles/2026-10-05-cyclic-peptide-upstream-2026-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-05-cyclic-peptide-upstream-2026-en.html","source":"網站","access":"Business Analysis","category":"商業分析","tags":["口服環肽","enlicitide","Orbis","Novo Nordisk","製程"],"summary":"On September 17, 2026, Novo Nordisk and Orbis Medicines announced a collaboration to develop oral macrocycles for cardiometabolic diseases. Upfront payments and potential development and commercial milestones total up to US$1.4 billion, with additional sales royalties; Novo will also make a strategic investment in Orbis. A large drugmaker is buying opportunities to discover new medicines. That headline ceiling is not yet an order held by a raw-material factory, and the announcement does not disclose commercial purchase volumes or suppliers.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-10-05-cyclic-peptide-upstream-2026.html"}},{"title":"從每天一顆藥到工廠訂單：口服環肽的錢，誰賺得到？","date":"2026-10-05","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-05-cyclic-peptide-upstream-2026.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-05-cyclic-peptide-upstream-2026.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["口服環肽","enlicitide","Orbis","Novo Nordisk","製程"],"summary":"2026年9月17日，諾和諾德（Novo Nordisk）與Orbis Medicines宣布合作，開發心血管代謝疾病的口服大環肽。前期款與可能達成的開發、商業里程碑合計最高14億美元，另計銷售權利金，Novo亦將策略投資Orbis。大藥廠正在買新的藥物發現機會；這筆上限金額，還不是原料工廠手上的訂單，公告也未披露商業採購量或供應商。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-10-05-cyclic-peptide-upstream-2026-en.html"}},{"title":"Migraine Around Your Period? How Much Can a Seven-Day Prevention Strategy Help?","date":"2026-10-04","language":"en","url":"https://drugnews.com.tw/articles/2026-10-04-luna-atogepant-menstrual-migraine-2026-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-04-luna-atogepant-menstrual-migraine-2026-en.html","source":"網站","access":"Business Analysis","category":"商業分析","tags":["LUNA","atogepant","AbbVie","CGRP","偏頭痛"],"summary":"The days around menstruation can already be uncomfortable. Add migraine, sensitivity to light or nausea, and work, school pickups and carefully planned activities can be disrupted. For people whose attacks repeatedly cluster in this window, the question is straightforward: can the burden be reduced before the headache arrives?","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-10-04-luna-atogepant-menstrual-migraine-2026.html"}},{"title":"偏頭痛總挑月經前後來？7天預防研究，能少痛多少？","date":"2026-10-04","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-04-luna-atogepant-menstrual-migraine-2026.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-04-luna-atogepant-menstrual-migraine-2026.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["LUNA","atogepant","AbbVie","CGRP","偏頭痛"],"summary":"月經前後已經不好受，再碰上偏頭痛、怕光或噁心，工作、接送與原本排好的行程都可能被打亂。對發作時間反覆落在這個窗口的人，問題很直接：能不能在頭痛來之前，先降低那幾天的負擔？","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-10-04-luna-atogepant-menstrual-migraine-2026-en.html"}},{"title":"PharmaEssentia Acquires FormuRx. Could Making Drugs Inside Cells Be Next?","date":"2026-10-03","language":"en","url":"https://drugnews.com.tw/articles/2026-10-03-pharmaessentia-formurx-rna-lnp-acquisition-2026-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-03-pharmaessentia-formurx-rna-lnp-acquisition-2026-en.html","source":"網站","access":"Business Analysis","category":"商業分析","tags":["PharmaEssentia","FormuRx","RNA","LNP"],"summary":"PharmaEssentia (6446) has acquired FormuRx for approximately NT$168 million. According to company-provided news published by Global Bio & Investment, FormuRx develops delivery technologies for getting RNA into cells. The acquisition brings lipid nanoparticle (LNP) formulations, microfluidic processes, analytical capabilities, equipment and a team.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-10-03-pharmaessentia-formurx-rna-lnp-acquisition-2026.html"}},{"title":"藥華藥買下予宇，下一步讓細胞造藥？","date":"2026-10-03","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-03-pharmaessentia-formurx-rna-lnp-acquisition-2026.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-03-pharmaessentia-formurx-rna-lnp-acquisition-2026.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["PharmaEssentia","FormuRx","RNA","LNP"],"summary":"藥華藥（6446）買下予宇生技，交易金額約新台幣1.68億元。依環球生技刊載的公司消息，予宇做的是把RNA送進細胞的遞送研發，帶進來的包括脂質奈米顆粒（LNP）配方、微流體製程、分析、設備與團隊。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-10-03-pharmaessentia-formurx-rna-lnp-acquisition-2026-en.html"}},{"title":"One Less Search for a Vein, a Little More Freedom in Life with Hemophilia","date":"2026-10-03","language":"en","url":"https://drugnews.com.tw/articles/2026-10-03-hemlibra-hemophilia-lasker-2026-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-03-hemlibra-hemophilia-lasker-2026-en.html","source":"網站","access":"Business Analysis","category":"商業分析","tags":["Hemlibra","emicizumab","血友病","Lasker"],"summary":"The 2026 Lasker–DeBakey Clinical Medical Research Award recognizes an invention that changed the treatment of hemophilia A: Hemlibra, a bispecific antibody that can be injected under the skin.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-10-03-hemlibra-hemophilia-lasker-2026.html"}},{"title":"少找一次血管，血友病的日常就多一點自由","date":"2026-10-03","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-03-hemlibra-hemophilia-lasker-2026.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-03-hemlibra-hemophilia-lasker-2026.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["Hemlibra","emicizumab","血友病","Lasker"],"summary":"2026年Lasker–DeBakey臨床醫學研究獎，表彰了一項改變A型血友病治療的發明：Hemlibra，一支可以皮下注射的雙特異性抗體。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-10-03-hemlibra-hemophilia-lasker-2026-en.html"}},{"title":"Weight-Loss Injections: The Goal Is to Lose Weight, Not Hair","date":"2026-10-02","language":"en","url":"https://drugnews.com.tw/articles/2026-10-02-glp1-weight-loss-speed-hair-gallbladder-safety-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-02-glp1-weight-loss-speed-hair-gallbladder-safety-en.html","source":"網站","access":"Business Analysis","category":"商業分析","tags":["GLP-1","瘦瘦針","semaglutide","tirzepatide","掉髮","膽結石","藥物安全","減重藥"],"summary":"Two meta-analyses quantify hair-loss and gallbladder/biliary risk around GLP-1-related obesity treatment. Relative risk, absolute risk and different analytical pools must be kept separate, while dose, duration and weight-loss indication do not by themselves prove a speed-of-weight-loss mechanism. The article then examines how tolerability and persistence may shape product differentiation.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-10-02-glp1-weight-loss-speed-hair-gallbladder-safety.html"}},{"title":"瘦瘦針：想減的是體重，不是頭髮","date":"2026-10-02","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-02-glp1-weight-loss-speed-hair-gallbladder-safety.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-02-glp1-weight-loss-speed-hair-gallbladder-safety.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["GLP-1","瘦瘦針","semaglutide","tirzepatide","掉髮","膽結石","藥物安全","減重藥"],"summary":"兩份統合分析把GLP-1相關減重藥的掉髮與膽囊／膽道風險量化：RR要和絕對風險分開看，減重用途、高劑量與較長療程的關聯也不能直接等同於減重速度因果。本文進一步討論耐受性、依從性與長期使用如何成為產品差異化。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-10-02-glp1-weight-loss-speed-hair-gallbladder-safety-en.html"}},{"title":"Adding an ADC to Lung Cancer Immunotherapy: More Tumor Responses, but Why Did Phase 3 Fall Short?","date":"2026-10-01","language":"en","url":"https://drugnews.com.tw/articles/2026-10-01-trodelvy-evoke03-east-asia-subgroup-phase3-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-01-trodelvy-evoke03-east-asia-subgroup-phase3-en.html","source":"網站","access":"Business Analysis","category":"醫學大會","tags":["Trodelvy","EVOKE-03","肺癌","TROP2 ADC","東亞次群","浩鼎"],"summary":"Adding an ADC increased response rates but missed the prespecified PFS threshold and increased toxicity in EVOKE-03. What evidence would justify further development, and what must regional hypotheses and distinct TROP2 products demonstrate?","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-10-01-trodelvy-evoke03-east-asia-subgroup-phase3.html"}},{"title":"肺癌免疫治療再加ADC：腫瘤更常縮小，為何三期仍未過關？","date":"2026-10-01","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-10-01-trodelvy-evoke03-east-asia-subgroup-phase3.html","canonical_url":"https://drugnews.com.tw/articles/2026-10-01-trodelvy-evoke03-east-asia-subgroup-phase3.html","source":"網站","access":"商業分析文","category":"醫學大會","tags":["Trodelvy","EVOKE-03","肺癌","TROP2 ADC","東亞次群","浩鼎"],"summary":"肺癌第一線加上ADC，腫瘤反應率提高卻未通過預設PFS門檻，毒性負擔也上升。EVOKE-03如何改變後續開發判斷，東亞訊號與浩鼎的TROP2產品又各需要什麼人體證據？","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-10-01-trodelvy-evoke03-east-asia-subgroup-phase3-en.html"}},{"title":"Novo Nordisk Already Has Weight-Loss Injections. Why Pursue Another Path?","date":"2026-09-30","language":"en","url":"https://drugnews.com.tw/articles/2026-09-30-novo-kallyope-non-incretin-obesity-programs-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-30-novo-kallyope-non-incretin-obesity-programs-en.html","source":"網站","access":"Business Analysis","category":"製藥巨頭","tags":["Novo Nordisk","Kallyope","肥胖症","GLP-1","非腸泌素","K-554"],"summary":"Why pursue non-incretin programs alongside an established GLP-1 franchise? K-554’s neural-circuit hypothesis, human evidence and usable dose range frame the relationship between efficacy, tolerability, persistence and product value.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-09-30-novo-kallyope-non-incretin-obesity-programs.html"}},{"title":"已有瘦瘦針，諾和諾德為何還要布局另一條減重路？","date":"2026-09-30","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-30-novo-kallyope-non-incretin-obesity-programs.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-30-novo-kallyope-non-incretin-obesity-programs.html","source":"網站","access":"商業分析文","category":"製藥巨頭","tags":["Novo Nordisk","Kallyope","肥胖症","GLP-1","非腸泌素","K-554"],"summary":"諾和諾德已有GLP-1減重產品，為何仍布局非腸泌素計畫？從K-554的神經迴路假說、人體證據進度與可用劑量，分析效果、耐受性及持續使用如何影響產品價值。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-09-30-novo-kallyope-non-incretin-obesity-programs-en.html"}},{"title":"Drug Approval in Hand—But Is the Cash in the Bank? How Formosa and PharmaEngine Turn Licensing Payments Into Cash","date":"2026-09-29","language":"en","url":"https://drugnews.com.tw/articles/2026-09-29-biotech-milestone-payments-formosa-pharmaengine-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-29-biotech-milestone-payments-formosa-pharmaengine-en.html","source":"網站","access":"Business Analysis","category":"商業分析","tags":["新藥授權","里程碑付款","台新藥","智擎","Genmab","現金流","BD交易"],"summary":"Historical Genmab milestones, Formosa's equity settlement and gross-profit-based collaboration, and PharmaEngine's first-half 2026 accounts show how contractual achievements become—or differ from—collectable proceeds.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-09-29-biotech-milestone-payments-formosa-pharmaengine.html"}},{"title":"藥證到手，錢就到帳？從台新藥、智擎看懂授權金怎麼變成現金","date":"2026-09-29","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-29-biotech-milestone-payments-formosa-pharmaengine.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-29-biotech-milestone-payments-formosa-pharmaengine.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["新藥授權","里程碑付款","台新藥","智擎","Genmab","現金流","BD交易"],"summary":"藥證、付款事件與實際收款之間，有哪些條件？以Genmab歷史里程碑、台新藥的股票結算與毛利合作，以及智擎2026上半年財報，解析新藥授權生意如何從進展走向可運用資源。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-09-29-biotech-milestone-payments-formosa-pharmaengine-en.html"}},{"title":"US$9.2 Billion in Annual Sales—Why Does J&J Still Want to Separate Orthopaedics?","date":"2026-09-28","language":"en","url":"https://drugnews.com.tw/articles/2026-09-28-jnj-orthopaedics-separation-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-28-jnj-orthopaedics-separation-en.html","source":"網站","access":"Business Analysis","category":"商業分析","tags":["Johnson & Johnson","DePuy Synthes","Orthopaedics","Business separation","Apollo","United Orthopedic"],"summary":"Why might an orthopaedics business with US$9.2 billion in annual sales lose priority for J&J’s next investment? Growth differences, the value flows in a spin-off versus a sale, and the costs of implants and surgical support explain the economic questions behind the proposed DePuy Synthes separation.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-09-28-jnj-orthopaedics-separation.html"}},{"title":"年營收 92 億美元，強生為什麼還想把骨科拆出去？","date":"2026-09-28","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-28-jnj-orthopaedics-separation.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-28-jnj-orthopaedics-separation.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["強生","DePuy Synthes","骨科","業務分離","Apollo","聯合骨科"],"summary":"一年銷售92億美元的骨科業務，為何仍可能排不到強生下一筆資金？從成長差異、分拆與出售的價值流向，到人工關節與手術支援的經營成本，拆解DePuy Synthes分離案真正要算的帳。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-09-28-jnj-orthopaedics-separation-en.html"}},{"title":"New Hepatitis B Drug Approved in Japan: About One in Five Treated Trial Patients Achieved a “Functional Cure”","date":"2026-09-27","language":"en","url":"https://drugnews.com.tw/articles/2026-09-27-hibsago-finite-hbv-care-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-27-hibsago-finite-hbv-care-en.html","source":"網站","access":"Business Analysis","category":"商業分析","tags":["Hepatitis B","GSK","Hibsago","Finite treatment","GBC"],"summary":"On August 24, 2026, GSK announced that Hibsago (bepirovirsen) had been approved in Japan for eligible adults with chronic hepatitis B. The Phase III results supporting the approval had already been published in May; this development moves a finite course of treatment from trial evidence into a treatment option for a defined population.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-09-27-hibsago-finite-hbv-care.html"}},{"title":"B 肝新藥在日本獲准，新藥組約兩成受試者達「功能性治癒」","date":"2026-09-27","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-27-hibsago-finite-hbv-care.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-27-hibsago-finite-hbv-care.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["B 型肝炎","GSK","Hibsago","有限療程","普生"],"summary":"2026 年 8 月 24 日，GSK 宣布 Hibsago（bepirovirsen）在日本獲准，用於符合條件的成人慢性 B 肝患者。支持核准的第三期結果已於 5 月發表；這次進展，是有限療程從試驗證據走向特定人群的治療選擇。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-09-27-hibsago-finite-hbv-care-en.html"}},{"title":"A new US therapy for muscle-wasting disease: bringing four-weekly infusions into everyday care","date":"2026-09-26","language":"en","url":"https://drugnews.com.tw/articles/2026-09-26-scholar-rock-isembyld-sma-care-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-26-scholar-rock-isembyld-sma-care-en.html","source":"網站","access":"Business Analysis","category":"商業分析","tags":["SMA","Scholar Rock","ISEMBYLD","Muscle-directed therapy","AnnJi"],"summary":"US approval of ISEMBYLD adds a muscle-directed option for people with SMA receiving SMN2-targeting therapy. This analysis connects functional trial gains and safety follow-up with payment, four-weekly infusions and continued care, while distinguishing AnnJi's adjacent Taiwanese neuromuscular drug-development program from SMA or a proven commercial partnership.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-09-26-scholar-rock-isembyld-sma-care.html"}},{"title":"肌肉萎縮新藥在美獲准，每四週輸注如何走進生活？","date":"2026-09-26","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-26-scholar-rock-isembyld-sma-care.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-26-scholar-rock-isembyld-sma-care.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["脊髓性肌肉萎縮症","Scholar Rock","ISEMBYLD","肌肉療法","安基生技"],"summary":"ISEMBYLD在美獲准，為接受SMN2治療的脊髓性肌肉萎縮症患者增加肌肉端療法。從一年功能增益、適用人群與安全追蹤，分析支付、每四週輸注及持續治療的商業考驗，並以安基AJ201說明台灣相鄰神經肌肉新藥開發能力與界線。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-09-26-scholar-rock-isembyld-sma-care-en.html"}},{"title":"Novo Nordisk teams up with Anthropic to bring Claude's reasoning and coding into drug R&D","date":"2026-09-25","language":"en","url":"https://drugnews.com.tw/articles/2026-09-25-novo-nordisk-anthropic-ai-rd-workflow-free-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-25-novo-nordisk-anthropic-ai-rd-workflow-free-en.html","source":"網站","access":"Business Analysis","category":"商業分析","tags":["Novo Nordisk","Anthropic","AI drug discovery","R&D workflows","Taiwan biotech"],"summary":"Novo Nordisk's collaboration with Anthropic tests scientific reasoning and R&D software engineering alongside capabilities provided by Valo, OpenAI and AWS. This analysis examines workflows, computational acceleration and collaboration economics, while distinguishing Taiwanese platform capabilities from proven partnerships and the experimental and clinical gates that remain.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-09-25-novo-nordisk-anthropic-ai-rd-workflow-free.html"}},{"title":"諾和諾德攜手Anthropic：讓Claude推理、寫程式，投入新藥研發測試","date":"2026-09-25","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-25-novo-nordisk-anthropic-ai-rd-workflow-free.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-25-novo-nordisk-anthropic-ai-rd-workflow-free.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["諾和諾德","Anthropic","AI新藥研發","研發流程","台灣生技"],"summary":"諾和諾德與Anthropic合作測試科學推理及研發軟體工程，與Valo、OpenAI、AWS分別提供的能力形成對照。從研發流程、運算加速和合作款項拆解AI製藥的商業價值，並區分台灣平台能力、合作證據與仍須通過的實驗及臨床關卡。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-09-25-novo-nordisk-anthropic-ai-rd-workflow-free-en.html"}},{"title":"Why Are Lilly and Novartis Betting on How Medicines Are Delivered?","date":"2026-09-24","language":"en","url":"https://drugnews.com.tw/articles/2026-09-24-delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-24-delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026-en.html","source":"網站","access":"Business Analysis","category":"商業分析","tags":["藥物遞送","BD交易","細胞治療","in vivo CAR-T","皮下注射劑型","Eli Lilly","Kelonia","Novartis","Alteogen","平台型Biotech"],"summary":"Lilly's in vivo CAR-T acquisition and Novartis' subcutaneous formulation options address different delivery problems. Human evidence, drug exposure and payment terms clarify how each platform could create product value.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-09-24-delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026.html"}},{"title":"禮來與諾華的大交易，為什麼都看上「怎麼給藥」？","date":"2026-09-24","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-24-delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-24-delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["藥物遞送","BD交易","細胞治療","in vivo CAR-T","皮下注射劑型","Eli Lilly","Kelonia","Novartis","Alteogen","平台型Biotech"],"summary":"禮來押注體內CAR-T製程，諾華取得皮下劑型選擇權。從人體研究、藥物暴露到付款條件，解析兩種遞送平台如何形成產品價值。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-09-24-delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026-en.html"}},{"title":"Moderna癌症疫苗報喜，投資人還該看懂這個「更早出手」的範例","date":"2026-09-23","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-23-lynch-nous209-cancer-interception.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-23-lynch-nous209-cancer-interception.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["Lynch syndrome","NOUS-209","Nouscom","癌症攔截","癌症疫苗","臨床試驗"],"summary":"從Moderna癌症疫苗三期頂線消息，讀懂NOUS-209更早介入高風險族群的人體研究：個人化與共享抗原的產品模式、臨床證據、製造與支付門檻，以及台灣的製造與研發參與者。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-09-23-lynch-nous209-cancer-interception-en.html"}},{"title":"Moderna’s Cancer Vaccine Delivers Positive News—Investors Should Also Understand This Example of “Acting Earlier”","date":"2026-09-23","language":"en","url":"https://drugnews.com.tw/articles/2026-09-23-lynch-nous209-cancer-interception-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-23-lynch-nous209-cancer-interception-en.html","source":"網站","access":"Free Article","category":"商業分析","tags":["Lynch syndrome","NOUS-209","Nouscom","癌症攔截","癌症疫苗","臨床試驗"],"summary":"Moderna’s Phase 3 topline news offers an entry point to NOUS-209 research in people at inherited high risk: personalized versus shared-antigen products, human evidence, manufacturing and reimbursement hurdles, and relevant Taiwanese developers and manufacturers.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-09-23-lynch-nous209-cancer-interception.html"}},{"title":"After Novartis’ 8,323-Patient Trial Setback, How Should the Cardiovascular Business Case Be Rebuilt?","date":"2026-09-22","language":"en","url":"https://drugnews.com.tw/articles/2026-09-22-pelacarsen-horizon-topline-evidence-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-22-pelacarsen-horizon-topline-evidence-en.html","source":"網站","access":"Free Article","category":"商業分析","tags":["Lp(a)","pelacarsen","HORIZON","Novartis","心血管","臨床試驗"],"summary":"Pelacarsen’s Phase III Lp(a)HORIZON trial enrolled 8,323 patients with established cardiovascular disease and elevated Lp(a). The September 4 initial announcements showed Lp(a) lowering but a missed primary cardiovascular endpoint. This should not be read as an effect precisely equal to zero, nor as a failure of the entire Lp(a) field. The September 4 announcements did not provide full effect estimates, event components, prespecified-population results or complete safety details.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-09-22-pelacarsen-horizon-topline-evidence.html"}},{"title":"諾華8,323人試驗受挫，心血管新藥的生意要怎麼重算？","date":"2026-09-22","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-22-pelacarsen-horizon-topline-evidence.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-22-pelacarsen-horizon-topline-evidence.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["Lp(a)","pelacarsen","HORIZON","Novartis","心血管","臨床試驗"],"summary":"Pelacarsen 的 Lp(a)HORIZON 三期試驗納入 8,323 名既有心血管疾病且 Lp(a) 升高病人，9 月 4 日初步公告顯示 Lp(a) 下降，但主要心血管終點未達標。這不是效果精確為零，也不是 Lp(a) 題材全盤失敗；9 月 4 日公告未列完整效果量、事件組成、預先指定族群與完整安全性資料。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-09-22-pelacarsen-horizon-topline-evidence-en.html"}},{"title":"PharmaEssentia Wins a New Indication: How Can a Taiwan-Developed Drug Become a Global Business?","date":"2026-09-21","language":"en","url":"https://drugnews.com.tw/articles/2026-09-21-pharmaessentia-besremi-et-mimrylo-fda-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-21-pharmaessentia-besremi-et-mimrylo-fda-en.html","source":"網站","access":"Free Article","category":"商業分析","tags":["藥華藥","6446","BESREMi","MIMRYLO","ET","PV","PMF","DSMB","SOHO"],"summary":"PharmaEssentia’s story has entered the post-approval phase. The key questions are now physician adoption, payer access, long-term treatment persistence, supply capacity and fixed-cost execution. The Puerto Rico plan shows preparation for U.S. and global demand, but it remains a planned investment rather than an operating supply site. Clinical progress, competition and manufacturing commitments should be read on separate timelines.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-09-21-pharmaessentia-besremi-et-mimrylo-fda.html"}},{"title":"藥華藥新適應症獲准：一款台灣新藥，如何長成全球生意？","date":"2026-09-21","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-21-pharmaessentia-besremi-et-mimrylo-fda.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-21-pharmaessentia-besremi-et-mimrylo-fda.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["藥華藥","6446","BESREMi","MIMRYLO","ET","PV","PMF","DSMB","SOHO"],"summary":"藥華藥的故事已進入核准後階段：真正的考題變成醫師採用、支付准入、長期治療、供應與固定成本。波多黎各未來工廠計畫顯示公司正在為美國與全球需求布局，但這仍是計畫投資，不是已營運產能。臨床進展、競爭變化與製造投資要分開看，才能理解 6446 下一段價值。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-09-21-pharmaessentia-besremi-et-mimrylo-fda-en.html"}},{"title":"大藥廠不是沒錢，是交易條件變窄了：M&A beta 降溫後，asset alpha 為何可能上升","date":"2026-09-18","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-18-ma-beta-asset-alpha-biopharma-deals.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-18-ma-beta-asset-alpha-biopharma-deals.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["M&A","biotech","asset alpha","IQVIA","EY","授權交易"],"summary":"大型併購共同溢價降溫不代表買方沒錢；當臨床證據、上市時點、權利結構與團隊承接能力都能驗證，少數資產的個別價值反而可能上升。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"26 家藥廠、89% 市場覆蓋：MFN 藥價協議真正落地到哪一層？","date":"2026-09-17","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-17-mfn26-beone-policy-bargain.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-17-mfn26-beone-policy-bargain.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["MFN","Medicaid","GENEROUS","BeOne","Teva","藥價政策"],"summary":"白宮所稱 26 家與 89% 描述政策廣度，不等於各家公司條款、各州執行與逐藥價格已同步定案；BeOne 與 Teva 正好呈現成熟度差異。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Pfizer 22.6 億美元收購 Trillium 後，maplirpacept 停止開發，CD47 還剩哪四條路？","date":"2026-09-14","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-14-cd47-after-pipeline-exits.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-14-cd47-after-pipeline-exits.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["CD47","Pfizer","Gilead","ALX Oncology","巨噬細胞","生技投資"],"summary":"三種不同退出不能被壓成一次 class verdict；CD47 的剩餘價值要分開看組合、分層、減毒設計與人體證據。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"1,432 人三期未達標：Eplontersen 加上標準治療後還剩多少價值？","date":"2026-09-13","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-13-eplontersen-attr-cm-incremental-value.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-13-eplontersen-attr-cm-incremental-value.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["ATTR-CM","eplontersen","CARDIO-TTRansform","RNA silencing","stabilizer","增量價值"],"summary":"CARDIO-TTRansform 整體主要終點未達標後，eplontersen 的價值必須回到背景 stabilizer、時間分層與真正可驗證的加成效果。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"自免 CAR-T 第一次被迫重算：療效之外，尾端安全風險如何縮小市場？","date":"2026-09-12","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-12-autoimmune-car-t-safety-market-reset.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-12-autoimmune-car-t-safety-market-reset.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["CAR-T","自體免疫","Novartis","Bristol Myers Squibb","細胞治療","安全性"],"summary":"自免 CAR-T 的早期療效不能與尾端免疫安全風險分開計算；市場大小同時取決於病人選擇、長期監測與治療中心承接能力。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"AI 一小時做完實驗？Google Co-Scientist 真正跨過的，是「動手」這一關","date":"2026-09-11","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-11-google-coscientist-real-world-lab-loop.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-11-google-coscientist-real-world-lab-loop.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["Google Co-Scientist","AI for Science","Gemini","實驗自動化","研究基礎設施"],"summary":"Google Co-Scientist 從假說生成走向實驗執行，但真正的採購與產業價值仍取決於設備整合、可重現性、失敗紀錄與責任治理。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Codex 變身 AI 科學家？OpenAI 真正搶的是整套生命科學工作流","date":"2026-09-10","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-10-openai-rosalind-workbench.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-10-openai-rosalind-workbench.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["OpenAI","Rosalind Workbench","GPT-Rosalind","生命科學","AI Agent"],"summary":"文獻在資料庫、定序檔在伺服器、蛋白質結構在另一套工具、分析程式留在某位研究員的電腦，最後的實驗紀錄又散落在不同表單。科學家花掉大量時間，不是在解生物學，而是在搬資料、補上下文、確認上一個人到底做了什麼。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"「一針近 50 萬美元」有證據嗎？Moderna 三期後真正要算的四筆帳","date":"2026-09-09","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-09-personalized-mrna-cancer-vaccine-economics.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-09-personalized-mrna-cancer-vaccine-economics.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["個人化癌症疫苗","mRNA","intismeran","臨床開發","生技商業化"],"summary":"個人化 mRNA 癌症疫苗三期頂線陽性，不等於已核准或已有正式藥價。intismeran 的商業化，還要算清患者批次、交付時間、支付價值與平行產能。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Big Pharma 集體養馬！血腦屏障為何成了 CNS 新藥必爭入口？","date":"2026-09-08","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-08-big-pharma-bbb-delivery.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-08-big-pharma-bbb-delivery.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["血腦屏障","CNS","藥物遞送","授權交易","阿茲海默症"],"summary":"大藥廠以收購、選擇權及授權布局血腦屏障遞送。本文拆解不同交易買到的權利，區分抗體與AAV路線、遞送和臨床受益，並更新Sanofi停止開發等管線狀態。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"FDA AI 副局長仍待官宣：新藥估值先看證據鏈","date":"2026-09-07","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-07-fda-ai-review-institutionalization.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-07-fda-ai-review-institutionalization.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["FDA","AI 審評","AI 製藥","監管科學"],"summary":"一則「FDA 將增設 AI 副局長」的消息，這幾天讓 AI 製藥圈非常興奮。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"兩款口服大環肽新藥獲批：大藥廠押注的，不只是一顆藥片","date":"2026-09-06","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-06-oral-macrocyclic-peptide-platform.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-06-oral-macrocyclic-peptide-platform.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["口服大環肽","oral macrocyclic peptide","藥物開發","口服生物可用率"],"summary":"ICOTYDE 與 LIPFENDRA 為口服大環肽帶來兩項核准里程碑，但 LDL-C 改善不等於心血管結局已證實；平台價值仍要跨過人體暴露、治療窗、製造與可複製性考驗。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"18分鐘驗血，就能揪出阿茲海默症？禮來、羅氏真正搶的是「患者入口」","date":"2026-09-05","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-05-elecsys-ptau217-alzheimers-blood-test.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-05-elecsys-ptau217-alzheimers-blood-test.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["阿茲海默症","pTau217","血液檢測","診斷","羅氏","禮來"],"summary":"Elecsys pTau217協助評估Aβ病理可能性，18分鐘不是確診承諾。本文拆解羅氏、禮來及檢驗通路的角色，以及患者評估、採用與支付的限制。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Ivonescimab Moves Beyond Lung Cancer: Phase 3 Survival Win Against the Biliary Tract Cancer Standard","date":"2026-09-04","language":"en","url":"https://drugnews.com.tw/articles/2026-09-04-ivonescimab-biliary-tract-cancer-harmoni-gi1-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-04-ivonescimab-biliary-tract-cancer-harmoni-gi1-en.html","source":"Facebook","access":"Free Article","category":"商業分析","tags":["Ivonescimab","HARMONi-GI1","biliary tract cancer","Akeso","Summit Therapeutics","durvalumab","PD-1 VEGF bispecific","Phase 3"],"summary":"Ivonescimab plus chemotherapy beat durvalumab plus chemotherapy on overall survival in the Phase 3 HARMONi-GI1 interim analysis, but the hazard ratio, median survival, curves, safety and subgroup results remain undisclosed.","image":"https://drugnews.com.tw/assets/articles/ivonescimab-biliary-tract-cancer-harmoni-gi1-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-09-04-ivonescimab-biliary-tract-cancer-harmoni-gi1.html"}},{"title":"Ivonescimab 跨出肺癌！正面挑戰膽道癌金標準，總生存期告捷","date":"2026-09-04","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-04-ivonescimab-biliary-tract-cancer-harmoni-gi1.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-04-ivonescimab-biliary-tract-cancer-harmoni-gi1.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["Ivonescimab","HARMONi-GI1","膽道癌","康方生物","Summit Therapeutics","Durvalumab","PD-1 VEGF 雙抗","臨床三期"],"summary":"Ivonescimab 合併化療在一線晚期膽道癌三期 HARMONi-GI1 達到總生存期主要終點，正面勝過 durvalumab 合併化療；完整風險比、生存曲線、安全性與亞組數據仍待公布。","image":"https://drugnews.com.tw/assets/articles/ivonescimab-biliary-tract-cancer-harmoni-gi1/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-09-04-ivonescimab-biliary-tract-cancer-harmoni-gi1-en.html"}},{"title":"Claude Starts Running Experiments: AI Enters the Physical Lab","date":"2026-09-03","language":"en","url":"https://drugnews.com.tw/articles/2026-09-03-anthropic-mhs-ai-lab-hardware-standard-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-03-anthropic-mhs-ai-lab-hardware-standard-en.html","source":"Facebook","access":"Free Article","category":"商業分析","tags":["Anthropic","Claude","Model Hardware Standard","MHS","AI for Science","Claude Science","laboratory automation","scientific instruments"],"summary":"Anthropic's Model Hardware Standard research preview gives AI agents a shared interface for microscopes, liquid handlers, robots and laser-control systems. The proof-of-concept results are important, but they do not mean autonomous laboratories are already mature.","image":"https://drugnews.com.tw/assets/articles/anthropic-mhs-ai-lab-hardware-standard-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-09-03-anthropic-mhs-ai-lab-hardware-standard.html"}},{"title":"Claude 開始動手做實驗！AI 搶進真實實驗室，遊戲規則變了","date":"2026-09-03","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-03-anthropic-mhs-ai-lab-hardware-standard.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-03-anthropic-mhs-ai-lab-hardware-standard.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["Anthropic","Claude","Model Hardware Standard","MHS","AI for Science","Claude Science","實驗室自動化","科學儀器"],"summary":"Anthropic 公開模型硬體標準 MHS 研究預覽，讓 AI 代理透過共通介面讀取與操作顯微鏡、移液工作站、機械手臂與雷射控制系統；這是概念驗證，不是無人實驗室已成熟。","image":"https://drugnews.com.tw/assets/articles/anthropic-mhs-ai-lab-hardware-standard/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-09-03-anthropic-mhs-ai-lab-hardware-standard-en.html"}},{"title":"A New Drug Launched. Seven Months Later, the Company Sought Liquidation","date":"2026-09-02","language":"en","url":"https://drugnews.com.tw/articles/2026-09-02-post-approval-biotech-commercialization-death-valley-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-02-post-approval-biotech-commercialization-death-valley-en.html","source":"Facebook","access":"Free Article","category":"商業分析","tags":["biotech commercialization","Iterum Therapeutics","ORLYNVAH","Karyopharm","XPOVIO","Theravance Biopharma","drug launch","biotech finance","cash runway","biopharma"],"summary":"FDA approval does not erase business risk. Iterum, Karyopharm and Theravance show how revenue, cost, pipeline and capital clocks can begin running at the same time after a drug reaches the market.","image":"https://drugnews.com.tw/assets/articles/post-approval-biotech-commercialization-death-valley-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-09-02-post-approval-biotech-commercialization-death-valley.html"}},{"title":"新藥上市才 7 個月，公司就聲請清盤：真正的死亡谷在核准之後","date":"2026-09-02","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-02-post-approval-biotech-commercialization-death-valley.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-02-post-approval-biotech-commercialization-death-valley.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["Iterum Therapeutics","ORLYNVAH","Karyopharm","XPOVIO","Theravance Biopharma","生技商業化","現金流","新藥上市"],"summary":"ORLYNVAH 上市第一季只有 40 萬美元淨產品收入，同季銷售、一般與管理費約 650 萬美元；約七個月後，Iterum 聲請清盤。Karyopharm 與 Theravance 的情況不同，卻共同顯示新藥核准後，收入、成本、管線與資本四座時鐘會同時啟動。","image":"https://drugnews.com.tw/assets/articles/post-approval-biotech-commercialization-death-valley/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-09-02-post-approval-biotech-commercialization-death-valley-en.html"}},{"title":"Can New Drugs Be Tested in a Computer First? The Virtual Cell Is Here","date":"2026-09-01","language":"en","url":"https://drugnews.com.tw/articles/2026-09-01-aido-cell-virtual-cell-drug-discovery-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-01-aido-cell-virtual-cell-drug-discovery-en.html","source":"Facebook","access":"Free Article","category":"商業分析","tags":["AIDO Cell","GenBio AI","virtual cell","AI drug discovery","single-cell biology","drug discovery","New Approach Methodologies","X-Cell"],"summary":"GenBio AI's AIDO Cell attempts to connect DNA, RNA, proteins and cell phenotypes through a shared state that supports sequential perturbations. The company says it matched or exceeded specialist models on 24 of 31 internal metrics, but the preview covers only K-562 and Hep-G2 cells, and novel predictions still require physical experiments, external replication and blinded testing.","image":"https://drugnews.com.tw/assets/articles/aido-cell-virtual-cell-drug-discovery-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-09-01-aido-cell-virtual-cell-drug-discovery.html"}},{"title":"新藥能先在電腦裡試？「虛擬細胞」來了！","date":"2026-09-01","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-09-01-aido-cell-virtual-cell-drug-discovery.html","canonical_url":"https://drugnews.com.tw/articles/2026-09-01-aido-cell-virtual-cell-drug-discovery.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["AIDO Cell","GenBio AI","虛擬細胞","AI 製藥","單細胞","藥物發現","新方法學","X-Cell"],"summary":"GenBio AI 的 AIDO Cell 嘗試用共享狀態串起 DNA、RNA、蛋白質與細胞表型，並連續模擬基因、藥物與抗藥性擾動。公司基準顯示 31 項指標中有 24 項追平或超越專用模型，但目前只有 K-562、Hep-G2 兩種原型細胞，新預測仍待實體實驗、外部重現與盲測。","image":"https://drugnews.com.tw/assets/articles/aido-cell-virtual-cell-drug-discovery/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-09-01-aido-cell-virtual-cell-drug-discovery-en.html"}},{"title":"GLP-1 Drugs Are Making Luxury Guests Eat Less. How Can Five-Star Hotels Protect Revenue?","date":"2026-08-31","language":"en","url":"https://drugnews.com.tw/articles/2026-08-31-glp1-luxury-hospitality-spending-shift-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-31-glp1-luxury-hospitality-spending-shift-en.html","source":"Facebook","access":"Free Article","category":"商業分析","tags":["GLP-1","luxury hospitality","hotel food and beverage","consumer spending","zero-proof beverages","wellness tourism","service design","semaglutide"],"summary":"A U.S. household transaction study found that grocery spending fell 5.3% on average six months after GLP-1 adoption and 8.2% among higher-income households. Some luxury hotels are already testing smaller portions, protein-forward menus, zero-proof drinks and wellness services. The strategic question is whether hospitality operators can translate lower food volume into better service, pricing and repeat demand.","image":"https://drugnews.com.tw/assets/articles/glp1-luxury-hospitality-spending-shift-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-31-glp1-luxury-hospitality-spending-shift.html"}},{"title":"減重針逼瘋五星級飯店？客人吃少了，飯店靠什麼賺？","date":"2026-08-31","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-31-glp1-luxury-hospitality-spending-shift.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-31-glp1-luxury-hospitality-spending-shift.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["GLP-1","五星級飯店","高端旅宿","餐飲消費","無酒精飲品","健康旅遊","服務設計","semaglutide"],"summary":"美國家戶交易研究顯示，採用 GLP-1 六個月後，雜貨支出平均下降 5.3%，高收入家庭下降 8.2%；部分高端飯店也開始測試小份餐、高蛋白、無酒精飲品與健康陪伴服務。真正的商業題目，不是客人吃少了多少，而是飯店能否把食物的量重新翻譯成服務、價格與回購。","image":"https://drugnews.com.tw/assets/articles/glp1-luxury-hospitality-spending-shift/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-31-glp1-luxury-hospitality-spending-shift-en.html"}},{"title":"Avexitide Reduced the Composite Rate of Level 2/3 Hypoglycemia Events by 55%—and Repriced Amylyx Overnight","date":"2026-08-30","language":"en","url":"https://drugnews.com.tw/articles/2026-08-30-amylyx-avexitide-pbh-phase3-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-30-amylyx-avexitide-pbh-phase3-en.html","source":"Facebook","access":"Free Article","category":"基本面","tags":["Amylyx","avexitide","GLP-1","post-bariatric hypoglycemia","PBH","LUCIDITY","Relyvrio","MBX Biosciences","biotech asset acquisition"],"summary":"Avexitide reduced the combined rate of Level 2 and Level 3 hypoglycemic events by 55% versus placebo in Amylyx's Phase 3 LUCIDITY trial, sending the shares up about 64% in one session. This analysis examines the GLP-1 mechanism in post-bariatric hypoglycemia, the evidence still missing from the topline release, Amylyx's $35.1 million asset acquisition, its $500.2 million financing and the regulatory and commercial gates ahead.","image":"https://drugnews.com.tw/assets/articles/amylyx-avexitide-pbh-phase3-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-30-amylyx-avexitide-pbh-phase3.html"}},{"title":"減重手術後，吃飯竟可能昏倒？一款新藥讓 Amylyx 暴漲 64%！","date":"2026-08-30","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-30-amylyx-avexitide-pbh-phase3.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-30-amylyx-avexitide-pbh-phase3.html","source":"Facebook","access":"商業分析文","category":"基本面","tags":["Amylyx","avexitide","GLP-1","減重手術後低血糖","PBH","LUCIDITY","Relyvrio","MBX Biosciences","生技資產交易"],"summary":"Amylyx 的 avexitide 在 LUCIDITY 三期試驗中，讓第二級與第三級低血糖事件合併發生率較安慰劑降低 55%，帶動股價單日上漲約 64%。本文拆解 PBH 的 GLP-1 機制、三期證據、3,510 萬美元資產收購、5 億美元募資，以及核准與商業化前仍須跨越的關卡。","image":"https://drugnews.com.tw/assets/articles/amylyx-avexitide-pbh-phase3/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-30-amylyx-avexitide-pbh-phase3-en.html"}},{"title":"Pancreatic Cancer Finally Gets a Broad RAS(ON) Drug: Inside RASONQUE's FDA Approval","date":"2026-08-29","language":"en","url":"https://drugnews.com.tw/articles/2026-08-29-revolution-rasonque-pancreatic-cancer-ras-on-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-29-revolution-rasonque-pancreatic-cancer-ras-on-en.html","source":"Facebook","access":"Free Article","category":"基本面","tags":["Revolution Medicines","RASONQUE","daraxonrasib","RAS(ON)","pancreatic cancer","FDA","BeOne Medicines","Royalty Pharma","biotech commercialization"],"summary":"The FDA approved Revolution Medicines' RASONQUE 6.5 months ahead of schedule for a defined metastatic pancreatic adenocarcinoma population. This analysis examines the RASolute 302 survival data, the RAS(ON) mechanism, Revolution's eleven-year strategic pivot and the pricing, access, safety and global execution tests that begin after approval.","image":"https://drugnews.com.tw/assets/articles/revolution-rasonque-pancreatic-cancer-ras-on-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-29-revolution-rasonque-pancreatic-cancer-ras-on.html"}},{"title":"胰臟癌終於被撬開一道縫！FDA 提前 6.5 個月批准首款廣譜 RAS 新藥","date":"2026-08-29","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-29-revolution-rasonque-pancreatic-cancer-ras-on.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-29-revolution-rasonque-pancreatic-cancer-ras-on.html","source":"Facebook","access":"商業分析文","category":"基本面","tags":["Revolution Medicines","RASONQUE","daraxonrasib","RAS(ON)","胰臟癌","FDA","BeOne Medicines","Royalty Pharma","生技商業化"],"summary":"FDA 提前 6.5 個月核准 Revolution Medicines 的 RASONQUE，用於特定轉移性胰臟腺癌成人。本文拆解 RASolute 302 的生存數據、RAS(ON) 技術、Revolution 十一年轉向史，以及藥證之後的定價、給付、安全性與全球商業化考驗。","image":"https://drugnews.com.tw/assets/articles/revolution-rasonque-pancreatic-cancer-ras-on/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-29-revolution-rasonque-pancreatic-cancer-ras-on-en.html"}},{"title":"A New Rival for PharmaEssentia? What Zealand Actually Sold for $100 Million","date":"2026-08-28","language":"en","url":"https://drugnews.com.tw/articles/2026-08-28-zealand-rusfertide-royalty-pharma-pv-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-28-zealand-rusfertide-royalty-pharma-pv-en.html","source":"CMoney","access":"Free Article","category":"基本面","tags":["Zealand Pharma","Royalty Pharma","rusfertide","Protagonist Therapeutics","Takeda","PharmaEssentia","BESREMi","polycythemia vera","royalty financing"],"summary":"Zealand Pharma sold rusfertide-related milestones and a 1% global net-sales royalty for up to $100 million, not control of the drug itself. The transaction clarifies how Zealand, Protagonist and Takeda hold very different economics—and what rusfertide could mean for PharmaEssentia's BESREMi.","image":"https://drugnews.com.tw/assets/articles/zealand-rusfertide-royalty-pharma-pv-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-28-zealand-rusfertide-royalty-pharma-pv.html"}},{"title":"藥華藥迎新對手？1 億美元賣分潤","date":"2026-08-28","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-28-zealand-rusfertide-royalty-pharma-pv.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-28-zealand-rusfertide-royalty-pharma-pv.html","source":"CMoney","access":"商業分析文","category":"基本面","tags":["Zealand Pharma","Royalty Pharma","rusfertide","Protagonist Therapeutics","Takeda","藥華藥","BESREMi","真性紅血球增多症","權利金交易"],"summary":"Zealand Pharma 以總對價 1 億美元出售 rusfertide 的里程碑與 1% 全球淨銷售權利金，交易不是出售藥物控制權。本文拆解 Zealand、Protagonist 與武田的不同經濟位置，並分析 rusfertide 對藥華藥 BESREMi 的競爭、互補與治療分層。","image":"https://drugnews.com.tw/assets/articles/zealand-rusfertide-royalty-pharma-pv/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-28-zealand-rusfertide-royalty-pharma-pv-en.html"}},{"title":"DNA Is Not the Nvidia of AI Drug Discovery, At Least Not Yet","date":"2026-08-27","language":"en","url":"https://drugnews.com.tw/articles/2026-08-27-twist-dna-ai-drug-discovery-shovels-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-27-twist-dna-ai-drug-discovery-shovels-en.html","source":"Facebook","access":"Free Article","category":"商業分析","tags":["Twist Bioscience","TWST","AI drug discovery","DNA synthesis","protein engineering","wet lab automation","Design-Build-Test-Learn","biotech investing"],"summary":"Twist Bioscience is seeing rapid growth in AI-enabled drug-discovery orders and DSPS revenue, but demand growth, unit value and industry moat are not the same thing. The scarce asset may be the full wet-lab system that converts massive sequence volumes into proteins, functional data and model feedback.","image":"https://drugnews.com.tw/assets/articles/twist-dna-ai-drug-discovery-shovels-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-27-twist-dna-ai-drug-discovery-shovels.html"}},{"title":"DNA 不是 AI 製藥的輝達，至少現在還不是","date":"2026-08-27","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-27-twist-dna-ai-drug-discovery-shovels.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-27-twist-dna-ai-drug-discovery-shovels.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["Twist Bioscience","TWST","AI 製藥","DNA 合成","蛋白質工程","濕實驗室","Design-Build-Test-Learn","生技投資"],"summary":"Twist Bioscience 的 AI 輔助藥物發現訂單與 DSPS 營收快速成長，但需求增加、單位價值與產業壁壘不是同一件事。真正稀缺的，可能不是單一 DNA 合成步驟，而是能把海量序列轉成蛋白質、功能數據並回饋模型的整座濕實驗工廠。","image":"https://drugnews.com.tw/assets/articles/twist-dna-ai-drug-discovery-shovels/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-27-twist-dna-ai-drug-discovery-shovels-en.html"}},{"title":"Merck’s Oral PCSK9 Drug Enters an Injectable Market: Who Really Loses?","date":"2026-08-26","language":"en","url":"https://drugnews.com.tw/articles/2026-08-26-merck-lipfendra-oral-pcsk9-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-26-merck-lipfendra-oral-pcsk9-en.html","source":"Facebook","access":"Free Article","category":"商業分析","tags":["Merck","Lipfendra","enlicitide","PCSK9","LDL cholesterol","cardiovascular outcomes","Novartis","Leqvio","Taiwan market access"],"summary":"Lipfendra is the first FDA-approved oral PCSK9 inhibitor, lowering LDL-C by 56% and 59% in two Phase 3 trials. Oral dosing opens a major market, but cardiovascular outcomes, fasting adherence, payer access and Taiwan approval will decide whether it expands the category or displaces injections.","image":"https://drugnews.com.tw/assets/articles/merck-lipfendra-oral-pcsk9-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-26-merck-lipfendra-oral-pcsk9.html"}},{"title":"默沙東口服藥殺進「降膽固醇針」市場，誰會被搶走？","date":"2026-08-26","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-26-merck-lipfendra-oral-pcsk9.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-26-merck-lipfendra-oral-pcsk9.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["默沙東","Lipfendra","enlicitide","PCSK9","膽固醇","心血管","諾華","Leqvio","台灣健保"],"summary":"FDA 核准首款每日口服 PCSK9 抑制劑 Lipfendra，兩項第三期試驗在第 24 週降低 LDL-C 56% 與 59%。但口服不等於針劑退場：心血管硬終點、每日空腹依從性、保險准入與台灣核准，才會決定市場如何重切。","image":"https://drugnews.com.tw/assets/articles/merck-lipfendra-oral-pcsk9/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-26-merck-lipfendra-oral-pcsk9-en.html"}},{"title":"The Stronger the Backbone, the More Valuable the Missing Layer: Can Anbogen's ABT-301 Enter the Next Wave of Oncology BD?","date":"2026-08-25","language":"en","url":"https://drugnews.com.tw/articles/2026-08-25-anbogen-abt-301-combination-layer-tokyo-comparative-oncology-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-25-anbogen-abt-301-combination-layer-tokyo-comparative-oncology-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["AnBogen Therapeutics","ABT-301","imofinostat","Combination Layer","colorectal cancer","University of Tokyo","oncology BD","Taiwan biotech"],"summary":"Big Pharma is paying for incremental efficacy around established therapies. ABT-301 has completed Phase 1; the CRC triplet's efficacy, sustainable dosing, durability and biomarker readouts will determine whether it can become a Combination Layer and open substantive partnering opportunities.","image":"https://drugnews.com.tw/assets/articles/anbogen-abt-301-combination-layer-tokyo-comparative-oncology-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-25-anbogen-abt-301-combination-layer-tokyo-comparative-oncology.html"}},{"title":"主藥越強，旁邊缺的那一層越值錢：安邦ABT-301能否進入下一輪腫瘤BD名單？","date":"2026-08-25","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-25-anbogen-abt-301-combination-layer-tokyo-comparative-oncology.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-25-anbogen-abt-301-combination-layer-tokyo-comparative-oncology.html","source":"Website","access":"商業分析文","category":"商業分析","tags":["安邦生技","ABT-301","imofinostat","Combination Layer","大腸直腸癌","東京大學","腫瘤BD","台灣生技"],"summary":"大藥廠正為主藥旁的增量療效付費。安邦ABT-301已完成Phase I，接下來由CRC三聯的療效、劑量持續性、耐久性與biomarker決定其能否走向Combination Layer與大型藥廠合作。","image":"https://drugnews.com.tw/assets/articles/anbogen-abt-301-combination-layer-tokyo-comparative-oncology/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-25-anbogen-abt-301-combination-layer-tokyo-comparative-oncology-en.html"}},{"title":"Curium and Lantheus Agree to an Up-to-$8 Billion Merger: Radiopharma Becomes a Full-Stack Business","date":"2026-08-24","language":"en","url":"https://drugnews.com.tw/articles/2026-08-24-curium-lantheus-definitive-merger-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-24-curium-lantheus-definitive-merger-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["Curium","Lantheus","radiopharma","theranostics","PSMA","PYLARIFY","Pluvicto","M&A","nuclear medicine","Taiwan biotech"],"summary":"The $7 billion Curium-Lantheus rumor covered in June became a definitive agreement on August 3: $102.50 in cash plus up to $12.00 per share in CVRs, for total consideration of up to $8 billion. The strategic prize is an integrated chain spanning isotopes, manufacturing, distribution, diagnostics, therapy and U.S. hospital access.","image":"https://drugnews.com.tw/assets/articles/curium-lantheus-definitive-merger-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-24-curium-lantheus-definitive-merger.html"}},{"title":"核藥史上最大併購：Curium 與 Lantheus 合併，改寫的不只是交易金額","date":"2026-08-24","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-24-curium-lantheus-definitive-merger.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-24-curium-lantheus-definitive-merger.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["Curium","Lantheus","核藥","放射性藥物","診療一體化","PSMA","PYLARIFY","Pluvicto","併購","長佳智能"],"summary":"6 月官網追蹤的 Curium–Lantheus 70 億美元收購傳聞，已在 8 月 3 日推進為最終合併協議：每股 102.50 美元現金加最高 12 美元 CVR，總交易價值最高約 80 億美元。真正被整合的是核素、製造、配送、診斷、治療與美國院端網絡。","image":"https://drugnews.com.tw/assets/articles/curium-lantheus-definitive-merger/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-24-curium-lantheus-definitive-merger-en.html"}},{"title":"Who Could Be Big Pharma's Next Major Biotech Acquisition?","date":"2026-08-23","language":"en","url":"https://drugnews.com.tw/articles/2026-08-23-big-pharma-biotech-ma-next-targets-2026-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-23-big-pharma-biotech-ma-next-targets-2026-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["biotech M&A","Big Pharma","Alkermes","Dyne Therapeutics","First Tracks Biotherapeutics","Legend Biotech","Sail Biomedicines","Pharmosa Biopharm","Belite Bio","BD licensing"],"summary":"Biopharma acquisition capital in 2026 is clustering around a narrow window: human risk has started to fall, but strategic value is not yet fully priced. Alkermes, Dyne, First Tracks, Legend and Sail illustrate five ways a biotech can enter that window, while Taiwan's Pharmosa Biopharm and Belite Bio show how late-stage assets can speak the same global language.","image":"https://drugnews.com.tw/assets/articles/big-pharma-biotech-ma-next-targets-2026-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-23-big-pharma-biotech-ma-next-targets-2026.html"}},{"title":"Biotech 下一筆重磅併購，會落在誰身上？","date":"2026-08-23","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-23-big-pharma-biotech-ma-next-targets-2026.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-23-big-pharma-biotech-ma-next-targets-2026.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["生技併購","Big Pharma","Alkermes","Dyne Therapeutics","First Tracks Biotherapeutics","Legend Biotech","Sail Biomedicines","國邑","仁新","BD 授權"],"summary":"2026 年的生技併購資金，正集中到臨床風險開始下降、商業價值尚未完全定價的公司。從 Alkermes、Dyne、First Tracks、Legend 到 Sail，再回看國邑與仁新，真正值得追的是人體概念驗證、平台外延、商業化距離與買方策略契合度。","image":"https://drugnews.com.tw/assets/articles/big-pharma-biotech-ma-next-targets-2026/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-23-big-pharma-biotech-ma-next-targets-2026-en.html"}},{"title":"BeOne Bets on Four RAS Drugs: The Real Asset Is Development Optionality","date":"2026-08-22","language":"en","url":"https://drugnews.com.tw/articles/2026-08-22-revolution-medicines-beone-four-ras-programs-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-22-revolution-medicines-beone-four-ras-programs-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["BeOne Medicines","Revolution Medicines","RAS(ON)","daraxonrasib","zoldonrasib","BGB-58067","BG-T187","biotech licensing","oncology","drug development"],"summary":"BeOne is taking regional rights to four RAS(ON) programs, opening two candidate combination routes and funding one global registrational Phase 3. The strategic asset is not the sum of four drugs, but the optionality to decide where capital and development speed matter most.","image":"https://drugnews.com.tw/assets/articles/revolution-medicines-beone-four-ras-programs-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-22-revolution-medicines-beone-four-ras-programs.html"}},{"title":"百濟神州一口氣押上 4 款 RAS 新藥","date":"2026-08-22","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-22-revolution-medicines-beone-four-ras-programs.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-22-revolution-medicines-beone-four-ras-programs.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["BeOne Medicines","百濟神州","Revolution Medicines","RAS(ON)","daraxonrasib","zoldonrasib","BGB-58067","BG-T187","BD 授權","腫瘤"],"summary":"百濟神州一次接進四款成熟度不同的 RAS(ON) 資產、兩條候選聯用路線與一項全球註冊三期。真正值得追的不是四藥相加，而是區域權利、開發分工與選擇權如何替雙方搶時間。","image":"https://drugnews.com.tw/assets/articles/revolution-medicines-beone-four-ras-programs/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-22-revolution-medicines-beone-four-ras-programs-en.html"}},{"title":"Moderna Surges 176.97% After Its Personalized Cancer Vaccine Clears a Phase 3 Test","date":"2026-08-21","language":"en","url":"https://drugnews.com.tw/articles/2026-08-21-moderna-merck-intismeran-phase3-melanoma-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-21-moderna-merck-intismeran-phase3-melanoma-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["Moderna","Merck","intismeran autogene","INTerpath-001","personalized cancer vaccine","melanoma","mRNA manufacturing","Phase 3"],"summary":"Positive topline results from INTerpath-001 sent Moderna shares up 176.97% in one session. The deeper valuation question is whether patient-specific design, manufacturing, release and clinical delivery can become a scalable platform.","image":"https://drugnews.com.tw/assets/articles/moderna-merck-intismeran-phase3-melanoma-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh":"2026-08-21-moderna-merck-intismeran-phase3-melanoma.html"}},{"title":"再見癌症？癌症疫苗來了！莫德納單日暴漲176.97%","date":"2026-08-21","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-21-moderna-merck-intismeran-phase3-melanoma.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-21-moderna-merck-intismeran-phase3-melanoma.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["Moderna","Merck","intismeran autogene","INTerpath-001","mRNA 癌症疫苗","黑色素瘤","個人化醫療","臨床三期"],"summary":"INTerpath-001 第三期頂線結果讓莫德納股價單日上漲 176.97%。真正被重新估價的，不只是一款黑色素瘤療法，而是個人化設計、製造、質控與臨床交付能否成為可擴張的平台。","image":"https://drugnews.com.tw/assets/articles/moderna-merck-intismeran-phase3-melanoma/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-21-moderna-merck-intismeran-phase3-melanoma-en.html"}},{"title":"NVIDIA Enters Pharma: BMS Readies 576 GPUs as Lilly Commits Up to $1 Billion","date":"2026-08-20","language":"en","url":"https://drugnews.com.tw/articles/2026-08-20-big-pharma-ai-arms-race-nvidia-bms-lilly-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-20-big-pharma-ai-arms-race-nvidia-bms-lilly-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["AI drug discovery","NVIDIA","Bristol Myers Squibb","Eli Lilly","Roche","drug development","GPU infrastructure","Taiwan semiconductor supply chain"],"summary":"BMS is preparing to deploy what NVIDIA's published specifications imply is a 576-GPU Rubin system, while Lilly and NVIDIA plan to commit up to $1 billion over five years. The real contest is whether proprietary data, wet-lab execution and clinical evidence can become one learning loop.","image":"https://drugnews.com.tw/assets/articles/big-pharma-ai-arms-race-nvidia-bms-lilly-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh":"2026-08-20-big-pharma-ai-arms-race-nvidia-bms-lilly.html"}},{"title":"輝達殺進製藥業！BMS 搶 576 顆 GPU，禮來砸 10 億美元","date":"2026-08-20","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-20-big-pharma-ai-arms-race-nvidia-bms-lilly.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-20-big-pharma-ai-arms-race-nvidia-bms-lilly.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["AI 製藥","NVIDIA","BMS","禮來","Roche","新藥研發","GPU","台灣供應鏈"],"summary":"BMS 準備部署依 NVIDIA 規格推算共 576 顆 Rubin GPU，禮來與 NVIDIA 五年共同投入上限 10 億美元；真正的競爭不只在算力，而在能否把專有資料、濕實驗與臨床證據接成研發閉環。","image":"https://drugnews.com.tw/assets/articles/big-pharma-ai-arms-race-nvidia-bms-lilly/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-20-big-pharma-ai-arms-race-nvidia-bms-lilly-en.html"}},{"title":"Just $74 Million Short: Can Skyrizi Succeed Humira as the Autoimmune Drug King?","date":"2026-08-19","language":"en","url":"https://drugnews.com.tw/articles/2026-08-19-skyrizi-humira-autoimmune-drug-king-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-19-skyrizi-humira-autoimmune-drug-king-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["Skyrizi","Humira","AbbVie","Psoriasis","Autoimmune","IL-23","ICOTYDE","Biopharma"],"summary":"Skyrizi generated $5.505 billion in Q2 2026, only $74 million below Humira's historic quarterly peak. The real succession test spans efficacy, treatment burden, multi-indication reach and access.","image":"https://drugnews.com.tw/assets/articles/skyrizi-humira-autoimmune-drug-king-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh":"2026-08-19-skyrizi-humira-autoimmune-drug-king.html"}},{"title":"55 億美元只差一步：Skyrizi 要接棒 Humira 當自體免疫藥王？","date":"2026-08-19","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-19-skyrizi-humira-autoimmune-drug-king.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-19-skyrizi-humira-autoimmune-drug-king.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["Skyrizi","喜開悅","Humira","復邁","AbbVie","乾癬","自體免疫","IL-23","ICOTYDE"],"summary":"Skyrizi 2026 年第二季收入達 55.05 億美元，距 Humira 的歷史單季高點只差 7,400 萬美元；真正的接班考驗，是療效、治療負擔、多適應症與支付能力能否一起延續。","image":"https://drugnews.com.tw/assets/articles/skyrizi-humira-autoimmune-drug-king/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-19-skyrizi-humira-autoimmune-drug-king-en.html"}},{"title":"Eli Lilly Sold $23 Billion in One Quarter. Why Is It Still Rushing to Buy the Next Drug King?","date":"2026-08-18","language":"en","url":"https://drugnews.com.tw/articles/2026-08-18-eli-lilly-tirzepatide-next-drug-king-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-18-eli-lilly-tirzepatide-next-drug-king-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["Eli Lilly","Tirzepatide","Mounjaro","Zepbound","GLP-1","Retatrutide","Orforglipron","Caliway"],"summary":"Tirzepatide has allowed Eli Lilly to dominate both diabetes and obesity, but revenue concentration, pricing pressure and the next product relay are the investment questions that matter now.","image":"https://drugnews.com.tw/assets/articles/eli-lilly-tirzepatide-next-drug-king-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh":"2026-08-18-eli-lilly-tirzepatide-next-drug-king.html"}},{"title":"一季狂賣 230 億美元，禮來卻急著買下一個藥王","date":"2026-08-18","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-18-eli-lilly-tirzepatide-next-drug-king.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-18-eli-lilly-tirzepatide-next-drug-king.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["Eli Lilly","禮來","Tirzepatide","Mounjaro","Zepbound","GLP-1","Retatrutide","Orforglipron","康霈"],"summary":"Tirzepatide 讓禮來同時吃下糖尿病與減重兩個大市場，但收入集中、價格壓力與下一代產品接班，才是市場真正該看的投資問題。","image":"https://drugnews.com.tw/assets/articles/eli-lilly-tirzepatide-next-drug-king/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-18-eli-lilly-tirzepatide-next-drug-king-en.html"}},{"title":"Revenue Jumped 39%, Yet Iovance Still Lost $47 Million: Can Cancer Cell Therapy Become a Business?","date":"2026-08-17","language":"en","url":"https://drugnews.com.tw/articles/2026-08-17-iovance-amtagvi-til-commercialization-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-17-iovance-amtagvi-til-commercialization-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["Iovance","Amtagvi","TIL","cancer cell therapy","melanoma","cell therapy","Timing Pharma"],"summary":"Iovance's Amtagvi rebounded sharply in the second quarter, but the central question is no longer whether TIL therapy can work. It is whether a personalized cell therapy can become a reproducible, reimbursable and scalable medical service.","image":"https://drugnews.com.tw/assets/articles/iovance-amtagvi-til-commercialization-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh":"2026-08-17-iovance-amtagvi-til-commercialization.html"}},{"title":"營收跳增 39%，還是虧了 4,700 萬美元：癌症細胞療法翻身了？","date":"2026-08-17","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-17-iovance-amtagvi-til-commercialization.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-17-iovance-amtagvi-til-commercialization.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["Iovance","Amtagvi","TIL","癌症細胞療法","黑色素瘤","細胞治療","天明製藥"],"summary":"Iovance 的 Amtagvi 第二季營收明顯反彈，但真正要驗證的不是 TIL 是否有療效，而是個人化細胞療法能否被做成可複製、可支付、可放大的醫療服務。","image":"https://drugnews.com.tw/assets/articles/iovance-amtagvi-til-commercialization/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-17-iovance-amtagvi-til-commercialization-en.html"}},{"title":"Pfizer Paid Billions for Obesity Assets. Is It Already Cutting Its Losses?","date":"2026-08-16","language":"en","url":"https://drugnews.com.tw/articles/2026-08-16-obesity-drug-shakeout-pfizer-roche-amgen-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-16-obesity-drug-shakeout-pfizer-roche-amgen-en.html","source":"Facebook","access":"Free Article","category":"商業分析","tags":["Business Analysis","obesity","weight-loss drugs","GLP-1","Pfizer","Roche","Amgen","Metsera","Caliway","ANYA Biopharm"],"summary":"Pfizer, Roche and Amgen are pruning obesity programs that lack clear differentiation. The GLP-1 market has moved from a race to enter the clinic to a contest across efficacy, safety, convenience and commercial execution.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-16-obesity-drug-shakeout-pfizer-roche-amgen.html"}},{"title":"百億美元搶來的減肥藥，輝瑞冤大頭又丟掉了？","date":"2026-08-16","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-16-obesity-drug-shakeout-pfizer-roche-amgen.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-16-obesity-drug-shakeout-pfizer-roche-amgen.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["肥胖症","減重藥","GLP-1","Pfizer","Roche","Amgen","Metsera","康霈","奧孟亞"],"summary":"Pfizer、Roche 與 Amgen 同步清理缺乏差異化的肥胖症管線，顯示 GLP-1 下半場的門檻已從「有藥可做」升高為療效、安全、便利性與商業化能力的全面競爭。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-16-obesity-drug-shakeout-pfizer-roche-amgen-en.html"}},{"title":"GSK's US$2 Billion Cough-Drug Bet Hit a Phase 3 Reproducibility Wall","date":"2026-08-15","language":"en","url":"https://drugnews.com.tw/articles/2026-08-15-gsk-camlipixant-calm-phase3-reproducibility-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-15-gsk-camlipixant-calm-phase3-reproducibility-en.html","source":"Facebook","access":"Free Article","category":"商業分析","tags":["Business Analysis","GSK","camlipixant","P2X3","refractory chronic cough","CALM-1","CALM-2","Phase 3","drug development","biopharma M&A"],"summary":"After GSK's roughly US$2 billion acquisition of BELLUS Health, CALM-1 met its endpoint but CALM-2 did not reproduce the result. The divergence shows why Phase 2 promise, patient experience and reproducibility must move together.","image":"https://drugnews.com.tw/assets/articles/gsk-camlipixant-calm-phase3-reproducibility-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-15-gsk-camlipixant-calm-phase3-reproducibility.html"}},{"title":"GSK 砸 20 億美元買止咳新藥，三期卻翻車！","date":"2026-08-15","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-15-gsk-camlipixant-calm-phase3-reproducibility.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-15-gsk-camlipixant-calm-phase3-reproducibility.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["GSK","camlipixant","P2X3","慢性咳嗽","CALM-1","CALM-2","臨床三期","新藥研發","生技併購"],"summary":"GSK 約 20 億美元收購 BELLUS Health 後，camlipixant 的 CALM-1 達標、CALM-2 卻未能複製。這場第三期落差揭示：二期訊號、患者感受與可重現性必須一起過關。","image":"https://drugnews.com.tw/assets/articles/gsk-camlipixant-calm-phase3-reproducibility/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-15-gsk-camlipixant-calm-phase3-reproducibility-en.html"}},{"title":"This Taiwanese Biotech Is Building a Nanorocket Inside the Human Body","date":"2026-08-13","language":"en","url":"https://drugnews.com.tw/articles/2026-08-13-intelligene-rna-delivery-nanorocket-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-13-intelligene-rna-delivery-nanorocket-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Intelligene","RNA delivery","oligonucleotide therapeutics","siRNA","ASO","extracellular vesicles","LNP","extrahepatic delivery","Taiwan biotech"],"summary":"Oligonucleotide therapeutics are moving from sequence design to extrahepatic delivery. Intelligene is using EV and LNP platforms to target the lung and airways, testing whether RNA medicines can truly reach disease sites beyond the liver.","image":"https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-13-intelligene-rna-delivery-nanorocket.html"}},{"title":"這家台灣Biotech正在打造人體內奈米火箭","date":"2026-08-13","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-13-intelligene-rna-delivery-nanorocket.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-13-intelligene-rna-delivery-nanorocket.html","source":"Website","access":"商業分析文","category":"商業分析","tags":["智新生物","Intelligene","RNA 遞送","小核酸藥物","siRNA","ASO","EV 外泌體","LNP","肝外遞送","台灣生技"],"summary":"小核酸藥物的競爭正從 RNA 序列設計走向肝外遞送；智新生技以 EV 與 LNP 平台切入肺部與呼吸道，挑戰小核酸下半場最值錢的問題：能否真正抵達病灶。","image":"https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-13-intelligene-rna-delivery-nanorocket-en.html"}},{"title":"Novo Nordisk’s 6,300-Patient ZEUS Failure: A Textbook Lesson in Translational Risk","date":"2026-08-13","language":"en","url":"https://drugnews.com.tw/articles/2026-08-13-ziltivekimab-zeus-mace-phase3-failure-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-13-ziltivekimab-zeus-mace-phase3-failure-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["Novo Nordisk","ziltivekimab","ZEUS","MACE","IL-6","hsCRP","cardiovascular outcomes","Phase 3","biomarker risk"],"summary":"ZEUS showed the central translational risk in cardiovascular drug development: ziltivekimab suppressed the IL-6 pathway, but the 6,300-patient outcomes trial did not reduce three-point MACE.","image":"https://drugnews.com.tw/assets/articles/ziltivekimab-zeus-mace-phase3-failure-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-13-ziltivekimab-zeus-mace-phase3-failure.html"}},{"title":"諾和諾德大三期慘敗！6,300 人的教科書級教訓","date":"2026-08-13","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-13-ziltivekimab-zeus-mace-phase3-failure.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-13-ziltivekimab-zeus-mace-phase3-failure.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["Novo Nordisk","ziltivekimab","ZEUS","MACE","IL-6","hsCRP","心血管","慢性腎臟病","NVO","合一生技"],"summary":"ZEUS 超過 6,300 人卻交出 HR 0.99：ziltivekimab 壓低 free IL-6 與 hsCRP，卻沒有證明能降低三點 MACE。這不是抗發炎假說死亡，而是 biomarker 不能替患者硬終點預支成功。","image":"https://drugnews.com.tw/assets/articles/ziltivekimab-zeus-mace-phase3-failure/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-13-ziltivekimab-zeus-mace-phase3-failure-en.html"}},{"title":"Can $1.2 Billion Help AI Double the Pace of Drug R&D?","date":"2026-08-12","language":"en","url":"https://drugnews.com.tw/articles/2026-08-12-bio-genesis-mission-ai-drug-rd-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-12-bio-genesis-mission-ai-drug-rd-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["Bio Genesis Mission","AI drug discovery","NIH","DOE","biomedical data","drug development","digital pathology","multi-omics","Taiwan biotech"],"summary":"The Bio Genesis Mission is an attempt to connect supercomputing, biomedical data, AI agents, automated laboratories, clinical networks, and regulation into one R&D loop. Its real test is whether governed data and reproducible experiments can reach patients faster.","image":"https://drugnews.com.tw/assets/articles/bio-genesis-mission-ai-drug-rd-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-12-bio-genesis-mission-ai-drug-rd.html"}},{"title":"美國砸 12 億美元，想用 AI 把新藥研發快一倍！","date":"2026-08-12","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-12-bio-genesis-mission-ai-drug-rd.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-12-bio-genesis-mission-ai-drug-rd.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["Bio Genesis Mission","AI製藥","NIH","DOE","生醫資料","藥物研發","數位病理","多體學","雲象科技","基米"],"summary":"美國以 Bio Genesis Mission 串起超算、生醫資料、AI 代理、自動化實驗、臨床與監管能力；真正的成敗不在模型口號，而在資料治理、實驗重現與患者轉譯能否形成閉環。","image":"https://drugnews.com.tw/assets/articles/bio-genesis-mission-ai-drug-rd/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-12-bio-genesis-mission-ai-drug-rd-en.html"}},{"title":"After 20 Years, Have HDAC Inhibitors Finally Found Their Role? Why ABT-301 Could Become a Next-Generation Combination Backbone","date":"2026-08-11","language":"en","url":"https://drugnews.com.tw/articles/2026-08-11-anbogen-abt301-next-generation-hdaci-backbone-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-11-anbogen-abt301-next-generation-hdaci-backbone-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["AnBogen Therapeutics","ABT-301","imofinostat","HDAC inhibitor","Chidamide","pMMR colorectal cancer","cancer immunotherapy","Taiwan biotech"],"summary":"Chidamide has brought HDAC inhibition back into solid-tumor development. ABT-301 must now show that a wider therapeutic window, triplet combinability, and human immune-mechanism data can support a next-generation combination backbone.","image":"https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-11-anbogen-abt301-next-generation-hdaci-backbone.html"}},{"title":"20年後，HDAC抑制劑終於找到真正的位置？ABT-301能否成為下一代聯合治療骨幹","date":"2026-08-11","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-11-anbogen-abt301-next-generation-hdaci-backbone.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-11-anbogen-abt301-next-generation-hdaci-backbone.html","source":"Website","access":"商業分析文","category":"商業分析","tags":["安邦生技","ABT-301","imofinostat","HDAC抑制劑","Chidamide","pMMR大腸直腸癌","癌症免疫治療","台灣生技"],"summary":"Chidamide以pMMR大腸癌44% ORR與黑色素瘤第三期PFS達標，重新降低HDAC抑制劑的類別風險；安邦ABT-301接下來必須用治療窗口、三聯可組合性與人體免疫機轉，證明資產差異。","image":"https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-11-anbogen-abt301-next-generation-hdaci-backbone-en.html"}},{"title":"禮來領頭，大藥廠半年豪砸 1,300 億美元搶時間！","date":"2026-08-10","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-10-biopharma-ma-buying-time-2026h1.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-10-biopharma-ma-buying-time-2026h1.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["生技併購","藥廠併購","專利懸崖","Eli Lilly","Merck","AbbVie","Gilead","GSK","IQVIA","Biotech"],"summary":"2026 年上半年生技製藥併購總額約 1,300 億美元，買家偏向臨床後期與接近上市的資產。這一輪不是全面牛市，而是大藥廠在專利懸崖前，用交易結構與現金購買可計算的開發時間。","image":"https://drugnews.com.tw/assets/articles/biopharma-ma-buying-time-2026h1/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-10-biopharma-ma-buying-time-2026h1-en.html"}},{"title":"$130 Billion in Six Months: Big Pharma Is Buying Time","date":"2026-08-10","language":"en","url":"https://drugnews.com.tw/articles/2026-08-10-biopharma-ma-buying-time-2026h1-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-10-biopharma-ma-buying-time-2026h1-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["biopharma M&A","pharma acquisitions","patent cliff","Eli Lilly","Merck","AbbVie","Gilead","GSK","IQVIA","biotech"],"summary":"Biopharma M&A reached approximately $130 billion in the first half of 2026 as buyers favored late-stage and near-launch assets. This is not a broad biotech bull market; it is Big Pharma using cash and contingent deal structures to buy measurable development time before the patent cliff.","image":"https://drugnews.com.tw/assets/articles/biopharma-ma-buying-time-2026h1-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-10-biopharma-ma-buying-time-2026h1.html"}},{"title":"J&J's Oral Psoriasis Drug Logged 18,000 Prescriptions in Its First Full Quarter. Is It Coming for Injectables?","date":"2026-08-09","language":"en","url":"https://drugnews.com.tw/articles/2026-08-09-icotyde-oral-il23r-launch-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-09-icotyde-oral-il23r-launch-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["ICOTYDE","icotrokinra","Johnson & Johnson","Psoriasis","IL-23R","Oral Peptide","Drug Commercialization"],"summary":"ICOTYDE logged more than 18,000 prescriptions in its first full quarter. The oral IL-23R peptide has earned entry into the high-efficacy psoriasis market, but durable value still depends on paid fills, persistence, payer quality, safety, and additional indications.","image":"https://drugnews.com.tw/assets/articles/icotyde-oral-il23r-launch-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-09-icotyde-oral-il23r-launch.html"}},{"title":"嬌生口服藥首季 1.8 萬張處方，針劑飯碗要被搶了？","date":"2026-08-09","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-09-icotyde-oral-il23r-launch.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-09-icotyde-oral-il23r-launch.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["ICOTYDE","icotrokinra","Johnson & Johnson","乾癬","IL-23R","口服胜肽","新藥商業化"],"summary":"ICOTYDE 上市後第一個完整季度累積逾 18,000 張處方。口服 IL-23R 胜肽已取得進入高療效市場的資格，真正的商業答案仍取決於續方、支付品質、長期留存與多適應症。","image":"https://drugnews.com.tw/assets/articles/icotyde-oral-il23r-launch/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-09-icotyde-oral-il23r-launch-en.html"}},{"title":"Why These Four Biotechs Can Afford Not to Sell","date":"2026-08-08","language":"en","url":"https://drugnews.com.tw/articles/2026-08-08-biotech-independence-not-selling-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-08-biotech-independence-not-selling-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["Biotech","Biopharma","argenx","Insmed","Revolution Medicines","Incyte","Royalty Pharma","Drug Development","Biotech Investing"],"summary":"argenx, Insmed, Incyte, and Revolution Medicines show why biotech independence depends on product evidence, cash generation, a second growth curve, global execution, and financing without surrendering control.","image":"https://drugnews.com.tw/assets/articles/biotech-independence-not-selling-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-08-biotech-independence-not-selling.html"}},{"title":"不賣給大藥廠，4 家生技公司憑什麼自己做大？","date":"2026-08-08","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-08-biotech-independence-not-selling.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-08-biotech-independence-not-selling.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["Biotech","Biopharma","argenx","Insmed","Revolution Medicines","Incyte","Royalty Pharma","新藥開發","生技投資"],"summary":"argenx、Insmed、Incyte 與 Revolution Medicines 選擇保留獨立經營權。真正的不賣資格，來自產品證據、現金引擎、第二曲線、全球執行與不交出控制權也能取得資金的能力。","image":"https://drugnews.com.tw/assets/articles/biotech-independence-not-selling/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-08-biotech-independence-not-selling-en.html"}},{"title":"22 億美元，買下一個自體免疫藥王？","date":"2026-08-07","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-07-argenx-forte-fb102-acquisition.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-07-argenx-forte-fb102-acquisition.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["argenx","Forte Biosciences","FB102","VYVGART","CD122","自體免疫","白斑","乳糜瀉","健喬","安立璽榮"],"summary":"argenx 擬以 22 億美元現金收購 Forte，把早期抗 CD122 抗體 FB102 納入管線。真正的考題不是一組一期 p 值，而是 VYVGART 的單品成功能否被複製成可重複的公司能力。","image":"https://drugnews.com.tw/assets/articles/argenx-forte-fb102-acquisition/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-07-argenx-forte-fb102-acquisition-en.html"}},{"title":"$2.2 Billion for the Next Autoimmune Blockbuster?","date":"2026-08-07","language":"en","url":"https://drugnews.com.tw/articles/2026-08-07-argenx-forte-fb102-acquisition-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-07-argenx-forte-fb102-acquisition-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["argenx","Forte Biosciences","FB102","VYVGART","CD122","autoimmune disease","vitiligo","celiac disease","biotech M&A","Taiwan biotech"],"summary":"argenx plans to pay $2.2 billion in cash for Forte and its early anti-CD122 antibody FB102. The real test is not one Phase 1b p-value, but whether VYVGART's product success reflects a development engine the company can repeat.","image":"https://drugnews.com.tw/assets/articles/argenx-forte-fb102-acquisition-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-07-argenx-forte-fb102-acquisition.html"}},{"title":"Investors, Take Note: Hair Loss Could Be Biotech's Next Weight-Loss-Drug-Sized Blockbuster","date":"2026-08-06","language":"en","url":"https://drugnews.com.tw/articles/2026-08-06-anhorn-ah001-hair-loss-blockbuster-market-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-06-anhorn-ah001-hair-loss-blockbuster-market-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["AnHorn Medicines","AH-001","Androgenetic Alopecia","Hair-Loss Drug","AR Degrader","PROTAC","Eli Lilly","Veradermics","Absci","Taiwan Biotech"],"summary":"Lilly has placed a $40 million bet on next-generation hair-loss drugs. With roughly 80 million U.S. patients still constrained by two legacy therapies, AH-001's Phase 2 data could become the next global asset-revaluation trigger.","image":"https://drugnews.com.tw/assets/articles/anhorn-ah001-hair-loss-blockbuster-market-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-06-anhorn-ah001-hair-loss-blockbuster-market.html"}},{"title":"投資人請注意，下一個減肥藥級別賽道來了！","date":"2026-08-06","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-06-anhorn-ah001-hair-loss-blockbuster-market.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-06-anhorn-ah001-hair-loss-blockbuster-market.html","source":"Website","access":"商業分析文","category":"商業分析","tags":["安宏生醫","AH-001","雄性禿","掉髮新藥","AR 降解劑","PROTAC","禮來","Veradermics","Absci","台灣生技"],"summary":"禮來用 4,000 萬美元卡位掉髮新藥；當美國約 8,000 萬名患者仍受限於兩款老藥，安宏 AH-001 的二期數據可能成為下一次全球資產重估關鍵。","image":"https://drugnews.com.tw/assets/articles/anhorn-ah001-hair-loss-blockbuster-market/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-06-anhorn-ah001-hair-loss-blockbuster-market-en.html"}},{"title":"More Than $1 Billion in One Quarter: Why Did Alnylam Plunge 28%?","date":"2026-08-05","language":"en","url":"https://drugnews.com.tw/articles/2026-08-05-alnylam-amvuttra-ttr-growth-reset-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-05-alnylam-amvuttra-ttr-growth-reset-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["Alnylam","Amvuttra","RNA interference","ATTR amyloidosis","small nucleic acid drugs","biotech valuation","Taiwan biotech","clinical data","biotech business analysis"],"summary":"Amvuttra surpassed $1 billion in quarterly sales, yet Alnylam cut its TTR guidance and lost 28% in one day. The reset was not about RNAi technology failing; it was about pent-up demand normalizing, revenue concentration and the timing gap before a second commercial pillar arrives.","image":"https://drugnews.com.tw/assets/articles/alnylam-amvuttra-ttr-growth-reset-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-05-alnylam-amvuttra-ttr-growth-reset.html"}},{"title":"一季賣破 10 億，Alnylam 為何崩 28%？","date":"2026-08-05","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-05-alnylam-amvuttra-ttr-growth-reset.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-05-alnylam-amvuttra-ttr-growth-reset.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["Alnylam","Amvuttra","RNAi","ATTR","小核酸藥物","生技股","合一","中天","智新生技","基米"],"summary":"Amvuttra 單季銷售突破 10 億美元，Alnylam 卻下修 TTR 指引並重挫 28%。真正被重估的不是 RNAi 技術，而是積壓需求退潮、收入集中與下一個商業支柱的時間差。","image":"https://drugnews.com.tw/assets/articles/alnylam-amvuttra-ttr-growth-reset/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-05-alnylam-amvuttra-ttr-growth-reset-en.html"}},{"title":"A $400 Billion Pharma Merger? AstraZeneca and Bristol Myers Squibb Are Reportedly Talking","date":"2026-08-04","language":"en","url":"https://drugnews.com.tw/articles/2026-08-04-astrazeneca-bms-400b-merger-talks-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-04-astrazeneca-bms-400b-merger-talks-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["AstraZeneca","Bristol Myers Squibb","BMS","pharma M&A","patent cliff","oncology","antibody-drug conjugates","ADC","CAR-T","antitrust"],"summary":"AstraZeneca and BMS reportedly explored a combination with a combined market value approaching $400 billion. There is no announced transaction. The real questions are AstraZeneca's 2030 growth target, BMS's Eliquis and Opdivo exclusivity timeline, oncology-pipeline overlap, antitrust and whether integration can actually buy time.","image":"https://drugnews.com.tw/assets/articles/astrazeneca-bms-400b-merger-talks-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-04-astrazeneca-bms-400b-merger-talks.html"}},{"title":"超級大藥廠 4,000 億美元合併？阿斯特捷利康＋BMS！","date":"2026-08-04","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-04-astrazeneca-bms-400b-merger-talks.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-04-astrazeneca-bms-400b-merger-talks.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["AstraZeneca","阿斯特捷利康","Bristol Myers Squibb","BMS","百時美施貴寶","生技併購","大藥廠","專利懸崖","腫瘤新藥","ADC"],"summary":"Financial Times 報導 AstraZeneca 與 BMS 曾探討結合，合計市值接近 4,000 億美元。這不是已簽交易；真正的產業問題是 2030 成長、Eliquis／Opdivo 獨占期、腫瘤管線重疊、反壟斷與整合能否買到時間。","image":"https://drugnews.com.tw/assets/articles/astrazeneca-bms-400b-merger-talks/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-04-astrazeneca-bms-400b-merger-talks-en.html"}},{"title":"Tau Earned a Retest: Why Biogen Is Taking Diranersen Into Phase 3 After CELIA Missed Its Primary Endpoint","date":"2026-08-03","language":"en","url":"https://drugnews.com.tw/articles/2026-08-03-diranersen-celia-tau-phase3-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-03-diranersen-celia-tau-phase3-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["Alzheimer's disease","tau","diranersen","BIIB080","IONIS-MAPTRx","Biogen","Ionis","antisense oligonucleotide","ASO","CDR-SB"],"summary":"CELIA missed its prespecified dose-response primary endpoint, yet the lowest dose produced a 0.54-point CDR-SB difference, or 26% slowing, while CSF total tau and tau PET moved in the expected direction. That is enough to justify Phase 3 planning, but not enough to declare tau a validated second disease-modifying pathway.","image":"https://drugnews.com.tw/assets/articles/diranersen-celia-tau-phase3-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-03-diranersen-celia-tau-phase3.html"}},{"title":"Tau 拿到補考資格：Diranersen 主終點失敗，為什麼 Biogen 仍要進三期？","date":"2026-08-03","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-03-diranersen-celia-tau-phase3.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-03-diranersen-celia-tau-phase3.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["阿茲海默症","Tau","Diranersen","BIIB080","IONIS-MAPTRx","Biogen","Ionis","反義寡核苷酸","ASO","CDR-SB"],"summary":"CELIA 未達預設劑量反應主要終點，最低劑量卻在 CDR-SB 看到 26% 惡化減緩，CSF total tau 與 Tau PET 也同向下降。這些訊號足以讓 Biogen 與 Ionis 規劃三期，還不足以宣布 Tau 已成為第二條獲確認的疾病修飾路線。","image":"https://drugnews.com.tw/assets/articles/diranersen-celia-tau-phase3/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-03-diranersen-celia-tau-phase3-en.html"}},{"title":"Bempikibart in Alopecia Areata: A 33-Patient Signal Is Not Yet a Win Over JAK Inhibitors","date":"2026-08-02","language":"en","url":"https://drugnews.com.tw/articles/2026-08-02-bempikibart-alopecia-areata-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-02-bempikibart-alopecia-areata-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["alopecia areata","bempikibart","Q32 Bio","QTTB","IL-7Rα","JAK inhibitors","SALT","biotech valuation","clinical data","drug development"],"summary":"Q32 Bio nearly doubled after a 33-patient, single-arm Phase 2a readout. The investable questions are whether efficacy survives randomization, whether responses persist after treatment stops, and whether a larger safety database can support a differentiated place beside JAK inhibitors.","image":"https://drugnews.com.tw/assets/articles/bempikibart-alopecia-areata-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-08-02-bempikibart-alopecia-areata.html"}},{"title":"鬼剃頭新藥，先別封神","date":"2026-08-02","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-08-02-bempikibart-alopecia-areata.html","canonical_url":"https://drugnews.com.tw/articles/2026-08-02-bempikibart-alopecia-areata.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["斑禿","鬼剃頭","Bempikibart","Q32 Bio","QTTB","IL-7Rα","JAK 抑制劑","SALT","生技股","新藥研發"],"summary":"33 人、單臂、開放標籤的 Phase 2a 資料讓 Q32 Bio 股價近乎翻倍；真正的問題是療效能否重現、停藥後能否維持，以及安全性是否足以改變 JAK 抑制劑的臨床位置。","image":"https://drugnews.com.tw/assets/articles/bempikibart-alopecia-areata/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-08-02-bempikibart-alopecia-areata-en.html"}},{"title":"AnBogen Therapeutics: Building a “Starlink” for Cancer Immunotherapy","date":"2026-07-31","language":"en","url":"https://drugnews.com.tw/articles/2026-07-31-anbogen-immunotherapy-starlink-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-31-anbogen-immunotherapy-starlink-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["AnBogen Therapeutics","ABT-301","Cancer Immunotherapy","PD-1","Metastatic Colorectal Cancer","HDAC","Taiwan Biotech","Oncology"],"summary":"Can a small molecule from Taiwan extend the $30 billion PD-1 ecosystem into the 95% of metastatic colorectal cancer patients still beyond immunotherapy’s reach?","image":"https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-31-anbogen-immunotherapy-starlink.html"}},{"title":"安邦生技：免疫治療的「星鏈計畫」","date":"2026-07-31","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-31-anbogen-immunotherapy-starlink.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-31-anbogen-immunotherapy-starlink.html","source":"Website","access":"商業分析文","category":"商業分析","tags":["安邦生技","ABT-301","癌症免疫治療","PD-1","轉移性大腸直腸癌","HDAC","台灣生技","腫瘤"],"summary":"一顆台灣小分子，有機會把三百億美元級PD-1藥王送進九成五患者仍無法受益的治療盲區嗎？","image":"https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-31-anbogen-immunotherapy-starlink-en.html"}},{"title":"Xtandi 之後，安斯泰來靠誰？從單一明星藥到腫瘤平台的四道驗證門","date":"2026-07-30","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-23-astellas-oncology-platform.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-23-astellas-oncology-platform.html","source":"facebook","access":"商業分析文","category":"製藥巨頭","tags":["Astellas","Xtandi","Padcev","Vyloy","腫瘤","藥物開發"],"summary":"Xtandi 仍主導安斯泰來腫瘤收入；Padcev、Vyloy 與下一代 CLDN18.2 資產能否在 LOE 後形成可重複的產品平台，才是下一段考題。","image":"https://drugnews.com.tw/assets/articles/astellas-oncology-platform/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-23-astellas-oncology-platform-en.html"}},{"title":"After Xtandi: Can Astellas Build an Oncology Platform?","date":"2026-07-30","language":"en","url":"https://drugnews.com.tw/articles/2026-07-23-astellas-oncology-platform-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-23-astellas-oncology-platform-en.html","source":"facebook","access":"Business Analysis","category":"製藥巨頭","tags":["Astellas","Xtandi","Padcev","Vyloy","oncology","drug development"],"summary":"Xtandi still dominates Astellas oncology sales. The real test is whether Padcev, Vyloy and the next CLDN18.2 assets can become a repeatable post-LOE platform.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-23-astellas-oncology-platform.html"}},{"title":"Pelacarsen's HORIZON Test: Does Lowering Lp(a) Prevent Cardiovascular Events?","date":"2026-07-29","language":"en","url":"https://drugnews.com.tw/articles/2026-07-19-pelacarsen-lpa-horizon-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-19-pelacarsen-lpa-horizon-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","pelacarsen","Lp(a)","HORIZON","cardiovascular disease","clinical trials","antisense oligonucleotide","Novartis","Ionis","biotech investing"],"summary":"Pelacarsen can substantially lower Lp(a), but HORIZON must show whether biomarker reduction on top of standard care translates into fewer cardiovascular deaths, myocardial infarctions, strokes and urgent revascularizations.","image":"https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-19-pelacarsen-lpa-horizon.html"}},{"title":"HORIZON：Lp(a) 降了，心梗會少嗎？","date":"2026-07-29","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-19-pelacarsen-lpa-horizon.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-19-pelacarsen-lpa-horizon.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["Pelacarsen","Lp(a)","HORIZON","心血管疾病","臨床試驗","ASO","Novartis","Ionis","生技投資"],"summary":"Pelacarsen 已證明能大幅降低 Lp(a)，但 HORIZON 真正要回答的是：在標準治療之上，生物標記下降能否轉成更少的心血管死亡、心肌梗塞、中風與緊急再血管化。","image":"https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-19-pelacarsen-lpa-horizon-en.html"}},{"title":"T-cell Exhaustion Across PD-1, CAR-T and TCE: Immunotherapy's Next Contest Is Durability","date":"2026-07-28","language":"en","url":"https://drugnews.com.tw/articles/2026-07-28-t-cell-exhaustion-immunotherapy-durability-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-28-t-cell-exhaustion-immunotherapy-durability-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["T-cell exhaustion","immunotherapy","PD-1 blockade","CAR-T","T-cell engager","bispecific antibody","TCF1","Taiwan biotech","Shine-On Biomedical","Ever Supreme"],"summary":"PD-1 blockade, CAR-T and T-cell engagers ultimately depend on T cells that can expand, renew and persist. This analysis connects exhaustion biology, product engineering and clinical evidence to the next competitive threshold in immunotherapy.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-28-t-cell-exhaustion-immunotherapy-durability.html"}},{"title":"T 細胞耗竭卡住 PD-1、CAR-T 與 TCE：免疫治療下半場，拼的是誰能撐到最後","date":"2026-07-28","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-28-t-cell-exhaustion-immunotherapy-durability.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-28-t-cell-exhaustion-immunotherapy-durability.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["T 細胞耗竭","免疫治療","PD-1","CAR-T","TCE","雙特異性抗體","TCF1","聖安生醫","長聖","沛爾生醫"],"summary":"PD-1、CAR-T 與 TCE 最後都仰賴可增殖、可補充且能持久的 T 細胞戰力。本文從耗竭分化、產品工程與臨床資料，拆解免疫治療下半場的真正競爭門檻。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-28-t-cell-exhaustion-immunotherapy-durability-en.html"}},{"title":"半年千億，買的是時間","date":"2026-07-27","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-27-h1-2026-biopharma-ma-buying-time.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-27-h1-2026-biopharma-ma-buying-time.html","source":"CMoney","access":"商業分析文","category":"商業分析","tags":["生技併購","藥廠併購","Biopharma M&A","專利懸崖","Lilly","Merck","AbbVie","Gilead","GSK","Terns"],"summary":"2026 上半年生醫併購轉熱，但 BioSpace 的 52 筆與 IQVIA 的 42 筆不能硬拼。真正的主線，是專利懸崖迫使大藥廠用現金購買可計算的臨床時間。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-27-h1-2026-biopharma-ma-buying-time-en.html"}},{"title":"$130 Billion in Six Months: Big Pharma Is Buying Time","date":"2026-07-27","language":"en","url":"https://drugnews.com.tw/articles/2026-07-27-h1-2026-biopharma-ma-buying-time-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-27-h1-2026-biopharma-ma-buying-time-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["biopharma M&A","Big Pharma","patent cliff","loss of exclusivity","Lilly","Merck","AbbVie","Gilead","GSK","Terns"],"summary":"Biopharma M&A accelerated in the first half of 2026, but BioSpace's 52 deals and IQVIA's 42 deals cannot be combined. The deeper story is that patent cliffs are pushing Big Pharma to pay for measurable clinical time.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-27-h1-2026-biopharma-ma-buying-time.html"}},{"title":"Roche's Hidden Succession Engine: How 19 New Molecules Could Power the Next Growth Cycle","date":"2026-07-25","language":"en","url":"https://drugnews.com.tw/articles/2026-07-25-roche-19-molecule-succession-engine-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-25-roche-19-molecule-succession-engine-en.html","source":"facebook","access":"Business Analysis","category":"商業分析","tags":["Roche","Big Pharma","pharma strategy","giredestrant","fenebrutinib","trontinemab","petrelintide","bexobrutideg","BRIM Biotechnology","BD licensing"],"summary":"Roche generated CHF 47.669 billion in pharmaceutical sales in 2025, with Ocrevus, Hemlibra, and Vabysmo already accounting for roughly one-third of the total. The number that matters is not simply 19 potential new molecules, but whether giredestrant, fenebrutinib, obesity, Alzheimer's, and protein-degradation assets can inherit Roche's existing clinical, diagnostic, and commercial infrastructure on time.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-25-roche-19-molecule-succession-engine.html"}},{"title":"羅氏的隱藏底牌：19 個新分子排隊接棒，下一個成長週期怎麼長出來？","date":"2026-07-25","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-25-roche-19-molecule-succession-engine.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-25-roche-19-molecule-succession-engine.html","source":"facebook","access":"商業分析文","category":"商業分析","tags":["Roche","羅氏","Big Pharma","製藥巨頭","giredestrant","fenebrutinib","trontinemab","petrelintide","bexobrutideg","全福生技"],"summary":"羅氏 2025 年製藥銷售 476.69 億瑞士法郎，Ocrevus、Hemlibra 與 Vabysmo 已撐起約三分之一收入。真正值得追的不是 19 個新分子的總數，而是 giredestrant、fenebrutinib、減重、阿茲海默症與蛋白質降解資產能否沿既有臨床、診斷與商業通路準時接棒。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-25-roche-19-molecule-succession-engine-en.html"}},{"title":"SpaceX Goes to Orbit. Is the Money in the Crystals?","date":"2026-07-24","language":"en","url":"https://drugnews.com.tw/articles/2026-07-24-spacex-microgravity-drug-crystals-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-24-spacex-microgravity-drug-crystals-en.html","source":"cmoney","access":"Business Analysis","category":"商業分析","tags":["SpaceX","microgravity","space pharmaceuticals","drug crystallization","Keytruda","Redwire","SpaceMD","Varda","formulation development","Taiwan biotech"],"summary":"SpaceX is making low-Earth-orbit round trips more routine, but rockets do not discover drugs. From Keytruda crystallization and SpaceMD to Varda, UK regulation, and a Taiwan mission, this analysis asks whether microgravity-enabled manufacturing can pass the tests of repetition, scale-up, and regulation.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-24-spacex-microgravity-drug-crystals.html"}},{"title":"SpaceX 上太空，錢在晶體裡？微重力製藥的第一桶金","date":"2026-07-24","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-24-spacex-microgravity-drug-crystals.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-24-spacex-microgravity-drug-crystals.html","source":"cmoney","access":"商業分析文","category":"商業分析","tags":["SpaceX","微重力","太空製藥","藥物結晶","Keytruda","Redwire","SpaceMD","Varda","製劑開發","台灣生技"],"summary":"SpaceX 讓低軌往返逐漸有了班次，但火箭不是新藥公司。本文從 Keytruda 結晶、SpaceMD、Varda、英國監管與台灣任務，拆解微重力製藥能否通過重複、放大與監管三道商業考驗。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-24-spacex-microgravity-drug-crystals-en.html"}},{"title":"When a Biotech Says No to a Sale: Five Tests of Whether It Can Become a Biopharma","date":"2026-07-24","language":"en","url":"https://drugnews.com.tw/articles/2026-07-24-biotech-independence-five-engines-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-24-biotech-independence-five-engines-en.html","source":"cmoney","access":"Business Analysis","category":"商業分析","tags":["Biotech","Biopharma","argenx","Insmed","Incyte","Revolution Medicines","Royalty Pharma","business development","commercialization","biotech investing"],"summary":"An acquisition is not the only successful outcome for a biotech. Using argenx, Insmed, Incyte, and Revolution Medicines as four operating snapshots, this analysis tests product evidence, cash generation, a second growth curve, global execution, and financing options—and shows what retaining control really costs.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-24-biotech-independence-five-engines.html"}},{"title":"Biotech 不賣，憑什麼？五張門票決定它能否長成 Biopharma","date":"2026-07-24","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-24-biotech-independence-five-engines.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-24-biotech-independence-five-engines.html","source":"cmoney","access":"商業分析文","category":"商業分析","tags":["Biotech","Biopharma","argenx","Insmed","Incyte","Revolution Medicines","Royalty Pharma","BD","商業化","生技投資"],"summary":"被收購不是 Biotech 唯一的成功終點。本文以 argenx、Insmed、Incyte 與 Revolution Medicines 為四個截面，檢驗產品證據、現金引擎、第二曲線、全球執行與融資選項，並拆解保留控制權的真實成本。","image":"https://drugnews.com.tw/assets/articles/biotech-independence-five-engines/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-24-biotech-independence-five-engines-en.html"}},{"title":"Madrigal's MASH Platform Strategy: Rezdiffra as the Cornerstone, siRNA as the Next Growth Engine","date":"2026-07-20","language":"en","url":"https://drugnews.com.tw/articles/2026-07-20-madrigal-mash-sirna-platform-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-20-madrigal-mash-sirna-platform-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","MASH","Madrigal Pharmaceuticals","Rezdiffra","resmetirom","siRNA","Ribo Life Science","Ribocure","Arrowhead Pharmaceuticals","ARO-PNPLA3"],"summary":"Rezdiffra has opened the MASH market and built its commercialization infrastructure. Madrigal is now adding six Ribo siRNA programs and Arrowhead's ARO-PNPLA3 to create a cornerstone-plus-precision-combination treatment matrix.","image":"https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-20-madrigal-mash-sirna-platform.html"}},{"title":"聯手巨頭卡位 MASH：Madrigal 把 Rezdiffra 做成基石藥，小核酸開始接棒","date":"2026-07-20","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-20-madrigal-mash-sirna-platform.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-20-madrigal-mash-sirna-platform.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["MASH","Madrigal Pharmaceuticals","Rezdiffra","resmetirom","siRNA","Ribo Life Science","Ribocure","Arrowhead Pharmaceuticals","ARO-PNPLA3","PNPLA3"],"summary":"Rezdiffra 已把 MASH 市場與商業化基礎設施打開；Madrigal 再以 Ribo 六條 siRNA 管線與 Arrowhead ARO-PNPLA3，建立基石藥加精準聯用矩陣。","image":"https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-20-madrigal-mash-sirna-platform-en.html"}},{"title":"Animal Studies Are Not Disappearing. Drug Development Rules Are Changing.","date":"2026-07-19","language":"en","url":"https://drugnews.com.tw/articles/2026-07-19-nams-regulatory-shift-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-19-nams-regulatory-shift-en.html","source":"facebook","access":"Business Analysis","category":"商業分析","tags":["NAMs","CDE","Regulatory Science","Organoids","Organ-on-a-Chip","AI Drug Discovery"],"summary":"China's CDE PIONEER program opens a regulatory pathway for new approach methodologies. The real test is whether human-relevant evidence becomes reproducible, validated and reusable.","image":"https://drugnews.com.tw/assets/articles/nams-regulatory-shift-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-19-nams-regulatory-shift.html"}},{"title":"動物實驗不是消失，而是藥物研發規則開始換代","date":"2026-07-19","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-19-nams-regulatory-shift.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-19-nams-regulatory-shift.html","source":"facebook","access":"商業分析文","category":"商業分析","tags":["NAMs","CDE","監管科學","類器官","器官晶片","AI 製藥"],"summary":"CDE 的 NAMs 先鋒計畫為藥企與方法開發者開出雙軌入口；真正的考題是可重複、可驗證且被監管接受的人體相關證據。","image":"https://drugnews.com.tw/assets/articles/nams-regulatory-shift/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-19-nams-regulatory-shift-en.html"}},{"title":"When ADCs Enter Autoimmune Disease: Precision Immune Modulation, Not More Killing","date":"2026-07-18","language":"en","url":"https://drugnews.com.tw/articles/2026-07-18-autoimmune-adc-lfd200-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-18-autoimmune-adc-lfd200-en.html","source":"Dcard","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","antibody-drug conjugates","autoimmune disease","LFD-200","Lifordi Immunotherapeutics","VISTA","glucocorticoid","immune modulation","rheumatoid arthritis","biotech investing"],"summary":"The opportunity for autoimmune ADCs is not to transplant oncology cytotoxins into immune cells. It is to deliver powerful glucocorticoids, small molecules, ASOs or siRNAs selectively to the cells that drive disease. LFD-200 offers an early human proof-of-mechanism signal for that thesis.","image":"https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-18-autoimmune-adc-lfd200.html"}},{"title":"當 ADC 走進自體免疫：不是殺得更狠，而是調得更準","date":"2026-07-18","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-18-autoimmune-adc-lfd200.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-18-autoimmune-adc-lfd200.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["ADC","自體免疫疾病","LFD-200","Lifordi Immunotherapeutics","VISTA","glucocorticoid","免疫調節","類風濕性關節炎","生技投資"],"summary":"自體免疫 ADC 的價值不在把腫瘤細胞毒 payload 搬到免疫細胞，而在把 glucocorticoid、ASO、siRNA 等強效免疫調節作用定向送到真正需要干預的細胞；LFD-200 的早期人體訊號，是這條路第一次重要的機制驗證。","image":"https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-18-autoimmune-adc-lfd200-en.html"}},{"title":"又一次RevMed 直接掀桌，胰臟癌進入 RAS 組合療法時代","date":"2026-07-17","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-17-revmed-ras.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-17-revmed-ras.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["Revolution Medicines","RevMed","胰臟癌","KRAS G12D","RAS(ON)","Zoldonrasib","Daraxonrasib","ESMO GI 2026","臨床數據","組合療法"],"summary":"Daraxonrasib 已用第三期總生存期資料抬高胰臟癌 RAS 賽道門檻；zoldonrasib 與 pan-RAS 或化療的早期組合訊號，則把競爭從單藥推向治療生態系。","image":"https://drugnews.com.tw/assets/articles/revmed-ras/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-17-revmed-ras-en.html"}},{"title":"RevMed Upends Pancreatic Cancer Again: The RAS Combination Era Has Arrived","date":"2026-07-17","language":"en","url":"https://drugnews.com.tw/articles/2026-07-17-revmed-ras-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-17-revmed-ras-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Revolution Medicines","RevMed","pancreatic cancer","KRAS G12D","RAS(ON)","zoldonrasib","daraxonrasib","ESMO GI 2026","clinical data"],"summary":"Daraxonrasib has already raised the bar with phase 3 overall-survival data. Early zoldonrasib combinations now suggest that pancreatic cancer's RAS competition is shifting from single agents to treatment ecosystems.","image":"https://drugnews.com.tw/assets/articles/revmed-ras-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-17-revmed-ras.html"}},{"title":"Big Pharma's New $10 Billion M&A Wave: Why Differentiation Now Beats Scale and Hype","date":"2026-07-16","language":"en","url":"https://drugnews.com.tw/articles/2026-07-16-big-pharma-ma-new-aesthetic-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-16-big-pharma-ma-new-aesthetic-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Big Pharma","biotech M&A","Vertex","Crinetics","AbbVie","Apogee Therapeutics","Novartis","Avidity Biosciences","Merck"],"summary":"Vertex's roughly $10 billion deal for Crinetics captures a wider change in Big Pharma's acquisition taste: away from scale and fashionable platforms, toward niche leadership, technological step-changes and commercial visibility.","image":"https://drugnews.com.tw/assets/articles/big-pharma-ma-new-aesthetic-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-16-big-pharma-ma-new-aesthetic.html"}},{"title":"百億美元併購新狂潮","date":"2026-07-16","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-16-big-pharma-ma-new-aesthetic.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-16-big-pharma-ma-new-aesthetic.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["Big Pharma","生技併購","Vertex","Crinetics","AbbVie","Apogee Therapeutics","Novartis","Avidity Biosciences","Merck","Cidara Therapeutics"],"summary":"Vertex 以約 100 億美元收購 Crinetics，映照 Big Pharma 併購審美的轉向：不再只買規模或熱門平台，而是買細分市場統治力、技術代差與商業確定性。","image":"https://drugnews.com.tw/assets/articles/big-pharma-ma-new-aesthetic/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-16-big-pharma-ma-new-aesthetic-en.html"}},{"title":"After the Nobel Prize, Do Not Rush the First-Approved Treg Story: The Real Test Is Turning Immune Tolerance Into a Product","date":"2026-07-15","language":"en","url":"https://drugnews.com.tw/articles/2026-07-15-treg-immune-tolerance-productization-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-15-treg-immune-tolerance-productization-en.html","source":"Facebook","access":"Free Article","category":"商業分析","tags":["Business Analysis","regulatory T cells","Treg","immune tolerance","cell therapy","autoimmune disease","transplantation","CMC","Taiwan Bio Therapeutics","Taiwan biotech"],"summary":"The Nobel Prize illuminated Treg biology, but commercial value will depend on whether immune tolerance can become a releasable, trackable, scalable and reimbursable product, not on an unverified first-approval headline.","image":"https://drugnews.com.tw/assets/articles/treg-immune-tolerance-productization-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-15-treg-immune-tolerance-productization.html"}},{"title":"諾貝爾獎後，Treg 第一個獲批藥還不能急著喊：真正的考題是免疫耐受怎麼做成產品","date":"2026-07-15","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-15-treg-immune-tolerance-productization.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-15-treg-immune-tolerance-productization.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["Treg","免疫耐受","細胞療法","自體免疫","移植","CMC","台寶生醫","臨床開發","生技投資"],"summary":"諾貝爾獎照亮 Treg 科學，但產業價值要看免疫耐受能否被做成可放行、可追蹤、可定價、可複製的產品，而不是急著追逐未經核實的第一款獲批敘事。","image":"https://drugnews.com.tw/assets/articles/treg-immune-tolerance-productization/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-15-treg-immune-tolerance-productization-en.html"}},{"title":"The Next ADC War: Novartis Is Paying Up to $1.5 Billion for Myricx, but the Real Prize Is a New Payload Class","date":"2026-07-14","language":"en","url":"https://drugnews.com.tw/articles/2026-07-14-novartis-myricx-nmti-adc-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-14-novartis-myricx-nmti-adc-en.html","source":"Facebook","access":"Free Article","category":"商業分析","tags":["Business Analysis","ADC","Novartis","Myricx Bio","NMT inhibitor","ADC payload","BD licensing","oncology","Taiwan biotech","biotech valuation"],"summary":"Novartis is paying up to $1.5 billion for Myricx. The strategic prize is not merely two ADC assets, but an NMT-inhibitor payload platform that could reopen the questions of therapeutic window, resistance and platform value.","image":"https://drugnews.com.tw/assets/articles/novartis-myricx-nmti-adc-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-14-novartis-myricx-nmti-adc.html"}},{"title":"ADC 下一場戰爭：諾華 15 億美元買 Myricx，真正搶的是新型 payload","date":"2026-07-14","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-14-novartis-myricx-nmti-adc.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-14-novartis-myricx-nmti-adc.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["ADC","Novartis","Myricx Bio","NMTi","payload","BD 授權","腫瘤","浩鼎","諦醫生技","嘉正生技"],"summary":"諾華最高 15 億美元收購 Myricx，真正買下的不只是兩條 ADC 管線，而是可能改寫安全窗、耐藥與平台估值的新型 NMTi payload。","image":"https://drugnews.com.tw/assets/articles/novartis-myricx-nmti-adc/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-14-novartis-myricx-nmti-adc-en.html"}},{"title":"Foundation Models Enter Drug Discovery: Anthropic Launches Claude Science as AI Companies Move Into the Real R&D Arena","date":"2026-07-13","language":"en","url":"https://drugnews.com.tw/articles/2026-07-13-anthropic-claude-science-ai-drug-discovery-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-13-anthropic-claude-science-ai-drug-discovery-en.html","source":"Facebook","access":"Free Article","category":"商業分析","tags":["Business Analysis","AI drug discovery","Claude Science","Anthropic","foundation models","drug development","AnHorn Medicines","PROTAC","CMC","clinical assets"],"summary":"Anthropic's launch of Claude Science and its move into drug discovery show foundation-model companies shifting from research tools into real R&D workflows. AI drug discovery will ultimately be judged by experiments, clinical data and tradable assets.","image":"https://drugnews.com.tw/assets/articles/anthropic-claude-science-ai-drug-discovery-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-13-anthropic-claude-science-ai-drug-discovery.html"}},{"title":"大模型公司走進 AI 製藥：Anthropic 推出 Claude Science，模型公司開始把藥物研發當成真實戰場","date":"2026-07-13","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-13-anthropic-claude-science-ai-drug-discovery.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-13-anthropic-claude-science-ai-drug-discovery.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["AI 製藥","Claude Science","Anthropic","大型語言模型","新藥研發","安宏生醫","PROTAC","CMC","臨床資產"],"summary":"Anthropic 推出 Claude Science 並啟動藥物發現計畫，顯示大模型公司正從科研工具走向真實研發工作流；AI 製藥最終仍要用實驗、臨床資料與可交易資產證明價值。","image":"https://drugnews.com.tw/assets/articles/anthropic-claude-science-ai-drug-discovery/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-13-anthropic-claude-science-ai-drug-discovery-en.html"}},{"title":"Winning First Is Not Winning: Roche's Divarasib Pushes KRAS Into a Generational Elimination Race","date":"2026-07-12","language":"en","url":"https://drugnews.com.tw/articles/2026-07-12-roche-divarasib-kras-generation-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-12-roche-divarasib-kras-generation-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","KRAS G12C","divarasib","Roche","oncology","clinical data","PFS","OS","biotech business analysis","Taiwan biotech"],"summary":"Roche's divarasib beat first-generation KRAS G12C inhibitors in a head-to-head Phase III study, moving the RAS field from proving druggability to replacing earlier products with harder clinical evidence.","image":"https://drugnews.com.tw/assets/articles/roche-divarasib-kras-generation-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-12-roche-divarasib-kras-generation.html"}},{"title":"先贏不是贏：Roche divarasib 把 KRAS 賽道推進世代淘汰戰","date":"2026-07-12","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-12-roche-divarasib-kras-generation.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-12-roche-divarasib-kras-generation.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["KRAS G12C","divarasib","Roche","腫瘤新藥","臨床數據","PFS","OS","生技投資"],"summary":"Roche 的 divarasib 在頭對頭三期試驗中擊敗第一代 KRAS G12C 抑制劑，代表 RAS 賽道已從證明可成藥，進入用臨床硬終點淘汰上一代產品的競爭。","image":"https://drugnews.com.tw/assets/articles/roche-divarasib-kras-generation/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-12-roche-divarasib-kras-generation-en.html"}},{"title":"社恐神藥三期踩煞車：Fasedienol 不是輸在故事，而是輸在 CNS 新藥最難證明的一格","date":"2026-07-11","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-11-fasedienol-cns.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-11-fasedienol-cns.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["臨床數據","生技投資"],"summary":"一款藥最迷人的時候，常常也是它最危險的時候：市場先愛上故事，臨床才慢慢追問證據。","image":"https://drugnews.com.tw/assets/articles/fasedienol-cns/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-11-fasedienol-cns-en.html"}},{"title":"Fasedienol's Phase 3 Brake: The Story Did Not Fail. The CNS Evidence Bar Did Its Job.","date":"2026-07-11","language":"en","url":"https://drugnews.com.tw/articles/2026-07-11-fasedienol-cns-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-11-fasedienol-cns-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Business Analysis","biotech business analysis","Taiwan biotech","drug development","CNS drug development","social anxiety disorder","fasedienol","PALISADE-4","Vistagen"],"summary":"Fasedienol's PALISADE-4 miss was not simply a failed Phase 3 headline. It exposed the core CNS drug-development problem: a beautiful mechanism and a real unmet need still have to survive subjective endpoints, placebo response, patient selection, and a commercial repositioning test.","image":"https://drugnews.com.tw/assets/articles/fasedienol-cns-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-11-fasedienol-cns.html"}},{"title":"Sobi's NASP Received an FDA CRL: The Problem Was Manufacturing Credibility, Not Efficacy","date":"2026-07-10","language":"en","url":"https://drugnews.com.tw/articles/2026-07-10-fda-nasp-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-10-fda-nasp-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Business Analysis","biotech business analysis","Taiwan biotech","drug development","FDA CRL","NASP","Sobi","CMC","contract manufacturing"],"summary":"FDA identified no clinical efficacy or safety concerns that affected NASP's approvability. The setback centered on CMC controls and contract-manufacturing deficiencies, showing biotech investors why manufacturing credibility becomes part of asset value near launch.","image":"https://drugnews.com.tw/assets/articles/fda-nasp-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-10-fda-nasp.html"}},{"title":"痛風新藥被 FDA 打回票：NASP 沒輸在療效，而是卡在製造可信度","date":"2026-07-10","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-10-fda-nasp.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-10-fda-nasp.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["FDA","NASP","Sobi","CMC","委託製造","製造品質","難治性痛風","URAT1","臨床數據","生技投資"],"summary":"FDA 並未指出影響 NASP 核准可能性的臨床療效或安全性問題，真正要求補強的是 CMC 控制策略與委託製造設施缺失。這封 CRL 提醒投資人：越接近上市，製造可信度越是藥品價值的一部分。","image":"https://drugnews.com.tw/assets/articles/fda-nasp/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-10-fda-nasp-en.html"}},{"title":"【基本面系列】泰福-KY 合理估值是多少？TX05 CRL 後，41.65 元買到的是什麼？","date":"2026-07-10","language":"zh-Hant","url":"https://vocus.cc/article/6a4029aefd897800016e6e48","canonical_url":"https://vocus.cc/article/6a4029aefd897800016e6e48","source":"方格子","access":"深度分析","category":"基本面","tags":["泰福-KY","生物相似藥","CRL","CDMO","SOTP"],"summary":"泰福-KY 不是單純 biosimilar 題材股。這篇把 TX01、TX05、Bora Biologics、San Diego 生物製劑 CDMO、現金水位與股本稀釋拆成 SOTP，判斷 38.55 元附近是否真的便宜。","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a4029aefd897800016e6e48-source.webp","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"Why Has Japan Struggled to Build Global-Scale Biotech Companies?","date":"2026-07-09","language":"en","url":"https://drugnews.com.tw/articles/2026-07-09-japan-biotech-ecosystem-global-gap-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-09-japan-biotech-ecosystem-global-gap-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Business Analysis","biotech business analysis","Japan biotech","Taiwan biotech","startup ecosystem","drug development","clinical data","CMC","BD licensing"],"summary":"Japan has strong science, major pharmaceutical companies, and a large drug market. The harder question is why that foundation has not produced more global-scale biotech startups. The answer is not scientific weakness, but an ecosystem gap across assets, talent, capital, clinical execution, and exits.","image":"https://drugnews.com.tw/assets/articles/japan-biotech-ecosystem-global-gap-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-09-japan-biotech-ecosystem-global-gap.html"}},{"title":"日本為什麼長不出全球級 Biotech？問題不在科學，而在產業生態","date":"2026-07-09","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-09-japan-biotech-ecosystem-global-gap.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-09-japan-biotech-ecosystem-global-gap.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["日本生技","Biotech ecosystem","startup ecosystem","創新藥","大藥廠","BD","臨床數據","CMC","資本市場","生技投資"],"summary":"日本不是缺少科學，也不是缺少大藥廠，而是缺少把大學技術、人才、資本、臨床與 BD 串成全球級 Biotech 的連續生態。","image":"https://drugnews.com.tw/assets/articles/japan-biotech-ecosystem-global-gap/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-09-japan-biotech-ecosystem-global-gap-en.html"}},{"title":"生技公司估值不是看新聞標題：6 個會改變模型的參數","date":"2026-07-09","language":"zh-Hant","url":"https://vocus.cc/article/6a42b340fd897800012cc406","canonical_url":"https://vocus.cc/article/6a42b340fd897800012cc406","source":"方格子","access":"商業分析","category":"深度商業分析","tags":["生技估值","rNPV","臨床成功率","上市時間","BD 授權"],"summary":"新聞只告訴你發生了什麼；估值要問的是，事件究竟改變成功率、上市時間、患者池、峰值銷售、權利經濟，還是現金與稀釋風險。","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a42b340fd897800012cc406-source.webp","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last","date":"2026-07-08","language":"en","url":"https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Business Analysis","biotech business analysis","Taiwan biotech","GLP-1","dorzagliatin","glucokinase activator","GKA","drug development","metabolic disease"],"summary":"GLP-1 competition is moving from peak weight loss toward long-term use, tolerability, rebound control, and combination design. Dorzagliatin matters not as a GLP-1 replacement, but as a possible metabolic base for the next phase of chronic therapy.","image":"https://drugnews.com.tw/assets/articles/glp1-dorzagliatin-long-term-metabolic-base-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html"}},{"title":"GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住","date":"2026-07-08","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["GLP-1","dorzagliatin","多格列艾汀","glucokinase activator","GKA","代謝疾病","糖尿病","MASH","臨床數據","慢病管理"],"summary":"GLP-1 競爭進入長期維持與聯用下半場，dorzagliatin 的價值不在取代減重藥，而是可能成為代謝治療的可持續底座。","image":"https://drugnews.com.tw/assets/articles/glp1-dorzagliatin-long-term-metabolic-base/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html"}},{"title":"下週雷達｜5 個可能重算台灣 biotech 估值的全球訊號：ADC、監管、公告、BD 與資金折現率","date":"2026-07-08","language":"zh-Hant","url":"https://vocus.cc/article/6a402ec5fd897800016f65cc","canonical_url":"https://vocus.cc/article/6a402ec5fd897800016f65cc","source":"方格子","access":"深度分析","category":"深度商業分析","tags":["ADC","FDA","EMA","BD 授權","生技估值","資金折現率"],"summary":"這篇不是新聞清單，而是會員版下週雷達：把 ADC、FDA／EMA、台灣公司公告、大藥廠 BD 與資金環境五個訊號，翻成會改變成功率、上市時間、峰值銷售、折現率、現金水位與 BD 機率的估值參數。","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a402ec5fd897800016f65cc-source.jpg","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"【基本面系列】保瑞合理估值是多少？它不是 CDMO 題材股，而是台灣少數能用併購把藥品現金流做大的製藥平台","date":"2026-07-07","language":"zh-Hant","url":"https://vocus.cc/article/6a401d9ffd897800016c1e2a","canonical_url":"https://vocus.cc/article/6a401d9ffd897800016c1e2a","source":"方格子","access":"深度分析","category":"基本面","tags":["保瑞","CDMO","併購","自由現金流"],"summary":"保瑞不是單純 CDMO 題材，也不是普通學名藥公司。這篇用營收、EBITDA、自由現金流、淨負債與平台倍數，重算 412 元附近到底買到什麼。","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a401d9ffd897800016c1e2a-source.jpg","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot","date":"2026-07-07","language":"en","url":"https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Business Analysis","biotech business analysis","Taiwan biotech","ADC","PD-1/VEGF","bispecific antibody","oncology","BD licensing","clinical data"],"summary":"After a Phase III setback for sigvotatug vedotin, Pfizer's $43 billion Seagen ADC bet is increasingly tied to whether 3SBio's PD-1/VEGF bispecific can become a new immuno-oncology combination backbone.","image":"https://drugnews.com.tw/assets/articles/pfizer-seagen-3sbio-adc-pd1-vegf-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.html"}},{"title":"【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】","date":"2026-07-07","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["ADC","PD-1/VEGF","雙特異性抗體","BD","臨床數據","生技投資","腫瘤藥物","製藥巨頭","台灣生技"],"summary":"sigvotatug vedotin Phase III 單藥失利後，輝瑞的 430 億美元 Seagen ADC 賭局正轉向 3SBio PD-1/VEGF 雙抗與聯合療法底座。","image":"https://drugnews.com.tw/assets/articles/pfizer-seagen-3sbio-adc-pd1-vegf/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html"}},{"title":"通用型 CAR-T 的 2026 從低谷回暖","date":"2026-07-06","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["臨床數據","生技投資","細胞治療","CAR-T","異體細胞治療","自體免疫疾病","台灣生技"],"summary":"邏輯很簡單：傳統自體 CAR-T 需要取出患者自己的 T 細胞，送到工廠改造、擴增、檢驗，再回輸到患者體內。療效可以很強，但等待時間長、成本高、製程複雜，病情進展太快或 T 細胞品質太差的患者，常常等不到治療。","image":"https://drugnews.com.tw/assets/articles/universal-car-t-2026-rebound/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-06-universal-car-t-2026-rebound-en.html"}},{"title":"Off-the-Shelf CAR-T in 2026: Rebounding From the Trough","date":"2026-07-06","language":"en","url":"https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Business Analysis","biotech business analysis","Taiwan biotech","cell therapy","CAR-T","allogeneic cell therapy","clinical data","drug development","autoimmune disease"],"summary":"Off-the-shelf allogeneic CAR-T is no longer just a beautiful manufacturing story. In 2026, better clinical signals and clearer positioning are bringing the field back to the table.","image":"https://drugnews.com.tw/assets/articles/universal-car-t-2026-rebound-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-06-universal-car-t-2026-rebound.html"}},{"title":"【事件型估值快評】浩鼎 ADC 重估：市場買的是 TROP2 題材，還是 GlycOBI 平台選擇權？","date":"2026-07-06","language":"zh-Hant","url":"https://vocus.cc/article/6a297eadfd89780001e9cbec","canonical_url":"https://vocus.cc/article/6a297eadfd89780001e9cbec","source":"方格子","access":"深度分析","category":"深度商業分析","tags":["浩鼎","ADC","TROP2","GlycOBI","SOTP"],"summary":"浩鼎 ADC 重估不能只看 TROP2 題材。這篇用 OBI-992、OBI-902、GlycOBI、BD 選擇權與 SOTP，重算合理市值與上修／下修條件。","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a297eadfd89780001e9cbec-source.jpg","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"半年併購 1,340 億美元：Big Pharma 到底在搶什麼？","date":"2026-07-05","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["BD","併購","臨床數據","生技投資","製藥巨頭","新藥開發","生技估值"],"summary":"2026 年才過一半，全球製藥業的併購節奏已經快到讓人有點恍神。","image":"https://drugnews.com.tw/assets/articles/big-pharma-134b-biotech-ma/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-05-big-pharma-134b-biotech-ma-en.html"}},{"title":"Big Pharma's $134 Billion M&A Rush: What Is It Really Buying?","date":"2026-07-05","language":"en","url":"https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html","source":"Facebook","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Business Analysis","biotech business analysis","Taiwan biotech","BD licensing","biotech M&A","biotech valuation","clinical data","drug development","capital markets"],"summary":"In the first half of 2026, Big Pharma's biotech M&A pace has accelerated sharply. The real question is not why large drugmakers have cash, but why they are suddenly less willing to wait.","image":"https://drugnews.com.tw/assets/articles/big-pharma-134b-biotech-ma-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-05-big-pharma-134b-biotech-ma.html"}},{"title":"Operation TrialBlazer: Why HHS Is Rewriting Clinical-Trial Rules and Biotech Competition","date":"2026-07-04","language":"en","url":"https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["HHS","FDA","Operation TrialBlazer","clinical trial reform","biotech business analysis","Taiwan biotech","drug development","clinical data","BD licensing","biotech valuation"],"summary":"Operation TrialBlazer is not just an FDA efficiency program. It signals that the United States is treating clinical-trial speed as part of national biotech competitiveness, with direct implications for biotech valuation, financing windows, and regulatory strategy.","image":"https://drugnews.com.tw/assets/articles/hhs-operation-trialblazer-clinical-trials-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-04-hhs-operation-trialblazer-clinical-trials.html"}},{"title":"美國 HHS 啟動 Operation TrialBlazer：臨床試驗規則要變了，新藥競爭也要變了","date":"2026-07-04","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["BD","臨床數據","生技投資","FDA","HHS","臨床試驗","新藥開發"],"summary":"2026 年 6 月 22 日，美國衛生與公共服務部，也就是 HHS，啟動了一項名為 Operation TrialBlazer 的部門級臨床試驗改革計畫。","image":"https://drugnews.com.tw/assets/articles/hhs-operation-trialblazer-clinical-trials/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html"}},{"title":"RevMed Says No to Being Bought: Biotech's Independent Era","date":"2026-07-03","language":"en","url":"https://drugnews.com.tw/articles/2026-07-03-revmed-biotech-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-03-revmed-biotech-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Revolution Medicines","RevMed","daraxonrasib","RAS oncology","biotech business analysis","Taiwan biotech","BD licensing","biotech valuation","clinical data","capital markets"],"summary":"Revolution Medicines is choosing not to make a sale its priority. The decision reflects a broader shift: top-tier biotech companies with breakthrough assets may once again have a credible path to grow into independent biopharma companies.","image":"https://drugnews.com.tw/assets/articles/revmed-biotech-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-03-revmed-biotech.html"}},{"title":"拒絕被併購的 RevMed：Biotech 的獨立時代","date":"2026-07-03","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-03-revmed-biotech.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-03-revmed-biotech.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["BD","臨床數據","生技投資","製藥巨頭"],"summary":"圍繞 Revolution Medicines（RevMed）的併購傳聞，一直沒有真正停過。","image":"https://drugnews.com.tw/assets/articles/revmed-biotech/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-03-revmed-biotech-en.html"}},{"title":"Synthetic Lethality After PARP: Why the Next Oncology Blockbuster Has Been So Hard to Find","date":"2026-07-02","language":"en","url":"https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["synthetic lethality","PARP","PRMT5","MTAP","RAS","oncology","biomarkers","Taiwan biotech","drug development"],"summary":"PARP inhibitors turned synthetic lethality into a commercial reality. Two decades later, the industry is still asking why the next PARP-like blockbuster has been so difficult to reproduce.","image":"https://drugnews.com.tw/assets/articles/synthetic-lethality-next-parp-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-02-synthetic-lethality-next-parp.html"}},{"title":"合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？","date":"2026-07-02","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["BD","臨床數據","生技投資"],"summary":"2005 年，《Nature》兩篇經典研究把 BRCA／PARP 這組關係推上舞台。","image":"https://drugnews.com.tw/assets/articles/synthetic-lethality-next-parp/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{}},{"title":"Centanafadine’s Phase 3b Win: Why ADHD Treatment Is Moving Beyond Discipline and Toward Neurobiology","date":"2026-07-01","language":"en","url":"https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["ADHD","centanafadine","Otsuka","clinical data","neuroscience","non-stimulant ADHD therapy","Taiwan biotech","drug development"],"summary":"Otsuka’s centanafadine has reported positive Phase 3b data in adults with ADHD and comorbid anxiety. The FDA has accepted the NDA and granted priority review, making the program a useful lens for how ADHD treatment is shifting from behavioral stigma toward more precise neurobiological intervention.","image":"https://drugnews.com.tw/assets/articles/adhd-centanafadine-phase3b-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-07-01-adhd-centanafadine-phase3b.html"}},{"title":"摒棄「鐵拳教育」：ADHD 新藥 centanafadine IIIb 期成功，上市只差臨門一腳","date":"2026-07-01","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b.html","canonical_url":"https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["ADHD","centanafadine","Otsuka","臨床數據","神經科學","美時","瑩碩生技"],"summary":"Otsuka 的 ADHD 新藥 centanafadine 公布成人 ADHD 合併焦慮症 IIIb 期積極結果，FDA 已接受 NDA 並給予優先審查。這不只是新藥進度，也反映 ADHD 治療正在從單一路徑走向更多機制與病人分層。","image":"https://drugnews.com.tw/assets/articles/adhd-centanafadine-phase3b/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-07-01-adhd-centanafadine-phase3b-en.html"}},{"title":"GSK Goes Big: The $10.6B Nuvalent Deal Is Not Just a Lung-Cancer Pipeline Buy","date":"2026-06-30","language":"en","url":"https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["GSK","Nuvalent","Oncology","Lung cancer","ROS1","ALK","BD","M&A","Biotech investing","Big Pharma"],"summary":"GSK's $10.6 billion all-cash acquisition of Nuvalent is more than a late-stage lung-cancer pipeline deal. It is a strategic attempt to rebuild oncology, buy time before major revenue pressure, and regain a seat at the precision-oncology table.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-30-gsk-nuvalent-oncology-comeback.html"}},{"title":"GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌","date":"2026-06-30","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["疫苗","BD","臨床數據","生技投資","製藥巨頭"],"summary":"2026 年 6 月，GSK 宣布以 106 億美元全現金收購 Nuvalent，收購價格為每股 124 美元。這筆交易不是小修小補，而是新任 CEO Luke Miels 上任後，替 GSK 腫瘤版圖打下的一記重拳。","image":"https://drugnews.com.tw/assets/articles/gsk-nuvalent-oncology-comeback/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-30-gsk-nuvalent-oncology-comeback-en.html"}},{"title":"The Largest Biotech IPO in US Market History: What Parabilis Is Really Teaching Investors","date":"2026-06-29","language":"en","url":"https://drugnews.com.tw/articles/2026-06-29-biotech-ipo-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-29-biotech-ipo-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Biotech IPO","Parabilis Medicines","Helicons","Zolucatetide","Wnt beta-catenin","Regeneron","Biotech investing","Capital markets"],"summary":"Parabilis Medicines' record-setting US biotech IPO is not a sign that speculative biotech is back. It shows that investors are willing to fund high-risk innovation when the platform, clinical asset, external validation, and capital-market window all line up.","image":"https://drugnews.com.tw/assets/articles/biotech-ipo-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-29-biotech-ipo.html"}},{"title":"美股迎來史上最大 Biotech IPO","date":"2026-06-29","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-29-biotech-ipo.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-29-biotech-ipo.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["臨床數據","生技投資"],"summary":"台股生技板塊還在低谷裡掙扎，美股生技市場卻突然打出一個極端反差。","image":"https://drugnews.com.tw/assets/articles/biotech-ipo/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-29-biotech-ipo-en.html"}},{"title":"The FDA Tone Has Shifted: Why Biotech’s Rebound Is Starting at the Regulatory Layer","date":"2026-06-28","language":"en","url":"https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["FDA","Biotech rebound","Regulatory risk","Rare disease","Gene therapy","mRNA vaccines","M&A","Capital markets"],"summary":"Biotech’s recent rebound is not only a risk-on trade. FDA review signals, rare-disease flexibility, mRNA vaccine momentum, and renewed pharma M&A are changing how investors price clinical-stage assets.","image":"https://drugnews.com.tw/assets/articles/fda-regulatory-shift-biotech-rebound-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-28-fda-regulatory-shift-biotech-rebound.html"}},{"title":"FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起","date":"2026-06-28","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["疫苗","感染症","BD","臨床數據","生技投資"],"summary":"代表中小型 Biotech 的 XBI（SPDR S&P Biotech ETF）近期走勢強勁，資金也重新流入。照理說，在利率仍未完全放鬆、風險資產仍會被折現率壓制的環境下，高波動的 Biotech 不應該是最輕鬆的族群。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-28-fda-regulatory-shift-biotech-rebound-en.html"}},{"title":"Pancreatic Cancer Breakthrough: After RAS Inhibitors, PRMT5/MAT2A Combinations Open the Next Layer of Upside","date":"2026-06-27","language":"en","url":"https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Pancreatic Cancer","RAS","PRMT5","MAT2A","Synthetic Lethality","Clinical Data","Biotech Investing","BD"],"summary":"Pancreatic cancer is moving into a new phase of precision combination therapy, as RAS inhibition meets MTAP-selective PRMT5 and MAT2A strategies.","image":"https://drugnews.com.tw/assets/articles/pancreatic-cancer-ras-prmt5-mat2a-combination-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination.html"}},{"title":"胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開","date":"2026-06-27","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["胰臟癌","RAS","PRMT5","MAT2A","臨床數據","生技投資","BD"],"summary":"胰臟癌正在進入 RAS 抑制劑與 PRMT5／MAT2A 合成致死聯合療法的新階段，市場開始重新評估 daraxonrasib 作為治療骨架的價值。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.html"}},{"title":"Tirzepatide Enters Autoimmune Disease: Is Immunometabolism Lilly's Next Expansion Path?","date":"2026-06-26","language":"en","url":"https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["GLP-1","tirzepatide","Zepbound","Taltz","Omvoh","immunometabolism","autoimmune disease","psoriasis","IBD","Eli Lilly"],"summary":"Lilly is testing whether tirzepatide can move beyond weight loss and become part of an immunometabolism strategy for chronic immune-inflammatory diseases.","image":"https://drugnews.com.tw/assets/articles/tirzepatide-autoimmune-immunometabolism-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-26-tirzepatide-autoimmune-immunometabolism.html"}},{"title":"神藥 猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？","date":"2026-06-26","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["GLP-1","臨床數據","生技投資","製藥巨頭"],"summary":"它不像急性感染，用藥幾天或幾週就結束。類風濕性關節炎、乾癬、乾癬性關節炎、發炎性腸道疾病、氣喘、異位性皮膚炎，這些疾病往往跟著患者一輩子。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html"}},{"title":"【深度商業分析系列】BD 最高金額不是成交價：真正要拆的是誰承擔了風險","date":"2026-06-26","language":"zh-Hant","url":"https://vocus.cc/article/6a3b5c8afd897800011d8d0d","canonical_url":"https://vocus.cc/article/6a3b5c8afd897800011d8d0d","source":"方格子","access":"深度分析","category":"深度商業分析","tags":[],"summary":"BD 交易不能只看最高總金額。真正要拆的是 upfront、近端付款、遠期 milestone、royalty / profit share，以及買方到底接走了哪一段風險。","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a3b5c8afd897800011d8d0d-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"Toward the “Roche of Pet Medicine”: Protect Biotech’s Platform Bet","date":"2026-06-25","language":"en","url":"https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Protect Biotech","Companion Animal Medicine","Pet Precision Medicine","Platform Company","Biotech Investing","Roche","Animal Health"],"summary":"As companion animals age and owners become more willing to pay for serious-disease care, the next major question in pet medicine is whether a platform company can connect drugs, diagnostics, veterinary clinics, regulation, manufacturing, channels, and data into one defensible system.","image":"https://drugnews.com.tw/assets/articles/protect-pet-medical-roche-platform-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-25-protect-pet-medical-roche-platform.html"}},{"title":"邁向「寵物醫療界羅氏」的寶泰生醫","date":"2026-06-25","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["寶泰生醫","寵物醫療","羅氏","平台型公司","生技投資","製藥巨頭"],"summary":"當毛孩高齡化趨勢推動癌症、心臟病與自體免疫等重症治療的需求升級，市場的長期觀察核心，在於誰能率先打造一座寵物重症新藥平台，成為『寵物醫療界羅氏』。而這一改寫行業格局的答案，正於台灣的一家生技公司加速浮現。","image":"https://drugnews.com.tw/assets/articles/protect-pet-medical-roche-platform/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-25-protect-pet-medical-roche-platform-en.html"}},{"title":"Is the First AI-Designed Drug Finally Arriving? Takeda's Zasocitinib Beats Sotyktu Head-to-Head","date":"2026-06-24","language":"en","url":"https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["AI drug discovery","zasocitinib","Takeda","Sotyktu","TYK2","psoriasis","PASI 100","Schrodinger","biotech investing","Big Pharma"],"summary":"Takeda's zasocitinib beat Sotyktu in a head-to-head Phase 3 psoriasis study, turning AI-enabled drug design into a real commercial test.","image":"https://drugnews.com.tw/assets/articles/ai-zasocitinib-sotyktu-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-24-ai-zasocitinib-sotyktu.html"}},{"title":"AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu","date":"2026-06-24","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["AI","臨床數據","生技投資","製藥巨頭"],"summary":"過去，口服藥在中重度乾癬市場裡，常常扮演的是「方便但療效有限」的角色。真正能把皮膚清得很乾淨的，仍然是 Skyrizi（risankizumab，瑞莎奇珠單抗）、Tremfya（guselkumab，古塞奇尤單抗）、Cosentyx（secukinumab，司庫奇尤單抗）、Taltz（ixekizu…","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-24-ai-zasocitinib-sotyktu-en.html"}},{"title":"The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk?","date":"2026-06-22","language":"en","url":"https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Obesity medicine","GLP-1","Eli Lilly","Novo Nordisk","Pfizer","Roche","AstraZeneca","Regeneron","Biotech investing","Capital markets"],"summary":"Lilly and Novo Nordisk dominate the first phase of the obesity-drug market. The next investment question is who can become the third major player by solving the problems GLP-1 leaders have not fully solved.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-22-obesity-drug-third-place-competition.html"}},{"title":"減重藥「第三名」爭奪戰：禮來 與 諾和諾德 之外，誰能成為下一個代謝巨頭？","date":"2026-06-22","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["GLP-1","臨床數據","生技投資","製藥巨頭"],"summary":"今年 ADA，也就是美國糖尿病學會年會，減重藥戰場又一次被點燃。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-22-obesity-drug-third-place-competition-en.html"}},{"title":"Merck's Shift on PD-1/VEGF Bispecifics: Keytruda Still Rules, but the Next IO Backbone Is Getting Closer","date":"2026-06-21","language":"en","url":"https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Merck","Keytruda","PD-1 VEGF","MK-2010","Oncology","Bispecific antibodies"],"summary":"Merck's more serious positioning of MK-2010 suggests that PD-1/VEGF bispecifics are moving from a watch item to a strategic option in the post-Keytruda oncology landscape.","image":"https://drugnews.com.tw/assets/articles/merck-pd1-vegf-mk2010-keytruda-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-21-merck-pd1-vegf-mk2010-keytruda.html"}},{"title":"默沙東 對 PD-1／VEGF 雙抗改口：Keytruda 王座還在，但下一代免疫底盤已經逼近","date":"2026-06-21","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["BD","臨床數據","生技投資","製藥巨頭"],"summary":"在全球腫瘤藥市場裡，很少有一家公司比 Merck（默沙東）更懂 PD-1。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-21-merck-pd1-vegf-mk2010-keytruda-en.html"}},{"title":"Enlivex's RAIN Token Windfall: When a Biotech Balance Sheet Starts Looking Like Crypto Treasury Strategy","date":"2026-06-20","language":"en","url":"https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Enlivex","RAIN token","Biotech treasury","Crypto","Capital markets"],"summary":"Enlivex's paper gain from RAIN tokens shows how fragile biotech business models can create unusual treasury stories when operating revenue is absent and capital markets are difficult.","image":"https://drugnews.com.tw/assets/articles/enlivex-rain-token-biotech-treasury-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-20-enlivex-rain-token-biotech-treasury.html"}},{"title":"【Enlivex 的幣圈豪賭：Biotech 沒收入，卻靠 RAIN 代幣賺出 12 億美元帳面利潤】","date":"2026-06-20","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["AI","BD","臨床數據","生技投資","製藥巨頭"],"summary":"一家臨床階段 Biotech，沒有藥品銷售收入，卻在一年內做出 12 億美元級別的淨利。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-20-enlivex-rain-token-biotech-treasury-en.html"}},{"title":"大藥廠的客氣話，真的別太當真","date":"2026-06-19","language":"zh-Hant","url":"https://vocus.cc/article/6a2e1308fd897800013f3925","canonical_url":"https://vocus.cc/article/6a2e1308fd897800013f3925","source":"方格子","access":"深度分析","category":"深度商業分析","tags":["商業","FDA","投資人","生物","長期投資","投資理財","美股","醫師","治療","醫藥"],"summary":"很多 台灣的生技公司 做完一場 大藥廠 一對一會議後，最容易陷入一種甜蜜誤會。 會議氣氛很好。 對方科學家頻頻點頭。 BD 問題很精準。 最後還留下一句：「Interesting, let’s discuss internally.」 然後團隊回到公司，大家開始覺得事情好像有戲。有人說對方","image":"https://drugnews.com.tw/assets/articles/external-vocus/pharma-giants-history-cover.svg","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"GSK's US$10.6 Billion Nuvalent Deal Is Really a Bet on Resistance and Brain Metastases","date":"2026-06-19","language":"en","url":"https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["GSK","Nuvalent","Lung cancer","Precision oncology","Resistance","Brain metastases"],"summary":"GSK is not merely buying three lung-cancer pipelines. It is buying a next-generation precision-oncology strategy around resistance, CNS activity, and cleaner kinase inhibition.","image":"https://drugnews.com.tw/assets/articles/gsk-nuvalent-lung-cancer-resistance-brain-metastasis-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis.html"}},{"title":"GSK 用 106 億美元買下 Nuvalent：真正買的不是三條肺癌管線，而是「耐藥與腦轉移」的下一代解法","date":"2026-06-19","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["AI","BD","臨床數據","生技投資"],"summary":"2026 年 6 月 9 日，GSK 宣布以 106 億美元全現金收購 Nuvalent，收購價格為每股 124 美元，較 Nuvalent 前一交易日收盤價溢價約 40%。這是 GSK 近年最大型的腫瘤併購之一，也讓它瞬間補上肺癌精準治療版圖中最缺的一塊。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis-en.html"}},{"title":"GLP-1「頭對頭」大戰：輝瑞＆諾和諾德必有一戰？","date":"2026-06-17","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["GLP-1","肥胖藥","Ecnoglutide","Wegovy","輝瑞","諾和諾德","臨床數據","生技投資"],"summary":"ADA 2026 剛落幕，GLP-1 賽道又被一組頭對頭資料點燃。Ecnoglutide 在 20 週減重數字上勝出，但真正的競爭不只看短期體重下降，而是長期健康結局、耐受性、產品矩陣與全球商業化。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-17-glp1-head-to-head-ecnoglutide-wegovy-en.html"}},{"title":"Ecnoglutide Versus Wegovy: A 20-Week Head-to-Head Signal Is Not the Same as a New GLP-1 King","date":"2026-06-17","language":"en","url":"https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["GLP-1","Ecnoglutide","Wegovy","Pfizer","Novo Nordisk","Obesity medicine"],"summary":"Ecnoglutide's head-to-head weight-loss data versus semaglutide are interesting, but the GLP-1 race will be decided by long-term outcomes, tolerability, labels, supply, and global evidence.","image":"https://drugnews.com.tw/assets/articles/glp1-head-to-head-ecnoglutide-wegovy-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-17-glp1-head-to-head-ecnoglutide-wegovy.html"}},{"title":"Why Would Lilly, the Obesity-Drug Giant, Spend US$3.8 Billion on Vaccine Companies?","date":"2026-06-16","language":"en","url":"https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Eli Lilly","Vaccines","M&A","Prevention medicine","Obesity medicine"],"summary":"Lilly's vaccine acquisitions show that the company is using obesity-drug cash flow to widen its long-term disease-prevention and immunology strategy.","image":"https://drugnews.com.tw/assets/articles/lilly-vaccine-acquisitions-prevention-medicine-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-16-lilly-vaccine-acquisitions-prevention-medicine.html"}},{"title":"禮來 38 億美元買三家疫苗公司：減肥藥巨頭，為什麼突然回頭買「預防醫學」？","date":"2026-06-16","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine.html","source":"Facebook","access":"商業分析文","category":"商業分析","tags":["GLP-1","疫苗","感染症","BD","臨床數據","生技投資","製藥巨頭"],"summary":"市場現在最熟悉的禮來，是 Mounjaro、Zepbound 背後那個 GLP-1 巨頭。2026 年第一季，禮來營收達到 198 億美元，年增 56%，主要動能還是來自 Mounjaro 與 Zepbound 的放量。簡單說，禮來現在手上最強的現金流，是減重與糖尿病藥物。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-16-lilly-vaccine-acquisitions-prevention-medicine-en.html"}},{"title":"ADA 2026 會後深度判讀包：GLP-1 後半場，為什麼已經不是「誰減重比較多」？","date":"2026-06-16","language":"zh-Hant","url":"https://vocus.cc/article/6a2d0f86fd8978000100e761","canonical_url":"https://vocus.cc/article/6a2d0f86fd8978000100e761","source":"方格子","access":"深度分析","category":"醫學大會","tags":["retatrutide","糖尿病","BMI","減重","代謝","體重","肥胖","市場","藥物","支付"],"summary":"ADA 2026 會後深度判讀：從 retatrutide、口服 GLP-1、小分子 incretin、代謝共病與 CGM 照護，拆解 GLP-1 後半場如何從減重競賽走向代謝疾病平台。","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a2d0f86fd8978000100e761-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"【商業分析】亞果生醫暴漲後，合理估值到底是多少？從三類醫材、患者池到 rNPV 重算一遍","date":"2026-06-16","language":"zh-Hant","url":"https://vocus.cc/article/6a2a61fffd89780001269792","canonical_url":"https://vocus.cc/article/6a2a61fffd89780001269792","source":"方格子","access":"深度分析","category":"基本面","tags":["商業","FDA","投資人","生物","美股","醫師","投資理財","長期投資","治療","醫藥"],"summary":"投資理財內容聲明 本文為產業研究與估值框架分析，目的在於拆解生技醫藥公司價值驅動因子、患者池、手術池、醫材證照、通路放量、財務結構與資本市場變數，不構成任何投資建議、買賣推薦或收益保證。文中部分估值參數為藥時事模型假設，所有數字都應該隨公司財報、股本變化、上市櫃時程、證照進展、訂單放量、醫院採用與市","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a2a61fffd89780001269792-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"ASCO 2026: RAS, ADCs, Bispecifics, and In Vivo CAR-T Point to a New Oncology Cycle","date":"2026-06-15","language":"en","url":"https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t-en.html","source":"Website","access":"Business Analysis","category":"醫學大會","tags":["ASCO","Oncology","RAS","ADC","PD-1 VEGF","In vivo CAR-T"],"summary":"ASCO 2026 showed that oncology is moving from single-mechanism breakthroughs toward platform combinations across RAS targeting, ADCs, PD-1/VEGF bispecifics, and in vivo CAR-T.","image":"https://drugnews.com.tw/assets/articles/2026-asco-car-t-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-15-2026-asco-car-t.html"}},{"title":"2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代","date":"2026-06-15","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t.html","source":"Facebook","access":"商業分析文","category":"醫學大會","tags":["ASCO","腫瘤治療","CAR-T","RAS","ADC","臨床數據","生技投資","製藥巨頭"],"summary":"2026 年美國臨床腫瘤學會年會，也就是 ASCO，最該被記住的贏家，並不是任何一家藥廠，而是癌症患者。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-15-2026-asco-car-t-en.html"}},{"title":"ASCO 2026 會後深度判讀包：哪些新藥真的改變治療格局，哪些只是會場熱度？","date":"2026-06-15","language":"zh-Hant","url":"https://vocus.cc/article/6a2a7858fd897800012dfd91","canonical_url":"https://vocus.cc/article/6a2a7858fd897800012dfd91","source":"方格子","access":"深度分析","category":"醫學大會","tags":["商業","投資人","FDA","生物","美股","醫師","長期投資","投資理財","治療","醫藥"],"summary":"投資理財與醫療內容聲明：本文為醫藥產業研究、臨床資料判讀與新藥開發趨勢整理，不構成任何投資建議、買賣建議、醫療診斷或治療建議。臨床資料、監管狀態與藥品適應症可能隨正式發表、期刊全文、監管審查與各國上市核准而改變。臨床用藥請依各國核准仿單、專科醫師判斷與正式治療指引為準。 2026 年 ASCO 最","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a2a7858fd897800012dfd91-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"Revolution Medicines: Why Biotech Winners Need Capital Strategy, Not Just Good Science","date":"2026-06-14","language":"en","url":"https://drugnews.com.tw/articles/2026-06-14-revolution-medicines-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-14-revolution-medicines-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["RAS","Revolution Medicines","Daraxonrasib","Biotech financing","Pancreatic cancer","Capital markets"],"summary":"Revolution Medicines shows why next-generation biotech companies need to convert clinical momentum into capital momentum if they want to finish expensive global drug-development races.","image":"https://drugnews.com.tw/assets/articles/revolution-medicines-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-14-revolution-medicines.html"}},{"title":"Revolution Medicines 神話：會研發還不夠，會融資才撐得過新藥長跑","date":"2026-06-14","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-14-revolution-medicines.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-14-revolution-medicines.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["臨床數據","生技投資"],"summary":"2026 年，全球最受矚目的 Biotech 之一，毫無疑問是 Revolution Medicines。這家公司站在一個極難、也極誘人的位置：RAS-addicted cancers。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-14-revolution-medicines-en.html"}},{"title":"The Next Phase of AI Drug Development: Making Molecules Survive as Drugs","date":"2026-06-13","language":"en","url":"https://drugnews.com.tw/articles/2026-06-13-anhorn-ai-drug-development-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-13-anhorn-ai-drug-development-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["AI Drug Development","AnHorn Medicines","AI+PROTAC","AIMCADD","NVIDIA","Clinical Asset Engine","Biotech"],"summary":"AI drug development is moving from molecular generation to clinical survival. AnHorn Medicines shows how AI+PROTAC, experimental feedback, and human translation may form a Taiwan-born clinical-asset engine.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-13-dcard-261654701.html"}},{"title":"AI製藥下半場：讓藥活下來","date":"2026-06-13","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-13-dcard-261654701.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-13-dcard-261654701.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["AI","BD","臨床數據","生技投資","製藥巨頭"],"summary":"AI 醫藥上半場比生成分子，下半場比成藥存活率。安宏真正值得被看見的，不是單純曝光，而是用 AI + PROTAC（蛋白質降解技術）、實驗閉環與人體轉譯，嘗試形成高資本效率的 clinical asset engine（臨床資產生成引擎）。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-13-anhorn-ai-drug-development-en.html"}},{"title":"Where Does AI Drug Discovery Stand Now? A Pipeline-Based Reality Check","date":"2026-06-12","language":"en","url":"https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["AI drug discovery","Clinical pipelines","Biotech investing","Business development","Drug development","Big Pharma"],"summary":"AI drug discovery has moved beyond the concept stage and into clinical validation. This article reviews Zasocitinib, GB-0895, Zovegalisib, and REC-4881 to examine how different AI strategies are being converted into real drug assets.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-12-ai-drug-discovery-pipeline-20260612.html"}},{"title":"盤點整理，AI藥物開發走得如何了？","date":"2026-06-12","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["AI 製藥","臨床管線","BD","生技投資","藥物開發"],"summary":"AI 製藥已從概念走向臨床驗證。這篇盤點 Zasocitinib、GB-0895、Zovegalisib、REC-4881 等代表管線，拆解不同 AI 路線如何轉化成真正的藥物資產。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-12-ai-drug-discovery-pipeline-20260612-en.html"}},{"title":"【基本面系列】逸達合理估值是多少？CAMCEVI 是現金流還是選擇權？","date":"2026-06-12","language":"zh-Hant","url":"https://vocus.cc/article/6a28c7e7fd89780001e3daca","canonical_url":"https://vocus.cc/article/6a28c7e7fd89780001e3daca","source":"方格子","access":"深度分析","category":"基本面","tags":["商業","投資人","生物","FDA","醫師","治療","長期投資","投資理財","美股","醫藥"],"summary":"逸達不是純夢想股，也還不是完全兌現的獲利股。本文拆 CAMCEVI 已上市現金流、3 個月劑型與海外 CPP 增量、FP-045 與 FP-025 選擇權及 SOTP 估值。","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a28c7e7fd89780001e3daca-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"管線估值：為還沒上市的未來定價，BD 最難也最值錢的一課","date":"2026-06-11","language":"zh-Hant","url":"https://vocus.cc/article/6a2a30f7fd89780001162667","canonical_url":"https://vocus.cc/article/6a2a30f7fd89780001162667","source":"方格子","access":"深度分析","category":"深度商業分析","tags":["商業","FDA","投資人","生物","美股","醫師","長期投資","投資理財","治療","醫藥"],"summary":"一個新藥，從實驗室走到臨床，再從臨床走到上市，燒錢速度常常快得嚇人。 但如果成功，回報也可能大到改變一家公司的命運。 這就是生技製藥產業最迷人的地方，也是最殘酷的地方：在產品真正賣錢以前，市場就必須先替它定價。問題是，這些資產很多時候還沒有營收，甚至還沒有大規模臨床資料，卻已經要進行授權、併購、","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a2a30f7fd89780001162667-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"生技公司估值模型如何計算","date":"2026-06-11","language":"zh-Hant","url":"https://vocus.cc/article/6a2a2b68fd89780001147e9e","canonical_url":"https://vocus.cc/article/6a2a2b68fd89780001147e9e","source":"方格子","access":"商業分析文","category":"商業分析","tags":["生技估值","rNPV","SOTP","YouTube","投資入門","資本市場","公司研究","商業判斷"],"summary":"方格子同步收錄藥時事 YouTube 影片入口，介紹生技公司估值模型如何計算，適合想建立 rNPV、SOTP 與管線估值基礎的讀者。","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a2a2b68fd89780001147e9e-cover.svg","is_accessible_for_free":true,"is_external":true,"alternate_language_versions":{}},{"title":"Obesity Becomes King: How GLP-1 Is Reshuffling Global Biotech Capital","date":"2026-06-11","language":"en","url":"https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Biotech Valuation","Obesity medicine","Business development","Capital markets","Biotech business analysis","Drug development"],"summary":"GLP-1 is no longer only a weight-loss topic. It is redirecting biotech capital, BD urgency, manufacturing attention, and valuation imagination across global pharma.","image":"https://drugnews.com.tw/assets/articles/glp1-biotech-capital-reshuffle-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-11-glp1-biotech-capital-reshuffle.html"}},{"title":"減肥成王：GLP-1 正在把全球生技資本重新洗牌","date":"2026-06-11","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["GLP-1","減肥藥","生技資本","腫瘤管線","BD","代謝疾病"],"summary":"GLP-1 不只是減重藥題材，而是重新配置全球藥廠研發預算、產能投資、BD 談判與生技估值規則的核心變數。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-11-glp1-biotech-capital-reshuffle-en.html"}},{"title":"Pipeline 估值雷達 001｜FDA CRL 不是價值歸零，而是估值參數重排","date":"2026-06-10","language":"zh-Hant","url":"https://vocus.cc/user/@Drugnews","canonical_url":"https://vocus.cc/user/@Drugnews","source":"方格子","access":"深度分析","category":"深度商業分析","tags":["FDA","CRL","CMC","label","現金","稀釋風險"],"summary":"FDA CRL 不該只看成藥證失敗，而是要拆成產品、臨床、CMC、label 與補件完整性，重算成功率、上市時間、峰值銷售與稀釋風險。","image":"https://drugnews.com.tw/assets/articles/external-vocus/vocus-pipeline-crl-radar-20260610-cover.svg","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"〖基本面系列〗全福生技合理估值是多少？BRM421 是乾眼症金礦，還是市場把眼科平台夢買得太早？","date":"2026-06-10","language":"zh-Hant","url":"https://vocus.cc/user/@Drugnews","canonical_url":"https://vocus.cc/user/@Drugnews","source":"方格子","access":"深度分析","category":"基本面","tags":["全福生技","BRM421","BRM424","乾眼症","PDSP","授權"],"summary":"全福不是單純乾眼症大市場概念股，也不是失敗新藥股；本文拆解 BRM421、BRM424、PDSP 平台、現金與稀釋風險，重算合理估值區間。","image":"https://drugnews.com.tw/assets/articles/external-vocus/vocus-brm421-valuation-20260610-cover.svg","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"RAS Targeting Opens a New Pancreatic-Cancer Window: How Senhwa's CX-5461 Positions for the Next Resistance-Management War","date":"2026-06-10","language":"en","url":"https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Company Research","Biotech business analysis","Drug development"],"summary":"Daraxonrasib opens a new pancreatic-cancer window, but the next value question is resistance management. Senhwa's CX-5461 matters if it can become a rational combination partner.","image":"https://drugnews.com.tw/assets/articles/sinphar-cx5461-ras-pancreatic-cancer-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-10-sinphar-cx5461-ras-pancreatic-cancer.html"}},{"title":"RAS 標靶打開胰臟癌新局：生華科 CX-5461 卡位下一場「抗藥性管理」戰","date":"2026-06-10","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer.html","source":"Dcard / Facebook","access":"商業分析文","category":"商業分析","tags":["生華科","CX-5461","Pidnarulex","RAS","胰臟癌","抗藥性","Tislelizumab"],"summary":"Daraxonrasib 打開胰臟癌 RAS 標靶時代後，真正的下一場戰爭是抗藥性管理；生華科 CX-5461 的價值在於能否成為 RAS 標靶後時代的免疫增敏與聯合治療候選策略。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-10-sinphar-cx5461-ras-pancreatic-cancer-en.html"}},{"title":"Biotech IR Is Not Making Slides Prettier; It Is Turning Pipelines Into Trackable Capital-Market Stories","date":"2026-06-10","language":"en","url":"https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["IR and Capital Markets","Capital markets","Biotech business analysis","Drug development"],"summary":"Biotech IR is not cosmetic storytelling. Good IR turns clinical, CMC, regulatory, commercial, and financing milestones into a capital-market narrative that investors can actually track.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-10-biotech-ir-capital-market-story.html"}},{"title":"生醫公司 IR 不是把簡報變漂亮，而是把管線變成可追蹤的資本市場故事","date":"2026-06-10","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story.html","source":"Dcard / Facebook","access":"商業分析文","category":"商業分析","tags":["IR","資本市場故事","公開資訊","投資人溝通"],"summary":"好的 IR 內容不是宣傳話術，而是把臨床、CMC、監管、商業化與對標公司轉成投資人可以追蹤的節點。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-10-biotech-ir-capital-market-story-en.html"}},{"title":"BD 解剖室 001｜BMS x 恆瑞：15.2B 美元交易不是「中國創新藥很強」這麼簡單，而是大藥廠正在買一套早期開發","date":"2026-06-10","language":"zh-Hant","url":"https://vocus.cc/salon/Drugnews/room/pharmagiants","canonical_url":"https://vocus.cc/salon/Drugnews/room/pharmagiants","source":"方格子","access":"深度分析","category":"深度商業分析","tags":["BMS","恆瑞","交易","upfront","milestone","royalty"],"summary":"BMS x 恆瑞最高 15.2B 美元合作不能只看 headline value；真正要拆的是 upfront、周年付款、milestone、royalty 與資料包能否讓國際買方承擔下一段風險。","image":"https://drugnews.com.tw/assets/articles/external-vocus/vocus-bms-hengrui-bd-20260610-cover.svg","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"The US$7 Billion Radiopharma Deal Rumor: Curium Wants Lantheus, but the Real Prize Is a Ticket to the Nuclear-Medicine Era","date":"2026-06-09","language":"en","url":"https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["BD and Licensing","Radiopharma","Business development","Biotech business analysis","Drug development"],"summary":"Curium's rumored interest in Lantheus is best read as a bid for nuclear-medicine infrastructure: isotope access, hospital channels, imaging workflow, and radiopharma commercialization depth.","image":"https://drugnews.com.tw/assets/articles/curium-lantheus-radiopharma-acquisition-en/cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-09-curium-lantheus-radiopharma-acquisition.html"}},{"title":"70億美元核藥併購傳聞：Curium想買Lantheus，真正買的是一張核藥時代的入場券","date":"2026-06-09","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition.html","source":"Dcard / Facebook","access":"商業分析文","category":"商業分析","tags":["Curium","Lantheus","核藥","放射性藥物","併購","PSMA","PYLARIFY"],"summary":"Curium 傳出有意以約 70 億美元收購 Lantheus。這不只是核藥併購傳聞，而是診斷、製造、配送、院端網絡與治療端能力整合的產業訊號。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-09-curium-lantheus-radiopharma-acquisition-en.html"}},{"title":"CAR-T Enters a New Era: From Blood Cancer to Autoimmune Disease","date":"2026-06-08","language":"en","url":"https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Clinical and CMC","CAR-T","Regulatory risk","Immunology","Biotech business analysis","Drug development"],"summary":"CAR-T's move from blood cancer into autoimmune disease could redefine cell therapy, but the value depends on whether deep immune reset can justify manufacturing complexity, safety risk, and cost.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-08-cart-autoimmune-new-era.html"}},{"title":"CAR-T 迎接新時代：從血癌走向自體免疫","date":"2026-06-08","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era.html","source":"Dcard / Facebook","access":"商業分析文","category":"商業分析","tags":["CAR-T","自體免疫","Kyverna","mivocabtagene autoleucel","細胞治療","FDA"],"summary":"Kyverna 啟動 mivocabtagene autoleucel 的 BLA 滾動式提交，象徵 CAR-T 從血癌治療走向自體免疫疾病的新階段，也重新打開細胞治療的商業想像。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-08-cart-autoimmune-new-era-en.html"}},{"title":"Drugmakers Without AI Capability May No Longer Be Called Drugmakers","date":"2026-06-07","language":"en","url":"https://drugnews.com.tw/articles/2026-06-07-pharma-ai-capability-future-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-07-pharma-ai-capability-future-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["IR and Capital Markets","AI drug discovery","Biotech business analysis","Drug development"],"summary":"AI is becoming a core operating capability for pharma, but its value comes from improving discovery, translation, trial design, and portfolio decisions rather than from marketing language alone.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-07-pharma-ai-capability-future.html"}},{"title":"沒有 AI 能力的藥廠，將不再被稱作藥廠","date":"2026-06-07","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-07-pharma-ai-capability-future.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-07-pharma-ai-capability-future.html","source":"Dcard / Facebook","access":"商業分析文","category":"商業分析","tags":["AI","藥廠","新藥研發","製藥產業","數位轉型","商業模式"],"summary":"AI 正在從工具變成製藥公司的底層能力。未來藥廠不只比管線，也會比資料、模型、實驗自動化與決策速度，沒有 AI 能力的公司將愈來愈難被視為現代藥廠。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-07-pharma-ai-capability-future-en.html"}},{"title":"Old Targets Are Crowded, but They Can Still Make Money","date":"2026-06-06","language":"en","url":"https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["BD and Licensing","Business development","Biotech business analysis","Drug development"],"summary":"Crowded drug targets can still create value when companies differentiate through patient selection, formulation, route of administration, clinical design, pricing, or commercial channel strategy.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-06-old-targets-differentiation-strategy.html"}},{"title":"老靶點都很捲，但不是不能賺錢","date":"2026-06-06","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy.html","source":"Dcard / Facebook","access":"商業分析文","category":"商業分析","tags":["熱門靶點","PD-1","BCMA","CD19","Biotech","BD","差異化"],"summary":"熱門靶點擁擠不代表沒有價值；真正關鍵是公司能否在身位、差異化、適應症切入、技術換代與 BD 對接中找到自己的獲利位置。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-06-old-targets-differentiation-strategy-en.html"}},{"title":"Starting With Ruxolitinib Cream: Why Not Every JAK Molecule Can Become a Topical Drug","date":"2026-06-05","language":"en","url":"https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Clinical and CMC","Biotech business analysis","Drug development"],"summary":"Topical JAK drugs are not won by target biology alone. The real value lies in skin delivery, local exposure, systemic safety, indication choice, and whether the product can fit daily dermatology practice.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-05-topical-jak-inhibitor-skin-delivery.html"}},{"title":"從 Ruxolitinib cream 說起：外用 JAK 抑制劑，為什麼不是每個分子都能做？","date":"2026-06-05","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery.html","source":"Dcard / Facebook","access":"商業分析文","category":"商業分析","tags":["Ruxolitinib","JAK 抑制劑","外用藥","皮膚遞送","Incyte","安成生技","CMC"],"summary":"外用 JAK 抑制劑的核心不是單純抑制 JAK，而是分子能否穿過皮膚、留在局部、降低全身暴露，並在適應症與製劑設計上建立差異化。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-05-topical-jak-inhibitor-skin-delivery-en.html"}},{"title":"Retatrutide Moves Toward Surgery-Level Weight Loss: Lilly's Triple-Agonist Pushes Obesity Treatment Into a New Arena","date":"2026-06-04","language":"en","url":"https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Company Research","Obesity medicine","Big Pharma","Biotech business analysis","Drug development"],"summary":"Retatrutide pushes obesity-drug efficacy toward surgery-level territory, but the real competitive battle will be durability, tolerability, body composition, comorbidity benefit, and access.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-04-retatrutide-obesity-surgery-level-weight-loss.html"}},{"title":"Retatrutide 殺進減重手術級別：禮來三重受體藥物，把肥胖治療推向新戰場","date":"2026-06-04","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss.html","source":"Dcard / Facebook","access":"商業分析文","category":"商業分析","tags":["Retatrutide","Eli Lilly","肥胖治療","GLP-1","GIP","Glucagon","減重藥"],"summary":"Eli Lilly 的 retatrutide 在三期試驗中把減重幅度推向接近手術級別，代表肥胖治療正從單一路徑抑制食慾，走向多受體代謝調控的新戰場。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-04-retatrutide-obesity-surgery-level-weight-loss-en.html"}},{"title":"A Genetic Disease With No New Treatment for 40 Years Finally Enters a New Drug Era","date":"2026-06-03","language":"en","url":"https://drugnews.com.tw/articles/2026-06-03-aatd-new-therapy-rna-gene-editing-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-03-aatd-new-therapy-rna-gene-editing-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Clinical and CMC","Immunology","Biotech business analysis","Drug development"],"summary":"AATD is entering a new treatment cycle after decades of limited options, with RNA and gene-based approaches trying to move the field beyond symptom control and protein replacement.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-03-aatd-new-therapy-rna-gene-editing.html"}},{"title":"40年沒藥的遺傳病迎來重磅進展","date":"2026-06-03","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-03-aatd-new-therapy-rna-gene-editing.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-03-aatd-new-therapy-rna-gene-editing.html","source":"Dcard / Facebook","access":"商業分析文","category":"商業分析","tags":["AATD","罕見疾病","Sanofi","Wave Life Sciences","Beam Therapeutics","RNA 編輯","基因編輯"],"summary":"AATD 治療在近 40 年後迎來新療法競速，Sanofi、Wave、Beam 分別以長效重組蛋白、RNA 編輯與基因鹼基編輯切入，代表罕見遺傳病治療正從補蛋白走向根源修正。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-03-aatd-new-therapy-rna-gene-editing-en.html"}},{"title":"Biogen's High-Risk Bet: Can Tau Find a Way Out of the Alzheimer's R&D Graveyard?","date":"2026-06-02","language":"en","url":"https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Clinical and CMC","CNS","Big Pharma","Capital markets","Biotech business analysis","Drug development"],"summary":"Biogen's BIIB080 tau program reflects a broader Alzheimer's reset: the field is no longer only asking whether amyloid matters, but whether tau biology can produce measurable disease-modifying benefit.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-02-biogen-alzheimers-tau-biib080-strategy.html"}},{"title":"Biogen 孤注一擲：Alzheimer’s Disease 研發墳場裡，tau 靶點能不能走出新路？","date":"2026-06-02","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy.html","source":"Dcard / Facebook","access":"商業分析文","category":"商業分析","tags":["Biogen","Alzheimer’s Disease","tau","BIIB080","diranersen","ASO","神經退化疾病"],"summary":"Biogen 在 BIIB080 / diranersen 的 Phase 2 CELIA 研究未達主要終點後仍推進 Phase 3，反映 AD 研發裡 tau 靶點的高風險、高需求與策略性押注。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-02-biogen-alzheimers-tau-biib080-strategy-en.html"}},{"title":"Pluvicto Is Selling Fast: What Radioligand Therapy Growth Really Means","date":"2026-06-01","language":"en","url":"https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Company Research","Radiopharma","Biotech business analysis","Drug development"],"summary":"Pluvicto's rapid growth shows radioligand therapy moving from specialist science into a real commercial infrastructure story, where isotope supply, hospital workflow, and patient selection become strategic assets.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-06-01-pluvicto-radioligand-therapy-growth.html"}},{"title":"核藥賣爆了","date":"2026-06-01","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth.html","canonical_url":"https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth.html","source":"Dcard / Facebook","access":"商業分析文","category":"商業分析","tags":["Pluvicto","Novartis","核藥","放射配體療法","攝護腺癌","PSMA","精準治療"],"summary":"Pluvicto 單季銷售達 6.42 億美元，顯示攝護腺癌治療正從荷爾蒙訊號攻防，走向 PSMA 核醫診療一體化與放射配體療法的新階段。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-06-01-pluvicto-radioligand-therapy-growth-en.html"}},{"title":"為什麼生技新聞不能只看成功或失敗？真正該問的是 5 個估值參數","date":"2026-05-31","language":"zh-Hant","url":"https://vocus.cc/article/6a15a6f6fd897800015ad19e","canonical_url":"https://vocus.cc/article/6a15a6f6fd897800015ad19e","source":"方格子","access":"商業分析文","category":"商業分析","tags":["成功","基本面","市場","生技","銷售","藥華藥","風險","患者","案例","估值參數"],"summary":"生技新聞不能只分利多利空。真正要問的是：成功率、上市時間、患者池、峰值銷售、風險折現，哪個估值參數真的被改變了。","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a15a6f6fd897800015ad19e-cover.svg","is_accessible_for_free":true,"is_external":true,"alternate_language_versions":{}},{"title":"【會員研究包】藥華藥 ET 現在該怎麼估值？從 PDUFA 到第二成長曲線重算","date":"2026-05-31","language":"zh-Hant","url":"https://vocus.cc/article/6a14397dfd89780001935730","canonical_url":"https://vocus.cc/article/6a14397dfd89780001935730","source":"方格子","access":"深度分析","category":"基本面","tags":["商業","投資理財","生物","醫師","美股","醫藥","投資人","長期投資","FDA","治療"],"summary":"藥華藥 ET 進入 PDUFA 倒數後，估值該重算哪幾個參數？這篇拆解成功率、上市時間、峰值銷售與折現率哪些能上修，哪些還不能先算滿。","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a14397dfd89780001935730-cover.svg","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"The Tavneos Crisis: Death Reports, Data-Integrity Questions, and an Amgen Rare-Disease Star at the Edge of Withdrawal","date":"2026-05-31","language":"en","url":"https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Clinical and CMC","Regulatory risk","Immunology","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Tavneos Crisis: Death Reports, Data-Integrity Questions, and an Amgen Rare-Disease Star at the Edge of Withdrawal, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-31-tavneos-safety-data-integrity-crisis.html"}},{"title":"⚠️ Tavneos 危機：20 例死亡通報、資料完整性疑雲，Amgen 罕病明星藥站上撤市邊緣","date":"2026-05-31","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["Tavneos","Amgen","罕病藥","FDA","資料完整性","肝毒性","撤市風險"],"summary":"Tavneos 從罕病明星藥站上撤市邊緣，真正危機不只是日本死亡通報與肝毒性，而是 FDA 對 ADVOCATE 試驗資料完整性的嚴重指控。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-31-tavneos-safety-data-integrity-crisis-en.html"}},{"title":"【會員研究包】近期臨床進展該怎麼重算估值？藥華藥 ET 與中裕 TMB-365/380 兩個對照案例","date":"2026-05-31","language":"zh-Hant","url":"https://vocus.cc/article/6a170cf3fd89780001dc3d78","canonical_url":"https://vocus.cc/article/6a170cf3fd89780001dc3d78","source":"方格子","access":"深度分析","category":"基本面","tags":["簡報","基本面","風險","資訊","會員","市場","商業","投資人","成功","授權"],"summary":"很多公司簡報聽完，市場第一個反應往往不是「哪個估值參數變了」，而是「管理層今天講得很有信心」。 這其實很危險。 因為簡報的任務，本來就不是替投資人做估值，而是替公司整理出一套最有利的敘事順序。 所以對我來說，簡報後真正要做的事，不是把投影片重抄一遍，而是立刻回答一個問題：","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a170cf3fd89780001dc3d78-cover.svg","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"公司簡報不能只抄重點：真正要聽的是公司沒說清楚什麼","date":"2026-05-31","language":"zh-Hant","url":"https://vocus.cc/article/6a15a61ffd897800015a854d","canonical_url":"https://vocus.cc/article/6a15a61ffd897800015a854d","source":"方格子","access":"商業分析文","category":"商業分析","tags":["簡報","基本面","授權","生技公司","市場","商業","風險","FDA","投資人","資本市場"],"summary":"聽生技公司簡報時，重點不是把公司想說的故事抄下來，而是判斷哪些假設、風險與估值參數還沒有被說清楚。","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a15a61ffd897800015a854d-cover.svg","is_accessible_for_free":true,"is_external":true,"alternate_language_versions":{}},{"title":"The Best Partner for a Drug King? When Combination Therapy Doubles Efficacy","date":"2026-05-30","language":"en","url":"https://drugnews.com.tw/articles/2026-05-30-drug-combination-efficacy-doubling-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-30-drug-combination-efficacy-doubling-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Clinical and CMC","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Best Partner for a Drug King? When Combination Therapy Doubles Efficacy, focusing on company strategy, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-30-drug-combination-efficacy-doubling.html"}},{"title":"藥王的最佳搭檔？療效翻倍！","date":"2026-05-30","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-30-drug-combination-efficacy-doubling.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-30-drug-combination-efficacy-doubling.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["Keytruda","INBRX-106","OX40","腫瘤免疫","聯合治療"],"summary":"Keytruda 專利懸崖前，下一代聯合治療能否提高療效天花板與延長生命週期，是藥王商業價值的關鍵問題。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-30-drug-combination-efficacy-doubling-en.html"}},{"title":"OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間","date":"2026-05-30","language":"zh-Hant","url":"https://vocus.cc/article/6a0540e0fd89780001e8806d","canonical_url":"https://vocus.cc/article/6a0540e0fd89780001e8806d","source":"方格子","access":"商業分析文","category":"商業分析","tags":["治療","商業","投資人","醫藥","生物","美股","FDA","長期投資","醫師","投資理財"],"summary":"OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間 中樞神經系統藥物開發，很久沒有出現一個這麼清楚、這麼有生物學邏輯、又這麼接近臨床突破的靶點。 這個靶點就是 Orexin Receptor 2（OX2R）。 如果只用一句話解釋 OX2R 的重要性，它不是單純讓人「比較不想睡","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a0540e0fd89780001e8806d-source.png","is_accessible_for_free":true,"is_external":true,"alternate_language_versions":{}},{"title":"Weight-Loss Drugs Are No Longer Only About Body Weight: Where Next-Generation Therapies Are Aiming","date":"2026-05-29","language":"en","url":"https://drugnews.com.tw/articles/2026-05-29-next-generation-obesity-therapy-directions-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-29-next-generation-obesity-therapy-directions-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Clinical and CMC","AI drug discovery","Obesity medicine","Capital markets","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Weight-Loss Drugs Are No Longer Only About Body Weight: Where Next-Generation Therapies Are Aiming, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-29-next-generation-obesity-therapy-directions.html"}},{"title":"減重藥物不只看體重了：下一代療法正在瞄準這些方向","date":"2026-05-29","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-29-next-generation-obesity-therapy-directions.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-29-next-generation-obesity-therapy-directions.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["減重藥物","GLP-1","肥胖治療","肌肉保留","代謝"],"summary":"下一代減重療法不只比體重下降，也要看肌肉保留、脂肪肝、心血管與代謝共病等更完整臨床價值。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-29-next-generation-obesity-therapy-directions-en.html"}},{"title":"減重藥物不只看體重了：下一代療法正在瞄準這些方向","date":"2026-05-29","language":"zh-Hant","url":"https://vocus.cc/article/6a0ea91efd897800015f1c9d","canonical_url":"https://vocus.cc/article/6a0ea91efd897800015f1c9d","source":"方格子","access":"商業分析文","category":"商業分析","tags":["藥物","減重","體重","脂肪","代謝","肌肉","肥胖","治療","患者","脂肪肝"],"summary":"減重藥物不只看體重了：下一代療法正在瞄準這些方向 肥胖治療正在成為全球創新藥研發中最重要的戰場之一。 過去，市場討論減重藥物，焦點多半放在一件事：能瘦多少？ 但現在，這個問題已經不夠用了。隨著 Wegovy（semaglutide）、Ozempic（semaglutide）、Mou","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a0ea91efd897800015f1c9d-cover.svg","is_accessible_for_free":true,"is_external":true,"alternate_language_versions":{}},{"title":"Biotech Investing Needs a Judgment System, Not More News","date":"2026-05-28","language":"en","url":"https://drugnews.com.tw/articles/2026-05-28-biotech-investment-judgment-system-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-28-biotech-investment-judgment-system-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Business development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Biotech Investing Needs a Judgment System, Not More News, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-28-biotech-investment-judgment-system.html"}},{"title":"🧬 生技投資圈｜不是更多新聞，是一套生技醫藥判斷系統","date":"2026-05-28","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-28-biotech-investment-judgment-system.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-28-biotech-investment-judgment-system.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["BD","生技投資"],"summary":"生技新聞很多。但真正難的不是「知道發生了什麼」，而是看懂：🔍 這件事到底改變了公司的基本面嗎？一個臨床結果，是降低失敗風險，還是市場短線情緒？一個授權案，是有真實商業價值，還是只是在包裝題材？一家公司","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-28-biotech-investment-judgment-system-en.html"}},{"title":"無針注射不是噱頭：從怕打針，到下一代藥物遞送平台","date":"2026-05-28","language":"zh-Hant","url":"https://vocus.cc/article/6a151ec7fd89780001cf534e","canonical_url":"https://vocus.cc/article/6a151ec7fd89780001cf534e","source":"方格子","access":"深度分析","category":"深度商業分析","tags":["商業","醫藥","生物","治療","FDA","美股","投資人","長期投資","投資理財","醫師"],"summary":"很多人對打針都有陰影。 輕一點的是緊張、皺眉、轉頭不看；嚴重一點的，甚至會暈針、冒冷汗、心跳加快。但很現實的是，人這一生幾乎很難完全逃過注射：疫苗、胰島素、局部麻醉、皮下注射藥物、醫美療程，或某些慢性病長期給藥，都可能需要針頭。 所以，無針注射這個技術乍聽之下很像噱頭。 但它並不是「隔空打針」","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a151ec7fd89780001cf534e-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"The First Step in Valuing Taiwanese Biotech: Stop Forcing Every Company Into the Same P/E Ratio","date":"2026-05-27","language":"en","url":"https://drugnews.com.tw/articles/2026-05-27-taiwan-biotech-valuation-framework-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-27-taiwan-biotech-valuation-framework-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Biotech Valuation","AI drug discovery","Capital markets","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The First Step in Valuing Taiwanese Biotech: Stop Forcing Every Company Into the Same P/E Ratio, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-27-taiwan-biotech-valuation-framework.html"}},{"title":"Sun Pharma, Teva, and the Transformation Anxiety of Global Generic Drugmakers","date":"2026-05-27","language":"en","url":"https://drugnews.com.tw/articles/2026-05-27-generic-pharma-transformation-anxiety-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-27-generic-pharma-transformation-anxiety-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Company Research","Big Pharma","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Sun Pharma, Teva, and the Transformation Anxiety of Global Generic Drugmakers, focusing on big pharma, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-27-generic-pharma-transformation-anxiety.html"}},{"title":"台灣生技估值第一步：不要把所有公司都塞進同一個本益比","date":"2026-05-27","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-27-taiwan-biotech-valuation-framework.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-27-taiwan-biotech-valuation-framework.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["生技估值","本益比","rNPV","SOTP"],"summary":"台灣生技股最常見的錯誤，不是模型算錯一點，而是公司類型一開始就分錯。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-27-taiwan-biotech-valuation-framework-en.html"}},{"title":"太陽製藥、梯瓦製藥 與 全球學名藥廠的轉型焦慮","date":"2026-05-27","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-27-generic-pharma-transformation-anxiety.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-27-generic-pharma-transformation-anxiety.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["太陽製藥","梯瓦製藥","學名藥","轉型"],"summary":"全球學名藥巨頭面對價格壓力與成長瓶頸，轉型重點從傳統製造規模走向特殊學名藥、創新藥與更高門檻產品。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-27-generic-pharma-transformation-anxiety-en.html"}},{"title":"藥時事會員版：不是更多新聞，是一套生技醫藥判斷系統","date":"2026-05-27","language":"zh-Hant","url":"https://vocus.cc/article/6a15289ffd89780001d2fdec","canonical_url":"https://vocus.cc/article/6a15289ffd89780001d2fdec","source":"方格子","access":"商業分析文","category":"商業分析","tags":["基本面","生技","商業","風險","案例","免費","監管","資本市場","投資理財","生物"],"summary":"這篇是藥時事會員版的產品介紹。 如果你是從 FB、爆料同學會或朋友轉貼進來，先講清楚： 藥時事會員版不是明牌。 也不是每日醫藥新聞摘要。 我想做的是一套給台灣讀者看的生技醫藥基本面判斷系統。 為什麼需要這個會員版 生技醫藥新聞很多。 但真正困難的不是知道發生了什麼，而是判斷： 這","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a15289ffd89780001d2fdec-source.png","is_accessible_for_free":true,"is_external":true,"alternate_language_versions":{}},{"title":"A New Weight-Loss Drug Side Effect Accidentally Opens a New Therapeutic Track","date":"2026-05-26","language":"en","url":"https://drugnews.com.tw/articles/2026-05-26-weight-loss-side-effect-new-track-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-26-weight-loss-side-effect-new-track-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Clinical and CMC","Obesity medicine","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on A New Weight-Loss Drug Side Effect Accidentally Opens a New Therapeutic Track, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-26-weight-loss-side-effect-new-track.html"}},{"title":"減肥藥新副作用，意外帶出新賽道？","date":"2026-05-26","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-26-weight-loss-side-effect-new-track.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-26-weight-loss-side-effect-new-track.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["GLP-1","減肥藥","掉髮","副作用","皮膚科"],"summary":"GLP-1 減重潮帶出的掉髮與身體組成問題，正在讓頭皮護理、營養管理與皮膚科成為減重藥外溢新賽道。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-26-weight-loss-side-effect-new-track-en.html"}},{"title":"創新藥的品味：真正的 BD，不只是把藥賣出去，而是看懂病人、疾病與全球市場","date":"2026-05-26","language":"zh-Hant","url":"https://vocus.cc/article/6a099ed7fd89780001a780f5","canonical_url":"https://vocus.cc/article/6a099ed7fd89780001a780f5","source":"方格子","access":"深度分析","category":"深度商業分析","tags":["FDA","商業","醫藥","長期投資","投資理財","治療","生物","投資人","美股","醫師"],"summary":"AI 時代留給人類的東西，可能只剩下三件事：品味、勇氣，還有價值觀。 更精準地說，價值觀其實也包含在品味裡。 因為品味不是美感而已。品味是一個人如何選擇問題、如何判斷價值、如何決定把有限資源下注在哪裡。勇氣則是當你看見一個尚未被共識承認的方向時，仍然願意承擔失敗風險，往前走。 在投資如此，在創","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a099ed7fd89780001a780f5-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"BD 找標的，不是看故事，而是先算帳：如何量化一條管線到底值不值得買？","date":"2026-05-26","language":"zh-Hant","url":"https://vocus.cc/article/6a13c8b2fd897800017126b7","canonical_url":"https://vocus.cc/article/6a13c8b2fd897800017126b7","source":"方格子","access":"深度分析","category":"深度商業分析","tags":["商業","投資理財","生物","醫師","美股","醫藥","投資人","長期投資","FDA","治療"],"summary":"每一次 BD 決策，本質上都不是「多買一條管線」這麼簡單。 它其實是在決定公司未來幾年的資金流向、研發資源分配、利潤結構，甚至是整條估值曲線。 很多公司做 BD 時，嘴上說的是「補強產品線」、「布局新技術」、「增加策略協同」，但真正進到內部審查時，常常發現問題很大：資產看起來很漂亮，但買不起；科","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a13c8b2fd897800017126b7-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"Asthma Drugs Are Shifting Gears: From Triple Inhalers to Upstream Immune Targets","date":"2026-05-25","language":"en","url":"https://drugnews.com.tw/articles/2026-05-25-asthma-new-drug-immune-targets-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-25-asthma-new-drug-immune-targets-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Clinical and CMC","Immunology","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Asthma Drugs Are Shifting Gears: From Triple Inhalers to Upstream Immune Targets, focusing on immunology, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-25-asthma-new-drug-immune-targets.html"}},{"title":"氣喘新藥正在換檔：從吸入三合一到上游免疫靶點!","date":"2026-05-25","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-25-asthma-new-drug-immune-targets.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-25-asthma-new-drug-immune-targets.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["氣喘","吸入三合一","免疫靶點","生物製劑","呼吸道疾病"],"summary":"氣喘治療正在從吸入三合一與症狀控制，走向上游免疫靶點、生物製劑與更精準的病人分型。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-25-asthma-new-drug-immune-targets-en.html"}},{"title":"氣喘新藥正在換檔：從吸入三合一到上游免疫靶點","date":"2026-05-25","language":"zh-Hant","url":"https://vocus.cc/article/6a091d1bfd897800017185f3","canonical_url":"https://vocus.cc/article/6a091d1bfd897800017185f3","source":"方格子","access":"商業分析文","category":"商業分析","tags":["FDA","美股","商業","醫藥","長期投資","投資理財","治療","生物","投資人","醫師"],"summary":"氣喘是全球最常見的慢性呼吸道疾病之一，也是醫學上仍難以「根治」的疾病。WHO 估計，2019 年全球約有 2.62 億名氣喘患者，並造成約 45.5 萬人死亡；若採用較早期的全球估算，患者人數甚至可達 3.39 億。這不只是過敏體質或空氣品質的生活議題，也是一條正在被國際大藥廠重新定義的創新藥賽道。","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a091d1bfd897800017185f3-source.png","is_accessible_for_free":true,"is_external":true,"alternate_language_versions":{}},{"title":"Why OX2R Is Heating Up: From Narcolepsy to the Next CNS Drug Opportunity","date":"2026-05-24","language":"en","url":"https://drugnews.com.tw/articles/2026-05-24-ox2r-cns-narcolepsy-opportunity-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-24-ox2r-cns-narcolepsy-opportunity-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Obesity medicine","CNS","Regulatory risk","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Why OX2R Is Heating Up: From Narcolepsy to the Next CNS Drug Opportunity, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-24-ox2r-cns-narcolepsy-opportunity.html"}},{"title":"OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間","date":"2026-05-24","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-24-ox2r-cns-narcolepsy-opportunity.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-24-ox2r-cns-narcolepsy-opportunity.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["GLP-1","CNS","FDA","OX2R"],"summary":"【 OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間】中樞神經系統藥物開發，很久沒有出現一個這麼清楚、這麼有生物學邏輯、又這麼接近臨床突破的靶點。這個靶點就是 Orexin Recept","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-24-ox2r-cns-narcolepsy-opportunity-en.html"}},{"title":"The Global Biotech Wave: Understanding the Main Phase and Scientific Pricing of the Five-Trillion Weight-Loss Market","date":"2026-05-23","language":"en","url":"https://drugnews.com.tw/articles/2026-05-23-global-biotech-obesity-megatrend-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-23-global-biotech-obesity-megatrend-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","AI drug discovery","Obesity medicine","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Global Biotech Wave: Understanding the Main Phase and Scientific Pricing of the Five-Trillion Weight-Loss Market, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-23-global-biotech-obesity-megatrend.html"}},{"title":"全球生技大浪來襲：看懂五兆減肥藥的主升段與科學定價","date":"2026-05-23","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-23-global-biotech-obesity-megatrend.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-23-global-biotech-obesity-megatrend.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["藥華藥","減重藥","生技投資"],"summary":"當台灣資本市場的資金與目光被 AI 半導體全面虹吸時，全球生技產業正悄悄用另一種方式重新定義人類的未來——那就是減肥藥的瘋狂狂潮。我們多次提到，AI 解決的是算力與效率問題，而生技醫療解決的是疾病與生","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-23-global-biotech-obesity-megatrend-en.html"}},{"title":"全球生技大浪來襲：看懂五兆減肥藥的主升段與科學定價","date":"2026-05-23","language":"zh-Hant","url":"https://vocus.cc/article/6a1004a2fd8978000174d22e","canonical_url":"https://vocus.cc/article/6a1004a2fd8978000174d22e","source":"方格子","access":"商業分析文","category":"商業分析","tags":["投資理財","醫藥","長期投資","醫師","FDA","商業","投資人","生物","美股","治療"],"summary":"當台灣資本市場的資金與目光被 AI 半導體全面虹吸時，全球生技產業正悄悄用另一種方式重新定義人類的未來——那就是減肥藥的瘋狂狂潮。 我們多次提到，AI 解決的是算力與效率問題，而生技醫療解決的是疾病與生命問題。這不是一場資源的對立，而是台灣必須並行的雙引擎。如果說 AI 半導體是矽基生產力的極致，","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a1004a2fd8978000174d22e-cover.svg","is_accessible_for_free":true,"is_external":true,"alternate_language_versions":{}},{"title":"How Mid-Sized Biotechs Are Turning Blockbuster Drugs From Dreams Into Cash Flow","date":"2026-05-22","language":"en","url":"https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Obesity medicine","CNS","Regulatory risk","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on How Mid-Sized Biotechs Are Turning Blockbuster Drugs From Dreams Into Cash Flow, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-22-mid-size-biotech-blockbuster-cashflow.html"}},{"title":"這些中型 Biotech，正在把「重磅炸彈藥物」從夢想變成現金流","date":"2026-05-22","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["Alzheimer","GLP-1","CNS","FDA","藥華藥","BESREMi"],"summary":"在很長一段時間裡，製藥業的 blockbuster drug，似乎是大型藥廠的專屬勳章。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-22-mid-size-biotech-blockbuster-cashflow-en.html"}},{"title":"這些中型 Biotech，正在把「重磅炸彈藥物」從夢想變成現金流","date":"2026-05-22","language":"zh-Hant","url":"https://vocus.cc/article/6a067b5efd89780001967900","canonical_url":"https://vocus.cc/article/6a067b5efd89780001967900","source":"方格子","access":"商業分析文","category":"商業分析","tags":["美股","醫藥","投資人","商業","醫師","長期投資","FDA","投資理財","生物","治療"],"summary":"在很長一段時間裡，製藥業的 blockbuster drug，似乎是大型藥廠的專屬勳章。 年銷售額突破 10 億美元，代表的不只是產品好賣，而是公司必須同時具備臨床開發能力、法規溝通能力、保險給付能力、醫師教育能力、銷售組織能力，以及後續適應症擴張能力。 這些資源過去多半掌握在大型跨國藥廠手中。","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a067b5efd89780001967900-source.png","is_accessible_for_free":true,"is_external":true,"alternate_language_versions":{}},{"title":"How AI Semiconductors Have Hidden the Biotech Opportunity in Plain Sight","date":"2026-05-21","language":"en","url":"https://drugnews.com.tw/articles/2026-05-21-ai-semiconductor-biotech-capital-neglect-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-21-ai-semiconductor-biotech-capital-neglect-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","AI drug discovery","Regulatory risk","Business development","Capital markets","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on How AI Semiconductors Have Hidden the Biotech Opportunity in Plain Sight, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-21-ai-semiconductor-biotech-capital-neglect.html"}},{"title":"AI半導體掩蓋生技光芒","date":"2026-05-21","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-21-ai-semiconductor-biotech-capital-neglect.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-21-ai-semiconductor-biotech-capital-neglect.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["BD","FDA","藥華藥","BESREMi","生技投資"],"summary":"台灣資本市場最近出現一個非 常清楚的現象：AI 半導體正在虹吸一切。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-21-ai-semiconductor-biotech-capital-neglect-en.html"}},{"title":"【基本面系列】藥華藥合理估值是多少？","date":"2026-05-21","language":"zh-Hant","url":"https://vocus.cc/article/6a0d4c86fd89780001809174","canonical_url":"https://vocus.cc/article/6a0d4c86fd89780001809174","source":"方格子","access":"深度分析","category":"基本面","tags":["美股","醫師","投資理財","治療","商業","投資人","生物","長期投資","醫藥","FDA"],"summary":"藥華藥 台灣生技股王市，值站到 3,000 億台幣，到底還有多少是基本面，多少是預付未來？ 藥華藥是少數已經走到全球銷售、營收放大、獲利兌現的公司。 2025 年藥華藥合併營收約 NT$156 億，稅後淨利約 NT$50 億，EPS 13.64 元。2026 年第一季營收約 NT$51 億，EP","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a0d4c86fd89780001809174-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"A Record AI Drug-Discovery Financing: Why a Google-Backed Company Raised US$2.1 Billion","date":"2026-05-20","language":"en","url":"https://drugnews.com.tw/articles/2026-05-20-ai-drug-discovery-google-funding-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-20-ai-drug-discovery-google-funding-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Company Research","AI drug discovery","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on A Record AI Drug-Discovery Financing: Why a Google-Backed Company Raised US$2.1 Billion, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-20-ai-drug-discovery-google-funding.html"}},{"title":"破紀錄 AI 製藥融資來了！Google 系公司一次募 21 億美元","date":"2026-05-20","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-20-ai-drug-discovery-google-funding.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-20-ai-drug-discovery-google-funding.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["AI 製藥","Isomorphic Labs","Google","融資","生技投資"],"summary":"Google 系 AI 製藥公司大型融資，真正要看的不是 AI 標籤，而是平台能否把模型轉成可臨床驗證與授權的藥物資產。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-20-ai-drug-discovery-google-funding-en.html"}},{"title":"第一三共最貴的一課：ADC 熱潮裡，產能也可能變成風險資產","date":"2026-05-20","language":"zh-Hant","url":"https://vocus.cc/article/6a099349fd89780001a468c4","canonical_url":"https://vocus.cc/article/6a099349fd89780001a468c4","source":"方格子","access":"深度分析","category":"深度商業分析","tags":["FDA","商業","醫藥","長期投資","投資理財","治療","生物","投資人","美股","醫師"],"summary":"在 ADC 賽道一路高歌猛進的 Daiichi Sankyo，正在為過去幾年的激進擴產付出代價。 這件事很值得台灣生技產業仔細看。 因為它表面上是一家日本大型藥廠的財務調整，實際上卻是一堂非常昂貴的產業課：新藥公司不能只看需求峰值，也要管理臨床失敗、法規延遲、產能閒置與 CMO 合約反噬的風險。","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a099349fd89780001a468c4-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"HIV Drugs Are Still Highly Profitable: What Gilead's Earnings Reveal","date":"2026-05-19","language":"en","url":"https://drugnews.com.tw/articles/2026-05-19-gilead-hiv-yeztugo-prep-growth-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-19-gilead-hiv-yeztugo-prep-growth-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","CAR-T","Targeted therapy","Regulatory risk","Big Pharma","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on HIV Drugs Are Still Highly Profitable: What Gilead's Earnings Reveal, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-19-gilead-hiv-yeztugo-prep-growth.html"}},{"title":"HIV 新藥很好賺呀...吉利德財報披露","date":"2026-05-19","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-19-gilead-hiv-yeztugo-prep-growth.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-19-gilead-hiv-yeztugo-prep-growth.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["CAR-T","ADC","J&J","FDA","Pfizer","Gilead"],"summary":"【Gilead 的 HIV 王朝沒有老去：Yeztugo 超預期，正在把 PrEP 推進「半年打一針」時代】💉 Gilead 最新一季財報，表面看起來只是一份穩健的藥廠成績單。2026 年第一季，Gi","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-19-gilead-hiv-yeztugo-prep-growth-en.html"}},{"title":"BD 怎麼跟 Big Pharma 1v1 開會？不是混臉熟，而是讓買方願意往下一步走","date":"2026-05-19","language":"zh-Hant","url":"https://vocus.cc/article/6a07e2e5fd8978000119a6c6","canonical_url":"https://vocus.cc/article/6a07e2e5fd8978000119a6c6","source":"方格子","access":"深度分析","category":"深度商業分析","tags":["商業","長期投資","FDA","美股","醫師","投資理財","生物","投資人","醫藥","治療"],"summary":"這幾年，新藥產業的 BD 交流會，已經變成各大 biotech 和 pharma 的標準行程。 海外的 JPM Healthcare Conference、BIO International Convention、BIO-Europe、LSX World Congress，到亞洲的 BioJapa","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a07e2e5fd8978000119a6c6-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"Where Pfizer Misjudged the Vepdegestrant Strategy","date":"2026-05-18","language":"en","url":"https://drugnews.com.tw/articles/2026-05-18-pfizer-vepdegestrant-strategy-mistake-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-18-pfizer-vepdegestrant-strategy-mistake-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Targeted therapy","Regulatory risk","Big Pharma","Business development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Where Pfizer Misjudged the Vepdegestrant Strategy, focusing on targeted therapy, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-18-pfizer-vepdegestrant-strategy-mistake.html"}},{"title":"大藥廠 輝瑞在兩個判斷上栽跟頭？","date":"2026-05-18","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-18-pfizer-vepdegestrant-strategy-mistake.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-18-pfizer-vepdegestrant-strategy-mistake.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["BD","ADC","PROTAC","FDA","Pfizer","Gilead"],"summary":"【「賤賣」重磅炸彈，Pfizer 為何在兩個判斷上栽跟頭？】Pfizer 正站在一個很微妙的十字路口。一邊，是它與 Arvinas 聯手研發的 Vepdegestrant（Veppanu） 獲 FDA","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-18-pfizer-vepdegestrant-strategy-mistake-en.html"}},{"title":"AI 製藥大單背後：百億美元交易案，不代表 AI 公司真的拿到百億美元","date":"2026-05-18","language":"zh-Hant","url":"https://vocus.cc/article/6a07dea6fd897800011862f7","canonical_url":"https://vocus.cc/article/6a07dea6fd897800011862f7","source":"方格子","access":"深度分析","category":"深度商業分析","tags":["商業","長期投資","FDA","美股","醫師","投資理財","生物","投資人","醫藥","治療"],"summary":"AI 製藥最近成為全球醫藥產業最容易被放大的敘事之一。 只要看新聞標題，很容易以為這個賽道已經進入「印鈔機模式」：一筆合作動不動 10 億美元、20 億美元、50 億美元，甚至上看百億美元。大型藥廠一邊喊專利懸崖，一邊大手筆擁抱 artificial intelligence、foundation","image":"https://drugnews.com.tw/assets/articles/external-vocus/6a07dea6fd897800011862f7-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"Johnson & Johnson（嬌生）砍掉兩條 自體淋巴瘤 CAR-T","date":"2026-05-17","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-17-jnj-auto-car-t-commercial-challenge.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-17-jnj-auto-car-t-commercial-challenge.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["CAR-T","Kelonia","BD","ADC","J&J","FDA"],"summary":"【嬌生 CAR-T 戰略折戟：不是數據不夠漂亮，而是自體 CD19/CD20 CAR-T 的商業死循環開始反噬】📌 誰能想到，幾個月前還被 Johnson & Johnson 管理層高度看好的淋巴瘤","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-17-jnj-auto-car-t-commercial-challenge-en.html"}},{"title":"Johnson & Johnson Cuts Two Autologous Lymphoma CAR-T Programs","date":"2026-05-17","language":"en","url":"https://drugnews.com.tw/articles/2026-05-17-jnj-auto-car-t-commercial-challenge-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-17-jnj-auto-car-t-commercial-challenge-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","CAR-T","Targeted therapy","Regulatory risk","Big Pharma","Business development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Johnson & Johnson Cuts Two Autologous Lymphoma CAR-T Programs, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-17-jnj-auto-car-t-commercial-challenge.html"}},{"title":"Daiichi Sankyo's Most Expensive Lesson: How an ADC Capacity Bet Can Backfire After a Blockbuster","date":"2026-05-17","language":"en","url":"https://drugnews.com.tw/articles/2026-05-17-daiichi-sankyo-adc-capacity-lesson-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-17-daiichi-sankyo-adc-capacity-lesson-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Clinical and CMC","AI drug discovery","Targeted therapy","Big Pharma","Capital markets","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Daiichi Sankyo's Most Expensive Lesson: How an ADC Capacity Bet Can Backfire After a Blockbuster, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-17-daiichi-sankyo-adc-capacity-lesson.html"}},{"title":"第一三共最貴的一課：ADC 爆款之後，產能豪賭如何反噬？","date":"2026-05-17","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-17-daiichi-sankyo-adc-capacity-lesson.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-17-daiichi-sankyo-adc-capacity-lesson.html","source":"網站","access":"商業分析文","category":"商業分析","tags":["第一三共","ADC","DXd","Enhertu","CDMO","CMO","供應鏈","浩鼎","永昕"],"summary":"第一三共因 ADC 供應鏈與產能承諾認列高額費用，提醒新藥公司與 CDMO：pipeline 要折現，產能也要折現。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-17-daiichi-sankyo-adc-capacity-lesson-en.html"}},{"title":"The FDA Commissioner's Exit: Why the World's Most Important Drug Referee Is Becoming Less Predictable","date":"2026-05-16","language":"en","url":"https://drugnews.com.tw/articles/2026-05-16-fda-commissioner-resignation-regulatory-risk-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-16-fda-commissioner-resignation-regulatory-risk-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Regulatory risk","Business development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The FDA Commissioner's Exit: Why the World's Most Important Drug Referee Is Becoming Less Predictable, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-16-fda-commissioner-resignation-regulatory-risk.html"}},{"title":"FDA 局長黯然離職：全球最重要的新藥裁判，正在變得更不可預測","date":"2026-05-16","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-16-fda-commissioner-resignation-regulatory-risk.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-16-fda-commissioner-resignation-regulatory-risk.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["BD","FDA","生技投資"],"summary":"2026 年 5 月 12 日，美國 FDA 局長 Marty Makary 正式辭職，結束他僅約 13 個月的任期。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-16-fda-commissioner-resignation-regulatory-risk-en.html"}},{"title":"Johnson & Johnson（嬌生）砍掉兩條 自體淋巴瘤 CAR-T","date":"2026-05-16","language":"zh-Hant","url":"https://vocus.cc/article/69fcaa65fd897800015160ba","canonical_url":"https://vocus.cc/article/69fcaa65fd897800015160ba","source":"方格子","access":"商業分析文","category":"商業分析","tags":["治療","長期投資","醫藥","生物","投資理財","醫師","FDA","投資人","商業","美股"],"summary":"嬌生 CAR-T 戰略折戟：不是數據不夠漂亮，而是自體 CD19/CD20 CAR-T 的商業死循環開始反噬 誰能想到，幾個月前還被 Johnson & Johnson 管理層高度看好的淋巴瘤 CAR-T 管線，會在 2026 年 4 月底被突然送進歷史檔案夾。 這不是普通的管線微調。","image":"https://drugnews.com.tw/assets/articles/external-vocus/69fcaa65fd897800015160ba-cover.svg","is_accessible_for_free":true,"is_external":true,"alternate_language_versions":{}},{"title":"A Complete Map of the New Antidepressant Drug Pipeline","date":"2026-05-15","language":"en","url":"https://drugnews.com.tw/articles/2026-05-15-antidepressant-new-drugs-pipeline-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-15-antidepressant-new-drugs-pipeline-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Obesity medicine","CNS","Regulatory risk","Business development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on A Complete Map of the New Antidepressant Drug Pipeline, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-15-antidepressant-new-drugs-pipeline.html"}},{"title":"全網最全的「抗憂鬱新藥」最新進展盤點","date":"2026-05-15","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-15-antidepressant-new-drugs-pipeline.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-15-antidepressant-new-drugs-pipeline.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["BD","GLP-1","CNS","FDA","生技投資"],"summary":"【精神科藥物終於走出單胺時代？】📌 憂鬱症從來不是一個小市場。依 WHO 統計，全球約有 2.8 億人受到憂鬱症影響；若加上不同國家、不同診斷口徑下的未診斷與亞臨床族群，實際醫療負擔只會更高。這不是一","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-15-antidepressant-new-drugs-pipeline-en.html"}},{"title":"三抗不是炒冷飯：成熟標靶背後，其實藏著三層商業邏輯","date":"2026-05-15","language":"zh-Hant","url":"https://vocus.cc/article/69fe9e3efd89780001db0c56","canonical_url":"https://vocus.cc/article/69fe9e3efd89780001db0c56","source":"方格子","access":"深度分析","category":"深度商業分析","tags":["治療","美股","商業","投資人","醫藥","長期投資","FDA","投資理財","生物","醫師"],"summary":"雙抗火完，現在輪到三抗。 過去幾年，抗體工程的故事一波接一波。單抗之後是雙抗，雙抗之後是 ADC，ADC 之後又有人喊出三特異性抗體（trispecific antibody）的新時代。乍看之下，這很像醫藥圈又開始炒冷飯：同樣一批標靶，被換個分子格式重新包裝，再拿到資本市場講一遍新故事。 但如果","image":"https://drugnews.com.tw/assets/articles/external-vocus/69fe9e3efd89780001db0c56-cover.svg","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"How PharmaEssentia's Besremi Opens a Larger Valuation Imagination","date":"2026-05-14","language":"en","url":"https://drugnews.com.tw/articles/2026-05-14-pharmaessentia-besremi-mpn-valuation-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-14-pharmaessentia-besremi-mpn-valuation-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Targeted therapy","Regulatory risk","Capital markets","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on How PharmaEssentia's Besremi Opens a Larger Valuation Imagination, focusing on targeted therapy, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-14-pharmaessentia-besremi-mpn-valuation.html"}},{"title":"藥華藥 打開估值想像空間","date":"2026-05-14","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-14-pharmaessentia-besremi-mpn-valuation.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-14-pharmaessentia-besremi-mpn-valuation.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["ADC","FDA","藥華藥","BESREMi","生技投資"],"summary":"因為 BESREMi（ropeginterferon alfa-2b）在台灣正式獲衛福部核准用於原發性血小板過多症（Essential Thrombocythemia, ET）成人病人，適用於接受 Hydroxyurea 治療後產生抗藥性或無法耐受的患者。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-14-pharmaessentia-besremi-mpn-valuation-en.html"}},{"title":"大藥廠 輝瑞在兩個判斷上栽跟頭？","date":"2026-05-14","language":"zh-Hant","url":"https://vocus.cc/article/69fca07afd897800014ec164","canonical_url":"https://vocus.cc/article/69fca07afd897800014ec164","source":"方格子","access":"商業分析文","category":"商業分析","tags":["治療","長期投資","醫藥","生物","投資理財","醫師","FDA","投資人","商業","美股"],"summary":"「賤賣」重磅炸彈，Pfizer 為何在兩個判斷上栽跟頭？ Pfizer 正站在一個很微妙的十字路口。 一邊，是它與 Arvinas 聯手研發的 Vepdegestrant（Veppanu） 獲 FDA 核准，用於治療 ER+/HER2-、帶有 ESR1 mutation 的晚期或轉移性乳癌。","image":"https://drugnews.com.tw/assets/articles/external-vocus/69fca07afd897800014ec164-source.png","is_accessible_for_free":true,"is_external":true,"alternate_language_versions":{}},{"title":"Could Neuroinflammation Bring CNS Drug Development Back?","date":"2026-05-13","language":"en","url":"https://drugnews.com.tw/articles/2026-05-13-neuroinflammation-cns-drug-comeback-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-13-neuroinflammation-cns-drug-comeback-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","CNS","Big Pharma","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Could Neuroinflammation Bring CNS Drug Development Back?, focusing on cns, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-13-neuroinflammation-cns-drug-comeback.html"}},{"title":"中樞神經新藥要靠「神經發炎」？","date":"2026-05-13","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-13-neuroinflammation-cns-drug-comeback.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-13-neuroinflammation-cns-drug-comeback.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["Alzheimer","CNS","Pfizer"],"summary":"【屢敗屢戰的中樞神經新藥，能否靠「神經發炎」打贏翻身仗？】中樞神經系統新藥研發，一直是創新藥裡最難啃的一塊骨頭。🧠 不是市場不大。恰恰相反，阿茲海默症、帕金森氏症、肌萎縮性脊髓側索硬化症、多發性硬化症","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-13-neuroinflammation-cns-drug-comeback-en.html"}},{"title":"BD 必看：License-out 資訊揭露節奏，不是越透明越好，而是要讓買方一步一步「付出代價」","date":"2026-05-13","language":"zh-Hant","url":"https://vocus.cc/article/69feced8fd89780001e8fb67","canonical_url":"https://vocus.cc/article/69feced8fd89780001e8fb67","source":"方格子","access":"深度分析","category":"深度商業分析","tags":["治療","美股","商業","投資人","醫藥","長期投資","FDA","投資理財","生物","醫師"],"summary":"做 BD，最常遇到的不是對方沒興趣，而是對方一上來就很有興趣。 問題也出在這裡。 手上好不容易有一條潛力管線，終於等到 Big Pharma 或資金雄厚的買方回信，對方開口第一句常常就是：「可以先把完整資料包發來看看嗎？」 這時候，賣方通常會陷入一種很難受的拉扯。 給太多，怕被白嫖。 尤其","image":"https://drugnews.com.tw/assets/articles/external-vocus/69feced8fd89780001e8fb67-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"The Autoimmune Twins That Could Save Johnson & Johnson","date":"2026-05-12","language":"en","url":"https://drugnews.com.tw/articles/2026-05-12-jnj-autoimmune-twins-stelara-transition-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-12-jnj-autoimmune-twins-stelara-transition-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","CAR-T","Regulatory risk","Big Pharma","Business development","Immunology","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Autoimmune Twins That Could Save Johnson & Johnson, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-12-jnj-autoimmune-twins-stelara-transition.html"}},{"title":"自體免疫 雙子星 拯救 嬌生","date":"2026-05-12","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-12-jnj-autoimmune-twins-stelara-transition.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-12-jnj-autoimmune-twins-stelara-transition.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["CAR-T","BD","J&J","Stelara","FDA","生技投資"],"summary":"【Johnson & Johnson 自免「雙子星」崛起：Stelara 退場後，Tremfya 與 Icotyde 正在重寫免疫版圖】📌 2026 年第一季，Johnson & Johnson（J&","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-12-jnj-autoimmune-twins-stelara-transition-en.html"}},{"title":"那個喊了 40 年的「創新藥回報率已死」鬼故事，唬住了多少人？","date":"2026-05-12","language":"zh-Hant","url":"https://vocus.cc/article/69cfe161fd897800019121ac","canonical_url":"https://vocus.cc/article/69cfe161fd897800019121ac","source":"方格子","access":"深度分析","category":"深度商業分析","tags":["治療","長期投資","醫藥","生物","投資理財","醫師","FDA","投資人","商業","美股"],"summary":"每隔幾年，製藥業就會流行一次「創新藥研發已經不賺錢」的說法。 這個說法通常會搭配一張很嚇人的圖：創新藥研發的內部報酬率一路下滑，從過去的雙位數，跌到只剩個位數，甚至一度跌到接近零。Deloitte 在 2025 年發布的《Measuring the return from pharmaceutic","image":"https://drugnews.com.tw/assets/articles/external-vocus/69cfe161fd897800019121ac-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"DAC（降解劑－抗體偶聯藥物）會是下一代標靶藥物的新引爆點嗎？","date":"2026-05-11","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-11-dac-adc-protac-next-targeted-therapy.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-11-dac-adc-protac-next-targeted-therapy.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["ADC","PROTAC"],"summary":"【強強聯手！當 ADC 遇上 PROTAC】生醫圈有兩個絕對頂流。📌 一個是 ADC（Antibody-Drug Conjugate，抗體藥物複合體）。📌 另一個是以 PROTAC（Proteolys","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-11-dac-adc-protac-next-targeted-therapy-en.html"}},{"title":"Could DAC Become the Next Breakout Format in Targeted Therapy?","date":"2026-05-11","language":"en","url":"https://drugnews.com.tw/articles/2026-05-11-dac-adc-protac-next-targeted-therapy-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-11-dac-adc-protac-next-targeted-therapy-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Targeted therapy","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Could DAC Become the Next Breakout Format in Targeted Therapy?, focusing on targeted therapy, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-11-dac-adc-protac-next-targeted-therapy.html"}},{"title":"Lilly 今年最貴併購案：為什麼一個「清醒開關」值 78 億美元？","date":"2026-05-11","language":"zh-Hant","url":"https://vocus.cc/article/69e8ebbffd897800011cc782","canonical_url":"https://vocus.cc/article/69e8ebbffd897800011cc782","source":"方格子","access":"深度分析","category":"深度商業分析","tags":["治療","長期投資","醫藥","生物","投資理財","醫師","FDA","投資人","商業","美股"],"summary":"Lilly 今年的併購節奏，已經不是「補管線」這麼簡單。 短短幾個月，從發炎、體內 CAR-T、ADC、AI 製藥到睡眠障礙，Lilly 幾乎把未來十年幾個最有想像力的技術方向都掃了一輪。 但如果把這幾筆交易攤開來看，最貴的一張支票其實不是給體內 CAR-T，也不是給 ADC，而是給一家做睡眠與","image":"https://drugnews.com.tw/assets/articles/external-vocus/69e8ebbffd897800011cc782-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"Trump Delays the Policy Signal: Did Weight-Loss Drugs Cut Prices for Nothing?","date":"2026-05-10","language":"en","url":"https://drugnews.com.tw/articles/2026-05-10-glp1-medicare-policy-delay-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-10-glp1-medicare-policy-delay-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Obesity medicine","CNS","Regulatory risk","Capital markets","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Trump Delays the Policy Signal: Did Weight-Loss Drugs Cut Prices for Nothing?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-10-glp1-medicare-policy-delay.html"}},{"title":"川普放政策鴿子，減肥藥價格白降了？","date":"2026-05-10","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-10-glp1-medicare-policy-delay.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-10-glp1-medicare-policy-delay.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["Alzheimer","GLP-1","Tirzepatide","FDA","減重藥"],"summary":"【川普政府放了 Eli Lilly（禮來）、Novo Nordisk （諾和諾德）的「鴿子」？GLP-1 進 Medicare，為什麼臨門一腳又卡住了】📌 2026 年 4 月下旬，美國減重藥市場出現","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-10-glp1-medicare-policy-delay-en.html"}},{"title":"Clinical-Trial Fraud and an FDA Withdrawal Storm","date":"2026-05-09","language":"en","url":"https://drugnews.com.tw/articles/2026-05-09-clinical-trial-fraud-fda-withdrawal-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-09-clinical-trial-fraud-fda-withdrawal-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Clinical and CMC","Regulatory risk","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Clinical-Trial Fraud and an FDA Withdrawal Storm, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-09-clinical-trial-fraud-fda-withdrawal.html"}},{"title":"臨床試驗作假，FDA 撤市風暴！","date":"2026-05-09","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-09-clinical-trial-fraud-fda-withdrawal.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-09-clinical-trial-fraud-fda-withdrawal.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["Tavneos","FDA","資料完整性","罕病藥","撤市風險"],"summary":"FDA 對 Tavneos 提出撤市程序，核心不是單純療效不足，而是 ADVOCATE 試驗資料完整性與事後重判問題。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-09-clinical-trial-fraud-fda-withdrawal-en.html"}},{"title":"做藥，正在從拆盲盒變成搭樂高","date":"2026-05-09","language":"zh-Hant","url":"https://vocus.cc/article/69f9e952fd8978000125e854","canonical_url":"https://vocus.cc/article/69f9e952fd8978000125e854","source":"方格子","access":"深度分析","category":"深度商業分析","tags":["生物","投資人","美股","長期投資","醫藥","投資理財","FDA","商業","醫師","治療"],"summary":"樂高公司在 1932 年成立時，只是丹麥一家木匠創辦的木製玩具小工坊。 真正改變世界的，是 1958 年那塊帶有鉚釘與管狀結構的互鎖塑膠積木。 那個設計最迷人的地方，不是單一積木本身有多複雜，而是它把複雜世界拆成一個個標準化、可相容、可重複使用的基礎單元。只要規格對了，不同積木就能拼出房子、車子","image":"https://drugnews.com.tw/assets/articles/external-vocus/69f9e952fd8978000125e854-cover.svg","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"Weight-Loss Drugs Are Still Too Strong: Lilly's Mounjaro Keeps Printing Money","date":"2026-05-08","language":"en","url":"https://drugnews.com.tw/articles/2026-05-08-lilly-tirzepatide-glp1-growth-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-08-lilly-tirzepatide-glp1-growth-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Obesity medicine","CAR-T","Targeted therapy","CNS","Big Pharma","Capital markets","Biotech business analysis"],"summary":"A Drugnews English brief on Weight-Loss Drugs Are Still Too Strong: Lilly's Mounjaro Keeps Printing Money, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-08-lilly-tirzepatide-glp1-growth.html"}},{"title":"減肥藥還是太強了，禮來 猛健樂 賺爛！","date":"2026-05-08","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-08-lilly-tirzepatide-glp1-growth.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-08-lilly-tirzepatide-glp1-growth.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["CAR-T","Kelonia","GLP-1","Tirzepatide","ADC","CNS"],"summary":"2026 年第一季，Eli Lilly 交出了一份讓整個製藥業都很難忽視的成績單：單季總營收 197.99 億美元，年增 56%；調整後 EPS 達 8.55 美元，大幅優於市場預期。真正撐起這份財報的，仍然是那個已經把全球代謝藥市場打穿的名字：tirzepatide。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-08-lilly-tirzepatide-glp1-growth-en.html"}},{"title":"慢病新貴 HDAC6：一個從腫瘤配角走向長期治療平台的表觀遺傳標靶","date":"2026-05-08","language":"zh-Hant","url":"https://vocus.cc/article/69f9ebb4fd8978000126c723","canonical_url":"https://vocus.cc/article/69f9ebb4fd8978000126c723","source":"方格子","access":"深度分析","category":"深度商業分析","tags":["生物","投資人","美股","長期投資","醫藥","投資理財","FDA","商業","醫師","治療"],"summary":"在創新藥研發裡，真正值得關注的標靶，往往不是一開始就站在聚光燈中央的那種。 有些標靶，是慢慢從配角變成主角。 HDAC6（Histone Deacetylase 6） 就是這樣一個標靶。 過去，HDAC 相關藥物最常被放在腫瘤語境裡討論。從早期 pan-HDAC inhibitor 到後來更選","image":"https://drugnews.com.tw/assets/articles/external-vocus/69f9ebb4fd8978000126c723-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"【台北場】藥時事｜捕捉生技飆股：用NPV框架算出翻倍重估點","date":"2026-05-07","language":"zh-Hant","url":"https://vocus.cc/article/69f89078fd897800018fdaa7","canonical_url":"https://vocus.cc/article/69f89078fd897800018fdaa7","source":"方格子","access":"商業分析文","category":"商業分析","tags":["生物","醫師","美股","治療","醫藥","投資理財","FDA","投資人","商業","長期投資"],"summary":"生技醫藥股往往囊括了市場單日最大漲幅與最大跌幅，是極具爆發力的投資領域。 然而，多數人將其視為妖股，是因為缺乏一套系統性的估值體系來了解其內在價值。 藥時事 作為擁有超過 35,000 名生醫菁英（包含醫師、科學家與專業投資人）關注的平台，將帶領你建立專業的投資判讀框架。 建立你的生醫投資「去","image":"https://drugnews.com.tw/assets/articles/external-vocus/69f89078fd897800018fdaa7-source.png","is_accessible_for_free":true,"is_external":true,"alternate_language_versions":{}},{"title":"The Shadow Behind the Next Century-Defining Drug","date":"2026-05-07","language":"en","url":"https://drugnews.com.tw/articles/2026-05-07-pan-ras-patent-safety-war-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-07-pan-ras-patent-safety-war-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","CAR-T","Targeted therapy","CNS","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Shadow Behind the Next Century-Defining Drug, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-07-pan-ras-patent-safety-war.html"}},{"title":"下一代世紀大藥的陰影？","date":"2026-05-07","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-07-pan-ras-patent-safety-war.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-07-pan-ras-patent-safety-war.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["CAR-T","RAS","ADC","CNS"],"summary":"【Pan-RAS 戰爭升級：Erasca 數據驚艷，卻撞上 Revolution 的專利戰與安全性陰影】📌 RAS 賽道，正在從「誰的療效更強」進入「誰能同時守住安全性、IP 與商業化窗口」的新階段。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-07-pan-ras-patent-safety-war-en.html"}},{"title":"下一代世紀大藥的陰影？","date":"2026-05-07","language":"zh-Hant","url":"https://vocus.cc/article/69f31b24fd8978000191b420","canonical_url":"https://vocus.cc/article/69f31b24fd8978000191b420","source":"方格子","access":"商業分析文","category":"商業分析","tags":["投資理財","投資人","長期投資","醫藥","生物","醫師","商業","美股","FDA","治療"],"summary":"Pan-RAS 戰爭升級：Erasca 數據驚艷，卻撞上 Revolution 的專利戰與安全性陰影 RAS 賽道，正在從「誰的療效更強」進入「誰能同時守住安全性、IP 與商業化窗口」的新階段。 過去幾十年，RAS 一直被視為 oncology 裡最難攻克、也最有價值的聖杯之一。尤其在","image":"https://drugnews.com.tw/assets/articles/external-vocus/69f31b24fd8978000191b420-source.png","is_accessible_for_free":true,"is_external":true,"alternate_language_versions":{}},{"title":"Free Taipei Workshop: Using an NPV Framework to Identify Biotech Re-Rating Points","date":"2026-05-06","language":"en","url":"https://drugnews.com.tw/articles/2026-05-06-taipei-biotech-npv-workshop-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-06-taipei-biotech-npv-workshop-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","AI drug discovery","Capital markets","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Free Taipei Workshop: Using an NPV Framework to Identify Biotech Re-Rating Points, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-06-taipei-biotech-npv-workshop.html"}},{"title":"【台北場】藥時事｜捕捉生技飆股：用NPV框架算出翻倍重估點","date":"2026-05-06","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-06-taipei-biotech-npv-workshop.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-06-taipei-biotech-npv-workshop.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["藥華藥","生技投資"],"summary":"✨講座介紹，生技醫藥股往往囊括了市場單日最大漲幅與最大跌幅，是極具爆發力的投資領域。然而，多數人將其視為妖股，是因為缺乏一套系統性的估值體系來了解其內在價值。藥時事 作為擁有超過 35，000 名生醫","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-06-taipei-biotech-npv-workshop-en.html"}},{"title":"深度解析：AI 製藥公司的估值體系","date":"2026-05-06","language":"zh-Hant","url":"https://vocus.cc/article/69f32410fd897800019466f9","canonical_url":"https://vocus.cc/article/69f32410fd897800019466f9","source":"方格子","access":"深度分析","category":"深度商業分析","tags":["投資理財","投資人","長期投資","醫藥","生物","醫師","商業","美股","FDA","治療"],"summary":"rNPV 之外，必須開始估一台「藥物生成機器」 AI 製藥公司最難被估值的地方，不在於模型有多炫，也不在於簡報裡寫了多少個 foundation model。 真正困難的是：傳統創新藥估值方法，往往只會估「已經看得見的管線」，卻很難估「持續生成管線的能力」。 這就是今天 AI drug dis","image":"https://drugnews.com.tw/assets/articles/external-vocus/69f32410fd897800019466f9-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"What Makes a Pipeline Attractive to Big Pharma?","date":"2026-05-05","language":"en","url":"https://drugnews.com.tw/articles/2026-05-05-pharma-pipeline-bd-attraction-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-05-pharma-pipeline-bd-attraction-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Obesity medicine","Targeted therapy","CNS","Regulatory risk","Business development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on What Makes a Pipeline Attractive to Big Pharma?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-05-pharma-pipeline-bd-attraction.html"}},{"title":"讓大藥廠心動的管線到底做了什麼？","date":"2026-05-05","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-05-pharma-pipeline-bd-attraction.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-05-pharma-pipeline-bd-attraction.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["BD","GLP-1","ADC","CNS","FDA","藥華藥"],"summary":"📌 醫藥產業的併購邏輯，正在發生一場非常明顯的結構性變化。過去幾年，許多 Biotech 都想往最大、最熱門、最容易被資本市場理解的賽道擠：腫瘤、ADC、自體免疫、GLP-1、雙抗、細胞治療。這些方向","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-05-pharma-pipeline-bd-attraction-en.html"}},{"title":"生醫藥人，如何在 SOP 與 AI 夾擊下，重新找回創造力？","date":"2026-05-05","language":"zh-Hant","url":"https://vocus.cc/article/69f2b637fd897800016fa618","canonical_url":"https://vocus.cc/article/69f2b637fd897800016fa618","source":"方格子","access":"深度分析","category":"深度商業分析","tags":["投資理財","投資人","長期投資","醫藥","生物","醫師","商業","美股","FDA","治療"],"summary":"有時候真的會覺得，做生物醫藥這一行，很容易精神分裂。 一方面，公司會議裡永遠都在喊創新。 老闆說，管線不能再跟著別人後面卷。 策略會說，我們要做 differentiated asset。投資人說，市場不想再聽 me-too 故事。BD 團隊說，現在 MNC 只買有非共識價值的資產。 但另一","image":"https://drugnews.com.tw/assets/articles/external-vocus/69f2b637fd897800016fa618-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"The Hair-Growth Drug That Jumped 47%: Why It Could Rewrite Three Decades of Hair-Loss Treatment","date":"2026-05-04","language":"en","url":"https://drugnews.com.tw/articles/2026-05-04-hair-growth-drug-breakthrough-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-04-hair-growth-drug-breakthrough-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Clinical and CMC","AI drug discovery","Capital markets","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Hair-Growth Drug That Jumped 47%: Why It Could Rewrite Three Decades of Hair-Loss Treatment, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-04-hair-growth-drug-breakthrough.html"}},{"title":"最強生髮藥暴漲 47%， 為什麼可能改寫掉髮治療三十年僵局？","date":"2026-05-04","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-04-hair-growth-drug-breakthrough.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-04-hair-growth-drug-breakthrough.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["Veradermics","生髮藥","掉髮治療","口服 minoxidil","皮膚科"],"summary":"Veradermics 的緩釋型口服 minoxidil 讀出正向臨床資料，讓掉髮治療從醫師經驗用藥走向正式新藥開發與市場重估。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-04-hair-growth-drug-breakthrough-en.html"}},{"title":"大藥廠怎麼衡量早期專案？真正的關鍵，不是人脈，而是確信度","date":"2026-05-04","language":"zh-Hant","url":"https://vocus.cc/article/69f2b40cfd897800016ee6d2","canonical_url":"https://vocus.cc/article/69f2b40cfd897800016ee6d2","source":"方格子","access":"深度分析","category":"深度商業分析","tags":["投資理財","投資人","長期投資","醫藥","生物","醫師","商業","美股","FDA","治療"],"summary":"很多 Biotech 跟跨國大藥廠打交道時，常常會覺得對方的態度像「薛丁格的貓」。 一開始好像很有興趣，會議也開了，問題也問了，CDA 也簽了；但過一陣子又突然變冷，甚至直接沒有下文。於是很多人會把原因歸結為人脈不夠、時機不好、對方內部政治複雜，或 BD 談判技巧還不夠成熟。 這些因素當然存在。","image":"https://drugnews.com.tw/assets/articles/external-vocus/69f2b40cfd897800016ee6d2-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"In Vivo CAR-T: Bubble or the Most Expensive Ticket to Next-Generation Cell Therapy?","date":"2026-05-03","language":"en","url":"https://drugnews.com.tw/articles/2026-05-03-in-vivo-cart-kelonia-lilly-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-03-in-vivo-cart-kelonia-lilly-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","CAR-T","Big Pharma","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on In Vivo CAR-T: Bubble or the Most Expensive Ticket to Next-Generation Cell Therapy?, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-03-in-vivo-cart-kelonia-lilly.html"}},{"title":"體內 CAR-T 的泡沫，還是下一代細胞治療最貴的門票？","date":"2026-05-03","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-03-in-vivo-cart-kelonia-lilly.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-03-in-vivo-cart-kelonia-lilly.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["CAR-T","Kelonia","J&J","Gilead","生技投資"],"summary":"📌 4 月 20 日，Eli Lilly 宣布將以最高 70 億美元收購臨床階段生技公司 Kelonia Therapeutics，其中包含 32.5 億美元現金預付款，其餘則取決於後續臨床、監管與商","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-03-in-vivo-cart-kelonia-lilly-en.html"}},{"title":"The Ambition of an Indian Pharma Giant: Acquiring a US Drugmaker","date":"2026-05-02","language":"en","url":"https://drugnews.com.tw/articles/2026-05-02-sun-pharma-organon-acquisition-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-02-sun-pharma-organon-acquisition-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Big Pharma","Business development","Capital markets","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Ambition of an Indian Pharma Giant: Acquiring a US Drugmaker, focusing on big pharma, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-02-sun-pharma-organon-acquisition.html"}},{"title":"印度製藥巨頭的野望！併購美國藥廠！","date":"2026-05-02","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-02-sun-pharma-organon-acquisition.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-02-sun-pharma-organon-acquisition.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["Sun Pharma","Organon","BD","Stelara"],"summary":"【Sun Pharma 117.5 億美元收購 Organon：印度學名藥巨頭「抄底」百年女性健康平台，全球藥廠版圖正在重新排位】📌 4 月 26 日，印度最大製藥公司 Sun Pharmaceuti","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-02-sun-pharma-organon-acquisition-en.html"}},{"title":"創新藥 License-out：名為授權許可，實為 IP 賣身？","date":"2026-05-02","language":"zh-Hant","url":"https://vocus.cc/article/69f2b20efd897800016e34c6","canonical_url":"https://vocus.cc/article/69f2b20efd897800016e34c6","source":"方格子","access":"深度分析","category":"深度商業分析","tags":["投資理財","投資人","長期投資","醫藥","生物","醫師","商業","美股","FDA","治療"],"summary":"在創新藥產業裡，License-out 幾乎是近幾年最火的關鍵字。 從 ADC、雙抗，到各種小分子、自體免疫、代謝與 CNS 管線，亞洲與全球 Biotech 靠一筆又一筆授權大單，在資本寒冬裡硬是殺出一條路。對很多早期公司來說，License-out 不只是交易事件，而是續命工具、估值錨點，甚至","image":"https://drugnews.com.tw/assets/articles/external-vocus/69f2b20efd897800016e34c6-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"Is the 20-Year Amyloid Hypothesis in Alzheimer's Disease Starting to Collapse?","date":"2026-05-01","language":"en","url":"https://drugnews.com.tw/articles/2026-05-01-alzheimers-amyloid-hypothesis-collapse-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-01-alzheimers-amyloid-hypothesis-collapse-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","CNS","Regulatory risk","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Is the 20-Year Amyloid Hypothesis in Alzheimer's Disease Starting to Collapse?, focusing on cns, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-05-01-alzheimers-amyloid-hypothesis-collapse.html"}},{"title":"阿茲海默症20年來的假說開始崩盤？","date":"2026-05-01","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-05-01-alzheimers-amyloid-hypothesis-collapse.html","canonical_url":"https://drugnews.com.tw/articles/2026-05-01-alzheimers-amyloid-hypothesis-collapse.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["Alzheimer","amyloid","FDA"],"summary":"【阿茲海默症的 Aβ 信仰，真的開始崩了嗎？】📌 4 月 16 日，一篇來自 Cochrane 的系統性綜述，再次把阿茲海默症領域最核心、也最具爭議的主軸，推回風暴中心。這份綜述的訊息極其刺耳：對輕度","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-05-01-alzheimers-amyloid-hypothesis-collapse-en.html"}},{"title":"阿茲海默症20年來的假說開始崩盤？","date":"2026-05-01","language":"zh-Hant","url":"https://vocus.cc/article/69e8650afd89780001f3f1da","canonical_url":"https://vocus.cc/article/69e8650afd89780001f3f1da","source":"方格子","access":"商業分析文","category":"商業分析","tags":["FDA","醫師","生物","商業","治療","美股","醫藥","投資人","投資理財","長期投資"],"summary":"4 月 16 日，一篇來自 Cochrane 的系統性綜述，再次把阿茲海默症領域最核心、也最具爭議的主軸，推回風暴中心。這份綜述的訊息極其刺耳：對輕度認知障礙（MCI）或輕度失智的阿茲海默症患者而言，amyloid-beta targeting monoclonal antibodies 在 18","image":"https://drugnews.com.tw/assets/articles/external-vocus/69e8650afd89780001f3f1da-source.png","is_accessible_for_free":true,"is_external":true,"alternate_language_versions":{}},{"title":"Amazon Enters AI Drug Discovery and Challenges Nvidia's Pharma Ambition","date":"2026-04-30","language":"en","url":"https://drugnews.com.tw/articles/2026-04-30-amazon-ai-nvidia-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-30-amazon-ai-nvidia-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","AI drug discovery","Business development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Amazon Enters AI Drug Discovery and Challenges Nvidia's Pharma Ambition, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-30-amazon-ai-nvidia.html"}},{"title":"亞馬遜（Amazon） 參戰 AI 製藥，挑戰輝達（Nvidia）","date":"2026-04-30","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-30-amazon-ai-nvidia.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-30-amazon-ai-nvidia.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["AI","BD","生技投資","製藥巨頭"],"summary":"過去幾年，科技巨頭切入生命科學，大多還停留在兩個角色：一種是賣算力，另一種是賣通用 AI。真正難的，是再往前跨一步，直接碰觸藥物發現這個最核心、也最挑剔的環節。因為這不只是把模型丟給研究員用而已，而是要同時解決模型選擇、資料標準、實驗流程、濕實驗驗證、結果回流與團隊協作這一整串問題。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-30-amazon-ai-nvidia-en.html"}},{"title":"A Clear Read on Lilly's Current M&A Logic","date":"2026-04-29","language":"en","url":"https://drugnews.com.tw/articles/2026-04-29-dcard-261388300-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-29-dcard-261388300-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","AI drug discovery","Obesity medicine","Big Pharma","Business development","Immunology","Clinical development","Biotech business analysis"],"summary":"A Drugnews English brief on A Clear Read on Lilly's Current M&A Logic, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-29-dcard-261388300.html"}},{"title":"一篇文章講通現在的“禮來”併購邏輯","date":"2026-04-29","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-29-dcard-261388300.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-29-dcard-261388300.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["AI","GLP-1","自體免疫","BD","臨床數據"],"summary":"💡 四個月，五筆交易，若把交易上限全部加總，Eli Lilly 在 2026 年前四個月已經丟出超過 187 億美元的併購火力：1 月的 Ventyx Biosciences、2 月的 Orna Therapeutics、3 月的 Centessa Pharmaceuticals、4 月的 Cro…","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-29-dcard-261388300-en.html"}},{"title":"When a Gray-Market Industry Gets a Seat at the Table","date":"2026-04-28","language":"en","url":"https://drugnews.com.tw/articles/2026-04-28-dcard-261381952-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-28-dcard-261381952-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","AI drug discovery","Obesity medicine","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on When a Gray-Market Industry Gets a Seat at the Table, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-28-dcard-261381952.html"}},{"title":"灰色產業上牌桌","date":"2026-04-28","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-28-dcard-261381952.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-28-dcard-261381952.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["AI","GLP-1","臨床數據","生技投資","製藥巨頭"],"summary":"🌪️ 在一處私人莊園裡，矽谷創業者、生技極客與華爾街資金坐在同一張桌上，話題從 AI、加密貨幣一路滑向更隱密的領域：BPC-157、MOTS-c、TB-500、Semax、Epitalon。這些名字不像藥，更像暗號。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-28-dcard-261381952-en.html"}},{"title":"Goodbye Autologous CAR-T: Why Taiwan's Cell-Therapy Bubble Also Needs to Break","date":"2026-04-27","language":"en","url":"https://drugnews.com.tw/articles/2026-04-27-car-t-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-27-car-t-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","AI drug discovery","CAR-T","Immunology","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Goodbye Autologous CAR-T: Why Taiwan's Cell-Therapy Bubble Also Needs to Break, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-27-car-t.html"}},{"title":"再見自體CAR-T，台灣的泡沫也該破了","date":"2026-04-27","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-27-car-t.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-27-car-t.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["自體免疫","臨床數據","生技投資"],"summary":"當市場還在用過去十年對自體 CAR-T 的理解框架看細胞治療時，異體 CAR-T 其實已經悄悄走到一個更關鍵的節點。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-27-car-t-en.html"}},{"title":"The Healthcare-Giant Spin-Off Wave","date":"2026-04-26","language":"en","url":"https://drugnews.com.tw/articles/2026-04-26-dcard-261370593-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-26-dcard-261370593-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Business development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Healthcare-Giant Spin-Off Wave, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-26-dcard-261370593.html"}},{"title":"醫療巨頭分拆潮？","date":"2026-04-26","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-26-dcard-261370593.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-26-dcard-261370593.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["BD","生技投資"],"summary":"這幾年，全球大型企業在醫療產業做了一個很有意思、而且愈來愈頻繁的動作：把原本放在大集團裡的醫療業務拆出來，讓它獨立上市、獨立融資、獨立做決策。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-26-dcard-261370593-en.html"}},{"title":"Why Platform Biotechs Can Generate Five Times More Licensing Revenue","date":"2026-04-25","language":"en","url":"https://drugnews.com.tw/articles/2026-04-25-biotech-5-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-25-biotech-5-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Business development","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Why Platform Biotechs Can Generate Five Times More Licensing Revenue, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-25-biotech-5.html"}},{"title":"平台型 Biotech 的授權收入是同業的 5 倍？","date":"2026-04-25","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-25-biotech-5.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-25-biotech-5.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["BD","臨床數據","生技投資","製藥巨頭"],"summary":"如果把 Biotech 的商業模式拆開來看，最容易被低估、但其實最值錢的一種公司，往往不是手上只有一顆明星分子的資產型公司，而是那些擁有底層技術引擎的平台型公司。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-25-biotech-5-en.html"}},{"title":"Investors Should Pay Attention: Drug Delivery Is a Blue Ocean","date":"2026-04-24","language":"en","url":"https://drugnews.com.tw/articles/2026-04-24-dcard-261359193-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-24-dcard-261359193-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Business development","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Investors Should Pay Attention: Drug Delivery Is a Blue Ocean, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-24-dcard-261359193.html"}},{"title":"投資人請注意，給藥方式是藍海！","date":"2026-04-24","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-24-dcard-261359193.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-24-dcard-261359193.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["BD","臨床數據","生技投資","製藥巨頭"],"summary":"這幾年，如果你把跨國藥廠的動作連起來看，會發現一個非常一致、幾乎帶著戰略共識的方向：把原本靠靜脈輸注（IV）的重磅生物藥，盡可能改造成皮下注射（SC）版本。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-24-dcard-261359193-en.html"}},{"title":"Do COPD Patients Finally Have Another New Drug Option?","date":"2026-04-23","language":"en","url":"https://drugnews.com.tw/articles/2026-04-23-dcard-261352566-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-23-dcard-261352566-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Business development","Immunology","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Do COPD Patients Finally Have Another New Drug Option?, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-23-dcard-261352566.html"}},{"title":"慢性阻塞性肺病患者又有新藥可以用了？","date":"2026-04-23","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-23-dcard-261352566.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-23-dcard-261352566.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["自體免疫","BD","臨床數據","生技投資","製藥巨頭"],"summary":"2025 年，對 IL-33/ST2 這條曾被寄予厚望的發炎路徑而言，幾乎是一整年的信心潰散。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-23-dcard-261352566-en.html"}},{"title":"The Three AI Giants Battling Inside Medicine","date":"2026-04-22","language":"en","url":"https://drugnews.com.tw/articles/2026-04-22-ai-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-22-ai-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","AI drug discovery","Business development","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Three AI Giants Battling Inside Medicine, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-22-ai.html"}},{"title":"AI三巨頭在醫藥裡廝殺","date":"2026-04-22","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-22-ai.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-22-ai.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["AI","BD","臨床數據","生技投資","製藥巨頭"],"summary":"ChatGPT、Claude、Gemini 這三大通用大模型，現在打的已經不只是消費端流量，也不是一般企業辦公市場，而是開始往生醫製藥產業鏈的深水區插旗。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-22-ai-en.html"}},{"title":"Did Lilly's Oral Drug Ignite the Market?","date":"2026-04-21","language":"en","url":"https://drugnews.com.tw/articles/2026-04-21-dcard-261339270-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-21-dcard-261339270-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","AI drug discovery","Obesity medicine","Big Pharma","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Did Lilly's Oral Drug Ignite the Market?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-21-dcard-261339270.html"}},{"title":"禮來口服藥引爆市場？","date":"2026-04-21","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-21-dcard-261339270.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-21-dcard-261339270.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["AI","GLP-1","臨床數據","生技投資","製藥巨頭"],"summary":"2026 年 4 月，Eli Lilly 的 Foundayo（orforglipron） 獲 FDA 核准，用於成人肥胖，或合併體重相關共病的過重族群。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-21-dcard-261339270-en.html"}},{"title":"A Historic Moment: The Next Century-Defining Drug Has Arrived","date":"2026-04-20","language":"en","url":"https://drugnews.com.tw/articles/2026-04-20-dcard-261332702-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-20-dcard-261332702-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Obesity medicine","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on A Historic Moment: The Next Century-Defining Drug Has Arrived, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-20-dcard-261332702.html"}},{"title":"歷史性一刻，世紀大藥來了","date":"2026-04-20","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-20-dcard-261332702.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-20-dcard-261332702.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["GLP-1","臨床數據","生技投資"],"summary":"4 月 13 日，Revolution Medicines 公布 daraxonrasib（RMC-6236） 在三期臨床 RASolute 302 的頂線結果。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-20-dcard-261332702-en.html"}},{"title":"Neuralink and the Next Trillion-Dollar Race: Ten Brain-Computer Interface Companies to Know","date":"2026-04-19","language":"en","url":"https://drugnews.com.tw/articles/2026-04-19-neuralink-10-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-19-neuralink-10-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","AI drug discovery","CNS","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Neuralink and the Next Trillion-Dollar Race: Ten Brain-Computer Interface Companies to Know, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-19-neuralink-10.html"}},{"title":"馬斯克的下一個兆元美金賽道 Neuralink，你必須知道的腦機介面 10 家！","date":"2026-04-19","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-19-neuralink-10.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-19-neuralink-10.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["AI","臨床數據","生技投資"],"summary":"到了 2026 年，腦機介面（brain-computer interface, BCI）已經不再只是科幻敘事或實驗室展示，而是逐漸分化成幾條很清楚的產業路線：一條走侵入式植入，目標是讓癱瘓患者重新溝通、操作設備甚至恢復部分功能；一條走非侵入式穿戴，強調腦訊號量測、認知監測與日常應用；還有一條則更像…","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-19-neuralink-10-en.html"}},{"title":"Could This Taiwanese Biotech Capture the Entire AI Infrastructure Dividend?","date":"2026-04-18","language":"en","url":"https://drugnews.com.tw/articles/2026-04-18-biotech-ai-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-18-biotech-ai-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","AI drug discovery","Capital markets","Immunology","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Could This Taiwanese Biotech Capture the Entire AI Infrastructure Dividend?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-18-biotech-ai.html"}},{"title":"台灣這家Biotech將吃下AI基礎建設的所有紅利？","date":"2026-04-18","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-18-biotech-ai.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-18-biotech-ai.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["AI","自體免疫","臨床數據","生技投資"],"summary":"AI 吃電，核電回來了：為什麼麗寶新藥，可能站在下一個被重估的位置？","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-18-biotech-ai-en.html"}},{"title":"The Valley of Death in Innovative Drug Development","date":"2026-04-17","language":"en","url":"https://drugnews.com.tw/articles/2026-04-17-dcard-261315054-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-17-dcard-261315054-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Business development","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Valley of Death in Innovative Drug Development, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-17-dcard-261315054.html"}},{"title":"創新藥開發的「死亡之谷」","date":"2026-04-17","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-17-dcard-261315054.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-17-dcard-261315054.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["BD","臨床數據","生技投資"],"summary":"創新藥研發最殘酷的地方，不在於它難，而在於你往往在一開始就知道，它極可能失敗，卻還是必須投入多年時間、巨額資本，以及一整個團隊的職業生涯去把它往前推。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-17-dcard-261315054-en.html"}},{"title":"The 2026 Q2 Drug Catalysts Biotech Readers Need to Know","date":"2026-04-16","language":"en","url":"https://drugnews.com.tw/articles/2026-04-16-2026-q2-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-16-2026-q2-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Immunology","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The 2026 Q2 Drug Catalysts Biotech Readers Need to Know, focusing on immunology, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-16-2026-q2.html"}},{"title":"生技人必須知道的 2026 Q2 重磅藥物","date":"2026-04-16","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-16-2026-q2.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-16-2026-q2.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["自體免疫","臨床數據","生技投資","製藥巨頭"],"summary":"2026 年第二季，全球生技醫藥產業正走進一個少見的高密度催化期。若把臨床讀數、監管決策與關鍵會議節點一起看，從 4 月到 6 月前後，至少有 17 個值得緊盯的重磅資產將陸續揭曉方向；更早一步，Eli Lilly 的口服減重藥 orforglipron（Foundayo） 已在 4 月 1 日獲 …","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-16-2026-q2-en.html"}},{"title":"The Fall of Two Star Biotechs","date":"2026-04-15","language":"en","url":"https://drugnews.com.tw/articles/2026-04-15-biotech-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-15-biotech-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Obesity medicine","Business development","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Fall of Two Star Biotechs, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-15-biotech.html"}},{"title":"兩家明星 Biotech 的隕落","date":"2026-04-15","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-15-biotech.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-15-biotech.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["GLP-1","BD","臨床數據","生技投資","製藥巨頭"],"summary":"2025 年的生技產業，表面上看起來不像 2022 年那麼驚慌，但真正懂產業的人都知道，市場其實正在經歷一場更深層的重估。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-15-biotech-en.html"}},{"title":"Investors Should Pay Attention to the Autoimmune Mega-Drug Race","date":"2026-04-14","language":"en","url":"https://drugnews.com.tw/articles/2026-04-14-dcard-261295358-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-14-dcard-261295358-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Business development","Immunology","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Investors Should Pay Attention to the Autoimmune Mega-Drug Race, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-14-dcard-261295358.html"}},{"title":"投資人請注意，自體免疫超大藥賽道","date":"2026-04-14","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-14-dcard-261295358.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-14-dcard-261295358.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["自體免疫","BD","臨床數據","生技投資","製藥巨頭"],"summary":"自體免疫藥物市場，從來都不是「穩定但無聊」的成熟市場。恰恰相反，它一直是全球最容易長出重磅藥物的沃土之一，而乾癬（psoriasis），正是這條價值鏈裡最具代表性的試驗場。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-14-dcard-261295358-en.html"}},{"title":"The King of Weight-Loss Drugs: Did US$7.8 Billion Buy the Next Era of Metabolic Medicine?","date":"2026-04-13","language":"en","url":"https://drugnews.com.tw/articles/2026-04-13-78-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-13-78-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","AI drug discovery","Obesity medicine","Business development","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The King of Weight-Loss Drugs: Did US$7.8 Billion Buy the Next Era of Metabolic Medicine?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-13-78.html"}},{"title":"減肥藥之王 78億美元，買下一個「清醒時代」？","date":"2026-04-13","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-13-78.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-13-78.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["AI","GLP-1","BD","臨床數據","生技投資"],"summary":"當 Eli Lilly（禮來） 以最高 78 億美元 收購 Centessa Pharmaceuticals，這筆交易表面上看，是大藥廠再一次用高溢價把一條中期臨床資產收入囊中；但若把時間線再拉長一點，它其實更像是一場很有方向感的提前卡位。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-13-78-en.html"}},{"title":"Idiopathic Pulmonary Fibrosis Is Entering an Acceleration Phase","date":"2026-04-12","language":"en","url":"https://drugnews.com.tw/articles/2026-04-12-dcard-261282303-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-12-dcard-261282303-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Immunology","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Idiopathic Pulmonary Fibrosis Is Entering an Acceleration Phase, focusing on immunology, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-12-dcard-261282303.html"}},{"title":"特發性肺纖維化 迎來爆發","date":"2026-04-12","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-12-dcard-261282303.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-12-dcard-261282303.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["自體免疫","臨床數據","生技投資"],"summary":"特發性肺纖維化，idiopathic pulmonary fibrosis（IPF），從來都不是一個容易講出樂觀故事的領域。這是一種慢性、進行性、不可逆的纖維化肺病，預後差、死亡風險高，過去長年幾乎等同於「只能拖慢，不能扭轉」。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-12-dcard-261282303-en.html"}},{"title":"Why Did the Market Like This Company More After a Clinical Failure?","date":"2026-04-11","language":"en","url":"https://drugnews.com.tw/articles/2026-04-11-dcard-261276232-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-11-dcard-261276232-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","AI drug discovery","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Why Did the Market Like This Company More After a Clinical Failure?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-11-dcard-261276232.html"}},{"title":"這家公司臨床試驗失敗，反而被更加看好？","date":"2026-04-11","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-11-dcard-261276232.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-11-dcard-261276232.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["臨床數據","生技投資"],"summary":"甲狀腺相關眼疾（thyroid eye disease, TED）這條賽道，最近又迎來一次很典型、也很殘酷的產業教育。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-11-dcard-261276232-en.html"}},{"title":"When Should a Company Decisively Abandon a Clinical Trial?","date":"2026-04-10","language":"en","url":"https://drugnews.com.tw/articles/2026-04-10-dcard-261269760-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-10-dcard-261269760-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Business development","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on When Should a Company Decisively Abandon a Clinical Trial?, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-10-dcard-261269760.html"}},{"title":"何時果斷放棄新藥臨床試驗開發？","date":"2026-04-10","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-10-dcard-261269760.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-10-dcard-261269760.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["BD","臨床數據","生技投資","製藥巨頭"],"summary":"新藥開發最難的，往往不是立項那一天，而是明明已經看見風險，卻仍不願按下停止鍵的那一天。每一個研發專案開始時，幾乎都帶著同樣的想像：要做到 first-in-class、要走到 pivotal study、要送件、要上市、要成為下一個成長引擎。然而現實比願景殘酷得多。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-10-dcard-261269760-en.html"}},{"title":"A New Drug Finally Arrives for This Group of Rare-Disease Patients","date":"2026-04-09","language":"en","url":"https://drugnews.com.tw/articles/2026-04-09-dcard-261263509-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-09-dcard-261263509-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","AI drug discovery","Immunology","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on A New Drug Finally Arrives for This Group of Rare-Disease Patients, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-09-dcard-261263509.html"}},{"title":"這一批罕見病患者終於等來新藥！","date":"2026-04-09","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-09-dcard-261263509.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-09-dcard-261263509.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["AI","臨床數據","生技投資"],"summary":"美國 FDA 近日加速核准 Denali Therapeutics 的 AVLAYAH（tividenofusp alfa-eknm），用於治療 Hunter syndrome （韓特氏症），也就是 mucopolysaccharidosis type II（MPS II） 的神經學表現。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-09-dcard-261263509-en.html"}},{"title":"The Abivax Story: How a European Biotech Became a 14-Fold Market Myth","date":"2026-04-08","language":"en","url":"https://drugnews.com.tw/articles/2026-04-08-abivax-14-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-08-abivax-14-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Business development","Immunology","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Abivax Story: How a European Biotech Became a 14-Fold Market Myth, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-08-abivax-14.html"}},{"title":"歐洲生技公司Abivax 一年暴漲14倍的神話","date":"2026-04-08","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-08-abivax-14.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-08-abivax-14.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["自體免疫","BD","臨床數據","生技投資","製藥巨頭"],"summary":"Abivax 近幾個月的股價與話題熱度，幾乎都圍繞著同一件事打轉：它到底會不會成為下一個大型藥廠出手收購的標的。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-08-abivax-14-en.html"}},{"title":"While the US CDC Was Still Looking for a Director","date":"2026-04-07","language":"en","url":"https://drugnews.com.tw/articles/2026-04-07-cdc-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-07-cdc-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Regulatory risk","Capital markets","Immunology","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on While the US CDC Was Still Looking for a Director, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-07-cdc.html"}},{"title":"當美國 CDC 還在找主任...","date":"2026-04-07","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-07-cdc.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-07-cdc.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["自體免疫","臨床數據"],"summary":"真正值得擔心的，從來不只是美國疾病管制與預防中心（CDC）這個位子到底由誰來坐，而是當一個國家的公共衛生指揮中樞長期處於權責模糊、科學威信受損、政策方向反覆擺盪的狀態時，它原本在全球健康治理與醫藥監管上的領導角色，也會跟著一起鬆動。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-07-cdc-en.html"}},{"title":"The Cut-Rate Weight-Loss Injection Has Arrived: What a NT$420 Monthly Price Really Means","date":"2026-04-06","language":"en","url":"https://drugnews.com.tw/articles/2026-04-06-420-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-06-420-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Obesity medicine","Business development","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Cut-Rate Weight-Loss Injection Has Arrived: What a NT$420 Monthly Price Really Means, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-06-420.html"}},{"title":"骨折價 瘦瘦針來了，每月420塊台幣","date":"2026-04-06","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-06-420.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-06-420.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["GLP-1","BD","臨床數據","生技投資"],"summary":"2026 年 3 月，semaglutide （瘦瘦針）在印度迎來一個足以寫進產業教科書的時刻。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-06-420-en.html"}},{"title":"How Far Are We From a Real Anti-Aging Drug?","date":"2026-04-05","language":"en","url":"https://drugnews.com.tw/articles/2026-04-05-dcard-261238352-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-05-dcard-261238352-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on How Far Are We From a Real Anti-Aging Drug?, focusing on clinical development, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-05-dcard-261238352.html"}},{"title":"我們離真正的抗老藥，究竟還有多遠？","date":"2026-04-05","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-05-dcard-261238352.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-05-dcard-261238352.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["臨床數據","生技投資"],"summary":"「抗老化」這三個字，很容易讓人聯想到不老神話、富人專屬科技，甚至公平性與可近性的爭議。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-05-dcard-261238352-en.html"}},{"title":"Did Weight-Loss Injections Backfire and Trigger Pancreatitis Risk?","date":"2026-04-04","language":"en","url":"https://drugnews.com.tw/articles/2026-04-04-dcard-261232633-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-04-dcard-261232633-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Obesity medicine","Capital markets","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Did Weight-Loss Injections Backfire and Trigger Pancreatitis Risk?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-04-dcard-261232633.html"}},{"title":"瘦瘦針翻車？導致胰臟炎？","date":"2026-04-04","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-04-dcard-261232633.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-04-dcard-261232633.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["GLP-1","臨床數據","生技投資"],"summary":"GLP-1 類藥物近兩年幾乎成了全球醫療市場最耀眼的明星。從 liraglutide（利拉魯肽）、semaglutide（司美格魯肽），到雙重受體機制的 tirzepatide（替爾泊肽），這一波藥物不只改變了第二型糖尿病治療，也快速跨入體重管理、心血管風險降低等更大的市場。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-04-dcard-261232633-en.html"}},{"title":"After GLP-1 and Mounjaro, What Is Happening in Weight-Loss Drug R&D?","date":"2026-04-03","language":"en","url":"https://drugnews.com.tw/articles/2026-04-03-dcard-261227197-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-03-dcard-261227197-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Obesity medicine","Business development","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on After GLP-1 and Mounjaro, What Is Happening in Weight-Loss Drug R&D?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-03-dcard-261227197.html"}},{"title":"瘦瘦針、猛健樂之後，減肥藥研發正在發生什麼事？","date":"2026-04-03","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-03-dcard-261227197.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-03-dcard-261227197.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["GLP-1","BD","臨床數據","生技投資","製藥巨頭"],"summary":"過去幾年，**司美格魯肽（semaglutide）與替爾泊肽（tirzepatide）**幾乎重寫了肥胖治療的市場想像。它們不只把減重從「意志力問題」拉回醫療管理，更把投資人、藥廠與臨床醫師對減重藥的預期，直接拉高到一個全新標準。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-03-dcard-261227197-en.html"}},{"title":"Can Merck Build Another Oncology Empire?","date":"2026-04-02","language":"en","url":"https://drugnews.com.tw/articles/2026-04-02-dcard-261221419-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-02-dcard-261221419-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","Big Pharma","Capital markets","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Can Merck Build Another Oncology Empire?, focusing on big pharma, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-02-dcard-261221419.html"}},{"title":"默沙東還能再造一個腫瘤帝國嗎？","date":"2026-04-02","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-02-dcard-261221419.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-02-dcard-261221419.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["生技投資","製藥巨頭"],"summary":"2026 年才過了不到三個月，默沙東已經用兩個動作，把自己對「後 Keytruda 時代」的答案講得愈來愈清楚。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-02-dcard-261221419-en.html"}},{"title":"Innovent's Globalization Train: Did Taiwan's Forward Therapeutics Get On Board?","date":"2026-04-01","language":"en","url":"https://drugnews.com.tw/articles/2026-04-01-dcard-261215001-en.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-01-dcard-261215001-en.html","source":"Website","access":"Business Analysis","category":"商業分析","tags":["Business Analysis","AI drug discovery","Business development","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Innovent's Globalization Train: Did Taiwan's Forward Therapeutics Get On Board?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"zh-Hant":"2026-04-01-dcard-261215001.html"}},{"title":"信達的全球化列車，台灣的圓祥搭上了？","date":"2026-04-01","language":"zh-Hant","url":"https://drugnews.com.tw/articles/2026-04-01-dcard-261215001.html","canonical_url":"https://drugnews.com.tw/articles/2026-04-01-dcard-261215001.html","source":"Dcard","access":"商業分析文","category":"商業分析","tags":["BD","臨床數據","生技投資"],"summary":"3 月 24 日，信達生物公布 efdamrofusp alfa（IBI302） 在中國新生血管型老年黃斑部病變（nAMD）關鍵三期 STAR 試驗達成 52 週主要終點。乍看之下，這像是一則典型的臨床里程碑新聞；但若把它放回全球眼科產業的競爭結構裡看，這件事的重要性遠不只是一款新藥在單一市場報捷。","image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","is_accessible_for_free":true,"is_external":false,"alternate_language_versions":{"en":"2026-04-01-dcard-261215001-en.html"}},{"title":"【製藥巨頭發展史20】再生元 (Regeneron) 如何從 Biotech 成長為 MNC？","date":"2025-09-17","language":"zh-Hant","url":"https://vocus.cc/article/68c9136dfd89780001a94ee3","canonical_url":"https://vocus.cc/article/68c9136dfd89780001a94ee3","source":"方格子","access":"深度分析","category":"製藥巨頭","tags":["Regeneron","再生元","Biotech","抗體藥物","研發策略"],"summary":"2020年4月初的某天清晨，一輛銀色轎車穿過紐約街頭，一位頭髮花白的男士坐在後座上，面容有幾分憔悴。在過去的兩三個月內，他每天只睡四、五個小時，即使是絕大多數紐約人都開始居家辦公的時候，他仍然每天都去公司實驗室報到。在冷清的街道上，他的汽車偶爾才與另一輛車交匯，這座城市已經不復存在他過去60年成長和","image":"https://drugnews.com.tw/assets/articles/external-vocus/68c9136dfd89780001a94ee3-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"【製藥巨頭發展史19】曾經的藥王艾伯維(Abbvie) 招招精狠！","date":"2025-09-17","language":"zh-Hant","url":"https://vocus.cc/article/68c91188fd89780001a8aab3","canonical_url":"https://vocus.cc/article/68c91188fd89780001a8aab3","source":"方格子","access":"深度分析","category":"製藥巨頭","tags":["AbbVie","艾伯維","Humira","專利懸崖","併購"],"summary":"2020年3月下旬，美國東部的陽光像水晶一樣地照進了芝加哥一間格調簡約卻又設施豪華的辦公室內。室內的溫度很舒適，但仍封鎖不了窗外的寒意，2020年對整個地球都是異常艱難的一年。一位下顎內收、眼光如炬的男士坐在寬大舒適的辦公桌前。他對著視訊螢幕上的對方和公司其他高管，聲音平靜且平和地說：「好的，沒有問","image":"https://drugnews.com.tw/assets/articles/external-vocus/68c91188fd89780001a8aab3-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"【製藥巨頭發展史18】藥王不在的 默沙東(MSD) 焦慮大家都看得見","date":"2025-09-17","language":"zh-Hant","url":"https://vocus.cc/article/68c90cf2fd89780001a738b9","canonical_url":"https://vocus.cc/article/68c90cf2fd89780001a738b9","source":"方格子","access":"深度分析","category":"製藥巨頭","tags":["MSD","默沙東","Keytruda","藥王接班","管線策略"],"summary":"01 一騎絕塵的哈姆雷特王子 2009年，風雪漫天的冬季又一次光臨了與波士頓緊鄰的小城麻省劍橋（Cambridge）。一位年輕人踏著街道上厚厚的積雪，重新裹了裹圍巾，走向自己的實驗室。他來到這個城市已經好幾年，但這個冬天似乎特別寒冷。畢竟，對任何一個在事業上有睏頓的年輕人，冬天的氣溫總要低幾度。","image":"https://drugnews.com.tw/assets/articles/external-vocus/68c90cf2fd89780001a738b9-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"【製藥巨頭發展史17】安進（Amgen）的法律能力你必需懂？","date":"2025-09-17","language":"zh-Hant","url":"https://vocus.cc/article/68c90c52fd89780001a704a4","canonical_url":"https://vocus.cc/article/68c90c52fd89780001a704a4","source":"方格子","access":"深度分析","category":"製藥巨頭","tags":["Amgen","安進","生物製劑","專利訴訟","法務策略"],"summary":"1981年初夏，在某一期的《科學》期刊上刊登了一則極為簡單的徵才廣告，一家科技新創公司要招募一名新藥研究員。可能這家公司想要省點錢，因此這則廣告的字數有限，既沒公司名稱，也沒職位介紹，並沒有引起多少讀者的注意。不過，還是有位四十歲的科學家給該公司遞了履歷，這點有限的廣告費沒有白花。這位求職者似乎在其","image":"https://drugnews.com.tw/assets/articles/external-vocus/68c90c52fd89780001a704a4-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"【製藥巨頭發展史16】羅氏(Roche)吞下超新星 基因泰克(Genentech)，自此高枕無憂？","date":"2025-09-17","language":"zh-Hant","url":"https://vocus.cc/article/68c90ba5fd89780001a6c993","canonical_url":"https://vocus.cc/article/68c90ba5fd89780001a6c993","source":"方格子","access":"深度分析","category":"製藥巨頭","tags":["Roche","羅氏","Genentech","基因泰克","併購整合"],"summary":"1999年的一個早晨，美國舊金山市，一位內心深沉憂傷的中年人為自己安排了一次特別的醫院探訪。出發前，他以為自己已經做好了足夠的心理準備，但當房門打開的那一瞬間，他看見病床上憔悴無言的老友向自己投來了一個虛弱無比的微笑，一顆心還是猛烈地顫抖起來，眼淚不禁奔湧而出。面前這位被晚期腦癌折磨到一句話都不能再","image":"https://drugnews.com.tw/assets/articles/external-vocus/68c90ba5fd89780001a6c993-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"【製藥巨頭發展史15】有了再生元的賽諾菲(Sanofi)，真正的絕招是啥?","date":"2025-09-16","language":"zh-Hant","url":"https://vocus.cc/article/68c9099ffd89780001a618b4","canonical_url":"https://vocus.cc/article/68c9099ffd89780001a618b4","source":"方格子","access":"深度分析","category":"製藥巨頭","tags":["Sanofi","賽諾菲","Regeneron","合作開發","免疫藥物"],"summary":"01 一顆治癒人心的良藥靈丹 1998年，美國舊金山市的一家醫院病房裡，一個像洋娃娃一般漂亮的寶寶甦醒過來，用她無辜的大眼睛看了看這個世界。寶寶的床邊，一位31歲的男子慈愛而溫柔地握著她的小手，內心卻有一種被揉碎了五腑六髒般的痛苦。剛在醫生的辦公室裡，他被告之自己剛剛15個月大的女兒Megan被確","image":"https://drugnews.com.tw/assets/articles/external-vocus/68c9099ffd89780001a618b4-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"【製藥巨頭發展史14】似乎 東山不再起的百年藥企，拜耳(Bayer)","date":"2025-09-16","language":"zh-Hant","url":"https://vocus.cc/article/68c90375fd89780001a3fe4d","canonical_url":"https://vocus.cc/article/68c90375fd89780001a3fe4d","source":"方格子","access":"深度分析","category":"製藥巨頭","tags":["Bayer","拜耳","Monsanto","併購風險","轉型壓力"],"summary":"01 不再被信任的CEO 2019年4月，德國勒沃庫森（Leverkusen）乍暖還寒。一個頭髮微禿的中年男士灰頭土臉地坐在會議中，承受著眾多投資者對他一浪高過一浪的指責。看到大家齊刷刷地投過來那種失望而憤怒的眼神，他只想逃避。如果此時此刻地上能夠裂出一道縫，相信他會毫不遲疑地鑽到裡面。 2016","image":"https://drugnews.com.tw/assets/articles/external-vocus/68c90375fd89780001a3fe4d-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"【製藥巨頭發展史13】宇宙大藥廠輝瑞(Pfizer)，還有併購以外的法寶嗎？","date":"2025-09-16","language":"zh-Hant","url":"https://vocus.cc/article/68c8c36ffd89780001906e65","canonical_url":"https://vocus.cc/article/68c8c36ffd89780001906e65","source":"方格子","access":"深度分析","category":"製藥巨頭","tags":["Pfizer","輝瑞","併購策略","疫苗","專利懸崖"],"summary":"01 一場寒冷的董事會議 2010年12月4日，紐約曼哈頓中城區的一幢豪華辦公大樓裡，一位中年男子勉為其難地向一間會議室走去。雖然他不願意麵對這一刻，但公司內部的政治鬥爭已經持續了相當長的一段時間，有一些面對面的衝突是逃避不了的。秘書把門打開之後，他看見自己所熟悉的幾位董事會成員面色鐵青地坐在裡面","image":"https://drugnews.com.tw/assets/articles/external-vocus/68c8c36ffd89780001906e65-source.webp","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"【製藥巨頭發展史12】新的減肥藥王禮來(Lilly)，自主研發究竟能走多遠？","date":"2025-09-15","language":"zh-Hant","url":"https://vocus.cc/article/68c7f521fd897800015d45b6","canonical_url":"https://vocus.cc/article/68c7f521fd897800015d45b6","source":"方格子","access":"深度分析","category":"製藥巨頭","tags":["Lilly","禮來","GLP-1","自主研發","減重藥"],"summary":"01 百憂解的問世 2014年8月，美國加州警方接獲報警電話後，便火速趕往位於克里夫海地的一棟豪宅。當他們打開門後，發現住宅的男主人在家中自縹身亡。讓他們震驚的是，死者竟是時年63歲的電影巨星羅賓威廉斯（Robin Williams）。這怎麼可能？他所演出的一系列電影角色都曾深深滋養過我們的靈魂：","image":"https://drugnews.com.tw/assets/articles/external-vocus/68c7f521fd897800015d45b6-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"【製藥巨頭發展史11】諾和諾德(Novo Nordisk) 想靠GLP-1通殺全場?","date":"2025-09-10","language":"zh-Hant","url":"https://vocus.cc/article/68c11d24fd89780001e89e7e","canonical_url":"https://vocus.cc/article/68c11d24fd89780001e89e7e","source":"方格子","access":"深度分析","category":"製藥巨頭","tags":["Novo Nordisk","諾和諾德","GLP-1","糖尿病","減重藥"],"summary":"01 一城輝煌再下兩城 2020年5月的一天，丹麥首都哥本哈根在夢幻般清澈的藍天白雲中迎來了一年最好的季節。一位中年男子望著窗外一幢幢童話般的房子，眼神中有一份禁不住的喜悅和滿足。手機再次響起'叮咚'的一聲，他低頭一看，又一次會心的一笑。自從新聞發布以後，他已經接到了無數朋友和同行的簡訊與電話，祝","image":"https://drugnews.com.tw/assets/articles/external-vocus/68c11d24fd89780001e89e7e-source.webp","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"【製藥巨頭發展史10】必治妥施貴寶(BMS)的興衰轉身與新週期","date":"2025-09-10","language":"zh-Hant","url":"https://vocus.cc/article/68c12548fd89780001eb6f9a","canonical_url":"https://vocus.cc/article/68c12548fd89780001eb6f9a","source":"方格子","access":"深度分析","category":"製藥巨頭","tags":["BMS","必治妥施貴寶","Revlimid","併購週期","管線轉型"],"summary":"01 世紀名藥，花落誰家 1977年，紐約曼哈頓每一天都繁華如昔。在白天的車水馬龍和夜晚的炫目霓虹中，它彷彿時時刻刻都在向世界宣告，「我就是地球的中心，我就是經濟的心臟」！然而，曼哈頓最北部的一間實驗室內，一位頭髮黝黑的白人女性正專注於顯微鏡和瓶瓶罐罐之中，她那份平和寧靜的神態與咫尺之外的喧囂有著","image":"https://drugnews.com.tw/assets/articles/external-vocus/68c12548fd89780001eb6f9a-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"【製藥巨頭發展史9】跨越300多歲的葛蘭素史克（GSK）能否再次回春？","date":"2025-09-06","language":"zh-Hant","url":"https://vocus.cc/article/68bbbeb5fd89780001477b27","canonical_url":"https://vocus.cc/article/68bbbeb5fd89780001477b27","source":"方格子","access":"深度分析","category":"製藥巨頭","tags":["GSK","葛蘭素史克","疫苗","消費醫療剝離","轉型"],"summary":"2015年3月初的某一天，春雨之後，緊鄰英國倫敦的布倫特福德市寒冷如冬。一間氣派豪華的會議室中，端坐著眾多舉止優雅且衣著光鮮的商業人士。在最中央的位置上，一位髮線退到了後腦勺的中年男士在厚厚的一疊法律文書上一一籤上了自己的名字。在所有人目光的聚焦之下，他像平常一樣表情鎮定，沒有人看得出他此時此刻的心","image":"https://drugnews.com.tw/assets/articles/external-vocus/68bbbeb5fd89780001477b27-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"【製藥巨頭發展史8】阿斯特捷利康(AZ)，如何從被收購走到光榮稱霸？","date":"2025-09-06","language":"zh-Hant","url":"https://vocus.cc/article/68bba6ccfd897800014174bc","canonical_url":"https://vocus.cc/article/68bba6ccfd897800014174bc","source":"方格子","access":"深度分析","category":"製藥巨頭","tags":["AstraZeneca","阿斯特捷利康","腫瘤藥物","研發轉型","全球化"],"summary":"01 守城者：索維奧與阿斯特捷利康的危機逆轉 2014年，新年後的一個早晨，英國劍橋市保持著千禧年不變的優雅與寧靜。由於世界名校劍橋大學的存在，這座10萬多人口的小城市有著不尋常的歷史和文化底蘊。它淳樸的田園風光中點輟學著各種時代的建築，有十五世紀哥德式的，也有十九世紀維多利亞式的，當晨光灑滿了田","image":"https://drugnews.com.tw/assets/articles/external-vocus/68bba6ccfd897800014174bc-source.jpeg","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"【製藥巨頭發展史7】福泰製藥 (Vertex)傳奇","date":"2025-09-02","language":"zh-Hant","url":"https://vocus.cc/article/68b70b82fd8978000158270b","canonical_url":"https://vocus.cc/article/68b70b82fd8978000158270b","source":"方格子","access":"深度分析","category":"製藥巨頭","tags":["Vertex","福泰製藥","罕見疾病","囊性纖維化","平台策略"],"summary":"01 被夢想逼到創業之路的一代英才 1989年，一位相貌老沉、髮際線靠後、留著濃密絡腮鬍子的男士，在他的新公司門口拍下了一張照片。他的笑容中有種堅定的樂觀，厚厚的鏡片也擋不住他眼神裡的雄心壯志。如果不說，誰也看不出這位男士才38歲。推開門，這家公司不過是一間又擁擠又簡陋的實驗室，一個月前它才剛從一","image":"https://drugnews.com.tw/assets/articles/external-vocus/68b70b82fd8978000158270b-source.webp","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"【製藥巨頭發展史6】當規模遇上聚焦：諾華(Novartis) 如何用「剝離＋併購」翻身為藥王","date":"2025-09-01","language":"zh-Hant","url":"https://vocus.cc/article/68b59b6bfd897800010008a9","canonical_url":"https://vocus.cc/article/68b59b6bfd897800010008a9","source":"方格子","access":"深度分析","category":"製藥巨頭","tags":["Novartis","諾華","剝離","併購","聚焦策略"],"summary":"01 一場寒冷的大規模裁員 2011年底的某天下午，兩位男士焦急不安地走進了一間超大的辦公室，其中一位手中捧著一份厚厚的報告。看到了辦公桌後的另一位男士，他們不約而同地先後說道：“我們四年前獲批上市的藥品最近的臨床試驗發現了一些頗為嚴重的副作用，公司的研發部門與獨立的安全顧問委員會都建議提早結束該","image":"https://drugnews.com.tw/assets/articles/external-vocus/68b59b6bfd897800010008a9-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"【製藥巨頭發展史5】唯一的亞洲藥廠巨頭---武田（Takeda）只有併購能走向巨大","date":"2025-08-31","language":"zh-Hant","url":"https://vocus.cc/article/68b2bd12fd897800014371b1","canonical_url":"https://vocus.cc/article/68b2bd12fd897800014371b1","source":"方格子","access":"深度分析","category":"製藥巨頭","tags":["Takeda","武田","亞洲藥廠","全球併購","Shire"],"summary":"01 意義重大的一場法日衝突 2018年12月的日本，初冬已經來臨。傍晚時分，一位中年日本男士在位於大阪的一間豪宅內安靜地沉思著。他的雙眼注視著一把武士刀，那是曾祖父輩手裡傳下來的家族信物。他暗問自己，「兩百多年前老祖宗代代傳下來的財產，會在我的手中丟失嗎？「 不過，這份財產不是這把武士刀，而是武","image":"https://drugnews.com.tw/assets/articles/external-vocus/68b2bd12fd897800014371b1-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"【製藥巨頭發展史4】百年 嬌生（JNJ），能否再走一百年？","date":"2025-08-30","language":"zh-Hant","url":"https://vocus.cc/article/68b05059fd8978000135cada","canonical_url":"https://vocus.cc/article/68b05059fd8978000135cada","source":"方格子","access":"深度分析","category":"製藥巨頭","tags":["J&J","嬌生","百年藥廠","消費醫療剝離","醫療器材"],"summary":"01 秦始皇兵馬俑所作的大媒 在1970年代中，在西安的一個悶熱夏天，一位金髮碧眼的外國人正看著一隻兵馬俑頭像憂心忡忡，他的焦慮感並不亞於醫生在照顧一位病入膏肓的病人。仔細端詳了二十多分鐘後，他請旁邊一位身穿藏青色卡嘰布外套的男士幫他向身後的翻譯，他要盡快給比利時撥一個國際長途電話。 電話接通後","image":"https://drugnews.com.tw/assets/articles/external-vocus/68b05059fd8978000135cada-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"【製藥巨頭發展史3】新基（Celgene）的崛起","date":"2025-08-28","language":"zh-Hant","url":"https://vocus.cc/article/68b04b99fd8978000134af9f","canonical_url":"https://vocus.cc/article/68b04b99fd8978000134af9f","source":"方格子","access":"深度分析","category":"製藥巨頭","tags":["Celgene","新基","Revlimid","Biotech","被併購"],"summary":"01 一個獵物的修練史 2011年12月，湖人隊對公牛隊的第一場比賽在斯坦普斯中心開戰， 科比以一個漂亮的打板扣籃，再次為湖人隊拿下了一場勝利，最終以102：89取得開門紅。這個球場的場內VIP席堪稱籃球史上最貴，一個賽季的門票就高達11萬美元。而且，這些座位並不是光有錢就能夠坐得上去的，它們每一","image":"https://drugnews.com.tw/assets/articles/external-vocus/68b04b99fd8978000134af9f-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"【製藥巨頭發展史2】吉利德（Gilead）搬起石頭砸自己的腳","date":"2025-08-28","language":"zh-Hant","url":"https://vocus.cc/article/68b02c44fd897800012cff7c","canonical_url":"https://vocus.cc/article/68b02c44fd897800012cff7c","source":"方格子","access":"深度分析","category":"製藥巨頭","tags":["Gilead","吉利德","HCV","抗病毒藥物","併購挑戰"],"summary":"2016 年 3 月的一個傍晚，加州福斯特城的陽光在下班鐘聲裡慢慢軟了下來。一位銀髮碧眼的中年人坐在辦公室裡反覆起身、又坐回去，像在等一通命運會挑在此刻撥出的電話。鈴聲終於響起，他幾乎是搶著按下接聽。話筒另一頭傳來公司首席法律顧問的聲音：「Milligan 先生，陪審團已經做出裁決，有一個好消息，也","image":"https://drugnews.com.tw/assets/articles/external-vocus/68b02c44fd897800012cff7c-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}},{"title":"【製藥巨頭發展史1】  勃林格殷格翰（BI）教你如何富可過三代!","date":"2025-08-28","language":"zh-Hant","url":"https://vocus.cc/article/68b00ecbfd897800012396c6","canonical_url":"https://vocus.cc/article/68b00ecbfd897800012396c6","source":"方格子","access":"深度分析","category":"製藥巨頭","tags":["BI","勃林格殷格翰","家族企業","私有藥廠","長期研發"],"summary":"01 傳承與棋局：Hubertus 帶路的 BI 大佈局 初夏的陽光把新英格蘭的天空擦得發亮。2001 年的劍橋，查爾斯河像一條緩緩流動的緞帶，映著兩千多頂學士帽的陰影。人群裡，有一位腦門略高、金髮碧眼的德國青年，正隨著隊伍踏入麻省理工學院的圓頂建築。","image":"https://drugnews.com.tw/assets/articles/external-vocus/68b00ecbfd897800012396c6-source.png","is_accessible_for_free":false,"is_external":true,"alternate_language_versions":{}}],"taiwan_biotech_tracks":[{"url":"https://drugnews.com.tw/topics/adc/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/en/topics/adc/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/topics/aesthetics-dermatology/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/en/topics/aesthetics-dermatology/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/topics/anti-infective/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/en/topics/anti-infective/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/topics/autoimmune/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/en/topics/autoimmune/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/topics/biosimilars-cdmo/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/en/topics/biosimilars-cdmo/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/topics/bispecific-io/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/en/topics/bispecific-io/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/topics/cell-therapy/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/en/topics/cell-therapy/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/topics/cns/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/en/topics/cns/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/topics/gene-nucleic-acid/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/en/topics/gene-nucleic-acid/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/topics/glp1-obesity/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/en/topics/glp1-obesity/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/topics/hdac/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/en/topics/hdac/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/topics/improved-new-drugs/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/en/topics/improved-new-drugs/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/topics/ipsc-stem-cell/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/en/topics/ipsc-stem-cell/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/topics/oncology-small-molecule/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/en/topics/oncology-small-molecule/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/topics/ophthalmology/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/en/topics/ophthalmology/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/topics/radiopharmaceuticals/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/en/topics/radiopharmaceuticals/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/topics/rare-disease/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/en/topics/rare-disease/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/topics/vaccines/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/en/topics/vaccines/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/topics/ai-drug-discovery/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/en/topics/ai-drug-discovery/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/topics/","dateModified":"2026-11-01"},{"url":"https://drugnews.com.tw/en/topics/","dateModified":"2026-11-01"}],"asia_biotech_tracks":[{"url":"https://drugnews.com.tw/en/asia-cell-therapy-leaders.html","dateModified":"2026-11-02","track":"cell-therapy","lang":"en","programs":25},{"url":"https://drugnews.com.tw/landscapes/asia-cell-therapy.html","dateModified":"2026-11-02","track":"cell-therapy","lang":"zh","programs":25},{"url":"https://drugnews.com.tw/en/asia-hdac-leaders.html","dateModified":"2026-11-02","track":"hdac","lang":"en","programs":11},{"url":"https://drugnews.com.tw/landscapes/asia-hdac.html","dateModified":"2026-11-02","track":"hdac","lang":"zh","programs":11}],"asia_out_licensing":{"url":"https://drugnews.com.tw/en/asia-out-licensing-deals.html","zh_url":"https://drugnews.com.tw/landscapes/asia-out-licensing-deals.html","dataset":"https://drugnews.com.tw/landscapes/asia-out-licensing-deals.json","csv":"https://drugnews.com.tw/landscapes/asia-out-licensing-deals.csv","updated_at":"2026-11-11","deal_count":147,"disclosed_upfront_usd":7955141000},"trackers":{"title":"Trackers / 追蹤頁","pages":[{"title":"亞洲 ADC 抗體藥物複合體｜藥時事","url":"https://drugnews.com.tw/landscapes/asia-adc.html","summary":"截至 2026-11-01，藥時事追蹤 40 項亞洲 ADC 抗體藥物複合體資產：日本 6 項、中國 33 項、韓國 1 項。9 項已核准，25 項處於第 3 期。進度最高的包括 Padcev (ASG-22ME) [co-originated] (Astellas Pharma (Japan) co-developed with Seagen (US, now Pfizer); Approved); Datroway (DS-1062) (Daiichi Sankyo; Approved); Enhertu (DS-8201) (Daiichi Sankyo; Approved)。","as_of":"2026-11-01","count":40,"language":"zh-Hant"},{"title":"Asia ADC Leaders 2026: Who Is Winning the Antibody-Drug Conjugate Race | Drugnews","url":"https://drugnews.com.tw/en/asia-adc-leaders.html","summary":"As of 2026-11-01, Drugnews tracks 40 Asian ADC antibody-drug conjugate assets: 6 from Japan, 33 from China, 1 from South Korea. 9 are approved and 25 are in Phase 3. The most advanced are Padcev (ASG-22ME) [co-originated] (Astellas Pharma (Japan) co-developed with Seagen (US, now Pfizer); Approved); Datroway (DS-1062) (Daiichi Sankyo; Approved); Enhertu (DS-8201) (Daiichi Sankyo; Approved).","as_of":"2026-11-01","count":40,"language":"en"},{"title":"Asia 細胞治療 | Drugnews","url":"https://drugnews.com.tw/landscapes/asia-cell-therapy.html","summary":"截至 2026-11-02，藥時事追蹤 25 項亞洲 CAR-T 與細胞治療資產：中國 17 項、韓國 1 項、日本 1 項、臺灣 6 項。9 項已核准，0 項處於第 3 期。進度最高的包括 Satricabtagene autoleucel (satri-cel / CT041) (CARsgen Therapeutics Holdings Limited; Approved); Zevorcabtagene autoleucel (zevor-cel / CT053) (CARsgen Therapeutics Holdings Limited; Approved); Puzolcabtagene autoleucel (puzol-cel / pCAR-19B) (Chongqing Precision Biotech Co., Ltd.; Approved)。","as_of":"2026-11-02","count":25,"language":"zh-Hant"},{"title":"Asia Cell therapy | Drugnews","url":"https://drugnews.com.tw/en/asia-cell-therapy-leaders.html","summary":"As of 2026-11-02, Drugnews tracks 25 Asian CAR-T and cell therapy assets: 17 from China, 1 from South Korea, 1 from Japan, 6 from Taiwan. 9 are approved and 0 are in Phase 3. The most advanced are Satricabtagene autoleucel (satri-cel / CT041) (CARsgen Therapeutics Holdings Limited; Approved); Zevorcabtagene autoleucel (zevor-cel / CT053) (CARsgen Therapeutics Holdings Limited; Approved); Puzolcabtagene autoleucel (puzol-cel / pCAR-19B) (Chongqing Precision Biotech Co., Ltd.; Approved).","as_of":"2026-11-02","count":25,"language":"en"},{"title":"亞洲 GLP-1 與肥胖藥 | Drugnews","url":"https://drugnews.com.tw/landscapes/asia-glp1.html","summary":"截至 2026-11-03，藥時事追蹤 28 項亞洲 GLP-1資產：日本 1 項、韓國 6 項、中國 20 項、印度 1 項。7 項已核准，8 項處於第 3 期。進度最高的包括 orforglipron (Chugai Pharmaceutical; Approved); efpeglenatide (Hanmi Pharmaceutical; Approved); polyethylene glycol loxenatide (Hansoh Pharma; Approved)。","as_of":"2026-11-03","count":28,"language":"zh-Hant"},{"title":"Asian GLP-1 and Obesity Drugs | Drugnews","url":"https://drugnews.com.tw/en/asia-glp1-leaders.html","summary":"As of 2026-11-03, Drugnews tracks 28 Asian GLP-1 and obesity drug assets: 1 from Japan, 6 from South Korea, 20 from China, 1 from India. 7 are approved and 8 are in Phase 3. The most advanced are orforglipron (Chugai Pharmaceutical; Approved); efpeglenatide (Hanmi Pharmaceutical; Approved); polyethylene glycol loxenatide (Hansoh Pharma; Approved).","as_of":"2026-11-03","count":28,"language":"en"},{"title":"Asia HDAC 抑制劑 | Drugnews","url":"https://drugnews.com.tw/landscapes/asia-hdac.html","summary":"截至 2026-11-02，藥時事追蹤 11 項亞洲 HDAC 抑制劑資產：中國 5 項、臺灣 1 項、韓國 4 項、日本 1 項。1 項已核准，2 項處於第 3 期。進度最高的包括 Tucidinostat / chidamide / Epidaza (Chipscreen Biosciences; Approved); Entinostat / SNDX-275 / MS-275 (Syndax; Taizhou EOC Pharma / Edding Genor (China); NDA/BLA filed); Purinostat mesylate (Chengdu Zenitar Biomedical Technology; Phase 3)。","as_of":"2026-11-02","count":11,"language":"zh-Hant"},{"title":"Asia HDAC inhibitors | Drugnews","url":"https://drugnews.com.tw/en/asia-hdac-leaders.html","summary":"As of 2026-11-02, Drugnews tracks 11 Asian HDAC inhibitors assets: 5 from China, 1 from Taiwan, 4 from South Korea, 1 from Japan. 1 are approved and 2 are in Phase 3. The most advanced are Tucidinostat / chidamide / Epidaza (Chipscreen Biosciences; Approved); Entinostat / SNDX-275 / MS-275 (Syndax; Taizhou EOC Pharma / Edding Genor (China); NDA/BLA filed); Purinostat mesylate (Chengdu Zenitar Biomedical Technology; Phase 3).","as_of":"2026-11-02","count":11,"language":"en"},{"title":"亞洲 PD-1/VEGF 與雙特異性抗體 | Drugnews","url":"https://drugnews.com.tw/landscapes/asia-pd1-vegf.html","summary":"截至 2026-11-01，藥時事追蹤 32 項亞洲 PD-1/VEGF資產：中國 28 項、臺灣 2 項、韓國 2 項。3 項已核准，4 項處於第 3 期。進度最高的包括 cadonilimab (Akeso; Approved); ivonescimab (Akeso; Approved); retlirafusp alfa (Hengrui Pharmaceuticals; Approved)。","as_of":"2026-11-01","count":32,"language":"zh-Hant"},{"title":"Asian PD-1/VEGF and Bispecific Antibodies | Drugnews","url":"https://drugnews.com.tw/en/asia-pd1-vegf-leaders.html","summary":"As of 2026-11-01, Drugnews tracks 32 Asian PD-1/VEGF and other bispecific antibody assets: 28 from China, 2 from Taiwan, 2 from South Korea. 3 are approved and 4 are in Phase 3. The most advanced are cadonilimab (Akeso; Approved); ivonescimab (Akeso; Approved); retlirafusp alfa (Hengrui Pharmaceuticals; Approved).","as_of":"2026-11-01","count":32,"language":"en"},{"title":"siRNA 與 ASO 小核酸藥物 | Drugnews","url":"https://drugnews.com.tw/landscapes/asia-sirna.html","summary":"截至 2026-11-02，藥時事追蹤 15 項亞洲 小核酸藥物資產：日本 4 項、中國 8 項、韓國 3 項。1 項已核准，1 項處於第 3 期。進度最高的包括 NS-065/NCNP-01 viltolarsen (Nippon Shinyaku Co., Ltd. / National Center of Neurology and Psychiatry; Approved); RBD7022 (QLC7401) (Suzhou Ribo Life Science Co. Ltd.; Phase 3); DS-5141b (renadirsen) (Daiichi Sankyo Co., Ltd.; Phase 2 ACTIVE_NOT_RECRUITING)。","as_of":"2026-11-02","count":15,"language":"zh-Hant"},{"title":"siRNA and antisense oligonucleotide drugs | Drugnews","url":"https://drugnews.com.tw/en/asia-sirna-leaders.html","summary":"As of 2026-11-02, Drugnews tracks 15 Asian siRNA and ASO assets: 4 from Japan, 8 from China, 3 from South Korea. 1 are approved and 1 are in Phase 3. The most advanced are NS-065/NCNP-01 viltolarsen (Nippon Shinyaku Co., Ltd. / National Center of Neurology and Psychiatry; Approved); RBD7022 (QLC7401) (Suzhou Ribo Life Science Co. Ltd.; Phase 3); DS-5141b (renadirsen) (Daiichi Sankyo Co., Ltd.; Phase 2 ACTIVE_NOT_RECRUITING).","as_of":"2026-11-02","count":15,"language":"en"},{"title":"T 細胞銜接器（含三抗） | Drugnews","url":"https://drugnews.com.tw/landscapes/asia-tce.html","summary":"截至 2026-11-02，藥時事追蹤 16 項亞洲 T 細胞銜接器資產：中國 16 項。0 項已核准，6 項處於第 3 期。進度最高的包括 GR1803 (velinotamig / CLN-803) (Genrix (Shanghai) Biopharmaceutical Co., Ltd.; Phase 3); IBI3003 (Innovent Biologics (Suzhou) Co. Ltd.; Phase 3); CM336 / OM336 (Keymed Biosciences Inc.; Phase 3)。","as_of":"2026-11-02","count":16,"language":"zh-Hant"},{"title":"T-cell engagers, including trispecific antibodies | Drugnews","url":"https://drugnews.com.tw/en/asia-tce-leaders.html","summary":"As of 2026-11-02, Drugnews tracks 16 Asian T-cell engagers assets: 16 from China. 0 are approved and 6 are in Phase 3. The most advanced are GR1803 (velinotamig / CLN-803) (Genrix (Shanghai) Biopharmaceutical Co., Ltd.; Phase 3); IBI3003 (Innovent Biologics (Suzhou) Co. Ltd.; Phase 3); CM336 / OM336 (Keymed Biosciences Inc.; Phase 3).","as_of":"2026-11-02","count":16,"language":"en"},{"title":"亞洲 KRAS 抑制劑｜藥時事","url":"https://drugnews.com.tw/landscapes/asia-kras.html","summary":"截至 2026-11-02，藥時事追蹤 8 項亞洲 KRAS 抑制劑資產：中國 7 項、日本 1 項。3 項已核准，5 項處於第 3 期。進度最高的包括 Fulzerasib (GFH925 / IBI351; brand Dupert) (GenFleet Therapeutics (Shanghai) Inc.; Approved); Garsorasib (D-1553; brand An Fang Ning) (InventisBio Co., Ltd.; Approved); Glecirasib (JAB-21822) (Jacobio Pharmaceuticals (Beijing); Approved)。","as_of":"2026-11-02","count":8,"language":"zh-Hant"},{"title":"Asia KRAS inhibitors | Drugnews","url":"https://drugnews.com.tw/en/asia-kras-leaders.html","summary":"As of 2026-11-02, Drugnews tracks 8 Asian KRAS inhibitors assets: 7 from China, 1 from Japan. 3 are approved and 5 are in Phase 3. The most advanced are Fulzerasib (GFH925 / IBI351; brand Dupert) (GenFleet Therapeutics (Shanghai) Inc.; Approved); Garsorasib (D-1553; brand An Fang Ning) (InventisBio Co., Ltd.; Approved); Glecirasib (JAB-21822) (Jacobio Pharmaceuticals (Beijing); Approved).","as_of":"2026-11-02","count":8,"language":"en"},{"title":"亞洲 放射性藥物（核藥）｜藥時事","url":"https://drugnews.com.tw/landscapes/asia-radiopharma.html","summary":"截至 2026-11-02，藥時事追蹤 7 項亞洲 核藥資產：韓國 2 項、中國 4 項、日本 1 項。0 項已核准，3 項處於第 3 期。進度最高的包括 Lu-177-DGUL (pocubotide) (Cellbion Co., Ltd.; NDA/BLA filed); FC705 ([177Lu]Ludotadipep) (FutureChem Co., Ltd.; Phase 3); HRS-4357 (Jiangsu Hengrui Pharmaceuticals; Phase 3)。","as_of":"2026-11-02","count":7,"language":"zh-Hant"},{"title":"Asia Radiopharmaceuticals | Drugnews","url":"https://drugnews.com.tw/en/asia-radiopharma-leaders.html","summary":"As of 2026-11-02, Drugnews tracks 7 Asian Radiopharmaceuticals assets: 2 from South Korea, 4 from China, 1 from Japan. 0 are approved and 3 are in Phase 3. The most advanced are Lu-177-DGUL (pocubotide) (Cellbion Co., Ltd.; NDA/BLA filed); FC705 ([177Lu]Ludotadipep) (FutureChem Co., Ltd.; Phase 3); HRS-4357 (Jiangsu Hengrui Pharmaceuticals; Phase 3).","as_of":"2026-11-02","count":7,"language":"en"},{"title":"亞洲 蛋白降解劑｜藥時事","url":"https://drugnews.com.tw/landscapes/asia-degraders.html","summary":"截至 2026-11-03，藥時事追蹤 7 項亞洲 蛋白降解劑資產：中國 7 項。0 項已核准，0 項處於第 3 期。進度最高的包括 GT20029 (Kintor Pharmaceutical Limited (Suzhou Kintor); Phase 2 — China (2023-04)); HP518 (Hinova Pharmaceuticals Inc.; Phase 2 — China (2024-12)); HRS-1358 (Jiangsu Hengrui Pharmaceuticals Co., Ltd.; Phase 2 — China (confirmed 2025-05)。","as_of":"2026-11-03","count":7,"language":"zh-Hant"},{"title":"Asia Protein degraders | Drugnews","url":"https://drugnews.com.tw/en/asia-degraders-leaders.html","summary":"As of 2026-11-03, Drugnews tracks 7 Asian Protein degraders assets: 7 from China. 0 are approved and 0 are in Phase 3. The most advanced are GT20029 (Kintor Pharmaceutical Limited (Suzhou Kintor); Phase 2 — China (2023-04)); HP518 (Hinova Pharmaceuticals Inc.; Phase 2 — China (2024-12)); HRS-1358 (Jiangsu Hengrui Pharmaceuticals Co., Ltd.; Phase 2 — China (confirmed 2025-05).","as_of":"2026-11-03","count":7,"language":"en"},{"title":"亞洲 下一代減重藥｜藥時事","url":"https://drugnews.com.tw/landscapes/asia-obesity-next.html","summary":"截至 2026-11-03，藥時事追蹤 8 項亞洲 下一代減重藥資產：中國 7 項、韓國 1 項。0 項已核准，2 項處於第 3 期。進度最高的包括 VCT220 / CX11 (Vincentage Pharma Co., Ltd. (Chengdu Vincentage); Phase 3); RAY1225 (Guangdong Raynovent Biotech Co., Ltd. (Zhongsheng subsidiary); Phase 3); HEC88473 / APL-18881 (Sunshine Lake Pharma Co., Ltd.; Phase 2 — China (2023-12))。","as_of":"2026-11-03","count":8,"language":"zh-Hant"},{"title":"Asia Next-generation obesity drugs | Drugnews","url":"https://drugnews.com.tw/en/asia-obesity-next-leaders.html","summary":"As of 2026-11-03, Drugnews tracks 8 Asian Next-generation obesity drugs assets: 7 from China, 1 from South Korea. 0 are approved and 2 are in Phase 3. The most advanced are VCT220 / CX11 (Vincentage Pharma Co., Ltd. (Chengdu Vincentage); Phase 3); RAY1225 (Guangdong Raynovent Biotech Co., Ltd. (Zhongsheng subsidiary); Phase 3); HEC88473 / APL-18881 (Sunshine Lake Pharma Co., Ltd.; Phase 2 — China (2023-12)).","as_of":"2026-11-03","count":8,"language":"en"},{"title":"亞洲 自體免疫與發炎藥物｜藥時事","url":"https://drugnews.com.tw/landscapes/asia-autoimmune.html","summary":"截至 2026-11-03，藥時事追蹤 8 項亞洲 自體免疫與發炎藥物資產：日本 2 項、中國 6 項。6 項已核准，2 項處於第 3 期。進度最高的包括 Peficitinib (ASP015K; Smyraf) (Astellas Pharma Inc.; Approved); Delgocitinib (JTE-052; Corectim / Anzupgo) (Japan Tobacco Inc.; Approved); Telitacicept (RC18; Taiai) (RemeGen Co., Ltd.; Approved)。","as_of":"2026-11-03","count":8,"language":"zh-Hant"},{"title":"Asia Autoimmune and inflammatory therapies | Drugnews","url":"https://drugnews.com.tw/en/asia-autoimmune-leaders.html","summary":"As of 2026-11-03, Drugnews tracks 8 Asian Autoimmune and inflammatory therapies assets: 2 from Japan, 6 from China. 6 are approved and 2 are in Phase 3. The most advanced are Peficitinib (ASP015K; Smyraf) (Astellas Pharma Inc.; Approved); Delgocitinib (JTE-052; Corectim / Anzupgo) (Japan Tobacco Inc.; Approved); Telitacicept (RC18; Taiai) (RemeGen Co., Ltd.; Approved).","as_of":"2026-11-03","count":8,"language":"en"},{"title":"亞洲 腫瘤免疫雙特異性抗體｜藥時事","url":"https://drugnews.com.tw/landscapes/asia-bispecific-io.html","summary":"截至 2026-11-03，藥時事追蹤 8 項亞洲 腫瘤免疫雙特異性抗體資產：中國 7 項、韓國 1 項。0 項已核准，1 項處於第 3 期。進度最高的包括 Amulirafusp alfa (IMM0306) (ImmuneOnco Biopharmaceuticals (Shanghai) Inc.; Phase 3); QLF31907 (Qilu Pharmaceutical Co., Ltd.; Phase 2 — China (2023-04); IMM2902 (ImmuneOnco Biopharmaceuticals (Shanghai) Inc.; Phase 1/2 — China (2022-02)。","as_of":"2026-11-03","count":8,"language":"zh-Hant"},{"title":"Asia Immuno-oncology bispecific antibodies | Drugnews","url":"https://drugnews.com.tw/en/asia-bispecific-io-leaders.html","summary":"As of 2026-11-03, Drugnews tracks 8 Asian Immuno-oncology bispecific antibodies assets: 7 from China, 1 from South Korea. 0 are approved and 1 are in Phase 3. The most advanced are Amulirafusp alfa (IMM0306) (ImmuneOnco Biopharmaceuticals (Shanghai) Inc.; Phase 3); QLF31907 (Qilu Pharmaceutical Co., Ltd.; Phase 2 — China (2023-04); IMM2902 (ImmuneOnco Biopharmaceuticals (Shanghai) Inc.; Phase 1/2 — China (2022-02).","as_of":"2026-11-03","count":8,"language":"en"},{"title":"亞洲 中樞神經｜藥時事","url":"https://drugnews.com.tw/landscapes/asia-cns.html","summary":"截至 2026-11-03，藥時事追蹤 8 項亞洲 中樞神經資產：日本 6 項、韓國 1 項、中國 1 項。7 項已核准，0 項處於第 3 期。進度最高的包括 Lurasidone (SM-13496; Latuda) (Sumitomo Pharma Co., Ltd. (formerly Dainippon Sumitomo Pharma); Approved); Perampanel (E2007; Fycompa) (Eisai Co., Ltd.; Approved); Brexpiprazole (OPC-34712; Rexulti) (Otsuka Pharmaceutical Co., Ltd.; Approved)。","as_of":"2026-11-03","count":8,"language":"zh-Hant"},{"title":"Asia CNS | Drugnews","url":"https://drugnews.com.tw/en/asia-cns-leaders.html","summary":"As of 2026-11-03, Drugnews tracks 8 Asian CNS assets: 6 from Japan, 1 from South Korea, 1 from China. 7 are approved and 0 are in Phase 3. The most advanced are Lurasidone (SM-13496; Latuda) (Sumitomo Pharma Co., Ltd. (formerly Dainippon Sumitomo Pharma); Approved); Perampanel (E2007; Fycompa) (Eisai Co., Ltd.; Approved); Brexpiprazole (OPC-34712; Rexulti) (Otsuka Pharmaceutical Co., Ltd.; Approved).","as_of":"2026-11-03","count":8,"language":"en"},{"title":"亞洲 眼科｜藥時事","url":"https://drugnews.com.tw/landscapes/asia-ophthalmology.html","summary":"截至 2026-11-03，藥時事追蹤 8 項亞洲 眼科資產：日本 5 項、中國 2 項、韓國 1 項。5 項已核准，1 項處於第 3 期。進度最高的包括 Rebamipide ophthalmic (OPC-12759; Mucosta) (Otsuka Pharmaceutical Co., Ltd.; Approved); Conbercept (KH902; Lumitin / Langmu) (Chengdu Kanghong Biotech Co., Ltd. (Kanghong Pharmaceutical Group); Approved); Ripasudil (K-115; Glanatec) (D. Western Therapeutics Institute, Inc.; Approved)。","as_of":"2026-11-03","count":8,"language":"zh-Hant"},{"title":"Asia Ophthalmology | Drugnews","url":"https://drugnews.com.tw/en/asia-ophthalmology-leaders.html","summary":"As of 2026-11-03, Drugnews tracks 8 Asian Ophthalmology assets: 5 from Japan, 2 from China, 1 from South Korea. 5 are approved and 1 are in Phase 3. The most advanced are Rebamipide ophthalmic (OPC-12759; Mucosta) (Otsuka Pharmaceutical Co., Ltd.; Approved); Conbercept (KH902; Lumitin / Langmu) (Chengdu Kanghong Biotech Co., Ltd. (Kanghong Pharmaceutical Group); Approved); Ripasudil (K-115; Glanatec) (D. Western Therapeutics Institute, Inc.; Approved).","as_of":"2026-11-03","count":8,"language":"en"},{"title":"亞洲 iPSC 與幹細胞療法｜藥時事","url":"https://drugnews.com.tw/landscapes/asia-ipsc-stem-cell.html","summary":"截至 2026-11-03，藥時事追蹤 8 項亞洲 iPSC 與幹細胞療法資產：日本 4 項、韓國 4 項。8 項已核准，0 項處於第 3 期。進度最高的包括 RiHEART (Cuorips Inc. (Osaka University / Daiichi Sankyo technology); Approved); AMCHEPRY (Sumitomo Pharma / RACTHERA (Kyoto University technology); Approved); AKUUGO (SB623) (SanBio Company Limited; Approved)。","as_of":"2026-11-03","count":8,"language":"zh-Hant"},{"title":"Asia iPSC and stem-cell therapies | Drugnews","url":"https://drugnews.com.tw/en/asia-ipsc-stem-cell-leaders.html","summary":"As of 2026-11-03, Drugnews tracks 8 Asian iPSC and stem-cell therapies assets: 4 from Japan, 4 from South Korea. 8 are approved and 0 are in Phase 3. The most advanced are RiHEART (Cuorips Inc. (Osaka University / Daiichi Sankyo technology); Approved); AMCHEPRY (Sumitomo Pharma / RACTHERA (Kyoto University technology); Approved); AKUUGO (SB623) (SanBio Company Limited; Approved).","as_of":"2026-11-03","count":8,"language":"en"},{"title":"亞洲 抗感染藥物｜藥時事","url":"https://drugnews.com.tw/landscapes/asia-anti-infective.html","summary":"截至 2026-11-03，藥時事追蹤 8 項亞洲 抗感染藥物資產：日本 4 項、中國 4 項。8 項已核准，0 項處於第 3 期。進度最高的包括 Favipiravir (Avigan) (Toyama Chemical (now FUJIFILM Toyama Chemical); Approved); Baloxavir marboxil (Xofluza; S-033188) (Shionogi & Co., Ltd.; Approved); Albuvirtide (Aikening; ABT) (Frontier Biotechnologies Inc.; Approved)。","as_of":"2026-11-03","count":8,"language":"zh-Hant"},{"title":"Asia Anti-infective medicines | Drugnews","url":"https://drugnews.com.tw/en/asia-anti-infective-leaders.html","summary":"As of 2026-11-03, Drugnews tracks 8 Asian Anti-infective medicines assets: 4 from Japan, 4 from China. 8 are approved and 0 are in Phase 3. The most advanced are Favipiravir (Avigan) (Toyama Chemical (now FUJIFILM Toyama Chemical); Approved); Baloxavir marboxil (Xofluza; S-033188) (Shionogi & Co., Ltd.; Approved); Albuvirtide (Aikening; ABT) (Frontier Biotechnologies Inc.; Approved).","as_of":"2026-11-03","count":8,"language":"en"},{"title":"亞洲 生物相似藥｜藥時事","url":"https://drugnews.com.tw/landscapes/asia-biosimilars-cdmo.html","summary":"截至 2026-11-03，藥時事追蹤 8 項亞洲 生物相似藥資產：中國 3 項、韓國 4 項、臺灣 1 項。8 項已核准，0 項處於第 3 期。進度最高的包括 Usymro (Bio-Thera Solutions; Approved); Opuviz (Samsung Bioepis; Approved); Steqeyma (Celltrion; Approved)。","as_of":"2026-11-03","count":8,"language":"zh-Hant"},{"title":"Asia Biosimilars | Drugnews","url":"https://drugnews.com.tw/en/asia-biosimilars-cdmo-leaders.html","summary":"As of 2026-11-03, Drugnews tracks 8 Asian Biosimilars assets: 3 from China, 4 from South Korea, 1 from Taiwan. 8 are approved and 0 are in Phase 3. The most advanced are Usymro (Bio-Thera Solutions; Approved); Opuviz (Samsung Bioepis; Approved); Steqeyma (Celltrion; Approved).","as_of":"2026-11-03","count":8,"language":"en"},{"title":"亞洲 疫苗｜藥時事","url":"https://drugnews.com.tw/landscapes/asia-vaccines.html","summary":"截至 2026-11-03，藥時事追蹤 8 項亞洲 疫苗資產：中國 7 項、韓國 1 項。4 項已核准，2 項處於第 3 期。進度最高的包括 Tripecia (CanSino Biologics; Approved); iPneucia (CanSino Biologics; Approved); Cecolin 9 (Xiamen Innovax Biotech / Xiamen University; Approved)。","as_of":"2026-11-03","count":8,"language":"zh-Hant"},{"title":"Asia Vaccines | Drugnews","url":"https://drugnews.com.tw/en/asia-vaccines-leaders.html","summary":"As of 2026-11-03, Drugnews tracks 8 Asian Vaccines assets: 7 from China, 1 from South Korea. 4 are approved and 2 are in Phase 3. The most advanced are Tripecia (CanSino Biologics; Approved); iPneucia (CanSino Biologics; Approved); Cecolin 9 (Xiamen Innovax Biotech / Xiamen University; Approved).","as_of":"2026-11-03","count":8,"language":"en"},{"title":"台灣 ADC 抗體藥物複合體公司與管線全景（2026 年 11 月更新）｜藥時事","url":"https://drugnews.com.tw/topics/adc/","summary":"抗體藥物複合體：把化療藥綁在抗體上，精準送進癌細胞。","as_of":"2026-11-01","count":12,"language":"zh-Hant"},{"title":"Taiwan ADC antibody-drug conjugates companies and pipeline landscape (November 2026) | Drugnews","url":"https://drugnews.com.tw/en/topics/adc/","summary":"At least 10 Taiwanese biotech companies are active in ADC antibody-drug conjugates, with 12 assets in development or on the market. The most advanced is Synmosa Biopharma (4114)’s Tivdak (Taiwan filing submitted; Recurrent or metastatic cervical cancer). Data as of 2026-11-01; updated as new information becomes available.","as_of":"2026-11-01","count":12,"language":"en"},{"title":"台灣 醫美與皮膚公司與管線全景（2026 年 11 月更新）｜藥時事","url":"https://drugnews.com.tw/topics/aesthetics-dermatology/","summary":"醫美與皮膚：從玻尿酸、肉毒到減脂，自費市場的新藥與新材料。","as_of":"2026-11-01","count":6,"language":"zh-Hant"},{"title":"Taiwan Aesthetics and dermatology companies and pipeline landscape (November 2026) | Drugnews","url":"https://drugnews.com.tw/en/topics/aesthetics-dermatology/","summary":"At least 5 Taiwanese biotech companies are active in Aesthetics and dermatology, with 6 assets in development or on the market. The most advanced is Caliway (6919)’s CBL-514 (Phase 3; Large-area abdominal fat reduction). Data as of 2026-11-01; updated as new information becomes available.","as_of":"2026-11-01","count":6,"language":"en"},{"title":"台灣 AI 新藥開發與數位醫療公司與管線全景（2026 年 11 月更新）｜藥時事","url":"https://drugnews.com.tw/topics/ai-drug-discovery/","summary":"AI 新藥研發：用電腦先篩、先設計，再進實驗室驗證。","as_of":"2026-11-01","count":1,"language":"zh-Hant"},{"title":"Taiwan AI drug discovery and digital medicine companies and pipeline landscape (November 2026) | Drugnews","url":"https://drugnews.com.tw/en/topics/ai-drug-discovery/","summary":"At least 1 Taiwanese biotech company is active in AI drug discovery and digital medicine, with 1 asset in development or on the market. The most advanced is Dasher (7829)’s YA-101 (Phase 2; Multiple System Atrophy). Data as of 2026-11-01; updated as new information becomes available.","as_of":"2026-11-01","count":1,"language":"en"},{"title":"台灣 抗感染公司與管線全景（2026 年 11 月更新）｜藥時事","url":"https://drugnews.com.tw/topics/anti-infective/","summary":"抗感染：對付抗藥性細菌、病毒與黴菌的新藥。","as_of":"2026-11-01","count":11,"language":"zh-Hant"},{"title":"Taiwan Anti-infectives companies and pipeline landscape (November 2026) | Drugnews","url":"https://drugnews.com.tw/en/topics/anti-infective/","summary":"At least 9 Taiwanese biotech companies are active in Anti-infectives, with 11 assets in development or on the market. The most advanced is TaiMed Biologics (4147)’s TMB-355 (FDA approved; Multidrug-resistant HIV-1 in heavily treatment-experienced adults failing their regimen). Data as of 2026-11-01; updated as new information becomes available.","as_of":"2026-11-01","count":11,"language":"en"},{"title":"台灣 自體免疫與發炎公司與管線全景（2026 年 11 月更新）｜藥時事","url":"https://drugnews.com.tw/topics/autoimmune/","summary":"自體免疫與發炎：讓失控的免疫系統冷靜下來。","as_of":"2026-11-01","count":4,"language":"zh-Hant"},{"title":"Taiwan Autoimmunity and inflammation companies and pipeline landscape (November 2026) | Drugnews","url":"https://drugnews.com.tw/en/topics/autoimmune/","summary":"At least 4 Taiwanese biotech companies are active in Autoimmunity and inflammation, with 4 assets in development or on the market. The most advanced is HSHC (4194)’s IBD98-M (Phase 2; Colitis, Ulcerative). Data as of 2026-11-01; updated as new information becomes available.","as_of":"2026-11-01","count":4,"language":"en"},{"title":"台灣 生物相似藥與 CDMO 代工公司與管線全景（2026 年 11 月更新）｜藥時事","url":"https://drugnews.com.tw/topics/biosimilars-cdmo/","summary":"生物相似藥與 CDMO：做原廠藥的平價版，或替別人代工生產。","as_of":"2026-11-01","count":12,"language":"zh-Hant"},{"title":"Taiwan Biosimilars and CDMO companies and pipeline landscape (November 2026) | Drugnews","url":"https://drugnews.com.tw/en/topics/biosimilars-cdmo/","summary":"At least 10 Taiwanese biotech companies are active in Biosimilars and CDMO, with 12 assets in development or on the market. The most advanced is Tanvex BioPharma (6541)’s NYPOZI (FDA approved in the United States; Chemotherapy-induced neutropenia in cancer patients). Data as of 2026-11-01; updated as new information becomes available.","as_of":"2026-11-01","count":12,"language":"en"},{"title":"台灣 雙特異性抗體與免疫治療公司與管線全景（2026 年 11 月更新）｜藥時事","url":"https://drugnews.com.tw/topics/bispecific-io/","summary":"雙特異性抗體與免疫治療：一個抗體同時抓兩個標靶。","as_of":"2026-11-01","count":4,"language":"zh-Hant"},{"title":"Taiwan bispecific antibodies and immunotherapy companies and pipeline landscape (November 2026) | Drugnews","url":"https://drugnews.com.tw/en/topics/bispecific-io/","summary":"At least 4 Taiwanese biotech companies are active in bispecific antibodies and immunotherapy, with 4 assets in development or on the market. The most advanced is AP Biosciences (6945)’s AP203 (Phase 1/2 study; Locally advanced or metastatic solid tumors). Data as of 2026-11-01; updated as new information becomes available.","as_of":"2026-11-01","count":4,"language":"en"},{"title":"台灣 CAR-T 與細胞治療公司與管線全景（2026 年 11 月更新）｜藥時事","url":"https://drugnews.com.tw/topics/cell-therapy/","summary":"細胞治療：把病人或捐贈者的免疫細胞改造成活的藥。","as_of":"2026-11-01","count":29,"language":"zh-Hant"},{"title":"Taiwan CAR-T and cell therapy companies and pipeline landscape (November 2026) | Drugnews","url":"https://drugnews.com.tw/en/topics/cell-therapy/","summary":"At least 18 Taiwanese biotech companies are active in CAR-T and cell therapy, with 29 assets in development or on the market. The most advanced is StemCyte (4178)’s REGENECYTE (U.S. FDA approval granted November 20; Hematopoietic and immune reconstitution in unrelated-donor transplantation for inherited, acquired or myeloablative-treatment-related hematopoietic disorders). Data as of 2026-11-01; updated as new information becomes available.","as_of":"2026-11-01","count":29,"language":"en"},{"title":"台灣 中樞神經公司與管線全景（2026 年 11 月更新）｜藥時事","url":"https://drugnews.com.tw/topics/cns/","summary":"中樞神經：失智、帕金森、憂鬱、疼痛等腦部疾病的新藥。","as_of":"2026-11-01","count":16,"language":"zh-Hant"},{"title":"Taiwan Central nervous system companies and pipeline landscape (November 2026) | Drugnews","url":"https://drugnews.com.tw/en/topics/cns/","summary":"At least 15 Taiwanese biotech companies are active in Central nervous system, with 16 assets in development or on the market. The most advanced is Standard Chem & Pharm (1720)’s Lurasidone HCl (Phase 4; Schizophrenia). Data as of 2026-11-01; updated as new information becomes available.","as_of":"2026-11-01","count":16,"language":"en"},{"title":"台灣 核酸與基因治療公司與管線全景（2026 年 11 月更新）｜藥時事","url":"https://drugnews.com.tw/topics/gene-nucleic-acid/","summary":"基因與核酸藥物：從 DNA、RNA 層次修正疾病。","as_of":"2026-11-01","count":5,"language":"zh-Hant"},{"title":"Taiwan nucleic-acid and gene therapy companies and pipeline landscape (November 2026) | Drugnews","url":"https://drugnews.com.tw/en/topics/gene-nucleic-acid/","summary":"At least 4 Taiwanese biotech companies are active in nucleic-acid and gene therapy, with 5 assets in development or on the market. The most advanced is Oneness Biotech (4743)’s SNS812 (Phase 2 complete; Coronavirus infection). Data as of 2026-11-01; updated as new information becomes available.","as_of":"2026-11-01","count":5,"language":"en"},{"title":"台灣 GLP-1 減重與代謝公司與管線全景（2026 年 11 月更新）｜藥時事","url":"https://drugnews.com.tw/topics/glp1-obesity/","summary":"GLP-1 與肥胖藥：模仿腸道激素，讓人吃得少、血糖穩。","as_of":"2026-11-01","count":10,"language":"zh-Hant"},{"title":"Taiwan GLP-1, obesity and metabolism companies and pipeline landscape (November 2026) | Drugnews","url":"https://drugnews.com.tw/en/topics/glp1-obesity/","summary":"At least 9 Taiwanese biotech companies are active in GLP-1, obesity and metabolism, with 10 assets in development or on the market. The most advanced is ScinoPharm (1789)’s Weight-management injection (U.S. weight-management drug application filed; Weight management). Data as of 2026-11-01; updated as new information becomes available.","as_of":"2026-11-01","count":10,"language":"en"},{"title":"台灣 改良型新藥與新劑型公司與管線全景（2026 年 11 月更新）｜藥時事","url":"https://drugnews.com.tw/topics/improved-new-drugs/","summary":"新劑型與改良型新藥：把已知藥物做得更好用、更有效。","as_of":"2026-11-01","count":6,"language":"zh-Hant"},{"title":"Taiwan improved new drugs and novel formulations companies and pipeline landscape (November 2026) | Drugnews","url":"https://drugnews.com.tw/en/topics/improved-new-drugs/","summary":"At least 6 Taiwanese biotech companies are active in improved new drugs and novel formulations, with 6 assets in development or on the market. The most advanced is PharmaEngine (4162)’s ONIVYDE (Initial U.S. approval in October 2015; First-line metastatic pancreatic adenocarcinoma in combination with oxaliplatin, fluorouracil and leucovorin). Data as of 2026-11-01; updated as new information becomes available.","as_of":"2026-11-01","count":6,"language":"en"},{"title":"台灣 iPSC 與幹細胞公司與管線全景（2026 年 11 月更新）｜藥時事","url":"https://drugnews.com.tw/topics/ipsc-stem-cell/","summary":"iPSC 與幹細胞：把細胞重新變回「萬用」狀態，再做成需要的組織。","as_of":"2026-11-01","count":7,"language":"zh-Hant"},{"title":"Taiwan iPSC and stem cells companies and pipeline landscape (November 2026) | Drugnews","url":"https://drugnews.com.tw/en/topics/ipsc-stem-cell/","summary":"At least 6 Taiwanese biotech companies are active in iPSC and stem cells, with 7 assets in development or on the market. The most advanced is UnicoCell (6794)’s ELIXCYTE-CKD (Phase 2/3 IND application submitted to TFDA; Severe chronic kidney disease). Data as of 2026-11-01; updated as new information becomes available.","as_of":"2026-11-01","count":7,"language":"en"},{"title":"台灣 癌症小分子標靶藥公司與管線全景（2026 年 11 月更新）｜藥時事","url":"https://drugnews.com.tw/topics/oncology-small-molecule/","summary":"腫瘤小分子：口服、標靶明確的抗癌藥。","as_of":"2026-11-01","count":2,"language":"zh-Hant"},{"title":"Taiwan Oncology small-molecule targeted therapies companies and pipeline landscape (November 2026) | Drugnews","url":"https://drugnews.com.tw/en/topics/oncology-small-molecule/","summary":"At least 1 Taiwanese biotech companies are active in Oncology small-molecule targeted therapies, with 2 assets in development or on the market. The most advanced is PharmaEngine (4162)’s PEP07 (Phase 1; Acute Myeloid Leukemia). Data as of 2026-11-01; updated as new information becomes available.","as_of":"2026-11-01","count":2,"language":"en"},{"title":"台灣 眼科新藥公司與管線全景（2026 年 11 月更新）｜藥時事","url":"https://drugnews.com.tw/topics/ophthalmology/","summary":"眼科：從黃斑部病變到乾眼症，保住視力的新藥。","as_of":"2026-11-01","count":9,"language":"zh-Hant"},{"title":"Taiwan Ophthalmology companies and pipeline landscape (November 2026) | Drugnews","url":"https://drugnews.com.tw/en/topics/ophthalmology/","summary":"At least 6 Taiwanese biotech companies are active in Ophthalmology, with 9 assets in development or on the market. The most advanced is Bora Pharmaceuticals (6472)’s Cyclosporine Ophthalmic Emulsion (FDA generic drug approval; Dry eye disease). Data as of 2026-11-01; updated as new information becomes available.","as_of":"2026-11-01","count":9,"language":"en"},{"title":"台灣 核醫藥物與放射性配體療法公司與管線全景（2026 年 11 月更新）｜藥時事","url":"https://drugnews.com.tw/topics/radiopharmaceuticals/","summary":"核藥：用放射性同位素當彈頭，精準照射腫瘤。","as_of":"2026-11-01","count":2,"language":"zh-Hant"},{"title":"Taiwan radiopharmaceuticals and radioligand therapy companies and pipeline landscape (November 2026) | Drugnews","url":"https://drugnews.com.tw/en/topics/radiopharmaceuticals/","summary":"At least 2 Taiwanese biotech companies are active in radiopharmaceuticals and radioligand therapy, with 2 assets in development or on the market. The most advanced is Heron Neutron Medical (7799)’s F18 FBPA (Phase 1/2; PET/CT diagnostic imaging of solid tumors). Data as of 2026-11-01; updated as new information becomes available.","as_of":"2026-11-01","count":2,"language":"en"},{"title":"台灣 罕見疾病新藥公司與管線全景（2026 年 11 月更新）｜藥時事","url":"https://drugnews.com.tw/topics/rare-disease/","summary":"罕見疾病：病人少、需求急，法規給予加速與獨占保護的藥物。","as_of":"2026-11-01","count":2,"language":"zh-Hant"},{"title":"Taiwan Rare-disease medicines companies and pipeline landscape (November 2026) | Drugnews","url":"https://drugnews.com.tw/en/topics/rare-disease/","summary":"At least 2 Taiwanese biotech companies are active in Rare-disease medicines, with 2 assets in development or on the market. The most advanced is Excelsior (6496)’s EX044 (Pipeline chart shows Phase III; Wilson disease). Data as of 2026-11-01; updated as new information becomes available.","as_of":"2026-11-01","count":2,"language":"en"},{"title":"台灣 疫苗公司與管線全景（2026 年 11 月更新）｜藥時事","url":"https://drugnews.com.tw/topics/vaccines/","summary":"疫苗：預防感染，也開始用來治療癌症。","as_of":"2026-11-01","count":6,"language":"zh-Hant"},{"title":"Taiwan Vaccines companies and pipeline landscape (November 2026) | Drugnews","url":"https://drugnews.com.tw/en/topics/vaccines/","summary":"At least 4 Taiwanese biotech companies are active in Vaccines, with 6 assets in development or on the market. The most advanced is ENIM (6564)’s EV71 (Macau marketing authorization obtained; Prevention of enterovirus 71 disease in children aged 2 months to under 6 years). Data as of 2026-11-01; updated as new information becomes available.","as_of":"2026-11-01","count":6,"language":"en"},{"title":"HDAC 抑制劑全景 | Drugnews","url":"https://drugnews.com.tw/landscapes/hdac-inhibitors.html","summary":"HDAC 抑制劑：調整基因開關，讓癌細胞或免疫細胞改變行為。","as_of":"2026-11-01","count":20,"language":"zh-Hant"},{"title":"HDAC inhibitors | Drugnews","url":"https://drugnews.com.tw/en/landscapes/hdac-inhibitors.html","summary":"HDAC inhibitors: adjusting gene switches to change how cancer and immune cells behave.","as_of":"2026-11-01","count":20,"language":"en"},{"title":"亞洲創新藥出海交易表 | Drugnews","url":"https://drugnews.com.tw/landscapes/asia-out-licensing-deals.html","summary":"截至 2026-11-11，藥時事追蹤自 2026-01-02 起，中國、日本、韓國與台灣企業向亞洲境內外夥伴授權的 147 筆交易，揭露首付款合計 79.55141 億美元；最高首付款為 石藥集團有限公司 → AstraZeneca (八項肥胖／第二型糖尿病計畫，初始四項含SYH2082及三項臨床前計畫；LiquidGel與AI多肽平台權利, 12 億美元)。","as_of":"2026-11-11","count":147,"language":"zh-Hant"},{"title":"Asian biotech out-licensing deals | Drugnews","url":"https://drugnews.com.tw/en/asia-out-licensing-deals.html","summary":"As of 2026-11-11, Drugnews tracks 57 out-licensing deals from Chinese, Japanese, Korean and Taiwanese companies to partners within and outside Asia since 2026-01-07, with US$3.011 billion in disclosed upfront payments; the largest upfront was Innovent Biologics, Inc. → Pfizer Inc. (Eight Innovent-originated early-stage oncology assets and four Pfizer-proposed discovery programs, US$650m).","as_of":"2026-11-11","count":147,"language":"en"},{"title":"2026 台灣生技授權與合作交易 | Drugnews","url":"https://drugnews.com.tw/taiwan-licensing-deals.html","summary":"截至 2026-11-11，Drugnews 收錄台灣生技公司於 2026 年公告的 24 筆已簽約授權與合作交易：對外授權 9 筆、引進授權 6 筆、合作／經銷 9 筆。已揭露總額上限最高為 逸達 FP-025, FP-020 and discovery-stage MMP-12 programs：簽約金 1,000 萬美元＋里程碑最高 5.745 億美元。","as_of":"2026-11-11","count":24,"language":"zh-Hant"},{"title":"Taiwan biotech licensing & partnership deals 2026 | Drugnews","url":"https://drugnews.com.tw/en/taiwan-licensing-deals.html","summary":"As of 2026-11-11, Drugnews tracks 13 signed licensing and partnership deals announced by Taiwan biotech companies in 2026: 6 out-licensing, 2 in-licensing and 5 commercial partnerships. The largest disclosed total ceiling is FP-025, FP-020 and discovery-stage MMP-12 programs / Foresee Pharmaceuticals / Foresee USA–Primevera Therapeutics LLC: 10 million USD upfront + up to 574.5 million USD milestones.","as_of":"2026-11-11","count":13,"language":"en"}]}}